


**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2022**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2022

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

**Cumulative Supplement 12
December 2022**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii

DRUG PRODUCT LISTS

Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

**CUMULATIVE SUPPLEMENT 12
DECEMBER 2022**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ATLANTIDE PHARMACEUTICALS AG (ATLANTIDE)	WOCKHARDT LTD (WOCKHARDT)
DAIICHI SANKYO INC (DAIICHI SANKYO)	COSETTE PHARMACEUTICALS INC (COSETTE)
DAIICHI SANKYO INC (DAIICHI SANKYO INC)	COSETTE PHARMACEUTICALS INC (COSETTE)
HERITAGE PHARMACEUTICALS INC (HERITAGE PHARMS INC)	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC (HERITAGE PHARMS)

LANNETT CO INC (LANNETT)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)
LANNETT CO INC (LANNETT CO INC)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)
MERCK AND CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK AND CO INC (MERCK AND CO INC)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK RESEARCH LABORATORIES DIV MERCK CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP (MERCK SHARP DOHME)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC (MSD MERCK CO)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
SANDOZ INC (SANDOZ)	EPIC PHARMA INC (EPIC PHARMA)
TELIGENT OU (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
TELIGENT PHARMA INC (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
WYTELLS PHARMA PRIVATE LTD (WYTELLS PHARMA)	EUGIA PHARMA SPECIALITIES LTD (EUGIA PHARMA SPECLTS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nateline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2021</u>	<u>MAR</u> <u>2022</u>	<u>JUN</u> <u>2022</u>	<u>SEP</u> <u>2022</u>	<u>DEC</u> <u>2022</u>
DRUG PRODUCTS	21133	21339	21640	21862	21983
LISTED SINGLE	2701	2716	2748	2709	2718
SOURCE	(12.8%)	(12.7%)	(12.7%)	(12.4%)	(12.4%)
MULTISOURCE	18432	18623	18892	19153	19265
	(87.2%)	(87.3%)	(87.3%)	(87.6%)	(87.6%)
THERAPEUTICALLY	18298	18493	18762	19036	19165
EQUIVALENT	(86.6%)	(86.7%)	(86.7%)	(87.1%)	(87.2%)
NOT	134	130	130	117	100
THERAPEUTICALLY	(0.6%)	(0.6%)	(0.6%)	(0.5%)	(0.5%)
EQUIVALENT					
EXCEPTIONS ⁴	54	53	53	53	46
	(0.3%)	(0.2%)	(0.2%)	(0.2%)	(0.2%)
NEW MOLECULAR					
ENTITIES	13	11	23	16	8
APPROVED					
NUMBER OF	1190	1204	1219	1210	1211
APPLICANTS					

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET, FOR SUSPENSION;ORAL
TRIUMEQ PD

+! VIIV HLTHCARE EQ 60MG BASE;EQ 5MG BASE;30MG N215413 001 Mar 30, 2022 Mar NEWA

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB LAURUS EQ 600MG BASE;300MG A216332 001 Jul 25, 2022 Jul NEWA
>D> AB TEVA PHARMS USA EQ 600MG BASE;300MG A079246 001 Sep 29, 2016 Dec DISC
>A> @ EQ 600MG BASE;300MG A079246 001 Sep 29, 2016 Dec DISC

ABAMETAPIR

LOTION;TOPICAL

XEGLYZE

+ @ HATCHTECH 0.74% N206966 001 Jul 24, 2020 Jul CAHN

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB GLENMARK PHARMS 500MG A209227 002 May 19, 2022 May NEWA
AB NOVUGEN 250MG A215947 001 Jan 05, 2022 Aug CAHN
AB 500MG A215947 002 Jan 05, 2022 Aug CAHN
>D> AB TEVA PHARMS USA 125MG A212206 001 Jun 24, 2022 Dec DISC
>A> @ 125MG A212206 001 Jun 24, 2022 Dec DISC
AB 125MG A212206 001 Jun 24, 2022 Jun NFTG
YONSA
>D> AB +! SUN PHARM 125MG N210308 001 May 22, 2018 Dec CTEC
>A> +! 125MG N210308 001 May 22, 2018 Dec CTEC
AB +! 125MG N210308 001 May 22, 2018 Jun CFTG
+! 125MG N210308 001 May 22, 2018 Feb CAHN

ABROCITINIB

TABLET;ORAL

CIBINQO

+ PFIZER 50MG N213871 001 Jan 14, 2022 Jan NEWA
+ 100MG N213871 002 Jan 14, 2022 Jan NEWA
+! 200MG N213871 003 Jan 14, 2022 Jan NEWA

ACALABRUTINIB MALEATE

TABLET;ORAL

CALQUENCE

+! ASTRAZENECA EQ 100MG BASE N216387 001 Aug 03, 2022 Aug NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

AB ! AMNEAL PHARM EQ 200MG BASE A075047 001 Dec 30, 1999 Jul CTEC
! EQ 200MG BASE A075047 001 Dec 30, 1999 Apr CTEC
AB ! EQ 400MG BASE A075047 002 Dec 30, 1999 Jul CTEC
! EQ 400MG BASE A075047 002 Dec 30, 1999 Apr CTEC
AB ANI PHARMS EQ 200MG BASE A074007 001 Oct 18, 1995 Jul CMFD
AB EQ 400MG BASE A074007 002 Oct 18, 1995 Jul CMFD
@ MYLAN EQ 200MG BASE A074288 001 Apr 24, 1995 Apr DISC
AB EQ 200MG BASE A074288 001 Apr 24, 1995 Apr CAHN
@ EQ 400MG BASE A074288 002 Apr 24, 1995 Apr DISC
AB EQ 400MG BASE A074288 002 Apr 24, 1995 Apr CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP ASPIRO 1GM/100ML (10MG/ML) A216617 001 Jul 27, 2022 Jul NEWA
AP HIKMA 1GM/100ML (10MG/ML) A202605 001 Jun 13, 2016 Aug CAHN
+! 1GM/100ML (10MG/ML) N206968 001 Jun 03, 2022 Jun CAHN
+! INNOPHARMA 1GM/100ML (10MG/ML) N206968 001 Jun 03, 2022 Jun NEWA
AP ! SANDOZ INC 1GM/100ML (10MG/ML) A204052 001 Mar 22, 2016 Feb CHRS
AP ZYDUS PHARMS 1GM/100ML (10MG/ML) A216467 001 Oct 25, 2022 Oct NEWA
OFIRMEV
+ @ MALLINCKRODT HOSP 1GM/100ML (10MG/ML) N022450 001 Nov 02, 2010 Feb DISC

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

ALLZITAL

AA	!	LARKEN LABS INC	325MG; 25MG	A203484	001	Dec 04, 2015	Apr CTEC
		BUTALBITAL AND ACETAMINOPHEN					
AA		AACE PHARMS	50MG; 300MG	A214955	001	Aug 16, 2022	Aug NEWA
AA			300MG; 50MG	A214955	001	Aug 16, 2022	Nov CPOT
>D> AA		ALVOGEN	325MG; 50MG	A205120	001	Oct 30, 2015	Dec DISC
>A>	@		325MG; 50MG	A205120	001	Oct 30, 2015	Dec DISC
AA		HAVIX	300MG; 50MG	A214088	001	Apr 07, 2022	Apr NEWA
AA			325MG; 25MG	A214088	002	Apr 07, 2022	Apr NEWA
AA			325MG; 50MG	A214088	003	Apr 07, 2022	Apr NEWA
AA		RISE PHARMA	300MG; 50MG	A214088	001	Apr 07, 2022	Sep CAHN
AA			325MG; 25MG	A214088	002	Apr 07, 2022	Sep CAHN
AA			325MG; 50MG	A214088	003	Apr 07, 2022	Sep CAHN
AA		SENORES PHARMS	300MG; 50MG	A214088	001	Apr 07, 2022	Jun CAHN
AA			325MG; 25MG	A214088	002	Apr 07, 2022	Jun CAHN
AA			325MG; 50MG	A214088	003	Apr 07, 2022	Jun CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	@	HIKMA	300MG; 50MG; 40MG	A215135	001	Mar 25, 2022	Sep DISC
AA			300MG; 50MG; 40MG	A215135	001	Mar 25, 2022	Mar NEWA
	@		325MG; 50MG; 40MG	A215135	002	Mar 25, 2022	Sep DISC
AA			325MG; 50MG; 40MG	A215135	002	Mar 25, 2022	Mar NEWA
AA		NOVAST LABS	300MG; 50MG; 40MG	A215047	001	Nov 17, 2021	Aug CAHN
		TABLET; ORAL					
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
>D> AA		ALVOGEN	325MG; 50MG; 40MG	A204984	001	Jan 10, 2017	Dec DISC
>A>	@		325MG; 50MG; 40MG	A204984	001	Jan 10, 2017	Dec DISC
AA		GRANULES	325MG; 50MG; 40MG	A040864	001	Dec 01, 2008	Jul CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		HIKMA	300MG; 50MG; 40MG; 30MG	A215138	002	Jan 26, 2022	Jan NEWA
AB			325MG; 50MG; 40MG; 30MG	A215138	001	Jan 26, 2022	Jan NEWA
AB		LGM PHARMA	300MG; 50MG; 40MG; 30MG	A076560	002	Jul 19, 2012	Jan CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		CHARTWELL	120MG/5ML; 12MG/5ML	A089450	001	Oct 27, 1992	Apr CAHN
AA		MIKART	120MG/5ML; 12MG/5ML	A089450	001	Oct 27, 1992	Mar CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@	CHARTWELL	300MG; 15MG	A089997	001	Dec 28, 1994	Feb CAHN
	@		300MG; 30MG	A089998	001	Dec 28, 1994	Feb CAHN
	@		300MG; 60MG	A089999	001	Dec 28, 1994	Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	!	CHARTWELL	325MG/15ML; 7.5MG/15ML	A040482	001	Sep 25, 2003	Apr CAHN
AA		EYWA	325MG/15ML; 7.5MG/15ML	A211023	001	Mar 08, 2019	Sep CAHN
	!	MIKART	300MG/15ML; 10MG/15ML	A040881	001	Feb 25, 2010	Apr CTEC
AA	!		325MG/15ML; 7.5MG/15ML	A040482	001	Sep 25, 2003	Mar CAHN
	@	TRIS PHARMA INC	300MG/15ML; 10MG/15ML	A201295	002	Dec 30, 2021	Apr DISC
	@		325MG/15ML; 7.5MG/15ML	A201295	001	Dec 30, 2021	Apr DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	ANDA REPOSITORY	325MG; 2.5MG	A040846	001	Jun 09, 2010	May DISC
	!	ASCENT PHARMS INC	325MG; 2.5MG	A211487	001	Nov 07, 2018	May CHRS
			325MG; 2.5MG	A211487	001	Nov 07, 2018	May CTEC
AA	!	CHARTWELL	300MG; 5MG	A040658	001	Jan 19, 2006	Apr CAHN
AA	!		300MG; 7.5MG	A040658	002	Mar 24, 2006	Apr CAHN
AA	!		300MG; 10MG	A040658	003	Jun 23, 2004	Apr CAHN
	@		325MG; 7.5MG	A040248	001	Apr 28, 2000	Feb CAHN
AA			325MG; 7.5MG	A040432	001	Jan 22, 2003	Apr CAHN
	@		325MG; 10MG	A040248	002	Apr 28, 2000	Feb CAHN

TABLET;ORAL		HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
AA	@ MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Nov	CAHN
		325MG;7.5MG	A040432	001	Jan 22, 2003	Mar	CAHN
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE</u>							
SOLUTION;ORAL		OXYCODONE AND ACETAMINOPHEN					
	MIKART	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018	Mar	CAHN
TABLET;ORAL		OXYCODONE 5/APAP 500					
	@ BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001		Jun	CRLD
<u>ACETAZOLAMIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL		ACETAZOLAMIDE					
AB	! CADILA	500MG	A205301	001	Jan 16, 2019	May	CHRS
	@ INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	May	DISC
<u>ACETIC ACID, GLACIAL</u>							
SOLUTION/DROPS;OTIC		ACETIC ACID					
	@ WOCKHARDT BIO AG	2%	A040166	001	Jul 26, 1996	Jun	DISC
VOSOL							
AT	! AKORN	2%	N012179	001		Jun	CHRS
<u>ACETYLCYSTEINE</u>							
INJECTABLE;INTRAVENOUS		ACETYLCYSTEINE					
AP	ASPEN	6GM/30ML (200MG/ML)	A213693	001	Feb 03, 2022	Jan	NEWA
	@ EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Feb	DISC
AP	INDOCO	6GM/30ML (200MG/ML)	A215620	001	Feb 23, 2022	Feb	NEWA
<u>ACLIDINIUM BROMIDE</u>							
POWDER, METERED;INHALATION		TUDORZA PRESSAIR					
	+! COVIS	0.4MG/INH	N202450	001	Jul 23, 2012	Apr	CAHN
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE</u>							
POWDER, METERED;INHALATION		DUAKLIR PRESSAIR					
	+! COVIS	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Apr	CAHN
<u>ACYCLOVIR</u>							
OINTMENT;TOPICAL		ACYCLOVIR					
AB	CHARTWELL RX	5%	A212495	001	Apr 07, 2020	Sep	CAHN
	@ PRINSTON INC	5%	A212202	001	Nov 15, 2021	Mar	DISC
SUSPENSION;ORAL		ACYCLOVIR					
	@ AUROBINDO PHARMA	200MG/5ML	A216331	001	Mar 31, 2022	Sep	DISC
AB		200MG/5ML	A216331	001	Mar 31, 2022	Mar	NEWA
AB	HETERO LABS LTD III	200MG/5ML	A215669	001	Jul 01, 2022	Jun	NEWA
AB	RUBICON	200MG/5ML	A215724	001	Aug 18, 2022	Aug	NEWA
<u>ACYCLOVIR SODIUM</u>							
INJECTABLE;INJECTION		ACYCLOVIR SODIUM					
AP	AM INJECTABLES	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Apr	CAHN
	@ CHARTWELL INJECTABLE	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar	CAHN
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar	CAHN
	@ DR REDDYS	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Oct	DISC
AP		EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Sep	CAHN
<u>ADAGRASIB</u>							
TABLET;ORAL		KRAZATI					
>A>	+! MIRATI THERAPS	200MG	N216340	001	Dec 12, 2022	Dec	CMS1

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB	ACTAVIS LABS UT INC	0.3%;2.5%	A209641	001	Jun 22, 2022	Jun NEWA
>D> AB	ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015	Dec DISC
>A>	@	0.1%;2.5%	A203790	001	Sep 30, 2015	Dec DISC
AB	PADAGIS ISRAEL	0.3%;2.5%	A212464	001	May 31, 2022	May NEWA
AB	ZYDUS PHARMS	0.3%;2.5%	A214553	001	Jun 03, 2022	May NEWA
AT		0.3%;2.5%	A214553	001	Jun 03, 2022	May NEWA

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

AB	! DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jun CHRS
	ALBENZA					
	+ @ IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Jun DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ACCUNEB

	+ @ MYLAN SPECIALITY LP	EQ 0.042% BASE	N020949	001	Apr 30, 2001	Nov DISC
	ALBUTEROL SULFATE					
	@ BAUSCH	EQ 0.083% BASE	A075358	001	Mar 29, 2000	Jun CAHN
	@	EQ 0.5% BASE	A075050	001	Jun 18, 1998	Jun CAHN
AN	! NEPHRON	EQ 0.042% BASE	A076355	001	Jun 28, 2004	Nov CHRS

SYRUP; ORAL

ALBUTEROL SULFATE

AA	CHARTWELL RX	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007	May CMFD
----	--------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

ALBUTEROL SULFATE

AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Sep CAHN
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Sep CAHN
	@ CHARTWELL RX	EQ 4MG BASE	A072151	002	Dec 05, 1989	Feb CMS1
	TABLET, EXTENDED RELEASE; ORAL					
	VOSPIRE ER					
	@ STRIDES PHARMA	EQ 4MG BASE	A076130	002	Sep 26, 2002	Oct DISC

ALCOHOL

SOLUTION; INTRA-ARTERIAL

ABLYSINOL

	+ BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jul CAHN
	+!	99% (5ML)	N207987	002	Jun 21, 2018	Jul CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTRUNA HCT

	+ @ NODEN PHARMA	EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008	May DISC
	+ @	EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008	May DISC

ALLOPURINOL

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Jan NEWA
----	------------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

ALLOPURINOL

AB	! ACCORD HLTHCARE	300MG	A203154	002	May 06, 2013	Apr CHRS
AB	HARMAN FINOCHEM	100MG	A214443	001	Mar 07, 2022	Feb NEWA
AB		300MG	A214443	002	Mar 07, 2022	Feb NEWA
	ZYLOPRIM					
	+ CASPER PHARMA LLC	200MG	N016084	003	Aug 04, 2022	Aug NEWA
AB	+	300MG	N016084	002		Apr CHRS

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Nov CTNA
AP		EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Nov CAIN
	ALOPRIM					
AP	+! MYLAN	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Apr CAHN

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

OSEN

+ @ TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013	Mar DISC
+ @	EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013	Mar DISC

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

@ PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	Apr DISC
@	EQ 1MG BASE	A206113	002	Feb 23, 2018	Apr DISC

ALPELISIB

TABLET;ORAL

VIJOICE

+ NOVARTIS	50MG	N215039	001	Apr 05, 2022	Apr NEWA
+	125MG	N215039	002	Apr 05, 2022	Apr NEWA
+!	200MG	N215039	003	Apr 05, 2022	Apr NEWA

ALPROSTADIL

SUPPOSITORY;URETHRAL

MUSE

+ @ MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Jul DISC
-------------------------	---------	---------	-----	--------------	----------

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

>A> AB	HUMANWELL PURACAP	100MG	A214580	001	Dec 20, 2022	Dec NEWA
>D>	@ STRIDES PHARMA	100MG	A211354	001	Feb 18, 2022	Dec CMFD
>A> AB		100MG	A211354	001	Feb 18, 2022	Dec CMFD
	@	100MG	A211354	001	Feb 18, 2022	Aug DISC
AB		100MG	A211354	001	Feb 18, 2022	Feb NEWA
>D> AB	WATSON LABS INC	100MG	A208107	001	Dec 06, 2016	Dec DISC
>A>	@	100MG	A208107	001	Dec 06, 2016	Dec DISC

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

+ ADAMAS OPERATIONS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug CAHN
+!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	@ ANDA REPOSITORY	50MG/5ML	A076352	001	Sep 10, 2004	Sep CAHN
	! CHARTWELL RX	50MG/5ML	A074028	001	Jun 28, 1993	Mar CAHN
	@ XTTRIUM LABS INC	50MG/5ML	A075060	001	Dec 24, 1998	Nov CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

>D> AB	EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022	Dec DISC
>A>	@	100MG	A212407	001	May 27, 2022	Dec DISC
AB		100MG	A212407	001	May 27, 2022	May NEWA
	@ JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	May DISC

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

+ ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug CAHN
+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug CAHN
+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug CAHN
+ @	EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug CAHN

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

AB	APOTEX	5MG	A210701	001	May 19, 2022	May NEWA
AB		10MG	A210701	002	May 19, 2022	May NEWA
AB	AUROBINDO PHARMA	5MG	A216531	001	Jul 21, 2022	Jul NEWA
AB		10MG	A216531	002	Jul 21, 2022	Jul NEWA

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

AB	! GENUS LIFESCIENCES	0.1%	A076065	001	May 15, 2003	Aug CAHN
----	----------------------	------	---------	-----	--------------	----------

LOTION; TOPICAL

AMCINONIDE

! ANDA REPOSITORY 0.1%
! GENUS LIFESCIENCES 0.1%

A076329 001 Nov 06, 2002 Sep CAHN
A076329 001 Nov 06, 2002 Aug CAHN

OINTMENT; TOPICAL

AMCINONIDE

AB ! ANDA REPOSITORY 0.1%
AB ! GENUS LIFESCIENCES 0.1%

A076096 001 Nov 19, 2002 Sep CAHN
A076096 001 Nov 19, 2002 Aug CAHN

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

@ EUGIA PHARMA SPECILTS 500MG/VIAL

A204363 001 Jul 17, 2017 Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

@ CHARTWELL RX 5MG
@ USPHARMA WINDLAS 5MG

A204180 001 Aug 07, 2015 Aug CAHN
A204180 001 Aug 07, 2015 May DISC

AMINOCAPROIC ACID

SOLUTION; ORAL

AMINOCAPROIC ACID

AA AGENIX 0.25GM/ML
AA ANNORA PHARMA 0.25GM/ML
AA AUROBINDO PHARMA 0.25GM/ML
AA CARNEGIE 0.25GM/ML
AA FLORIDA 0.25GM/ML

A215510 001 Mar 23, 2022 Mar NEWA
A216464 001 Nov 04, 2022 Oct NEWA
A216804 001 Sep 26, 2022 Sep NEWA
A214140 001 Jan 26, 2021 Jun CAHN
A215510 001 Mar 23, 2022 Oct CAHN

TABLET; ORAL

AMINOCAPROIC ACID

AB CARNEGIE 500MG
AB 1GM
AB OPTIMUS 500MG
AB 1GM

A213928 001 Feb 12, 2021 Jun CAHN
A213928 002 Feb 12, 2021 Jun CAHN
A213944 001 Sep 14, 2022 Sep NEWA
A213944 002 Sep 14, 2022 Sep NEWA

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

! EUROCEPT PHARMS 4GM/PACKET

A074346 001 Jun 30, 1994 Oct CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ EUGIA PHARMA 50MG/ML

A204550 001 Oct 25, 2017 Jul DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB ! TARO 200MG
@ UPSHER SMITH LABS 200MG
@ 400MG
>A> AB ZYDUS PHARMS USA INC 100MG
>A> AB 400MG

A075424 001 Mar 30, 2001 Oct CHRS
A075315 001 Dec 23, 1998 Oct DISC
A075315 002 Jun 30, 2000 Oct DISC
A079029 002 Jan 06, 2023 Dec NEWA
A079029 003 Jan 06, 2023 Dec NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

@ AIPING PHARM INC 10MG
@ 25MG
@ 50MG
@ 75MG
@ 100MG
@ 150MG
AB CENTAUR PHARMS PVT 10MG
AB 25MG
AB 50MG
AB 75MG
AB 100MG
AB 150MG
AB LEADING 10MG
AB 25MG
AB 50MG
AB 75MG
AB 100MG

A212654 002 Sep 29, 2021 Nov CAHN
A212654 001 Apr 07, 2020 Nov CAHN
A212654 003 Sep 29, 2021 Nov CAHN
A212654 004 Sep 29, 2021 Nov CAHN
A212654 005 Sep 29, 2021 Nov CAHN
A212654 006 Sep 29, 2021 Nov CAHN
A216243 001 Jun 06, 2022 May NEWA
A216243 002 Jun 06, 2022 May NEWA
A216243 003 Jun 06, 2022 May NEWA
A216243 004 Jun 06, 2022 May NEWA
A216243 005 Jun 06, 2022 May NEWA
A216243 006 Jun 06, 2022 May NEWA
A216243 001 Jun 06, 2022 Sep CAHN
A216243 002 Jun 06, 2022 Sep CAHN
A216243 003 Jun 06, 2022 Sep CAHN
A216243 004 Jun 06, 2022 Sep CAHN
A216243 005 Jun 06, 2022 Sep CAHN

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		150MG	A216243	006	Jun 06, 2022	Sep CAHN
	@ UPSHER SMITH LABS	10MG	A212654	002	Sep 29, 2021	May DISC
	@	25MG	A212654	001	Apr 07, 2020	May DISC
	@	50MG	A212654	003	Sep 29, 2021	May DISC
	@	75MG	A212654	004	Sep 29, 2021	May DISC
	@	100MG	A212654	005	Sep 29, 2021	May DISC
	@	150MG	A212654	006	Sep 29, 2021	May DISC
	@ VINTAGE PHARMS	10MG	A040218	001	Sep 11, 1997	Jun DISC
	@	25MG	A040218	002	Sep 11, 1997	Jun DISC
	@	50MG	A040218	003	Sep 11, 1997	Jun DISC
	@	75MG	A040218	004	Sep 11, 1997	Jun DISC
	@	100MG	A040218	005	Sep 11, 1997	Jun DISC
	@	150MG	A040218	006	Sep 11, 1997	Jun DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Jan NEWA
AB		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Jan NEWA
AB	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Jan CTEC
AB	!	EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Jan CTEC
	@ UNITED RES LABS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Apr CAHN
	@	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Apr CAHN

AMLODIPINE BESYLATE

SOLUTION;ORAL

NORLIQVA

+	!	CMP DEV LLC	EQ 1MG BASE/ML	N214439	001	Feb 24, 2022	Feb NEWA
---	---	-------------	----------------	---------	-----	--------------	----------

TABLET;ORAL

AMLODIPINE BESYLATE

	@	CHARTWELL RX	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
	@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN
	@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan CAHN
AB		TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Mar CMFD
AB			EQ 5MG BASE	A076846	002	Jun 28, 2007	Mar CMFD
AB			EQ 10MG BASE	A076846	003	Jun 28, 2007	Mar CMFD
		NORVASC					
AB	+	VIATRIS	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jan CAHN
AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992	Jan CAHN
AB	+	!	EQ 10MG BASE	N019787	003	Jul 31, 1992	Jan CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

+	@	SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007	Oct CRLD
+	@		EQ 5MG BASE	N022026	002	Sep 27, 2007	Oct CRLD
+	@		EQ 10MG BASE	N022026	003	Sep 27, 2007	Oct CRLD

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	STRIDES PHARMA	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Jun CMFD
AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Jun CMFD
AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Jun CMFD
AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Jun CMFD
AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Jun CMFD

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@	TORRENT	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Aug DISC
@		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Aug DISC
@		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Aug DISC
@		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Aug DISC

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

@	TORRENT	EQ 5MG BASE;40MG	A202517	001	Jan 08, 2014	Mar DISC
@		EQ 5MG BASE;80MG	A202517	003	Jan 08, 2014	Mar DISC
@		EQ 10MG BASE;40MG	A202517	002	Jan 08, 2014	Mar DISC
@		EQ 10MG BASE;80MG	A202517	004	Jan 08, 2014	Mar DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	HETERO LABS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Aug CAHN
AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Aug CAHN
AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Aug CAHN
AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Aug CAHN
AB	STRIDES PHARMA	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun CMFD
AB		EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun CMFD
AB		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun CMFD
AB		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun CMFD

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	UNIV ALABAMA BIRM	15mCi-150mCi/4ML (3.75-37.5mCi/ML)	A211698	001	Nov 03, 2022	Oct NEWA
AP		3.75-37.5mCi/ML	A211698	001	Nov 03, 2022	Oct NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN

	+ @ SUN PHARM INDS INC	EQ 12% BASE	N020508	001	Aug 29, 1996	Aug CRLD
--	------------------------	-------------	---------	-----	--------------	----------

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	MICRO LABS	250MG	A207471	001	Jun 24, 2022	Jun NEWA
AB		500MG	A207471	002	Jun 24, 2022	Jun NEWA

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET; ORAL

VOQUEZNA TRIPLE PACK

	+! PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May NEWA
	VOQUEZNA TRIPLE PAK					
	+ @ PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	Nov DISC
	+!	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May CMS1

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET; ORAL

VOQUEZNA DUAL PACK

	+! PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May NEWA
	VOQUEZNA DUAL PAK					
	+ @ PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	Nov DISC
	+!	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	@ LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	May DISC
	@	2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	May DISC
	@	3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	May DISC
	@	5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	May DISC
	@	6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	May DISC
	@	7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	May DISC
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
	@ ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jul DISC
>D> AB	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	Dec DISC
>A>	@	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	Dec DISC
>D> AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	Dec DISC
>A>	@	2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	Dec DISC
>D> AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	Dec DISC
>A>	@	3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	Dec DISC
>D> AB		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	Dec DISC
>A>	@	5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	Dec DISC
>D> AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	Dec DISC
>A>	@	6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	Dec DISC
>D> AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	Dec DISC
>A>	@	7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	Dec DISC
	@ TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Sep DISC
AB		3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan NEWA
	@	6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Sep DISC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan	NEWA
	@	9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Sep	DISC
AB		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan	NEWA
	@	12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Sep	DISC
AB		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan	NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
	@ ACCORD HLTHCARE	1.25MG;1.25MG;1.25MG;1.25MG	A214347	001	Nov 22, 2021	Jul	DISC
	@	1.875MG;1.875MG;1.875MG;1.875MG	A214347	002	Nov 22, 2021	Jul	DISC
	@	2.5MG;2.5MG;2.5MG;2.5MG	A214347	003	Nov 22, 2021	Jul	DISC
	@	3.125MG;3.125MG;3.125MG;3.125MG	A214347	004	Nov 22, 2021	Jul	DISC
	@	3.75MG;3.75MG;3.75MG;3.75MG	A214347	005	Nov 22, 2021	Jul	DISC
	@	5MG;5MG;5MG;5MG	A214347	006	Nov 22, 2021	Jul	DISC
	@	7.5MG;7.5MG;7.5MG;7.5MG	A214347	007	Nov 22, 2021	Jul	DISC
	@ CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Oct	DISC
AB		1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jun	NEWA
	@	2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Oct	DISC
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jun	NEWA
	@	3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Oct	DISC
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jun	NEWA
	@	5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Oct	DISC
AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jun	NEWA
	@	7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Oct	DISC
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jun	NEWA
	@ LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Sep	DISC
AB		1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Jul	NEWA
	@	1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Sep	DISC
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Jul	NEWA
	@	2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Sep	DISC
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Jul	NEWA
	@	3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Sep	DISC
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Jul	NEWA
	@	3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Sep	DISC
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Jul	NEWA
	@	5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Sep	DISC
AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Jul	NEWA
	@	7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Sep	DISC
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Jul	NEWA
AB	ZYDUS PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Mar	CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Mar	CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Mar	CAHN
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Mar	CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Mar	CAHN
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Mar	CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Mar	CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE							
AA	RISE PHARMA	5MG	A212901	001	May 22, 2020	Sep	CAHN
AA		10MG	A212901	002	May 22, 2020	Sep	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT							
	+ @ AZURITY	2.5MG	N209905	005	Apr 16, 2021	Apr	CAHN
	+	5MG	N209905	001	Jan 30, 2019	Apr	CAHN
	+	10MG	N209905	002	Jan 30, 2019	Apr	CAHN
	+	15MG	N209905	003	Jan 30, 2019	Apr	CAHN
	+!	20MG	N209905	004	Jan 30, 2019	Apr	CAHN

AMPHOTERICIN B

INJECTABLE, LIPOSOMAL;INJECTION

AMPHOTERICIN B							
AB	EUGIA PHARMA	50MG/VIAL	A214010	001	Nov 17, 2022	Nov	NEWA

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM							
	@ MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug	DISC
	@	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug	DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

@ RISING

EQ 0.5MG BASE

A077613 001 Jun 27, 2006 Oct CAHN

@

EQ 1MG BASE

A077613 002 Jun 27, 2006 Oct CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOKYN

AP +! MDD US 30MG/3ML (10MG/ML)

N021264 002 Apr 20, 2004 Feb CFTG

APOMORPHINE HYDROCHLORIDE

AP SAGE CHEMS 30MG/3ML (10MG/ML)

A212025 001 Feb 23, 2022 Feb NFTG

APRACLOINIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

IOPIDINE

AT +! IMPRIMIS PHARMS USA EQ 0.5% BASE

N020258 001 Jul 30, 1993 Jun CAHN

+! EQ 1% BASE

N019779 001 Dec 31, 1987 Jun CAHN

APREMILAST

TABLET;ORAL

APREMILAST

@ AMNEAL

10MG

A211782 001 Jun 30, 2021 Jan DISC

@

20MG

A211782 002 Jun 30, 2021 Jan DISC

@

30MG

A211782 003 Jun 30, 2021 Jan DISC

AB TEVA PHARMS USA INC 10MG

A211897 001 Aug 18, 2022 Aug NEWA

AB 20MG

A211897 002 Aug 18, 2022 Aug NEWA

AB 30MG

A211897 003 Aug 18, 2022 Aug NEWA

APREPITANT

EMULSION;INTRAVENOUS

APONVIE

+! HERON THERAPS INC 32MG/4.4ML (7.2MG/ML)

N216457 001 Sep 16, 2022 Sep NEWA

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN ALEMBIC PHARMS EQ 0.015MG BASE/2ML

A214779 001 May 10, 2022 Apr NEWA

AN LUPIN EQ 0.015MG BASE/2ML

A213068 001 Feb 07, 2022 Jan NEWA

AN MANKIND PHARMA EQ 0.015MG BASE/2ML

A216128 001 Nov 15, 2022 Nov NEWA

@ RITEDOSE CORP EQ 0.015MG BASE/2ML

A214736 001 Mar 02, 2022 Sep CAHN

AN SLATE RUN PHARMA EQ 0.015MG BASE/2ML

A213762 001 Jun 22, 2021 Sep CAHN

AN SLAYBACK PHARMA LLC EQ 0.015MG BASE/2ML

A216815 001 Nov 25, 2022 Nov NEWA

AN SUN PHARM EQ 0.015MG BASE/2ML

A215385 001 May 26, 2022 May NEWA

AN TAP EQ 0.015MG BASE/2ML

A213762 001 Jun 22, 2021 Apr CAHN

@ VISTAPHARM EQ 0.015MG BASE/2ML

A214736 001 Mar 02, 2022 Aug DISC

AN EQ 0.015MG BASE/2ML

A214736 001 Mar 02, 2022 Feb NEWA

BROVANA

AN +! LUPIN EQ 0.015MG BASE/2ML

N021912 001 Oct 06, 2006 Nov CAHN

ARGATROBAN

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

+ @ CIPLA 50MG/50ML (1MG/ML)

N022434 001 Jun 29, 2011 Apr CAHN

ARIPIPRAZOLE

SOLUTION;ORAL

ARIPIPRAZOLE

AA GLASSHOUSE PHARMS 1MG/ML

A215595 001 Oct 25, 2022 Oct NEWA

AA RUBICON 1MG/ML

A216351 001 Oct 27, 2022 Oct NEWA

TABLET;ORAL

ABILIFY

AB + OTSUKA 5MG

N021436 005 Nov 15, 2002 Nov CHRS

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP ! FRESENIUS KABI USA 1MG/ML

A208231 001 Aug 31, 2018 Apr CHRS

AP GLAND PHARMA LTD 1MG/ML

A215059 002 Apr 22, 2022 Apr NEWA

ARTESUNATEPOWDER; INTRAVENOUS
ARTESUNATE

+! AMIVAS 110MG/VIAL N213036 001 May 26, 2020 Feb CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN EFOR SOLUTION; INTRAVENOUS
M.V.I. PEDIATRIC+ @ HOSPIRA 80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL N018920 001 Sep 21, 2000 Jan DISC
; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL;
17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG
BASE/VIAL; 0.7MG/VIAL; 7MG/VIALASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN KINJECTABLE; INTRAVENOUS
M.V.I. ADULT+ @ HOSPIRA 200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL N021625 001 Jan 30, 2004 Jan DISC
L; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL;
40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ @ HOSPIRA 200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 1 N021643 001 Feb 18, 2004 Jan DISC
5MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5MLASENAPINESYSTEM; TRANSDERMAL
SECUADO+! HISAMITSU 3.8MG/24HR N212268 001 Oct 11, 2019 Mar CHRS
+ 7.6MG/24HR N212268 003 Oct 11, 2019 Mar CHRSASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

	@ LGM PHARMA	500MG; 50MG; 40MG	A205230	001	Oct 18, 2021	Apr	DISC
AA	NOSTRUM LABS INC	325MG; 50MG; 40MG	A078149	001	Jun 13, 2007	Apr	CMFD
	FIORINAL						
	+ @ ALLERGAN	325MG; 50MG; 40MG	N017534	005	Apr 16, 1986	Jun	DISC
AA	+	325MG; 50MG; 40MG	N017534	005	Apr 16, 1986	Apr	CHRS
	LANORINAL						
AA	! LANNETT	325MG; 50MG; 40MG	A086996	002	Oct 11, 1985	Apr	CHRS
	TABLET; ORAL						
	BUTALBITAL, ASPIRIN AND CAFFEINE						
	+ @ HIKMA INTL PHARMS	325MG; 50MG; 40MG	A086162	002	Feb 16, 1984	Mar	CRLD

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

	@ MAYNE PHARMA INC	325MG; 50MG; 40MG; 30MG	A203335	001	Oct 30, 2015	Jan	DISC
AB	! STEVENS J	325MG; 50MG; 40MG; 30MG	A074951	001	Aug 31, 1998	May	CHRS
	FIORINAL W/CODEINE						
	+ @ ALLERGAN	325MG; 50MG; 40MG; 30MG	N019429	003	Oct 26, 1990	May	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

GALT PHARMS 385MG; 30MG; 25MG A075141 001 May 29, 1998 Mar CMFD

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@ INGENUS PHARMS NJ 325MG; 200MG; 16MG A040860 001 Jan 07, 2010 Jul DISC

ASPIRIN; DIPYRIDAMOLE

	CAPSULE, EXTENDED RELEASE;ORAL					
	AGGRENEX					
	+ @ BOEHRINGER INGELHEIM	25MG;200MG	N020884	001	Nov 22, 1999	Oct DISC
	ASPIRIN AND DIPYRIDAMOLE					
AB	! GLENMARK PHARMS SA	25MG;200MG	A210318	001	May 24, 2019	Oct CHRS

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL						
HYDROCODONE BITARTRATE AND ASPIRIN						
!	LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021	Jul CMFD

ATAZANAVIR SULFATE

CAPSULE;ORAL							
ATAZANAVIR SULFATE							
AB	HETERO LABS LTD III	EQ 150MG BASE	A212278	001	Feb 02, 2022	Jan	NEWA
AB		EQ 200MG BASE	A212278	002	Feb 02, 2022	Jan	NEWA
AB		EQ 300MG BASE	A212278	003	Feb 02, 2022	Jan	NEWA
REYATAZ							
	+ @ BRISTOL MYERS SQUIBB	EQ 150MG BASE	N021567	002	Jun 20, 2003	Apr	DISC

ATENOLOL

TABLET; ORAL						
ATENOLOL						
@ CHARTWELL RX	25MG	A 074265	001	Feb 28, 1994	Nov	CAHN
@	50MG	A 074265	002	Feb 28, 1994	Nov	CAHN
@	100MG	A 074265	003	Feb 28, 1994	Nov	CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL						
ATOMOXETINE HYDROCHLORIDE						
@	STRIDES PHARMA	10MG	A079021	001	Feb 18, 2021	Nov CAHN
@		18MG	A079021	002	Feb 18, 2021	Nov CAHN
@		25MG	A079021	003	Feb 18, 2021	Nov CAHN
@		40MG	A079021	004	Feb 18, 2021	Nov CAHN
@		60MG	A079021	005	Feb 18, 2021	Nov CAHN
@		80MG	A079021	006	Feb 18, 2021	Nov CAHN
@		100MG	A079021	007	Feb 18, 2021	Nov CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL						
ATORVASTATIN CALCIUM						
AB	AGNITIO	EQ 10MG BASE	A214969	001	Sep 02, 2021	Sep CAHN
AB		EQ 20MG BASE	A214969	002	Sep 02, 2021	Sep CAHN
AB		EQ 40MG BASE	A214969	003	Sep 02, 2021	Sep CAHN
AB		EQ 80MG BASE	A214969	004	Sep 02, 2021	Sep CAHN
AB	BIOCON PHARMA	EQ 10MG BASE	A216436	001	Nov 23, 2022	Nov NEWA
AB		EQ 20MG BASE	A216436	002	Nov 23, 2022	Nov NEWA
AB		EQ 40MG BASE	A216436	003	Nov 23, 2022	Nov NEWA
AB		EQ 80MG BASE	A216436	004	Nov 23, 2022	Nov NEWA
AB	DR REDDYS	EQ 10MG BASE	A214659	001	Jul 14, 2021	Aug CMFD
AB		EQ 20MG BASE	A214659	002	Jul 14, 2021	Aug CMFD
AB		EQ 40MG BASE	A214659	003	Jul 14, 2021	Aug CMFD
AB		EQ 80MG BASE	A214659	004	Jul 14, 2021	Aug CMFD
AB	LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022	Oct NEWA
AB		EQ 20MG BASE	A216848	002	Nov 03, 2022	Oct NEWA
AB		EQ 40MG BASE	A216848	003	Nov 03, 2022	Oct NEWA
AB		EQ 80MG BASE	A216848	004	Nov 03, 2022	Oct NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL							
LYPQOZET							
SCOV3		EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Sep	CTNA
		EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Sep	CMFD
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Sep	CTNA
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Sep	CMFD
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Sep	CTNA
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Sep	CMFD
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Sep	CTNA
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Sep	CMFD

ATOVAQUONESUSPENSION; ORAL
ATOVAQUONE

AB	CHARTWELL RX	750MG/5ML	A207833	001	Apr 28, 2017	Oct CAHN
----	--------------	-----------	---------	-----	--------------	----------

ATROPINESOLUTION; INTRAMUSCULAR
ATROPEN

+	MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	May CAHN
+		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	May CAHN
+		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	May CAHN
+		EQ 2MG SULFATE/0.7ML	N017106	001		May CAHN

ATROPINE SULFATESOLUTION; INTRAVENOUS
ATROPINE SULFATE

AP	+	ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	May CFTG
AP	+		1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020	May CFTG
AP		AM REGENT	0.4MG/ML (0.4MG/ML)	A216120	001	May 26, 2022	May NFTG
AP			1MG/ML (1MG/ML)	A216120	002	May 26, 2022	May NFTG
AP		AMNEAL	0.5MG/5ML (0.1MG/ML)	A215342	001	Jan 26, 2022	Jan NEWA
AP	+	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jan CMFD
AP		MEDEFIL INC	1MG/10ML (0.1MG/ML)	A214970	001	Nov 04, 2022	Oct NEWA

SOLUTION/DROPS; OPHTHALMIC
ATROPINE SULFATE

AT		AMNEAL	1%	A214752	001	Jul 14, 2022	Jul NEWA
	+	BAUSCH AND LOMB INC	1%	N213581	001	Mar 15, 2022	Jul CAHN
	+	PARAGON BIOTECK	1%	N213581	001	Mar 15, 2022	Jul NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	CHARTWELL RX	0.025MG; 2.5MG	A207128	001	Oct 21, 2020	Jun CAHN
	@ MAYNE PHARMA INC	0.025MG; 2.5MG	A210789	001	Jun 03, 2020	Jan DISC

ATROPINE; PRALIDOXIME CHLORIDEINJECTABLE; INTRAMUSCULAR
DUODOTE

+	MMT	2.1MG/0.7ML; 600MG/2ML	N021983	001	Sep 28, 2006	Jan CAHN
---	-----	------------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP		AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Jan NEWA
>A> AP		EUGIA PHARMA	100MG/VIAL	A215066	001	Dec 30, 2022	Dec NEWA
	@	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Nov DISC
		VIDAZA					
AP	+	BRISTOL-MYERS	100MG/VIAL	N050794	001	May 19, 2004	Oct CAHN

TABLET; ORAL
ONUREG

+	BRISTOL	200MG	N214120	001	Sep 01, 2020	Nov CAHN
+		300MG	N214120	002	Sep 01, 2020	Nov CAHN

AZELAIC ACID

GEL; TOPICAL

AZELAIC ACID

>A> AB		ENCUBE	15%	A208724	001	Nov 19, 2018	Dec CAHN
>D> AB		TOLMAR	15%	A208724	001	Nov 19, 2018	Dec CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

@ AKORN

0.05%

A203660	001	Nov 08, 2016	Aug DISC
---------	-----	--------------	----------

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

@ APOTEX INC

0.2055MG/SPRAY

A201846	001	Aug 31, 2012	May DISC
---------	-----	--------------	----------

@ AUROBINDO PHARMA LTD

0.2055MG/SPRAY

A212775	001	Nov 12, 2020	May DISC
---------	-----	--------------	----------

@ HIKMA

0.2055MG/SPRAY

A207243	001	Sep 22, 2017	May DISC
---------	-----	--------------	----------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

	AZILSARTAN MEDOXOMIL						
	@	LUPIN LTD	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Aug DISC
AB			EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Jul NFTG
	@		EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Aug DISC
AB			EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Jul NFTG
	EDARBI						
	+	AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Aug CTEC
AB	+		EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jul CFTG
	+		EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Mar CAHN
	+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Aug CTEC
AB	+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jul CFTG
	+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Mar CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR								
+	AZURITY	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20,	2011	Mar	CAHN
+	!	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20,	2011	Mar	CAHN

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN							
@ CHARTWELL RX	EQ 100MG BASE/5ML	A065488	001	May 15,	2015	Nov	CAHN
@	EQ 200MG BASE/5ML	A065488	002	May 15,	2015	Nov	CAHN
@ TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11,	2019	Sep	DISC

SOLUTION/DROPS; OPHTHALMIC

AZASITE							
+!	THEA PHARMA	1%	N050810	001	Apr 27, 2007	Apr	CAHN

TABLET; ORAL

AZITHROMYCIN										
	AB	ATLANTIDE	EQ 250MG BASE	A065404	001	Feb 11, 2008	Apr	CAHN		
	AB		EQ 500MG BASE	A065405	001	Feb 11, 2008	Apr	CAHN		
	AB		EQ 600MG BASE	A065302	003	Feb 11, 2008	Apr	CAHN		
>A>	AB	CHARTWELL RX	EQ 250MG BASE	A065404	001	Feb 11, 2008	Dec	CAHN		
>A>	AB		EQ 500MG BASE	A065405	001	Feb 11, 2008	Dec	CAHN		
>A>	AB		EQ 600MG BASE	A065302	003	Feb 11, 2008	Dec	CAHN		
>D>	AB	WOCKHARDT	EQ 250MG BASE	A065404	001	Feb 11, 2008	Dec	CAHN		
>D>	AB		EQ 500MG BASE	A065405	001	Feb 11, 2008	Dec	CAHN		
>D>	AB		EQ 600MG BASE	A065302	003	Feb 11, 2008	Dec	CAHN		
	AB	YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Jul	NEWA		

BACLOFEN

GRANULES; ORAL

LYVISPAH							
+	AMNEAL	5MG/PACKET	N215422	001	Nov 22, 2021	Feb	CAHN
+		10MG/PACKET	N215422	002	Nov 22, 2021	Feb	CAHN
+	!	20MG/PACKET	N215422	003	Nov 22, 2021	Feb	CAHN

INJECTABLE; INTRATHECAL

	BACLOFEN						
AP	AMNEAL	0.05MG/ML	A091193	001	May 03, 2016	Jun	CAHN
AP		0.5MG/ML	A091193	002	May 03, 2016	Jun	CAHN
AP		2MG/ML	A091193	003	May 03, 2016	Jun	CAHN

LIORESAL

AP		+! AMNEAL	0.05MG/ML	N020075	003	Nov 07, 1996	Feb CAHN
AP		+!	0.5MG/ML	N020075	001	Jun 17, 1992	Feb CAHN
AP		+!	2MG/ML	N020075	002	Jun 17, 1992	Feb CAHN

SUSPENSION; ORAL

FLEQSUVY							
+!	AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Feb	NEWA

TABLET; ORAL

	BACLOFEN						
>A>	@	APPCO	10MG	A090334	001	Feb 18, 2010	Dec CAHN
>A>	@		20MG	A090334	002	Feb 18, 2010	Dec CAHN
AB		MANKIND PHARMA	5MG	A215885	001	Jan 25, 2022	Jan NEWA
AB			10MG	A215885	002	Jan 25, 2022	Jan NEWA
AB			20MG	A215885	003	Jan 25, 2022	Jan NEWA
>D>	@	MYLAN PHARMS INC	10MG	A090334	001	Feb 18, 2010	Dec CAHN
>D>	@		20MG	A090334	002	Feb 18, 2010	Dec CAHN

BARICITINIBTABLET; ORAL
OLUMIANT

+	ELI LILLY AND CO	2MG	N207924	001	May 31, 2018	Nov	CHRS
+	!	4MG	N207924	003	May 10, 2022	Nov	CHRS
+		4MG	N207924	003	May 10, 2022	May	NEWA

BELINOSTATPOWDER; INTRAVENOUS
BELEODAQ

+	!	ACROTECH BIOPHARMA	500MG/VIAL	N206256	001	Jul 03, 2014	Oct	CAHN
---	---	--------------------	------------	---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDETABLET; ORAL
BENAZEPRIL HYDROCHLORIDE

AB	!	AUROBINDO PHARMA	40MG	A078212	003	May 22, 2008	Oct	CHRS
>D>	@	HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004	Dec	CMFD
>A>	AB		5MG	A076267	001	Feb 11, 2004	Dec	CMFD
>D>	@		10MG	A076267	002	Feb 11, 2004	Dec	CMFD
>A>	AB		10MG	A076267	002	Feb 11, 2004	Dec	CMFD
>D>	@		20MG	A076267	003	Feb 11, 2004	Dec	CMFD
>A>	AB		20MG	A076267	003	Feb 11, 2004	Dec	CMFD
>D>	@		40MG	A076267	004	Feb 11, 2004	Dec	CMFD
>A>	AB		40MG	A076267	004	Feb 11, 2004	Dec	CMFD
		LOTENSIN						
	+	@ VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Jun	DISC
AB	+		40MG	N019851	004	Jun 25, 1991	Oct	CHRS

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDETABLET; ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		ANI PHARMS	5MG; 6.25MG	A076342	001	Feb 11, 2004	Oct	CMFD
AB			10MG; 12.5MG	A076342	002	Feb 11, 2004	Oct	CMFD
AB			20MG; 12.5MG	A076342	003	Feb 11, 2004	Oct	CMFD
AB			20MG; 25MG	A076342	004	Feb 11, 2004	Oct	CMFD
AB		SANDOZ	5MG; 6.25MG	A076631	001	Feb 11, 2004	Nov	CTEC

BENDAMUSTINE HYDROCHLORIDEPOWDER; IV (INFUSION)
BENDAMUSTINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	25MG/VIAL	A205574	001	Dec 07, 2022	Nov	NFTG	
AP			100MG/VIAL	A205574	002	Dec 07, 2022	Nov	NFTG	
AP		DR REDDYS	25MG/VIAL	A205376	001	Dec 07, 2022	Nov	NFTG	
AP			100MG/VIAL	A205376	002	Dec 07, 2022	Nov	NFTG	
		TREANDA							
AP	+	!	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Nov	CFTG
AP	+	!		100MG/VIAL	N022249	001	Mar 20, 2008	Nov	CFTG
		SOLUTION; INTRAVENOUS							
>A>		BENDAMUSTINE HYDROCHLORIDE							
>A>	+	!	APOTEX	100MG/4ML (25MG/ML)	N215033	001	Dec 07, 2022	Dec	NEWA
>A>	+	!	BAXTER HLTHCARE CORP	100MG/4ML (25MG/ML)	N216078	001	Dec 15, 2022	Dec	NEWA
>A>	+	!	HOSPIRA	25MG/ML (25MG/ML)	N211530	001	Dec 15, 2022	Dec	NEWA
>A>	+	!		100MG/4ML (25MG/ML)	N211530	002	Dec 15, 2022	Dec	NEWA
>A>	+	!		200MG/8ML (25MG/ML)	N211530	003	Dec 15, 2022	Dec	NEWA
>A>		VIVIMUSTA							
>A>	+	!	SLAYBACK PHARMA LLC	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022	Dec	NEWA

BENZONATATECAPSULE; ORAL
BENZONATATE

AA		ACELLA	100MG	A091310	001	Jan 16, 2015	Jan	CAHN
AA			200MG	A091310	002	Jan 16, 2015	Jan	CAHN
AA		CHARTWELL RX	100MG	A210562	001	Nov 09, 2018	Oct	CAHN
AA			150MG	A210562	002	Nov 09, 2018	Oct	CAHN
AA			200MG	A210562	003	Nov 09, 2018	Oct	CAHN
AA	!	THEPHARMANETWORK LLC	100MG	A040627	002	Mar 30, 2007	Jan	CMS1
AA	!		150MG	A040627	003	Sep 24, 2014	Jan	CMS1
AA	!		200MG	A040627	002	Jul 25, 2007	Mar	CMS1

BENZOYL PEROXIDECREAM;TOPICAL
EPSOLAY

+!	GALDERMA LABS LP	5%	N214510	001	Apr 22, 2022	Jun CAHN
+!	SOL GEL TECHNOLOGIES	5%	N214510	001	Apr 22, 2022	Apr NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL;TOPICAL
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>D>	@	ANDA REPOSITORY	2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019	Dec CAHN
>A>	@	ENCUBE	2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019	Dec CAHN

BENZOYL PEROXIDE; ERYTHROMYCINGEL;TOPICAL
ERYTHROMYCIN AND BENZOYL PEROXIDE
@ ENCUBE 5%;3%

A065112 001 Mar 29, 2004 Jul CAHN

BENZOYL PEROXIDE; TRETINOINCREAM;TOPICAL
TWYNEO

+!	GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021	Mar CMFD
+	@	3%;0.1%	N214902	001	Jul 26, 2021	Feb CAHN
+	@	SOL-GEL TECHNOLOGIES 3%;0.1%	N214902	001	Jul 26, 2021	Jan DISC

BENZPHETAMINE HYDROCHLORIDETABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE

	CHARTWELL	25MG	A090473	001	Sep 15, 2010	Apr CAHN
AA		50MG	A090473	002	Sep 15, 2010	Apr CAHN
	MIKART	25MG	A090473	001	Sep 15, 2010	Mar CAHN
AA		50MG	A090473	002	Sep 15, 2010	Mar CAHN

BENZTROPINE MESYLATEINJECTABLE;INJECTION
BENZTROPINE MESYLATE

AP	!	HIKMA FARMACEUTICA	1MG/ML	A090287	001	Aug 31, 2009	Mar CHRS
		COGENTIN					
	+	@ AKORN	1MG/ML	N012015	001		Mar DISC

TABLET;ORAL

BENZTROPINE MESYLATE

@	AIPING PHARM INC	0.5MG	A040103	001	Dec 12, 1996	Nov CAHN
@		1MG	A040103	002	Dec 12, 1996	Nov CAHN
@		2MG	A040103	003	Dec 12, 1996	Nov CAHN

BETAINEFOR SOLUTION;ORAL
BETAINE

AB		ETON	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Sep CAHN
AB		LUKARE MEDICAL LLC	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Jan NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

@	AKORN	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Sep DISC
---	-------	---------------	---------	-----	--------------	----------

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		PAI HOLDINGS PHARM	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Aug CAHN
----	--	--------------------	---------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		PADAGIS ISRAEL	EQ 0.05% BASE	A215847	001	Apr 12, 2022	Apr NEWA
AB		TASMAN PHARMA	EQ 0.05% BASE	A215186	001	Feb 18, 2022	Feb NEWA

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		PAI HOLDINGS PHARM	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Aug CAHN
----	--	--------------------	---------------	---------	-----	--------------	----------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL
 BETAMETHASONE VALERATE
 @ NOVAST LABS 0.12%

A207144 001 May 24, 2017 Aug CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL
 BETHANECHOL CHLORIDE

AA	AIPING LIFE SCI	5MG	A040728	002	Oct 26, 2007	Oct CAHN
AA		10MG	A040728	003	Oct 26, 2007	Oct CAHN
AA		25MG	A040728	004	Oct 26, 2007	Oct CAHN
AA		50MG	A040728	001	Oct 26, 2007	Oct CAHN
>D> AA	LANNETT CO INC	5MG	A040677	002	Mar 27, 2008	Dec DISC
>A>	@	5MG	A040677	002	Mar 27, 2008	Dec DISC
>D> AA		10MG	A040677	003	Mar 27, 2008	Dec DISC
>A>	@	10MG	A040677	003	Mar 27, 2008	Dec DISC
>D> AA		25MG	A040677	004	Mar 27, 2008	Dec DISC
>A>	@	25MG	A040677	004	Mar 27, 2008	Dec DISC
>D> AA		50MG	A040677	001	Mar 27, 2008	Dec DISC
>A>	@	50MG	A040677	001	Mar 27, 2008	Dec DISC

BEXAROTENE

GEL; TOPICAL
 BEXAROTENE

AB	AMNEAL	1%	A215398	001	Apr 27, 2022	Apr NFTG
AB	+! BAUSCH	1%	N021056	001	Jun 28, 2000	Apr CFTG

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC
 BIMATOPROST

AT	EUGIA PHARMA	0.03%	A205537	001	Oct 06, 2022	Sep NEWA
----	--------------	-------	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET; ORAL
 BISOPROLOL FUMARATE

AB	CADILA	5MG	A215680	001	Jul 25, 2022	Jul NEWA
AB		10MG	A215680	002	Jul 25, 2022	Jul NEWA
AB	UNITED RES LABS	5MG	A075474	001	Oct 25, 2002	Apr CAHN
AB		10MG	A075474	002	Oct 25, 2002	Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	CADILA	2.5MG; 6.25MG	A215666	001	Nov 04, 2022	Oct NEWA
AB		5MG; 6.25MG	A215666	002	Nov 04, 2022	Oct NEWA
AB		10MG; 6.25MG	A215666	003	Nov 04, 2022	Oct NEWA
	@ CHARTWELL RX	2.5MG; 6.25MG	A075527	001	Sep 25, 2000	Nov CAHN
	@	5MG; 6.25MG	A075527	003	Sep 25, 2000	Nov CAHN
	@	10MG; 6.25MG	A075527	002	Sep 25, 2000	Nov CAHN
AB	GLENMARK PHARMS LTD	2.5MG; 6.25MG	A215995	001	Jan 26, 2022	Jan NEWA
AB		5MG; 6.25MG	A215995	002	Jan 26, 2022	Jan NEWA
AB		10MG; 6.25MG	A215995	003	Jan 26, 2022	Jan NEWA

BIVALIRUDIN

INJECTABLE; INTRAVENOUS
 BIVALIRUDIN

AP	MEITHEAL	250MG/VIAL	A091602	001	Jul 16, 2018	Apr CAHN
	SOLUTION; INTRAVENOUS					
	BIVALIRUDIN IN 0.9% SODIUM CHLORIDE					
	+ @ BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Oct DISC
	+ @	500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Oct DISC

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
 BORTEZOMIB

AP	ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022	Jul NEWA
AP	APOTEX	3.5MG/VIAL	A205533	001	May 02, 2022	Apr NFTG
AP	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	Apr NFTG
AP	DR REDDYS	3.5MG/VIAL	A202963	001	Jul 26, 2022	Jul NEWA
AP	EUGIA PHARMA	3.5MG/VIAL	A212825	001	May 02, 2022	Apr NFTG

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP	FRESENIUS KABI USA	3.5MG/VIAL	A209659	001	May 02, 2022	Apr	NFTG
AP	HOSPIRA	3.5MG/VIAL	A208460	001	Jul 26, 2022	Jul	NEWA
AP	JIANGSU HANSON PHARM	3.5MG/VIAL	A215011	001	Jul 26, 2022	Jul	NEWA
AP	KINDOS	3.5MG/VIAL	A212958	001	Jul 26, 2022	Jul	NEWA
AP	MEITHEAL	3.5MG/VIAL	A212958	001	Jul 26, 2022	Sep	CAHN
AP	MSN	3.5MG/VIAL	A209622	001	Jul 26, 2022	Jul	NEWA
	@ MYLAN LABS LTD	3.5MG/VIAL	A205160	001	Oct 31, 2022	Nov	DISC
AP		3.5MG/VIAL	A205160	001	Oct 31, 2022	Oct	NEWA
AP	PHARMASCIENCE INC	3.5MG/VIAL	A208392	001	May 02, 2022	Apr	NFTG
AP	QILU PHARM HAINAN	3.5MG/VIAL	A210824	001	May 02, 2022	Apr	NFTG
AP	SANDOZ INC	3.5MG/VIAL	A203654	001	Jul 26, 2022	Jul	NEWA
	@ TEVA PHARMS USA	3.5MG/VIAL	A205857	001	May 02, 2022	Oct	DISC
AP		3.5MG/VIAL	A205857	001	May 02, 2022	Apr	NFTG
AP	WAVERLEY PHARMA INC	3.5MG/VIAL	A211898	001	Oct 11, 2022	Sep	NEWA
AP	ZYDUS PHARMS	3.5MG/VIAL	A210204	001	May 02, 2022	Apr	NFTG

VELCADE

AP	+! TAKEDA PHARMS USA	3.5MG/VIAL	N021602	001	May 13, 2003	Apr	CFTG
----	----------------------	------------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

+!	HOSPIRA	1MG/VIAL	N209191	001	May 02, 2022	May	NEWA
+!		2.5MG/VIAL	N209191	002	May 02, 2022	May	NEWA

SOLUTION; INTRAVENOUS

BORTEZOMIB

+!	ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML)	N215441	001	Jul 26, 2022	Jul	NEWA
+!		3.5MG/1.4ML (2.5MG/ML)	N215441	002	Jul 26, 2022	Jul	NEWA
+	@ MAIA PHARMS INC	3.5MG/3.5ML (1MG/ML)	N215331	001	Jul 27, 2022	Oct	DISC
+!		3.5MG/3.5ML (1MG/ML)	N215331	001	Jul 27, 2022	Jul	NEWA
+!		3.5MG/1.4ML (2.5MG/ML)	N215331	002	Jul 27, 2022	Jul	NEWA

BOSENTAN

TABLET; ORAL

BOSENTAN

	@ CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020	Mar	CAHN
	@	125MG	A210342	002	Jan 03, 2020	Mar	CAHN

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLE

>D>	AB	SANDOZ INC	0.25MG	A213570	001	Sep 26, 2022	Dec	DISC
>A>		@	0.25MG	A213570	001	Sep 26, 2022	Dec	DISC
	AB		0.25MG	A213570	001	Sep 26, 2022	Sep	NEWA
>D>	AB		0.5MG	A213570	002	Sep 26, 2022	Dec	DISC
>A>		@	0.5MG	A213570	002	Sep 26, 2022	Dec	DISC
	AB		0.5MG	A213570	002	Sep 26, 2022	Sep	NEWA
>D>	AB		1MG	A213570	003	Sep 26, 2022	Dec	DISC
>A>		@	1MG	A213570	003	Sep 26, 2022	Dec	DISC
	AB		1MG	A213570	003	Sep 26, 2022	Sep	NEWA
>D>	AB		2MG	A213570	004	Sep 26, 2022	Dec	DISC
>A>		@	2MG	A213570	004	Sep 26, 2022	Dec	DISC
	AB		2MG	A213570	004	Sep 26, 2022	Sep	NEWA
>D>	AB		3MG	A213570	005	Sep 26, 2022	Dec	DISC
>A>		@	3MG	A213570	005	Sep 26, 2022	Dec	DISC
	AB		3MG	A213570	005	Sep 26, 2022	Sep	NEWA
>D>	AB		4MG	A213570	006	Sep 26, 2022	Dec	DISC
>A>		@	4MG	A213570	006	Sep 26, 2022	Dec	DISC
	AB		4MG	A213570	006	Sep 26, 2022	Sep	NEWA
	AB	TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Aug	NFTG
	AB		0.5MG	A213692	002	Aug 11, 2022	Aug	NFTG
	AB		1MG	A213692	003	Aug 11, 2022	Aug	NFTG
	AB		2MG	A213692	004	Aug 11, 2022	Aug	NFTG
	AB		3MG	A213692	005	Aug 11, 2022	Aug	NFTG
	AB		4MG	A213692	006	Aug 11, 2022	Aug	NFTG
>A>	AB	ZYDUS PHARMS	0.25MG	A213660	001	Jan 10, 2023	Dec	NEWA
>A>	AB		0.5MG	A213660	002	Jan 10, 2023	Dec	NEWA
>A>	AB		1MG	A213660	003	Jan 10, 2023	Dec	NEWA
>A>	AB		2MG	A213660	004	Jan 10, 2023	Dec	NEWA
>A>	AB		3MG	A213660	005	Jan 10, 2023	Dec	NEWA
>A>	AB		4MG	A213660	006	Jan 10, 2023	Dec	NEWA

REXULTI

AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Aug	CFTG
AB	+		0.5MG	N205422	002	Jul 10, 2015	Aug	CFTG

TABLET;ORAL
REXULTI

AB	+	1MG	N205422	003	Jul 10, 2015	Aug CFTG
AB	+	2MG	N205422	004	Jul 10, 2015	Aug CFTG
AB	+	3MG	N205422	005	Jul 10, 2015	Aug CFTG
AB	+	4MG	N205422	006	Jul 10, 2015	Aug CFTG

BRIMONIDINE TARTRATE

GEL;TOPICAL

BRIMONIDINE TARTRATE

AB		PADAGIS ISRAEL	EQ 0.33% BASE	A209158	001	Sep 23, 2021	Nov CMFD
	@		EQ 0.33% BASE	A209158	001	Sep 23, 2021	Apr DISC
		MIRVASO					
AB	+	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013	Nov CTEC
	+		EQ 0.33% BASE	N204708	001	Aug 23, 2013	Apr CTEC

SOLUTION/DROPS;OPHTHALMIC

ALPHAGAN P

>D>	+	ALLERGAN	0.1%	N021770	001	Aug 19, 2005	Dec CFTG
>A> AB	+		0.1%	N021770	001	Aug 19, 2005	Dec CFTG
		BRIMONIDINE TARTRATE					
>A> AB		APOTEX	0.1%	A078480	001	Dec 21, 2022	Dec NFTG
AT			0.15%	A078479	001	Jan 31, 2022	Jan NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB		AKORN	0.2%;EQ 0.5% BASE	A091086	001	Oct 31, 2022	Oct NEWA
AB		APOTEX INC	0.2%;EQ 0.5% BASE	A091442	001	Apr 20, 2022	Apr NEWA
AB		SANDOZ INC	0.2%;EQ 0.5% BASE	A091087	001	Apr 04, 2022	Mar NFTG
>A> AB		UPSHER SMITH LABS	0.2%;EQ 0.5% BASE	A215598	001	Dec 12, 2022	Dec NEWA
AB		WATSON LABS TEVA	0.2%;EQ 0.5% BASE	A201949	001	Oct 04, 2022	Sep NEWA
		COMBIGAN					
AB	+	ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007	Mar CFTG

BRINCIDOFIVIR

SUSPENSION;ORAL

TEMBEXA

	+	EMERGENT BIODEFENSE	10MG/ML	N214460	001	Jun 04, 2021	Sep CAHN
		TABLET;ORAL					
		TEMBEXA					
	+	EMERGENT BIODEFENSE	100MG	N214461	001	Jun 04, 2021	Sep CAHN

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

BRINZOLAMIDE

AB		BAUSCH AND LOMB	1%	A204884	001	Aug 18, 2021	Mar CAHN
----	--	-----------------	----	---------	-----	--------------	----------

BRIVARACETAM

TABLET;ORAL

BRIVARACETAM

>A> AB		AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Dec NEWA
>A> AB			100MG	A214848	002	Jan 06, 2023	Dec NEWA
>A> AB		LUPIN LTD	10MG	A214918	001	Dec 20, 2022	Dec NEWA
>A> AB			25MG	A214918	002	Dec 20, 2022	Dec NEWA
>A> AB			50MG	A214918	003	Dec 20, 2022	Dec NEWA
>A> AB			75MG	A214918	004	Dec 20, 2022	Dec NEWA
>A> AB			100MG	A214918	005	Dec 20, 2022	Dec NEWA
	@	SUNSHINE	10MG	A214748	001	Jun 09, 2022	Aug DISC
AB			10MG	A214748	001	Jun 09, 2022	Jun NFTG
	@		25MG	A214748	002	Jun 09, 2022	Aug DISC
AB			25MG	A214748	002	Jun 09, 2022	Jun NFTG
	@		50MG	A214748	003	Jun 09, 2022	Aug DISC
AB			50MG	A214748	003	Jun 09, 2022	Jun NFTG
	@		75MG	A214748	004	Jun 09, 2022	Aug DISC
AB			75MG	A214748	004	Jun 09, 2022	Jun NFTG
	@		100MG	A214748	005	Jun 09, 2022	Aug DISC
AB			100MG	A214748	005	Jun 09, 2022	Jun NFTG
	@	ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022	Nov DISC
AB			10MG	A214501	001	Oct 03, 2022	Sep NEWA
	@		25MG	A214501	002	Oct 03, 2022	Nov DISC
AB			25MG	A214501	002	Oct 03, 2022	Sep NEWA
	@		50MG	A214501	003	Oct 03, 2022	Nov DISC

TABLET;ORAL
BRIVARACETAM

AB			50MG	A214501	003	Oct 03, 2022	Sep NEWA
	@		75MG	A214501	004	Oct 03, 2022	Nov DISC
AB			75MG	A214501	004	Oct 03, 2022	Sep NEWA
	@		100MG	A214501	005	Oct 03, 2022	Nov DISC
AB			100MG	A214501	005	Oct 03, 2022	Sep NEWA
BRIVIACT							
>D>	+	UCB INC	10MG	N205836	001	May 12, 2016	Dec CTEC
>A>	AB	+	10MG	N205836	001	May 12, 2016	Dec CTEC
		+	10MG	N205836	001	May 12, 2016	Nov CTEC
	AB	+	10MG	N205836	001	May 12, 2016	Sep CTEC
		+	10MG	N205836	001	May 12, 2016	Aug CTEC
	AB	+	10MG	N205836	001	May 12, 2016	Jun CFTG
>D>		+	25MG	N205836	002	May 12, 2016	Dec CTEC
>A>	AB	+	25MG	N205836	002	May 12, 2016	Dec CTEC
		+	25MG	N205836	002	May 12, 2016	Nov CTEC
	AB	+	25MG	N205836	002	May 12, 2016	Sep CTEC
		+	25MG	N205836	002	May 12, 2016	Aug CTEC
	AB	+	25MG	N205836	002	May 12, 2016	Jun CFTG
>D>		+	50MG	N205836	003	May 12, 2016	Dec CTEC
>A>	AB	+	50MG	N205836	003	May 12, 2016	Dec CTEC
		+	50MG	N205836	003	May 12, 2016	Nov CTEC
	AB	+	50MG	N205836	003	May 12, 2016	Sep CTEC
		+	50MG	N205836	003	May 12, 2016	Aug CTEC
	AB	+	50MG	N205836	003	May 12, 2016	Jun CFTG
>D>		+	75MG	N205836	004	May 12, 2016	Dec CTEC
>A>	AB	+	75MG	N205836	004	May 12, 2016	Dec CTEC
		+	75MG	N205836	004	May 12, 2016	Nov CTEC
	AB	+	75MG	N205836	004	May 12, 2016	Sep CTEC
		+	75MG	N205836	004	May 12, 2016	Aug CTEC
	AB	+	75MG	N205836	004	May 12, 2016	Jun CFTG
>D>		+!	100MG	N205836	005	May 12, 2016	Dec CTEC
>A>	AB	+!	100MG	N205836	005	May 12, 2016	Dec CTEC
		+!	100MG	N205836	005	May 12, 2016	Nov CTEC
	AB	+!	100MG	N205836	005	May 12, 2016	Sep CTEC
		+!	100MG	N205836	005	May 12, 2016	Aug CTEC
	AB	+!	100MG	N205836	005	May 12, 2016	Jun CFTG

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

	@	CHARTWELL RX	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Apr CAHN
AT2		EUGIA PHARMA	EQ 0.09% ACID	A204813	001	Mar 18, 2022	Mar NEWA
	@	VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Feb CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		PHARM ASSOC	2MG/5ML;10MG/5ML;30MG/5ML	A202940	001	Jul 21, 2014	Oct CMFD
	@	RHODES PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202955	001	Nov 05, 2020	Jun DISC

BUDESONIDE

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

	@	NATCO	3MG	A206724	001	Nov 23, 2016	Jan CAHN
	@	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Jul DISC
		ORTIKOS					
	+	SUN PHARM INDS INC	6MG	N211929	001	Jun 13, 2019	Jul CDFR
	+	!	9MG	N211929	002	Jun 13, 2019	Jul CDFR

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

BREYNA

AB		MYLAN	0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Jul CTNA
AB			0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Mar NFTG
AB			0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Jul CTNA
AB			0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Mar NFTG

SYMBICORT

AB	+	!	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Mar CFTG
AB	+	!		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Mar CFTG

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE

AP	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Feb CMFD
AP	GLAND PHARMA LTD	0.25MG/ML	A216434	001	May 26, 2022	May NEWA
AP	MSN	0.25MG/ML	A215364	001	Aug 04, 2022	Jul NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE; INFILTRATION
POSIMIR

+	DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CMFD
+	INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

	@ CIVICA	0.5%	A211096	001	Feb 19, 2019	Apr CAHN
	@ NOVOCOL PHARM	0.5%	A211096	001	Feb 19, 2019	Mar CAHN
	@ STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Feb CAHN
	@	0.5%	A091503	002	Oct 18, 2011	Feb CAHN
	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@ STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Feb CAHN
	@	0.5%	A091487	001	Oct 18, 2011	Feb CAHN
	@	0.75%	A091487	003	Oct 18, 2011	Feb CAHN
	SENSORCAINE					
AP	+ FRESSENIUS KABI USA	0.25%	N018304	001		Oct CRLD
AP	+	0.5%	N018304	002		Oct CRLD
AP	+	0.75%	N018304	003		Oct CRLD

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
SENSORCAINE

AP	+ FRESSENIUS KABI USA	0.5%; 0.0091MG/ML	N018304	004	Sep 02, 1983	Oct CRLD
AP	+	0.75%; 0.0091MG/ML	N018304	005	Sep 02, 1983	Oct CRLD

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE; PERIARTICULAR
ZYNRELEF KIT

+	@ HERON THERAPY INC	60MG/2.3ML (29.25MG/ML); 1.8MG/2.3ML	N211988	001	May 12, 2021	Apr DISC
+	@	300MG/10.5ML (29.25MG/ML); 9MG/10.5ML	N211988	003	May 12, 2021	Apr DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL
BUPRENORPHINE

AB	ALVOGEN	5MCG/HR	A207490	001	May 17, 2022	May CAHN
AB		10MCG/HR	A207490	002	May 17, 2022	May CAHN
AB		15MCG/HR	A207490	003	May 17, 2022	May CAHN
AB		20MCG/HR	A207490	004	May 17, 2022	May CAHN
AB	ALVOGEN PINE BROOK	5MCG/HR	A207490	001	May 17, 2022	May NEWA
AB		10MCG/HR	A207490	002	May 17, 2022	May NEWA
AB		15MCG/HR	A207490	003	May 17, 2022	May NEWA
AB		20MCG/HR	A207490	004	May 17, 2022	May NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL
BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CTEC
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CTEC
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CTEC
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CTEC
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CTEC
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CTEC
+		EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CTEC

BUPRENORPHINE HYDROCHLORIDE

@	ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jan DISC
@		EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jan DISC
@		EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jan DISC
@		EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jan DISC
@		EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jan DISC
@		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jan DISC

FILM;BUCCAL

BUPRENORPHINE HYDROCHLORIDE

@ EQ 0.9MG BASE

A211594 007 Aug 03, 2021 Jan DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB AVEVA

EQ 8MG BASE;EQ 2MG BASE

A212756 001 Jun 02, 2022 May NEWA

AB

EQ 12MG BASE;EQ 3MG BASE

A212756 002 Jun 02, 2022 May NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>D> AB ! ACTAVIS ELIZABETH

EQ 8MG BASE;EQ 2MG BASE

A091422 002 Feb 22, 2013 Dec CHRS

>A> AB

EQ 8MG BASE;EQ 2MG BASE

A091422 002 Feb 22, 2013 Dec CHRS

>D> AB HIKMA

EQ 8MG BASE;EQ 2MG BASE

A203326 002 Jun 27, 2014 Dec CHRS

>A> AB !

EQ 8MG BASE;EQ 2MG BASE

A203326 002 Jun 27, 2014 Dec CHRS

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3 GRANULES

150MG

A215568 001 Feb 02, 2022 Oct CMFD

@

150MG

A215568 001 Feb 02, 2022 Jul DISC

AB3

150MG

A215568 001 Feb 02, 2022 Jan NEWA

AB3

300MG

A215568 002 Feb 02, 2022 Oct CMFD

@

300MG

A215568 002 Feb 02, 2022 Jul DISC

AB3

300MG

A215568 002 Feb 02, 2022 Jan NEWA

AB3 GRAVITI PHARMS

150MG

A211020 001 Jan 28, 2019 Sep CAHN

AB3

300MG

A211020 002 Jan 28, 2019 Sep CAHN

AB3 WOCKHARDT LTD

300MG

A202189 002 Jan 28, 2022 Feb NEWA

>A> AB2 YICHANG HUMANWELL

150MG

A216766 001 Jan 09, 2023 Dec NEWA

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

AUVELITY

+! AXSOME

105MG;45MG

N215430 001 Aug 18, 2022 Aug NEWA

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL

BUSPAR

+ @ BRISTOL MYERS SQUIBB

5MG

N021190 001 Dec 20, 2000 Sep CRLD

+ @

7.5MG

N021190 002 Dec 20, 2000 Sep CRLD

+ @

10MG

N021190 003 Dec 20, 2000 Sep CRLD

+ @

15MG

N021190 004 Dec 20, 2000 Sep CRLD

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB ! ACCORD HLTHCARE

15MG

A202557 004 Dec 30, 2014 Feb CHRS

@ MYLAN

7.5MG

A075467 002 Mar 28, 2001 Feb DISC

AB TEVA

15MG

A075022 003 Feb 28, 2002 Feb CHRS

BUSULFAN

TABLET;ORAL

MYLERAN

+! WOODWARD SPECL

2MG

N009386 001 Apr CAHN

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL

+ @ ACCORD HLTHCARE

60MG/3ML (20MG/ML)

N207949 001 Dec 29, 2021 Jul DISC

AP 60MG/1.5ML (40MG/ML)

A207693 001 Oct 26, 2022 Oct NEWA

@ BRECKENRIDGE

60MG/1.5ML (40MG/ML)

A207619 001 Jun 23, 2022 Jul DISC

AP 60MG/1.5ML (40MG/ML)

A207619 001 Jun 23, 2022 Jun NFTG

JEVTANA KIT

AP +! SANOFI AVENTIS US

60MG/1.5ML (40MG/ML)

N201023 001 Jun 17, 2010 Oct CTEC

+!

60MG/1.5ML (40MG/ML)

N201023 001 Jun 17, 2010 Jul CTEC

AP +!

60MG/1.5ML (40MG/ML)

N201023 001 Jun 17, 2010 Jun CFTG

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB STRIDES PHARMA

0.5MG

A076310 001 Dec 29, 2005 Mar CMFD

CAFFEINE CITRATE

SOLUTION; ORAL

CAFCIT

	+ @ HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan DISC
	CAFFEINE CITRATE					
AA	! EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Jan CHRS

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

	+! COSETTE	100MG; 2MG	A086557	001	Oct 04, 1983	Jul CRLD
--	------------	------------	---------	-----	--------------	----------

CALCIPOTRIENE

OINTMENT; TOPICAL

CALCIPOTRIENE

AB	! GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	Sep CTEC
	DOVONEX					
AB	+ LEO PHARMA AS	0.005%	N020273	001	Dec 29, 1993	Sep CMFD

CALCITONIN SALMON

SPRAY, METERED; NASAL

CALCITONIN-SALMON

	! APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul CTEC
	@ PAR PHARM	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S

	@ FRESENIUS KABI USA	20MG/100ML; 5GM/100ML; 30MG/100ML; 60	A210332	001	Mar 28, 2022	Sep DISC
		0MG/100ML; 310MG/100ML				
AP		20MG/100ML; 5GM/100ML; 30MG/100ML; 60	A210332	001	Mar 28, 2022	Mar NEWA
		0MG/100ML; 310MG/100ML				
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
	@ FRESENIUS KABI USA	20MG/100ML; 5GM/100ML; 179MG/100ML; 6	A211428	001	Nov 09, 2021	Apr DISC
		00MG/100ML; 310MG/100ML				

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT

	@ AKORN	0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG	A075503	001	Sep 27, 2006	Aug DISC
		/ML; 6.4MG/ML; 1.7MG/ML				

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

>D>	@ FRESENIUS KABI USA	17.6MG/100ML; 325.3MG/100ML; 119.3MG	A214623	001	Feb 18, 2022	Dec CMFD
		/100ML; 643MG/100ML				
>A> AT		17.6MG/100ML; 325.3MG/100ML; 119.3MG	A214623	001	Feb 18, 2022	Dec CMFD
		/100ML; 643MG/100ML				
	@	17.6MG/100ML; 325.3MG/100ML; 119.3MG	A214623	001	Feb 18, 2022	Aug DISC
		/100ML; 643MG/100ML				
AT		17.6MG/100ML; 325.3MG/100ML; 119.3MG	A214623	001	Feb 18, 2022	Feb NEWA
		/100ML; 643MG/100ML				

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS

CALCIUM GLUCONATE

AP	+! FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	Oct CFTG
AP	NIVAGEN PHARMS INC	1GM/10ML (100MG/ML)	A213071	001	Oct 14, 2022	Oct NFTG

CAPECITABINE

TABLET; ORAL

CAPECITABINE

	@ AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Sep DISC
	@	500MG	A204741	002	Feb 28, 2017	Sep DISC

CARBAMAZEPINESUSPENSION; ORAL
CARBAMAZEPINE

AB	NOVITIUM PHARMA	100MG/5ML	A214277	001	Oct 06, 2022	Sep NEWA
----	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL
CARBAMAZEPINE

AB	UNICHEM	200MG	A213284	001	Aug 22, 2022	Aug NEWA
	@ VGYAAN	200MG	A214328	001	Aug 16, 2021	Feb DISC

TABLET, CHEWABLE; ORAL
CARBAMAZEPINE

AB	TARO PHARM INDS	100MG	A075687	001	Oct 24, 2000	Aug CHRS
----	-----------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

>D>	AB	RICONPHARMA LLC	100MG	A216404	001	Dec 02, 2022	Dec DISC
>A>		@	100MG	A216404	001	Dec 02, 2022	Dec DISC
	AB		100MG	A216404	001	Dec 02, 2022	Nov NEWA
>D>	AB		200MG	A216404	002	Dec 02, 2022	Dec DISC
>A>		@	200MG	A216404	002	Dec 02, 2022	Dec DISC
	AB		200MG	A216404	002	Dec 02, 2022	Nov NEWA
>D>	AB		400MG	A216404	003	Dec 02, 2022	Dec DISC
>A>		@	400MG	A216404	003	Dec 02, 2022	Dec DISC
	AB		400MG	A216404	003	Dec 02, 2022	Nov NEWA
	AB	UMEDICA LABS PVT LTD	100MG	A216594	001	Aug 18, 2022	Aug NEWA
	AB		200MG	A216594	002	Aug 18, 2022	Aug NEWA
	AB		400MG	A216594	003	Aug 18, 2022	Aug NEWA
	AB	ZHEJIANG JIUZHOU	100MG	A215591	001	Mar 31, 2022	Mar NEWA
	AB		200MG	A215591	002	Mar 31, 2022	Mar NEWA
	AB		400MG	A215591	003	Mar 31, 2022	Mar NEWA

CARBIDOPATABLET; ORAL
CARBIDOPA

	@ ANI PHARMS	25MG	A203261	001	Mar 10, 2014	Jun DISC
--	--------------	------	---------	-----	--------------	----------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	RISING	12.5MG; 200MG; 50MG	A213212	001	Jan 25, 2022	Jan NEWA
AB		18.75MG; 200MG; 75MG	A213212	002	Jan 25, 2022	Jan NEWA
AB		25MG; 200MG; 100MG	A213212	003	Jan 25, 2022	Jan NEWA
AB		31.25MG; 200MG; 125MG	A213212	004	Jan 25, 2022	Jan NEWA
AB		37.5MG; 200MG; 150MG	A213212	005	Jan 25, 2022	Jan NEWA
AB		50MG; 200MG; 200MG	A213212	006	Jan 25, 2022	Jan NEWA
	STALEVO 125					
AB	+ ORION PHARMA	31.25MG; 200MG; 125MG	N021485	006	Aug 29, 2008	Jan CTEC
	STALEVO 200					
AB	+! ORION PHARMA	50MG; 200MG; 200MG	N021485	004	Aug 02, 2007	Jan CTEC
	STALEVO 50					
AB	+! ORION PHARMA	12.5MG; 200MG; 50MG	N021485	001	Jun 11, 2003	Jan CTEC
	STALEVO 75					
AB	+ ORION PHARMA	18.75MG; 200MG; 75MG	N021485	005	Aug 29, 2008	Jan CTEC

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	AUROBINDO PHARMA LTD	10MG; 100MG	A216537	001	Nov 28, 2022	Nov NEWA
AB		25MG; 100MG	A216537	002	Nov 28, 2022	Nov NEWA
AB		25MG; 250MG	A216537	003	Nov 28, 2022	Nov NEWA
AB	RUBICON	10MG; 100MG	A216505	001	Sep 21, 2022	Sep NEWA
AB		25MG; 100MG	A216505	002	Sep 21, 2022	Sep NEWA
AB		25MG; 250MG	A216505	003	Sep 21, 2022	Sep NEWA

CARBOPLATININJECTABLE; INTRAVENOUS
CARBOPLATIN

AP	TEYRO LABS	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Apr CAHN
AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Apr CAHN
AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Apr CAHN
AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Apr CAHN

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP	AMNEAL	EQ 0.25MG BASE/ML	A215337	001	Jan 27, 2022	Jan NEWA
AP	LONG GROVE PHARMS	EQ 0.25MG BASE/ML	A214499	001	Aug 09, 2022	Jul NEWA

CARGLUMIC ACID

TABLET, FOR SUSPENSION;ORAL

CARGLUMIC ACID

AB	NAVINTA LLC	200MG	A213395	001	Jun 22, 2022	Jun NEWA
----	-------------	-------	---------	-----	--------------	----------

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE

	@ SUN PHARM	EQ 1.5MG BASE	A213932	001	Sep 30, 2022	Nov DISC
AB		EQ 1.5MG BASE	A213932	001	Sep 30, 2022	Sep NEWA
	@	EQ 3MG BASE	A213932	002	Sep 30, 2022	Nov DISC
AB		EQ 3MG BASE	A213932	002	Sep 30, 2022	Sep NEWA
	@	EQ 4.5MG BASE	A213932	003	Sep 30, 2022	Nov DISC
AB		EQ 4.5MG BASE	A213932	003	Sep 30, 2022	Sep NEWA
	@	EQ 6MG BASE	A213932	004	Sep 30, 2022	Nov DISC
AB		EQ 6MG BASE	A213932	004	Sep 30, 2022	Sep NEWA
>D> AB	ZYDUS PHARMS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	Dec DISC
>A>	@	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	Dec DISC
AB		EQ 1.5MG BASE	A213984	001	Sep 09, 2022	Sep NFTG
>D> AB		EQ 3MG BASE	A213984	002	Sep 09, 2022	Dec DISC
>A>	@	EQ 3MG BASE	A213984	002	Sep 09, 2022	Dec DISC
AB		EQ 3MG BASE	A213984	002	Sep 09, 2022	Sep NFTG
>D> AB		EQ 4.5MG BASE	A213984	003	Sep 09, 2022	Dec DISC
>A>	@	EQ 4.5MG BASE	A213984	003	Sep 09, 2022	Dec DISC
AB		EQ 4.5MG BASE	A213984	003	Sep 09, 2022	Sep NFTG
>D> AB		EQ 6MG BASE	A213984	004	Sep 09, 2022	Dec DISC
>A>	@	EQ 6MG BASE	A213984	004	Sep 09, 2022	Dec DISC
AB		EQ 6MG BASE	A213984	004	Sep 09, 2022	Sep NFTG
	VRAYLAR					
>D> AB	+! ALLERGAN	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Dec CTEC
>A>	+!	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Dec CTEC
AB	+!	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Oct CHRS
AB	+	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep CFTG
>D> AB	+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Dec CTEC
>A>	+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Dec CTEC
AB	+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep CFTG
>D> AB	+	EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Dec CTEC
>A>	+	EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Dec CTEC
AB	+	EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep CFTG
>D> AB	+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Dec CTEC
>A>	+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Dec CTEC
AB	+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Oct CHRS
AB	+!	EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep CFTG

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA	CHARTWELL RX	350MG	A040245	001	Sep 08, 1997	Sep CAHN
AA	WANBANG BIOPHARMS	350MG	A081025	001	Apr 13, 1989	Jun CAHN

CARMUSTINE

IMPLANT;INTRACRANIAL

GLIADEL

+!	AZURITY	7.7MG	N020637	001	Sep 23, 1996	Jun CAHN
----	---------	-------	---------	-----	--------------	----------

INJECTABLE;INJECTION

CARMUSTINE

AP	INGENUS PHARMS LLC	100MG/VIAL	A211011	001	Jun 21, 2022	Jun NEWA
	Carmustine					
>A> AP	ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022	Dec NEWA
	POWDER;INTRAVENOUS					
	CARMUSTINE					
+!	ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022	May NEWA
+!		300MG/VIAL	N215000	002	May 16, 2022	May NEWA

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS
CASPOFUNGIN ACETATE

@ XELLIA PHARMS APS	50MG/VIAL	A205923	001	Jul 02, 2018	Oct DISC
@	70MG/VIAL	A205923	002	Jul 02, 2018	Oct DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@ CHARTWELL RX	EQ 500MG BASE	A065309	001	Sep 18, 2006	Nov CAHN
@ ORCHID HLTHCARE	EQ 500MG BASE	A065309	001	Sep 18, 2006	Mar DISC

FOR SUSPENSION; ORAL

CEFADROXIL

@ CHARTWELL RX	EQ 250MG BASE/5ML	A065307	002	Oct 16, 2006	Nov CAHN
@	EQ 500MG BASE/5ML	A065307	003	Oct 16, 2006	Nov CAHN
@ ORCHID HLTHCARE	EQ 250MG BASE/5ML	A065307	002	Oct 16, 2006	Mar DISC
@	EQ 500MG BASE/5ML	A065307	003	Oct 16, 2006	Mar DISC

TABLET; ORAL

CEFADROXIL

@ CHARTWELL RX	EQ 1GM BASE	A065301	001	Sep 18, 2006	Nov CAHN
@ ORCHID HLTHCARE	EQ 1GM BASE	A065301	001	Sep 18, 2006	Mar DISC
AB ! TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987	Mar CTEC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

QILU

EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Mar NEWA
------------------	---------	-----	--------------	----------

POWDER; INTRAVENOUS

CEFAZOLIN SODIUM

+! HIKMA	EQ 2GM BASE/VIAL	N216109	001	Oct 07, 2022	Oct NEWA
+!	EQ 3GM BASE/VIAL	N216109	002	Oct 07, 2022	Oct NEWA

CEFDINIR

FOR SUSPENSION; ORAL

CEFDINIR

AB ! AUROBINDO PHARMA	250MG/5ML	A065473	002	Dec 14, 2007	Oct CHRS
AB SANDOZ	250MG/5ML	A065337	002	Apr 06, 2007	Oct CHRS

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Jan CMFD
AP	EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Jan CMFD

CEFIXIME

CAPSULE; ORAL

CEFIXIME

AB ALKEM LABS LTD	400MG	A210574	001	Oct 09, 2018	Aug CTEC
	400MG	A210574	001	Oct 09, 2018	Aug CHRS
AB +! LUPIN LTD	400MG	N203195	001	Jun 01, 2012	Aug CMFD

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN IN PLASTIC CONTAINER

@ PAI HOLDINGS PHARM EQ 20MG BASE/ML

@ EQ 40MG BASE/ML

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

+ @ B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jul DISC
+ @	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jul DISC

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB ALKEM LABS LTD	EQ 100MG BASE	A210568	001	May 18, 2022	May NEWA
AB	EQ 200MG BASE	A210568	002	May 18, 2022	May NEWA

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

@ CHARTWELL RX	125MG/5ML	A065236	001	Dec 08, 2005	Mar CAHN
@	250MG/5ML	A065236	002	Dec 08, 2005	Mar CAHN
@ SANDOZ	125MG/5ML	A065257	001	Dec 08, 2005	Oct DISC
@	250MG/5ML	A065257	002	Dec 08, 2005	Oct DISC

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

CEFTAROLINE FOSAMIL

@ APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Mar DISC
@	600MG/VIAL	A208075	002	Sep 21, 2021	Mar DISC
TEFLARO					
+! ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Mar CTEC
+!	600MG/VIAL	N200327	002	Oct 29, 2010	Mar CTEC

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME IN DEXTROSE CONTAINER

+ @ B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011	Jul DISC
+ @	EQ 2GM BASE	N050823	002	Jun 13, 2011	Jul DISC

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ATLANTIDE	EQ 125MG BASE	A065166	001	Jul 29, 2005	Mar CAHN
AB		EQ 250MG BASE	A065166	002	Jul 29, 2005	Mar CAHN
AB		EQ 500MG BASE	A065166	003	Jul 29, 2005	Mar CAHN
>A> AB	CHARTWELL RX	EQ 125MG BASE	A065166	001	Jul 29, 2005	Dec CAHN
>A> AB		EQ 250MG BASE	A065166	002	Jul 29, 2005	Dec CAHN
>A> AB		EQ 500MG BASE	A065166	003	Jul 29, 2005	Dec CAHN
>D> AB	WOCKHARDT	EQ 125MG BASE	A065166	001	Jul 29, 2005	Dec CAHN
>D> AB		EQ 250MG BASE	A065166	002	Jul 29, 2005	Dec CAHN
>D> AB		EQ 500MG BASE	A065166	003	Jul 29, 2005	Dec CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

AP	+! PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN
AP	+!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB	+! PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb CAHN
----	-----------------------	--------------------	---------	-----	--------------	----------

CELECOXIB

CAPSULE; ORAL

CELECOXIB

@ UNICHEM	50MG	A213301	001	Jan 12, 2021	Feb DISC
@	100MG	A213301	002	Jan 12, 2021	Feb DISC
@	200MG	A213301	003	Jan 12, 2021	Feb DISC
@	400MG	A213301	004	Jan 12, 2021	Feb DISC

SOLUTION; ORAL

ELYXYB

+ @ BDSI	25MG/ML	N212157	001	May 05, 2020	Nov DISC
----------	---------	---------	-----	--------------	----------

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

@ CHARTWELL RX	EQ 125MG BASE/5ML	A065326	001	Jul 10, 2006	Nov CAHN
@	EQ 250MG BASE/5ML	A065326	002	Jul 10, 2006	Nov CAHN
@ ORCHID HLTHCARE	EQ 125MG BASE/5ML	A065326	001	Jul 10, 2006	Mar DISC
@	EQ 250MG BASE/5ML	A065326	002	Jul 10, 2006	Mar DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Jun CAHN
	@ TORRENT	5MG/5ML	A078870	001	Apr 27, 2009	Jun DISC
AA		5MG/5ML	A078870	001	Apr 27, 2009	May CMFD

CETRORELIXPOWDER; SUBCUTANEOUS
CETROTIDE

AP	+!	EMD SERONO INC	EQ 0.25MG BASE/VIAL	N021197	001	Aug 11, 2000	Aug CFTG
----	----	----------------	---------------------	---------	-----	--------------	----------

CETRORELIX ACETATEINJECTABLE; INJECTION
CETROTIDE

	@	EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Aug CAIN
POWDER; SUBCUTANEOUS							
CETRORELIX ACETATE							
AP		AKORN	EQ 0.25MG BASE/VIAL	A215737	001	Aug 12, 2022	Aug NFTG
CETROTIDE							
AP	+!	EMD SERONO INC	EQ 0.25MG BASE/VIAL	N021197	001	Aug 11, 2000	Aug CAIN
	+ @		EQ 3MG BASE/VIAL	N021197	002	Aug 11, 2000	Aug CRLD
	@		EQ 3MG BASE/VIAL	N021197	002	Aug 11, 2000	Aug CPOT
	@		EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Aug CDFR

CHLORAMBUCILTABLET; ORAL
LEUKERAN

	+!	WOODWARD SPECL	2MG	N010669	002		Apr CAHN
--	----	----------------	-----	---------	-----	--	----------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	!	BARR	25MG	A084769	001		Aug CHRS
AB		CHARTWELL RX	5MG	A084678	001		Jul CMFD
AB			10MG	A084041	001		Jul CMFD
AB			25MG	A084679	002		Jul CMFD
LIBRIUM							
AB	+	BAUSCH	25MG	A085475	001		Aug CHRS
AB	+!		25MG	A085475	001		Jul CAHN
AB	+	VALEANT PHARM INTL	5MG	A085461	001		Jan CRLD
AB	+		10MG	A085472	001		Jan CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB		CHARTWELL RX	5MG; 2.5MG	A213530	001	Oct 20, 2020	Jun CAHN
>A>	AB	COREPHARMA	5MG; 2.5MG	A215453	001	Jul 29, 2022	Dec CAHN
	AB		5MG; 2.5MG	A215453	001	Jul 29, 2022	Jul NEWA
	AB	MICRO LABS	5MG; 2.5MG	A215835	001	Jul 19, 2022	Jul NEWA
	@	TEVA PHARMS USA	5MG; 2.5MG	A211476	001	Nov 02, 2021	Jun DISC
>D>	AB	WESTMINSTER PHARMS	5MG; 2.5MG	A215453	001	Jul 29, 2022	Dec CAHN
	AB		5MG; 2.5MG	A215453	001	Jul 29, 2022	Sep CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

	@	AKORN	0.12%	A074356	001	May 07, 1996	Jul DISC
PERIOGARD							
	@	COLGATE PALMOLIVE CO	0.12%	A073695	001	Jan 14, 1994	Apr DISC
TABLET; DENTAL							
PERIOCHIP							
	+ @	DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998	Aug DISC

CHLOROPROCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

IHEEZO

	+!	HARROW EYE	3%	N216227	001	Sep 27, 2022	Nov CAHN
	+!	SINETICA SA	3%	N216227	001	Sep 27, 2022	Sep NEWA

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA		IMPAX LABS	250MG	A080880	001		Oct CMFD
AA			500MG	A040516	001	Aug 29, 2003	Oct CMFD

>D> CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

>D> SUSPENSION, EXTENDED RELEASE;ORAL

>D> TUZISTRA XR

>D>	+	!	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Dec DISC
>A>	+	@		EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Dec DISC
		+	!	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

@ ECR PHARMA EQ 4MG MALEATE;EQ 5MG BITARTRATE A077273 002 Sep 24, 2007 Feb DISC

@ EQ 8MG MALEATE;EQ 10MG BITARTRATE A077273 001 Sep 24, 2007 Feb DISC

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

>D>	AB		TRIS PHARMA INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091632	001	Oct 01, 2010	Dec CTEC
>A>		!		EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091632	001	Oct 01, 2010	Dec CTEC

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

>D>	AB	!	NEOS THERAP INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Dec DISC
>A>		@	NEOS THERAPS INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Dec DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP	+	!	WEST-WARD PHARMS INT	25MG/ML	A083329	001		Sep CRLD
----	---	---	----------------------	---------	---------	-----	--	----------

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	@	APPCO	10MG	A213590	001	Aug 31, 2020	Mar CAHN
	@		25MG	A213590	002	Aug 31, 2020	Mar CAHN
	@		50MG	A213590	003	Aug 31, 2020	Mar CAHN
	@		100MG	A213590	004	Aug 31, 2020	Mar CAHN
	@		200MG	A213590	005	Aug 31, 2020	Mar CAHN
AB		MSN	25MG	A214827	001	Jan 27, 2022	Jan NEWA
AB			50MG	A214827	002	Jan 27, 2022	Jan NEWA
AB			100MG	A214827	003	Jan 27, 2022	Jan NEWA
AB			200MG	A214827	004	Jan 27, 2022	Jan NEWA
AB		ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Nov CAHN
AB			25MG	A212630	002	Nov 29, 2021	Nov CAHN
AB			50MG	A212630	003	Nov 29, 2021	Nov CAHN
AB			100MG	A212630	004	Nov 29, 2021	Nov CAHN
AB			200MG	A212630	005	Nov 29, 2021	Nov CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		ALEMBIC PHARMS	25MG	A216262	001	Aug 26, 2022	Aug NEWA
AB			50MG	A216262	002	Aug 26, 2022	Aug NEWA
AB		CHARTWELL RX	25MG	A211063	001	Feb 26, 2019	Jan CAHN
AB			50MG	A211063	002	Feb 26, 2019	Jan CAHN
AB		INVENTIA	25MG	A211320	001	Feb 09, 2022	Jan NEWA
AB			50MG	A211320	002	Feb 09, 2022	Jan NEWA
AB		MANKIND PHARMA	25MG	A215587	001	Aug 04, 2022	Jul NEWA
AB			50MG	A215587	002	Aug 04, 2022	Jul NEWA
AB		@ SUNNY	25MG	A209068	001	Jan 25, 2022	May DISC
AB			25MG	A209068	001	Jan 25, 2022	Jan NEWA
		@	50MG	A209068	002	Jan 25, 2022	May DISC
AB			50MG	A209068	002	Jan 25, 2022	Jan NEWA
AB		TAGI	25MG	A212878	001	Feb 24, 2022	Feb NEWA
AB			50MG	A212875	001	Feb 24, 2022	Feb NEWA
AB		UMEDICA LABS PVT LTD	25MG	A207222	001	May 24, 2018	Aug CTEC
AB			50MG	A207222	002	May 24, 2018	Aug CTEC

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AB	COREPHARMA	375MG	A214941	001	Oct 20, 2022	Oct	NEWA
AA		500MG	A214941	002	Oct 20, 2022	Oct	NEWA
AB		750MG	A214941	003	Oct 20, 2022	Oct	NEWA
AB	RISING	375MG	A213126	001	Apr 05, 2022	Mar	NEWA
AB		500MG	A213126	002	Apr 05, 2022	Mar	NEWA
AB		750MG	A213126	003	Apr 05, 2022	Mar	NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

	@ UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Mar	DISC
AB		EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jan	NEWA
	@	EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Mar	DISC
AB		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jan	NEWA

LOCHOLEST

>D>	@ CHARTWELL RX	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Dec	CMFD
>A> AB		EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Dec	CMFD
>D>	@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Dec	CMFD
>A> AB		EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Dec	CMFD

LOCHOLEST LIGHT

>D>	@ CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Dec	CMFD
>A> AB		EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Dec	CMFD
>D>	@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Dec	CMFD
>A> AB		EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Dec	CMFD

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB	GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Sep	CAHN
AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Sep	CAHN

CICLOPIROX

GEL; TOPICAL

CICLOPIROX

	+ @ ALVOGEN	0.77%	N020519	001	Jul 21, 1997	Aug	DISC
AB	! GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012	Aug	CHRS

SHAMPOO; TOPICAL

CICLOPIROX

AT	PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018	Mar	CAHN
----	--------------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	CHARTWELL RX	8%	A078046	001	Sep 18, 2007	Mar	CAHN
----	--------------	----	---------	-----	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

	@ HIKMA	50MG	A077024	001	May 17, 2005	Oct	DISC
	@	100MG	A077024	002	May 17, 2005	Oct	DISC

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	@ CHARTWELL RX	200MG	A074100	001	Jan 31, 1995	Jan	CAHN
	@	300MG	A074100	002	Jan 31, 1995	Jan	CAHN
	@	400MG	A074100	003	Jan 31, 1995	Jan	CAHN
	@	800MG	A074100	004	Jan 31, 1995	Jan	CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

	@ AMNEAL PHARMS	30MG	A204364	001	Dec 02, 2021	Feb	DISC
	@	60MG	A204364	002	Dec 02, 2021	Feb	DISC
	@	90MG	A204364	003	Dec 02, 2021	Feb	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ AIPING PHARM INC EQ 250MG BASE
 @ EQ 500MG BASE
 @ EQ 750MG BASE

A076593 002 Jun 09, 2004 Jan CAHN
 A076593 003 Jun 09, 2004 Jan CAHN
 A076593 004 Jun 09, 2004 Jan CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPROFLOXACIN AND DEXAMETHASONE

AB SUN PHARM 0.3%; 0.1%

A210470 001 Aug 30, 2022 Aug NEWA

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP HIKMA EQ 10MG BASE/ML
 AP PIRAMAL CRITICAL EQ 2MG BASE/ML
 >A> AP EQ 2MG BASE/ML
 AP EQ 10MG BASE/ML
 @ PIRAMAL HLTHCARE UK EQ 2MG BASE/ML
 AP EQ 2MG BASE/ML
 @ EQ 10MG BASE/ML
 AP EQ 10MG BASE/ML
 AP SAGENT PHARMS INC EQ 2MG BASE/ML

A203078 001 Jun 28, 2022 Jun NEWA
 A215516 001 May 24, 2022 May NEWA
 A215517 001 Dec 14, 2022 Dec NEWA
 A215516 002 May 24, 2022 May NEWA
 A212432 001 Mar 11, 2022 Sep DISC
 A212432 001 Mar 11, 2022 Mar NEWA
 A212432 002 Mar 11, 2022 Sep DISC
 A212432 002 Mar 11, 2022 Mar NEWA
 A201851 001 Nov 06, 2020 Mar CMFD

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

+! HQ SPCLT PHARMA 50MG/VIAL
 +! 50MG/VIAL

N018057 002 Nov CTNA
 N018057 002 Oct CMFD

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

+! ALMATICA EQ 30MG BASE

N215428 001 Jan 31, 2022 Jan NEWA

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

AA CHARTWELL MOLECULAR EQ 10MG BASE/5ML

A077629 001 Jun 14, 2006 Nov CMS1

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

! HETERO LABS LTD V 12GM/PACKET; 3.5GM/PACKET; 10MG/PACK A212789 001 Jul 18, 2022 Jul NFTG
 ET

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT: HP

+! MERIDIAN BIOSCIENCE 4GM; 75MG

N021314 001 Dec 17, 2002 Nov CAHN

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

>D> AP MYLAN LABS LTD 1MG/ML
 >A> @ 1MG/ML

A200510 001 Oct 06, 2011 Dec DISC
 A200510 001 Oct 06, 2011 Dec DISC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB ALEMBIC PHARMS 250MG
 AB 500MG

A210459 001 Jan 31, 2022 Jan NEWA
 A210459 002 Jan 31, 2022 Jan NEWA

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

>D> AB WATSON LABS EQ 150MG BASE
 >A> @ EQ 150MG BASE
 >D> AB EQ 300MG BASE
 >A> @ EQ 300MG BASE

A063083 001 Jul 31, 1991 Dec DISC
 A063083 001 Jul 31, 1991 Dec DISC
 A063083 002 Mar 18, 2003 Dec DISC
 A063083 002 Mar 18, 2003 Dec DISC

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT	TARO PHARM INDS LTD	1%		A210004	001	Mar 11, 2020	Oct CMFD
GEL;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AB2	AMNEAL	EQ 1% BASE		A214668	001	Aug 05, 2022	Jul NEWA
AB1		EQ 1% BASE		A215219	001	Nov 03, 2022	Oct NEWA
LOTION;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AB	ENCUBE	EQ 1% BASE		A215607	001	Jan 18, 2022	Jan NEWA
SOLUTION;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT	PAI HOLDINGS PHARM	EQ 1% BASE		A206945	001	Dec 30, 2016	Mar CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL							
CLINDAMYCIN PHOSPHATE AND TRETINOIN							
AB1	ACTAVIS MID ATLANTIC	1.2%;0.025%		A202564	001	Jun 12, 2015	Feb CTEC
AB2	SOLARIS PHARMA CORP	1.2%;0.025%		A212845	001	Feb 10, 2022	Feb NFTG
VELTIN							
AB2	+! ALMIRALL	1.2%;0.025%		N050803	001	Jul 16, 2010	Feb CFTG
ZIANA							
AB1	+! BAUSCH	1.2%;0.025%		N050802	001	Nov 07, 2006	Feb CTEC

CLOBAZAM

FILM;ORAL							
SYMPAZAN							
+	OTTER PHARMS	5MG		N210833	001	Nov 01, 2018	Nov CAHN
+		10MG		N210833	002	Nov 01, 2018	Nov CAHN
+		20MG		N210833	003	Nov 01, 2018	Nov CAHN
SUSPENSION;ORAL							
CLOBAZAM							
AB	ACCORD HLTHCARE	2.5MG/ML		A216008	001	Sep 06, 2022	Aug NEWA
AB	AUROBINDO PHARMA LTD	2.5MG/ML		A214404	001	Mar 24, 2022	Mar NEWA
	@ HIKMA	2.5MG/ML		A209715	001	Oct 22, 2018	Sep DISC
TABLET;ORAL							
CLOBAZAM							
	@ HIKMA	10MG		A208785	001	Oct 22, 2018	Sep DISC
	@	20MG		A208785	002	Oct 22, 2018	Sep DISC
AB	MSN	10MG		A213404	001	May 11, 2021	Feb CMFD
AB		20MG		A213404	002	May 11, 2021	Feb CMFD

CLOBETASOL PROPIONATE

CREAM;TOPICAL							
CLOBETASOL PROPIONATE							
	@ GLASSHOUSE PHARMS	0.05%		A211207	001	Mar 26, 2021	Aug CAHN
EMBELINE E							
	@ AKORN	0.05%		A075325	001	Dec 24, 1998	Sep DISC
GEL;TOPICAL							
CLOBETASOL PROPIONATE							
AB	PAI HOLDINGS PHARM	0.05%		A208881	001	Mar 06, 2017	Mar CAHN
LOTION;TOPICAL							
CLOBETASOL PROPIONATE							
AB	PAI HOLDINGS PHARM	0.05%		A208667	001	Nov 29, 2016	Mar CAHN
OINTMENT;TOPICAL							
CLOBETASOL PROPIONATE							
AB	PAI HOLDINGS PHARM	0.05%		A208589	001	Jan 23, 2019	Mar CAHN
SOLUTION;TOPICAL							
CLOBETASOL PROPIONATE							
	@ ENCUBE	0.05%		A076977	001	Aug 05, 2005	Jul CAHN
	@ PRINSTON INC	0.05%		A213139	001	Feb 08, 2021	Aug DISC
AT	QUAGEN	0.05%		A211240	001	Feb 17, 2022	Nov CAHN
AT	SOLARIS PHARMA CORP	0.05%		A211240	001	Feb 17, 2022	Feb NEWA
	@ TOLMAR	0.05%		A076977	001	Aug 05, 2005	Feb DISC
	@ WOCKHARDT BIO AG	0.05%		A075205	001	Nov 13, 1998	Jun DISC

CLOFARABINESOLUTION; INTRAVENOUS
CLOFARABINE

AP	EUGIA PHARMA	20MG/20ML (1MG/ML)	A212457	001	Oct 03, 2022	Sep NEWA
----	--------------	--------------------	---------	-----	--------------	----------

CLOMIPHENE CITRATETABLET; ORAL
CLOMIPHENE CITRATE

!	COSETTE	50MG	A075528	001	Aug 30, 1999	Jun CAHN
---	---------	------	---------	-----	--------------	----------

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

AB	RUBICON	0.5MG	A075468	001	Oct 06, 2000	Sep CMFD
AB		1MG	A075468	002	Oct 06, 2000	Sep CMFD
AB		2MG	A075468	003	Oct 06, 2000	Sep CMFD

CLONIDINETABLET, EXTENDED RELEASE; ORAL
NEXICLON XR

	ATHENA	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Feb CMFD
@		EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Jan CAHN
@		EQ 0.26MG BASE	N022500	002	Dec 03, 2009	Jan CAHN

CLONIDINE HYDROCHLORIDETABLET; ORAL
CLONIDINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988	May CMFD
AB		0.2MG	A070886	001	Aug 31, 1988	May CMFD
AB		0.3MG	A070886	003	Aug 31, 1988	May CMFD
AB	CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Aug CMFD
AB		0.2MG	A071785	003	Apr 05, 1988	Aug CMFD
AB		0.3MG	A071785	001	Apr 05, 1988	Aug CMFD
AB	URL LABS	0.1MG	A070923	003	Sep 04, 1987	Apr CAHN
AB		0.2MG	A070923	002	Sep 04, 1987	Apr CAHN
AB		0.3MG	A070923	001	Sep 04, 1987	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL
CLONIDINE HYDROCHLORIDE

@	MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018	Feb DISC
---	------------------	-------	---------	-----	--------------	----------

CLOPIDOGREL BISULFATETABLET; ORAL
CLOPIDOGREL BISULFATE

AB	DR REDDYS	EQ 75MG BASE	A076273	001	Jan 14, 2008	Apr CAHN
----	-----------	--------------	---------	-----	--------------	----------

CLORAZEPATE DIPOTASSIUMCAPSULE; ORAL
TRANXENE

+	@ KEY THERAP	3.75MG	N017105	001		Aug CAHN
+	@	7.5MG	N017105	002		Aug CAHN
+	@	15MG	N017105	003		Aug CAHN

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB	AUROBINDO PHARMA	3.75MG	A071858	002	Jul 17, 1987	Sep CAHN
AB		7.5MG	A071858	003	Jul 17, 1987	Sep CAHN
AB	!	15MG	A071858	001	Jul 17, 1987	Sep CAHN
AB	COREPHARMA	3.75MG	A215566	001	Jun 14, 2022	Jun NEWA
AB		7.5MG	A215566	002	Jun 14, 2022	Jun NEWA
AB		15MG	A215566	003	Jun 14, 2022	Jun NEWA
AB	NOVITIUM PHARMA	3.75MG	A213730	001	Jun 16, 2022	Jun NEWA
AB		7.5MG	A213730	002	Jun 16, 2022	Jun NEWA
>A> AB		15MG	A213730	003	Dec 16, 2022	Dec NEWA

TRANXENE

+	@ KEY THERAP	3.75MG	N017105	006		Aug CAHN
AB	+	7.5MG	N017105	007		Aug CAHN
	+	@	N017105	008		Aug CAHN
	TRANXENE SD					
+	@ KEY THERAP	11.25MG	N017105	005		Aug CAHN
+	@	22.5MG	N017105	004		Aug CAHN

COLCHICINE

	SOLUTION;ORAL						
	GLOPERBA						
	+! SCILEX PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019	Jun	CAHN
	TABLET;ORAL						
	COLCHICINE						
AB	PAR PHARM INC	0.6MG	A203976	001	Aug 12, 2021	Nov	CMFD
	@	0.6MG	A203976	001	Aug 12, 2021	Feb	DISC
AB	STRIDES PHARMA	0.6MG	A209173	001	Mar 10, 2022	Mar	NEWA

COLESEVELAM HYDROCHLORIDE

	TABLET;ORAL						
	COLESEVELAM HYDROCHLORIDE						
	@ LUPIN LTD	625MG	A201354	001	Dec 17, 2020	May	DISC
AB	SPH	625MG	A213456	001	Jan 21, 2022	Jan	NEWA

COLESTIPOL HYDROCHLORIDE

	TABLET;ORAL						
	COLESTID						
AB	+ PFIZER	1GM	N020222	001	Jul 19, 1994	Apr	CHRS
	COLESTIPOL HYDROCHLORIDE						
AB	! IMPAX LABS	1GM	A077510	001	Oct 24, 2006	Apr	CHRS
AB	ZYDUS PHARMS	1GM	A215223	001	Mar 10, 2022	Feb	NEWA

COPPER CU-64 DOTATATE

	SOLUTION;INTRAVENOUS						
	DETECTNET						
	+! RADIOMEDIX	4mL (1mCi/ML)	N213227	001	Sep 03, 2020	Sep	CAIN

CROMOLYN SODIUM

	SOLUTION;INHALATION						
	CROMOLYN SODIUM						
	@ BAUSCH	10MG/ML	A075585	001	Dec 21, 2000	Jun	CAHN
AN	FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Mar	CMFD
AN	MICRO LABS	10MG/ML	A213658	001	Apr 29, 2022	Apr	NEWA

CUPRIC CHLORIDE

	INJECTABLE;INJECTION						
	CUPRIC CHLORIDE						
AP	EXELA PHARMA	EQ 0.4MG COPPER/ML	A212071	001	Oct 31, 2022	Oct	NFTG
	CUPRIC CHLORIDE IN PLASTIC CONTAINER						
AP	+! HOSPIRA	EQ 0.4MG COPPER/ML	N018960	001	Jun 26, 1986	Oct	CFTG

CUPRIC SULFATE

	INJECTABLE;INJECTION						
	CUPRIC SULFATE						
	+ @ ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987	Apr	DISC
>A>	! AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Dec	NFTG

CYANOCOBALAMIN

	INJECTABLE;INJECTION						
	CYANOCOBALAMIN						
AP	SAGENT PHARMS INC	1MG/ML	A215107	001	Nov 15, 2022	Nov	NEWA
AP	SOLA PHARMS	1MG/ML	A215417	001	Apr 15, 2022	Sep	CAHN
AP	WELDING	1MG/ML	A215417	001	Apr 15, 2022	Apr	NEWA
AP	ZYDUS PHARMS	1MG/ML	A214655	001	Apr 15, 2022	Apr	NEWA
	DODEX						
AP	ACCORD HLTHCARE	1MG/ML	A083022	001		May	CTEC
		1MG/ML	A083022	001		Apr	CMFD

CYCLOPHOSPHAMIDE

	CAPSULE;ORAL						
	CYCLOPHOSPHAMIDE						
AB	ALEMBIC PHARMS	25MG	A215892	001	Nov 10, 2022	Nov	NEWA
AB		50MG	A215892	002	Nov 10, 2022	Nov	NEWA
	@ ANI PHARMS	25MG	A207014	001	Mar 19, 2018	May	DISC
	@	50MG	A207014	002	Mar 19, 2018	Apr	DISC
AB	ANIMA	25MG	A209872	001	May 07, 2018	Sep	CAHN
AB		50MG	A209872	002	May 07, 2018	Sep	CAHN

INJECTABLE; INJECTION									
CYCLOPHOSPHAMIDE									
AP	XELLIA PHARMS APS	500MG/VIAL	A211757	001	Oct 18, 2022	Oct	NEWA		
AP		1GM/VIAL	A211757	002	Oct 18, 2022	Oct	NEWA		
AP		2GM/VIAL	A211757	003	Oct 18, 2022	Oct	NEWA		
<u>CYCLOSERINE</u>									
CAPSULE; ORAL									
SEROMYCIN									
!	CEROVENE INC	250MG	A060593	001		Nov	CAHN		
!	PARSOLEX	250MG	A060593	001		Nov	CAHN		
<u>CYCLOSPORINE</u>									
CAPSULE; ORAL									
CYCLOSPORINE									
AB1	STRIDES PHARMA	25MG	A216046	001	Aug 02, 2022	Jul	NEWA		
AB1		50MG	A216046	002	Aug 02, 2022	Jul	NEWA		
AB1		100MG	A216046	003	Aug 02, 2022	Jul	NEWA		
EMULSION; OPHTHALMIC									
CYCLOSPORINE									
AB	MYLAN	0.05%	A205894	001	Feb 02, 2022	Jan	NFTG		
RESTASIS									
AB	+! ALLERGAN	0.05%	N050790	001	Dec 23, 2002	Jan	CFTG		
SOLUTION; ORAL									
CYCLOSPORINE									
@	MAYNE PHARMA	100MG/ML	A065054	001	Dec 18, 2001	Feb	DISC		
<u>CYPROHEPTADINE HYDROCHLORIDE</u>									
SYRUP; ORAL									
CYPROHEPTADINE HYDROCHLORIDE									
AA	CHARTWELL MOLECULAR	2MG/5ML	A203191	001	Jul 13, 2017	Jun	CAHN		
@	TRIS PHARMA INC	2MG/5ML	A205431	001	Dec 21, 2021	Apr	DISC		
<u>CYSTEAMINE BITARTRATE</u>									
GRANULE, DELAYED RELEASE; ORAL									
PROCYSBI									
+	HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	May	CAHN		
+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	May	CAHN		
<u>CYSTEINE HYDROCHLORIDE</u>									
SOLUTION; INTRAVENOUS									
CYSTEINE HYDROCHLORIDE									
@	DR REDDYS LABS SA	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Sep	DISC		
AP		500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Jun	CAHN		
AP	ETON	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Apr	NFTG		
ELCYS									
+	EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Sep	CTEC		
AP	+	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr	CFTG		
<u>CYTARABINE</u>									
INJECTABLE; INJECTION									
CYTARABINE									
AP	HONG KONG	20MG/ML	A208485	001	Feb 28, 2022	Feb	NEWA		
@	MEITHEAL	20MG/ML	A206189	001	Jun 26, 2020	Jun	CAHN		
AP		20MG/ML	A208485	001	Feb 28, 2022	Nov	CAHN		
<u>DABIGATRAN ETEXILATE MESYLATE</u>									
CAPSULE; ORAL									
DABIGATRAN ETEXILATE MESYLATE									
AB	ALKEM LABS LTD	EQ 150MG BASE	A208040	002	Mar 11, 2020	Aug	CMFD		
@		EQ 150MG BASE	A208040	002	Mar 11, 2020	Aug	DISC		
<u>DALFAMPRIDINE</u>									
TABLET, EXTENDED RELEASE; ORAL									
DALFAMPRIDINE									
@	HIKMA	10MG	A206646	001	Oct 24, 2018	May	DISC		

DALTEPARIN SODIUMINJECTABLE;SUBCUTANEOUS
FRAGMIN

+ PFIZER 10,000IU/4ML (2,500IU/ML) N020287 012 Mar 15, 2022 Mar NEWA

DANTROLENE SODIUMINJECTABLE;INJECTION
DANTROLENE SODIUM

@ EUGIA PHARMA SPECLTS 20MG/VIAL A205239 001 Feb 18, 2016 Mar CAHN

DAPAGLIFLOZIN

TABLET;ORAL

DAPAGLIFLOZIN

AB @ ZYDUS PHARMS 5MG A211582 001 Feb 22, 2022 Jul DISC

AB @ 5MG A211582 001 Feb 22, 2022 Feb NFTG

AB @ 10MG A211582 002 Feb 22, 2022 Jul DISC

AB @ 10MG A211582 002 Feb 22, 2022 Feb NFTG

FARXIGA

+ ASTRAZENECA AB 5MG N202293 001 Jan 08, 2014 Jul CTEC

AB + 5MG N202293 001 Jan 08, 2014 Feb CFTG

AB +! 10MG N202293 002 Jan 08, 2014 Jul CTEC

AB +! 10MG N202293 002 Jan 08, 2014 Feb CFTG

DAPSONE

GEL;TOPICAL

DAPSONE

AB COSETTE 5% A210178 001 Mar 31, 2022 Sep CAHN

AB MYLAN 7.5% A213847 001 Feb 04, 2022 Jan NEWA

AB SEEGPHARM SA 5% A210178 001 Mar 31, 2022 Mar NEWA

AB TORRENT 7.5% A214722 001 Feb 10, 2022 Feb NEWA

TABLET;ORAL

DAPSONE

AB @ ANDA REPOSITORY 25MG A204074 001 May 10, 2016 Sep CAHN

AB @ 100MG A204074 002 May 10, 2016 Sep CAHN

AB + EVEREST LIFE SCI 25MG A086841 001 Nov CAHN

AB +! 100MG A086842 001 Nov CAHN

AB @ VIRTUS PHARMS 25MG A204074 001 May 10, 2016 Jan DISC

AB @ 100MG A204074 002 May 10, 2016 Jan DISC

DAPTOMYCIN

POWDER;INTRAVENOUS

CUBICIN RF

+ @ CUBIST PHARMS LLC 500MG/VIAL N021572 003 Jul 06, 2016 Sep DISC

DAPTOMYCIN

>A> AP ASPIRO 350MG/VIAL A216445 001 Dec 23, 2022 Dec NEWA

AP HAINAN POLY PHARM 500MG/VIAL A215890 001 Aug 18, 2022 Aug NEWA

DAPZURA RT

+ @ BAXTER HLTHCARE CORP 500MG/VIAL N213645 001 Jan 25, 2022 Oct DISC

+! 500MG/VIAL N213645 001 Jan 25, 2022 Jan NEWA

DARIDOREXANT HYDROCHLORIDE

TABLET;ORAL

QUVIVIQ

+ IDORSIA EQ 25MG BASE N214985 001 Apr 07, 2022 Apr NEWA

+! EQ 50MG BASE N214985 002 Apr 07, 2022 Apr NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

>D> BX XIROMED EQ 7.5MG BASE A209571 002 Oct 22, 2019 Dec DISC

>A> @ EQ 7.5MG BASE A209571 002 Oct 22, 2019 Dec DISC

>D> BX EQ 15MG BASE A209571 001 Oct 22, 2019 Dec DISC

>A> @ EQ 15MG BASE A209571 001 Oct 22, 2019 Dec DISC

DARUNAVIR

TABLET;ORAL

DARUNAVIR

AB LUPIN LTD 600MG A202073 001 Sep 29, 2022 Sep NEWA

AB 800MG A202073 002 Sep 29, 2022 Sep NFTG

TABLET;ORAL						
PREZISTA						
AB	+! JANSSEN PRODS	800MG	N021976	006	Nov 09, 2012	Sep CFTG

DASATINIB

TABLET;ORAL						
DASATINIB						
	@ APOTEX	80MG	A203180	001	Nov 23, 2021	May DISC
	@	140MG	A203180	002	Nov 23, 2021	May DISC
SPRYCEL						
+	BRISTOL MYERS SQUIBB	80MG	N021986	005	Oct 28, 2010	May CTEC
+		140MG	N021986	006	Oct 28, 2010	May CTEC

DECITABINE

INJECTABLE;INTRAVENOUS						
DACOGEN						
+	@ OTSUKA	50MG/VIAL	N021790	001	May 02, 2006	Sep DISC
DECITABINE						
AP	! ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Sep CHRS
AP	JIANGSU HANSON PHARM	50MG/VIAL	A213472	001	Apr 15, 2022	Apr NEWA
AP	NOVAST LABS	50MG/VIAL	A210984	001	Sep 16, 2019	Aug CAHN

DEFERASIROX

GRANULE;ORAL						
DEFERASIROX						
	@ AMNEAL	90MG	A214194	003	Aug 02, 2021	Mar DISC
	@	180MG	A214194	001	Feb 09, 2021	Jul DISC
	@	360MG	A214194	002	Feb 09, 2021	Jul DISC
AB	ANNORA PHARMA	180MG	A216229	001	Sep 22, 2022	Sep NEWA
AB		360MG	A216229	002	Sep 22, 2022	Sep NEWA
AB	CIPLA	90MG	A215026	001	Feb 23, 2022	Feb NEWA
AB		180MG	A215026	002	Feb 23, 2022	Feb NEWA
AB		360MG	A215026	003	Feb 23, 2022	Feb NEWA
AB	MSN	90MG	A214650	003	Apr 20, 2022	Apr NEWA
AB	TEVA PHARMS USA	90MG	A214180	001	Nov 19, 2021	Aug CMFD
	@	90MG	A214180	001	Nov 19, 2021	Jun DISC
AB		180MG	A214180	002	Nov 19, 2021	Aug CMFD
	@	180MG	A214180	002	Nov 19, 2021	Jun DISC
AB		360MG	A214180	003	Nov 19, 2021	Aug CMFD
	@	360MG	A214180	003	Nov 19, 2021	Jun DISC
TABLET;ORAL						
DEFERASIROX						
	@ AMNEAL	180MG	A210727	003	Jun 15, 2020	Apr DISC
>D> AB	TEVA PHARMS USA	90MG	A209223	001	Nov 25, 2019	Dec DISC
>A>	@	90MG	A209223	001	Nov 25, 2019	Dec DISC
>D> AB		180MG	A209223	003	Apr 24, 2020	Dec DISC
>A>	@	180MG	A209223	003	Apr 24, 2020	Dec DISC
>D> AB		360MG	A209223	002	Nov 25, 2019	Dec DISC
>A>	@	360MG	A209223	002	Nov 25, 2019	Dec DISC
TABLET, FOR SUSPENSION;ORAL						
DEFERASIROX						
AB	TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Sep NEWA
AB		250MG	A207124	002	Sep 23, 2022	Sep NEWA
AB		500MG	A207124	003	Sep 23, 2022	Sep NEWA

DEFERIPRONE

TABLET;ORAL						
DEFERIPRONE						
AB	HIKMA	1GM	A213239	002	Feb 08, 2022	Jan NFTG
FERRIPROX						
AB	+ CHIESI	500MG	N021825	001	Oct 14, 2011	Nov CHRS
AB	+!	1GM	N021825	002	Jul 25, 2019	Nov CHRS
AB	+	1GM	N021825	002	Jul 25, 2019	Jan CFTG

DESLORATADINE

TABLET;ORAL						
DESLORATADINE						
	@ PERRIGO	5MG	A078361	001	Dec 22, 2011	Sep DISC
	@ SANDOZ	5MG	A078364	001	Dec 03, 2010	Sep DISC

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP	DR REDDYS	0.004MG/ML	A215961	001	Aug 19, 2022	Aug NEWA
AP	GLAND PHARMA LTD	0.004MG/ML	A216922	001	Nov 16, 2022	Nov NEWA
	SPRAY, METERED; NASAL					
	DESMOPRESSIN ACETATE					
AB	! BAUSCH	0.01MG/SPRAY	A074830	001	Jan 25, 1999	Jun CAHN
	NOCTIVA					
	+ @ ACERUS PHARMS	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Nov CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Nov CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

@ MAYNE PHARMA 0.15MG, N/A; 0.02MG, 0.01MG

@ 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG

A076916 001 Dec 29, 2008 Jan DISC
A077182 001 Jan 24, 2006 Jan DISC

DESONIDE

CREAM; TOPICAL

DESONIDE

>A> AB ALEOR DERMACEUTICALS 0.05% A214396 001 Dec 08, 2022 Dec NEWA

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

AB	PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	Mar CAHN
AB	THE J MOLNER	0.05%	A209973	001	Oct 23, 2018	Oct CAHN

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+ @ SUN PHARM EQ 50MG BASE
+ @ EQ 100MG BASE

N205583 001 Jan 28, 2014 Feb CAHN
N205583 002 Jan 28, 2014 Feb CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	LUPIN LTD	EQ 25MG BASE	A204172	003	Apr 13, 2022	Apr NEWA
AB	ZYDUS PHARMS	EQ 25MG BASE	A204020	003	Nov 30, 2022	Nov NEWA

DEUCRAVACITINIB

TABLET; ORAL

SOTYKTU

+! BRISTOL 6MG N214958 001 Sep 09, 2022 Sep NEWA

DEXAMETHASONE

SOLUTION; ORAL

DEXAMETHASONE

+! HIKMA 0.5MG/5ML

A088248 001 Sep 01, 1983 Mar CRLD

TABLET; ORAL

DEXAMETHASONE

AB	AMNEAL	2MG	A216295	001	Sep 08, 2022	Sep NEWA
BP	+ HIKMA	0.5MG	A084611	001		Jan CRLD
AB	+!	2MG	A087916	001	Aug 26, 1982	Sep CTEC
AB	NOVITIUM PHARMA	1.5MG	A215604	001	Aug 08, 2022	Jul NEWA
AB		4MG	A215604	002	Aug 08, 2022	Jul NEWA
AB		6MG	A215604	003	Aug 08, 2022	Jul NEWA
AB	PRASCO	4MG	A080399	002	Apr 20, 2022	Apr NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	+! FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb CRLD
----	-----------------------	---------------------	---------	-----	--	----------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OPHTHALMIC
MAXITROL

AT	+	IMPRIMIS PHARMS USA	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Jun	CAHN
----	---	---------------------	---------------------------------------	---------	-----	--	-----	------

DEXAMETHASONE; TOBRAMYCINSUSPENSION/DROPS;OPHTHALMIC
TOBRAMYCIN AND DEXAMETHASONE

AB		PADAGIS US	0.1%;0.3%	A212715	001	Feb 11, 2022	Feb	NEWA
----	--	------------	-----------	---------	-----	--------------	-----	------

DEXCHLORPHENIRAMINE MALEATESYRUP;ORAL
DEXCHLORPHENIRAMINE MALEATE

AA	+	PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Apr	CAHN
----	---	--------------------	---------	---------	-----	--------------	-----	------

DEXLANSOPRAZOLECAPSULE, DELAYED RELEASE;ORAL
DEXILANT

AB	+	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009	Jun	CFTG
----	---	-------------------	------	---------	-----	--------------	-----	------

		DEXLANSOPRAZOLE						
AB		PAR PHARM INC	30MG	A202294	002	Jun 16, 2022	Jun	NFTG
AB		TWI PHARMS	30MG	A202666	001	Sep 16, 2022	Sep	NEWA
AB			60MG	A202666	002	Sep 16, 2022	Sep	NEWA

DEXMEDETOMIDINE HYDROCHLORIDEFILM;BUCCAL, SUBLINGUAL
IGALMI

+	BIOXCEL	EQ 0.12MG BASE	N215390	001	Apr 05, 2022	Apr	NEWA
+		EQ 0.18MG BASE	N215390	002	Apr 05, 2022	Apr	NEWA

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		MEITHEAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Apr	CAHN
	@	PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A214794	001	Sep 03, 2021	Feb	DISC

DEXTROAMPHETAMINESYSTEM;TRANSDERMAL
XELSTRYM

>D>	+	@ NOVEN PHARMS INC	4.5MG/9HR	N215401	001	Mar 22, 2022	Dec	CMFD
>A>	+		4.5MG/9HR	N215401	001	Mar 22, 2022	Dec	CMFD
	+	@	4.5MG/9HR	N215401	001	Mar 22, 2022	Sep	DISC
	+		4.5MG/9HR	N215401	001	Mar 22, 2022	Mar	NEWA
>D>	+	@	9MG/9HR	N215401	002	Mar 22, 2022	Dec	CMFD
>A>	+		9MG/9HR	N215401	002	Mar 22, 2022	Dec	CMFD
	+	@	9MG/9HR	N215401	002	Mar 22, 2022	Sep	DISC
	+		9MG/9HR	N215401	002	Mar 22, 2022	Mar	NEWA
>D>	+	@	13.5MG/9HR	N215401	003	Mar 22, 2022	Dec	CMFD
>A>	+		13.5MG/9HR	N215401	003	Mar 22, 2022	Dec	CMFD
	+	@	13.5MG/9HR	N215401	003	Mar 22, 2022	Sep	DISC
	+		13.5MG/9HR	N215401	003	Mar 22, 2022	Mar	NEWA
>D>	+	@	18MG/9HR	N215401	004	Mar 22, 2022	Dec	CMFD
>A>	+	!	18MG/9HR	N215401	004	Mar 22, 2022	Dec	CMFD
	+	@	18MG/9HR	N215401	004	Mar 22, 2022	Sep	DISC
	+	!	18MG/9HR	N215401	004	Mar 22, 2022	Mar	NEWA

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

@	MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002	Feb	DISC
@		10MG	A076137	002	Jan 18, 2002	Feb	DISC
@		15MG	A076137	003	Jan 18, 2002	Feb	DISC

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022	Aug	NEWA
AA			10MG	A206095	002	Aug 18, 2022	Aug	NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%							
AP	FRESENIUS KABI USA	5GM/100ML; 75MG/100ML	A212346	001	Sep 10, 2020	Sep	CMFD
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%							
AP	FRESENIUS KABI USA	5GM/100ML; 150MG/100ML	A212346	002	Sep 10, 2020	Sep	CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%							
AP	FRESENIUS KABI USA	5GM/100ML; 149MG/100ML; 450MG/100ML	A213523	005	Oct 11, 2022	Sep	NEWA

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION; ORAL, RECTAL

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM							
AA	GUARDIAN DRUG	66%; 10%	A214201	001	Jun 27, 2022	Jun	NEWA

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM							
AA	CHARTWELL MOLECULAR	5MG/ML	A204433	001	Apr 14, 2014	Aug	CMFD
	@	5MG/ML	A204433	001	Apr 14, 2014	Jun	CAHN
DIAZEPAM INTENSOL							
AA	! HIKMA	5MG/ML	A071415	001	Apr 03, 1987	Aug	CTEC
GEL; RECTAL							
DIASTAT							
+! BAUSCH		2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	May	CHRS
DIASTAT ACUDIAL							
+! BAUSCH		10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	May	CHRS
INJECTABLE; INJECTION							
DIAZEPAM							
AP	FRESENIUS KABI USA	10MG/2ML (5MG/ML)	A214745	001	Nov 10, 2022	Nov	NEWA
SOLUTION; ORAL							
DIAZEPAM							
AA	CHARTWELL MOLECULAR	5MG/5ML	A206477	001	Jun 24, 2016	Jun	CAHN
TABLET; ORAL							
VALIUM							
AB	+ WAYLIS THERAP	2MG	N013263	002		Mar	CAHN
AB	+	5MG	N013263	004		Mar	CAHN
AB	+!	10MG	N013263	006		Mar	CAHN

DICHLORPHENAMIDE

TABLET; ORAL

>A>	DICHLORPHENAMIDE						
>A> AB	TORRENT	50MG	A215924	001	Dec 29, 2022	Dec	NFTG
KEVEYIS							
>D>	+! XERIS	50MG	N011366	002	Aug 07, 2015	Dec	CFTG
>A> AB	+!	50MG	N011366	002	Aug 07, 2015	Dec	CFTG

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX							
+ @ ZYLA		35MG	N204592	002	Oct 18, 2013	Jul	DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM							
AB	STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019	Apr	CMFD
FOR SOLUTION; ORAL							
DICLOFENAC POTASSIUM							
AB	ALKEM LABS LTD	50MG	A216635	001	Jul 20, 2022	Jul	NEWA
AB	ANNORA PHARMA	50MG	A215375	001	Mar 04, 2022	Feb	NEWA
TABLET; ORAL							
DICLOFENAC POTASSIUM							
AB	NOVAST LABS	50MG	A215585	001	Oct 08, 2021	Aug	CAHN
AB	UMEDICA LABS PVT LTD	50MG	A215750	001	May 11, 2022	Apr	NEWA

DICLOFENAC SODIUM

GEL; TOPICAL						
DICLOFENAC SODIUM						
	CIPLA	1%	A209903	001	Aug 03, 2018	Mar CTEC
SOLUTION; TOPICAL						
DICLOFENAC SODIUM						
AB	AMNEAL	2%	A208198	001	Aug 18, 2022	Aug NEWA
AB	APOTEX	2%	A207714	001	May 06, 2022	Apr NFTG
AB	LUPIN PHARMS	2%	A208021	001	Sep 20, 2022	Sep NEWA
AB	TARO	2%	A208098	001	Sep 29, 2022	Sep NEWA
PENNSAID						
AB	+! HORIZON	2%	N204623	001	Jan 16, 2014	Apr CFTG
SOLUTION/DROPS; OPHTHALMIC						
DICLOFENAC SODIUM						
	@ AKORN	0.1%	A077845	001	Apr 17, 2008	Aug DISC
TABLET, EXTENDED RELEASE; ORAL						
DICLOFENAC SODIUM						
AB	RICONPHARMA LLC	100MG	A216275	001	Sep 23, 2022	Sep NEWA

DICLOXACILLIN SODIUM

CAPSULE; ORAL						
DICLOXACILLIN SODIUM						
AB	AUROBINDO PHARMA	EQ 250MG BASE	A216845	001	Sep 23, 2022	Sep NEWA
AB		EQ 500MG BASE	A216845	002	Sep 23, 2022	Sep NEWA
AB	TEVA	EQ 250MG BASE	A062286	001	Jun 03, 1982	Oct CTEC
AB	!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Sep CTEC

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL						
DICYCLOMINE HYDROCHLORIDE						
AB	AUROBINDO PHARMA USA	10MG	A040319	001	Sep 07, 1999	Oct CAHN
>A> AB	TWI PHARMS	10MG	A217054	001	Dec 27, 2022	Dec NEWA
INJECTABLE; INJECTION						
DICYCLOMINE HYDROCHLORIDE						
	@ ATHENEX INC	10MG/ML	A212058	001	Apr 26, 2019	Oct CAHN
	@ GENE YORK PHARMS	10MG/ML	A212058	001	Apr 26, 2019	Feb DISC
	@ HIKMA	10MG/ML	A210788	001	Feb 11, 2019	Oct DISC
AP		10MG/ML	A210788	001	Feb 11, 2019	Oct CAHN
TABLET; ORAL						
DICYCLOMINE HYDROCHLORIDE						
AB	COREPHARMA	20MG	A216760	001	Nov 28, 2022	Nov NEWA
>A> AB	RUBICON	20MG	A216736	001	Dec 14, 2022	Dec NEWA

DIFLORASONE DIACETATE

OINTMENT; TOPICAL						
DIFLORASONE DIACETATE						
AB	THE J MOLNER	0.05%	A210753	001	Jun 12, 2018	Oct CAHN

DIFLUPREDNATE

EMULSION; OPHTHALMIC						
DIFLUPREDNATE						
AB	DR REDDYS	0.05%	A214894	001	Nov 16, 2022	Nov NEWA

DIGOXIN

ELIXIR; ORAL						
DIGOXIN						
AA	AMICI	0.05MG/ML	A215209	001	Mar 11, 2022	Mar NEWA
TABLET; ORAL						
DIGOXIN						
AB	AUROBINDO PHARMA LTD	0.0625MG	A214982	001	Feb 08, 2022	Jan NFTG
AB		0.125MG	A214982	002	Feb 08, 2022	Jan NEWA
AB		0.25MG	A214982	003	Feb 08, 2022	Jan NEWA
AB	NOVITIUM PHARMA	0.0625MG	A215307	003	Aug 25, 2022	Aug NEWA
LANOXIN						
AB	+ CONCORDIA	0.0625MG	N020405	001	Sep 30, 1997	Jan CFTG

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION					
D.H.E. 45					
	+ @ BAUSCH	1MG/ML	N005929	001	Jul DISC
DIHYDROERGOTAMINE MESYLATE					
AP	! HIKMA PHARMS	1MG/ML	A206621	001	Sep 15, 2017 Jul CHRS
SPRAY, METERED; NASAL					
DIHYDROERGOTAMINE MESYLATE					
	@ AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022 Jul DISC
AB	HIKMA	0.5MG/SPRAY	A211393	001	Feb 28, 2020 Aug CAHN
TRUDHESA					
	+! IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021 May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
DILTIAZEM HYDROCHLORIDE					
AB2	AMTA	120MG	A216304	001	Aug 08, 2022 Jul NEWA
AB2		180MG	A216304	002	Aug 08, 2022 Jul NEWA
AB2		240MG	A216304	003	Aug 08, 2022 Jul NEWA
AB1	MAYNE PHARMA INTL	60MG	A215775	001	May 05, 2022 Apr NEWA
AB1		90MG	A215775	002	May 05, 2022 Apr NEWA
AB1		120MG	A215775	003	May 05, 2022 Apr NEWA
	@ SUN PHARM	120MG	A090492	001	Oct 28, 2011 Nov DISC
	@	180MG	A090492	002	Oct 28, 2011 Nov DISC
	@	240MG	A090492	003	Oct 28, 2011 Nov DISC
	@	300MG	A090492	004	Oct 28, 2011 Nov DISC
SOLUTION; INTRAVENOUS					
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%					
	+ @ EXELA PHARMA	125MG/125ML (1MG/ML)	N215252	001	Oct 28, 2021 Feb DISC
	+ @	250MG/250ML (1MG/ML)	N215252	002	Oct 28, 2021 Feb DISC
TABLET; ORAL					
DILTIAZEM HYDROCHLORIDE					
AB	SCIEGEN PHARMS INC	30MG	A216521	001	Sep 23, 2022 Sep NEWA
AB		60MG	A216521	002	Sep 23, 2022 Sep NEWA
AB		90MG	A216521	003	Sep 23, 2022 Sep NEWA
AB		120MG	A216521	004	Sep 23, 2022 Sep NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL					
DIMETHYL FUMARATE					
>A> AB	AUROBINDO PHARMA	120MG	A210385	001	Dec 22, 2022 Dec NEWA
>A> AB		240MG	A210385	002	Dec 22, 2022 Dec NEWA
	@ PHARMATHEN	120MG	A210436	001	Mar 26, 2021 Apr DISC
	@	240MG	A210436	002	Mar 26, 2021 Apr DISC
AB	PRINSTON INC	120MG	A210414	001	Oct 18, 2022 Oct NEWA
AB		240MG	A210414	002	Oct 18, 2022 Oct NEWA
	@ SAWAI USA	120MG	A210285	001	Dec 21, 2021 Jun DISC
	@	240MG	A210285	002	Dec 21, 2021 Jun DISC
	@ SOLA PHARMS	120MG	A210436	001	Mar 26, 2021 Jul CAHN
	@	240MG	A210436	002	Mar 26, 2021 Jul CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION					
DIPYRIDAMOLE					
AP	! CHARTWELL INJECTABLE	5MG/ML	A074939	001	Apr 13, 1998 Mar CAHN
	@ EUGIA PHARMA SPECITS	5MG/ML	A075769	001	Nov 27, 2002 Mar CAHN
TABLET; ORAL					
DIPYRIDAMOLE					
	@ ANDA REPOSITORY	25MG	A040898	001	Apr 23, 2008 Sep CAHN
	@	50MG	A040898	002	Apr 23, 2008 Sep CAHN
	@	75MG	A040898	003	Apr 23, 2008 Sep CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL					
DISOPYRAMIDE PHOSPHATE					
AB	MAYNE PHARMA	EQ 100MG BASE	A070173	001	May 31, 1985 Feb CMFD
AB		EQ 150MG BASE	A070173	002	May 31, 1985 Feb CMFD

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

@ RISING

EQ 125MG VALPROIC ACID

A090407 001 Mar 28, 2011 Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB UNICHEM

EQ 250MG VALPROIC ACID

A214643 001 Feb 25, 2022 Feb NEWA

AB UNICHEM

EQ 500MG VALPROIC ACID

A214643 002 Feb 25, 2022 Feb NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

>A> AP HAINAN POLY

EQ 12.5MG BASE/ML

A216131 001 Dec 21, 2022 Dec NEWA

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP MEITHEAL

20MG/2ML (10MG/ML)

A209634 001 Aug 24, 2018 Apr CAHN

AP MEITHEAL

80MG/8ML (10MG/ML)

A209634 002 Aug 24, 2018 Apr CAHN

AP MEITHEAL

160MG/16ML (10MG/ML)

A209634 003 Aug 24, 2018 Apr CAHN

AP SUN PHARM

20MG/ML (20MG/ML)

N022534 003 Jan 08, 2019 Nov CDFR

AP SUN PHARM

80MG/4ML (20MG/ML)

N022534 004 Jan 08, 2019 Nov CDFR

AP SUN PHARM

160MG/8ML (20MG/ML)

N022534 005 Jan 08, 2019 Nov CDFR

SOLUTION;INTRAVENOUS

DOCETAXEL

+! MERIDIAN LABS

20MG/2ML (10MG/ML)

N215813 001 Nov 22, 2022 Nov NEWA

+! MERIDIAN LABS

80MG/8ML (10MG/ML)

N215813 002 Nov 22, 2022 Nov NEWA

+! MERIDIAN LABS

160MG/16ML (10MG/ML)

N215813 003 Nov 22, 2022 Nov NEWA

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

@ TEVA PHARMS USA

0.125MG

A210018 001 Apr 15, 2022 Oct DISC

AB TEVA PHARMS USA

0.125MG

A210018 001 Apr 15, 2022 Apr NEWA

@ TEVA PHARMS USA

0.25MG

A210018 002 Apr 15, 2022 Oct DISC

AB TEVA PHARMS USA

0.25MG

A210018 002 Apr 15, 2022 Apr NEWA

@ TEVA PHARMS USA

0.5MG

A210018 003 Apr 15, 2022 Oct DISC

AB TEVA PHARMS USA

0.5MG

A210018 003 Apr 15, 2022 Apr NEWA

>D> AB VGYAAN

0.125MG

A215323 001 Apr 14, 2022 Dec DISC

>A> AB VGYAAN

0.125MG

A215323 001 Apr 14, 2022 Dec DISC

AB VGYAAN

0.125MG

A215323 001 Apr 14, 2022 Nov CDFR

>D> AB VGYAAN

0.25MG

A215323 002 Apr 14, 2022 Dec DISC

>A> AB VGYAAN

0.25MG

A215323 002 Apr 14, 2022 Dec DISC

AB VGYAAN

0.25MG

A215323 002 Apr 14, 2022 Nov CDFR

>D> AB VGYAAN

0.5MG

A215323 003 Apr 14, 2022 Dec DISC

>A> AB VGYAAN

0.5MG

A215323 003 Apr 14, 2022 Dec DISC

AB VGYAAN

0.5MG

A215323 003 Apr 14, 2022 Nov CDFR

TABLET;ORAL

DOFETILIDE

AB NUVO PHARM

0.125MG

A215323 001 Apr 14, 2022 Aug CAHN

AB NUVO PHARM

0.25MG

A215323 002 Apr 14, 2022 Aug CAHN

AB NUVO PHARM

0.5MG

A215323 003 Apr 14, 2022 Aug CAHN

AB VGYAAN

0.125MG

A215323 001 Apr 14, 2022 Nov CAHN

AB VGYAAN

0.125MG

A215323 001 Apr 14, 2022 Apr NEWA

AB VGYAAN

0.25MG

A215323 002 Apr 14, 2022 Nov CAHN

AB VGYAAN

0.25MG

A215323 002 Apr 14, 2022 Apr NEWA

AB VGYAAN

0.5MG

A215323 003 Apr 14, 2022 Nov CAHN

AB VGYAAN

0.5MG

A215323 003 Apr 14, 2022 Apr NEWA

DONEPEZIL HYDROCHLORIDE

SYSTEM;TRANSDERMAL

ADLARTY

+ CORIUM

5MG/DAY

N212304 001 Mar 11, 2022 Mar NEWA

+! CORIUM

10MG/DAY

N212304 002 Mar 11, 2022 Mar NEWA

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB CHARTWELL RX

5MG

A090425 001 May 31, 2011 Mar CAHN

AB CHARTWELL RX

10MG

A090425 002 May 31, 2011 Mar CAHN

AB RISING

5MG

A202114 001 Jul 05, 2013 Sep CAHN

AB RISING

10MG

A202114 002 Jul 05, 2013 Sep CAHN

@ SANDOZ

5MG

A090290 001 May 31, 2011 Oct DISC

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

@ 10MG

A090290 002 May 31, 2011 Oct DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT GLAND PHARMA LTD EQ 2% BASE

A215660 001 Jan 27, 2022 Jan NEWA

AT ! MICRO LABS EQ 2% BASE

A204778 001 Nov 08, 2019 May CHRS

TRUSOPT

+ @ MERCK EQ 2% BASE

N020408 001 Dec 09, 1994 May DISC

+ @ MSD SUB MERCK EQ 2% BASE

N020408 001 Dec 09, 1994 Jun CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT +! THEA PHARMA EQ 2% BASE;EQ 0.5% BASE

N020869 001 Apr 07, 1998 Apr CAHN

COSOPT PF

AT +! THEA PHARMA EQ 2% BASE;EQ 0.5% BASE

N202667 001 Feb 01, 2012 Apr CAHN

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT GLAND PHARMA LTD EQ 2% BASE;EQ 0.5% BASE

A215520 001 Sep 19, 2022 Sep NEWA

AT MICRO LABS EQ 2% BASE;EQ 0.5% BASE

A215936 001 Jan 25, 2022 Jan NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

AP CHARTWELL INJECTABLE 20MG/ML

A076266 001 Jan 10, 2003 Mar CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

CARDURA

AB +! VIATRIS EQ 1MG BASE

N019668 001 Nov 02, 1990 Jan CAHN

AB + EQ 2MG BASE

N019668 002 Nov 02, 1990 Jan CAHN

AB + EQ 4MG BASE

N019668 003 Nov 02, 1990 Jan CAHN

AB + EQ 8MG BASE

N019668 004 Nov 02, 1990 Jan CAHN

DOXAZOSIN MESYLATE

@ CHARTWELL RX EQ 1MG BASE

A075646 001 Oct 18, 2000 Jan CAHN

@ EQ 2MG BASE

A075646 002 Oct 18, 2000 Jan CAHN

@ EQ 4MG BASE

A075646 003 Oct 18, 2000 Jan CAHN

@ EQ 8MG BASE

A075646 004 Oct 18, 2000 Jan CAHN

AB METHOD EQ 1MG BASE

A212727 001 Mar 15, 2022 Mar NEWA

AB EQ 2MG BASE

A212727 002 Mar 15, 2022 Mar NEWA

AB EQ 4MG BASE

A212727 003 Mar 15, 2022 Mar NEWA

AB EQ 8MG BASE

A212727 004 Mar 15, 2022 Mar NEWA

AB PHARMGEN EQ 1MG BASE

A212727 001 Mar 15, 2022 Sep CAHN

AB EQ 2MG BASE

A212727 002 Mar 15, 2022 Sep CAHN

AB EQ 4MG BASE

A212727 003 Mar 15, 2022 Sep CAHN

AB EQ 8MG BASE

A212727 004 Mar 15, 2022 Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+ VIATRIS EQ 4MG BASE

N021269 001 Feb 22, 2005 Jan CAHN

+! EQ 8MG BASE

N021269 002 Feb 22, 2005 Jan CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

>D> @ CHARTWELL RX EQ 10MG BASE

A210268 001 Sep 04, 2020 Dec CMFD

>A> AB EQ 10MG BASE

A210268 001 Sep 04, 2020 Dec CMFD

>D> @ EQ 25MG BASE

A210268 002 Sep 04, 2020 Dec CMFD

>A> AB EQ 25MG BASE

A210268 002 Sep 04, 2020 Dec CMFD

>D> @ EQ 50MG BASE

A210268 003 Sep 04, 2020 Dec CMFD

>A> AB EQ 50MG BASE

A210268 003 Sep 04, 2020 Dec CMFD

>D> @ EQ 75MG BASE

A210268 004 Sep 04, 2020 Dec CMFD

>A> AB EQ 75MG BASE

A210268 004 Sep 04, 2020 Dec CMFD

>D> @ EQ 100MG BASE

A210268 005 Sep 04, 2020 Dec CMFD

>A> AB EQ 100MG BASE

A210268 005 Sep 04, 2020 Dec CMFD

AB EDENBRIDGE PHARMS EQ 150MG BASE

A213796 001 Apr 19, 2022 Apr NEWA

AB EPIC PHARMA LLC EQ 50MG BASE

A210675 004 Mar 03, 2022 Feb NEWA

AB EQ 75MG BASE

A210675 005 Mar 03, 2022 Feb NEWA

AB JUBILANT CADISTA EQ 10MG BASE

A215483 001 Mar 14, 2022 Mar NEWA

AB EQ 25MG BASE

A215483 002 Mar 14, 2022 Mar NEWA

AB EQ 50MG BASE

A215483 003 Mar 14, 2022 Mar NEWA

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		EQ 75MG BASE	A215483	004	Mar 14, 2022	Mar NEWA
AB		EQ 100MG BASE	A215483	005	Mar 14, 2022	Mar NEWA
AB	MANKIND PHARMA	EQ 10MG BASE	A215710	001	Feb 09, 2022	Jan NEWA
AB		EQ 25MG BASE	A215710	002	Feb 09, 2022	Jan NEWA
AB		EQ 50MG BASE	A215710	003	Feb 09, 2022	Jan NEWA
AB		EQ 75MG BASE	A215710	004	Feb 09, 2022	Jan NEWA
AB		EQ 100MG BASE	A215710	005	Feb 09, 2022	Jan NEWA
AB	MSN	EQ 10MG BASE	A215113	001	Jun 24, 2022	Jun NEWA
AB		EQ 25MG BASE	A215113	002	Jun 24, 2022	Jun NEWA
AB		EQ 50MG BASE	A215113	003	Jun 24, 2022	Jun NEWA
AB		EQ 75MG BASE	A215113	004	Jun 24, 2022	Jun NEWA
AB		EQ 100MG BASE	A215113	005	Jun 24, 2022	Jun NEWA
	@ PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987	Oct DISC
	@	EQ 25MG BASE	A071422	003	Nov 09, 1987	Oct DISC
	@	EQ 50MG BASE	A071422	004	Nov 09, 1987	Oct DISC
	@	EQ 75MG BASE	A071422	005	Nov 09, 1987	Oct DISC
	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	Oct DISC
AB	!	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr CTEC

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

>D>	AA	WOCKHARDT BIO AG	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Dec CAHN
>A>	AA	XTTRIUM LABS INC	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Dec CAHN

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		STRIDES PHARMA	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jun CMFD
	@		EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan CAHN
AB			EQ 6MG BASE	A202510	002	Jul 24, 2020	Jun CMFD
	@		EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

	@	AKORN	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Aug DISC
	@		4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Aug DISC
AP		EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Jan NEWA
AP			4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

>D>	AP	TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995	Dec DISC
>A>		@	2MG/ML	A064140	001	Jul 28, 1995	Dec DISC
>D>	AP		200MG/100ML	A064140	002	Jul 28, 1995	Dec DISC
>A>		@	200MG/100ML	A064140	002	Jul 28, 1995	Dec DISC

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		AYANA PHARMA LTD	20MG/10ML (2MG/ML)	A207228	001	Oct 12, 2021	Oct CTNA
AB			50MG/25ML (2MG/ML)	A207228	002	Oct 12, 2021	Oct CTNA
AB		CELERITY PHARMS	20MG/10ML (2MG/ML)	A212219	001	Oct 19, 2022	Oct NEWA
AB			50MG/25ML (2MG/ML)	A212219	002	Oct 19, 2022	Oct NEWA
AB		ZYDUS	20MG/10ML (2MG/ML)	A212299	001	Sep 10, 2020	Oct CTNA
AB			50MG/25ML (2MG/ML)	A212299	002	Sep 10, 2020	Oct CTNA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

	@	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Mar DISC
	@	STRIDES PHARMA	EQ 150MG BASE	A202778	001	Jun 08, 2012	Aug CAHN
		MONODOX					
AB	+	CHARTWELL RX	EQ 150MG BASE	N050641	004	Feb 17, 2022	Feb NEWA

TABLET;ORAL

DOXYCYCLINE

>A>		@ APPCO	EQ 50MG BASE	A065377	001	Nov 07, 2006	Dec CAHN
>A>		@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Dec CAHN
>A>		@	EQ 100MG BASE	A065377	003	Nov 07, 2006	Dec CAHN
>A>		@	EQ 150MG BASE	A065427	001	Jun 07, 2007	Dec CAHN
>D>		@ MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006	Dec CAHN
>D>		@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Dec CAHN
>D>		@	EQ 100MG BASE	A065377	003	Nov 07, 2006	Dec CAHN
>D>		@	EQ 150MG BASE	A065427	001	Jun 07, 2007	Dec CAHN

TABLET;ORAL

DOXYCYCLINE

AB	STRIDES PHARMA	EQ 50MG BASE	A065070	001	Dec 15, 2000	Jul CMFD
AB		EQ 75MG BASE	A065070	003	Dec 30, 2002	Jul CMFD
AB		EQ 100MG BASE	A065070	002	Dec 15, 2000	Jul CMFD
AB		EQ 150MG BASE	A065070	004	Jul 14, 2005	Jul CMFD

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB	CADILA	EQ 50MG BASE	A207774	001	May 31, 2018	May CAHN
AB		EQ 100MG BASE	A207774	002	May 31, 2018	May CAHN
	@ STRIDES PHARMA	EQ 50MG BASE	A062337	001	Mar 29, 1982	Nov CAHN
	@	EQ 100MG BASE	A062337	002	Mar 29, 1982	Nov CAHN

CAPSULE, DELAYED RELEASE;ORAL

DORYX

	+ @ MAYNE PHARMA	EQ 75MG BASE	N050582	002	Aug 13, 2001	Nov CAHN
	+ @	EQ 100MG BASE	N050582	001	Jul 22, 1985	Nov CAHN

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	PAR STERILE PRODUCTS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Nov NEWA
----	----------------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

DOXYCYCLINE HYCLATE

>D>	AB	AMNEAL	EQ 100MG BASE	A216599	001	Oct 24, 2022	Dec DISC
>A>	AB	@	EQ 100MG BASE	A216599	001	Oct 24, 2022	Dec DISC
	AB		EQ 100MG BASE	A216599	001	Oct 24, 2022	Oct NEWA
	AB	! CHARTWELL MOLECULAR	EQ 20MG BASE	A065277	001	Nov 10, 2005	Jun CAHN
		@ EMCURE PHARMS LTD	EQ 100MG BASE	A209969	001	Nov 09, 2018	Jan DISC
		@ PRAXGEN	EQ 100MG BASE	A212487	001	Mar 30, 2022	Aug DISC
	AB		EQ 100MG BASE	A212487	001	Mar 30, 2022	Mar NEWA

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	+ MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Nov CAHN
AB	+	EQ 75MG BASE	N050795	001	May 06, 2005	Nov CAHN
	+	EQ 80MG BASE	N050795	004	Apr 11, 2013	Nov CAHN
AB	+	EQ 100MG BASE	N050795	002	May 06, 2005	Nov CAHN
AB	+	EQ 150MG BASE	N050795	003	Jun 20, 2008	Nov CAHN
AB	+!	EQ 200MG BASE	N050795	005	Apr 11, 2013	Nov CAHN
	DORYX MPC					
	+ MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Nov CMFD
	+ @	EQ 60MG BASE	N050795	007	May 20, 2016	Nov CAHN
	+!	EQ 120MG BASE	N050795	008	May 20, 2016	Nov CAHN

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

	+! DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016	Sep CTEC
AB	+!	20MG;20MG	N209661	001	Nov 07, 2016	Feb CFTG
	DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE					
	@ ACTAVIS LABS FL INC	20MG;20MG	A212472	001	Mar 01, 2022	Sep DISC
AB		20MG;20MG	A212472	001	Mar 01, 2022	Feb NFTG

DRONABINOL

CAPSULE;ORAL

DRONABINOL

@ LANNETT CO INC

2.5MG

A201463 001 May 18, 2018 Nov DISC

@

5MG

A201463 002 May 18, 2018 Nov DISC

@

10MG

A201463 003 May 18, 2018 Nov DISC

SOLUTION;ORAL

SYNDROS

	+! BENUVIA OPERATIONS	5MG/ML	N205525	001	Mar 23, 2017	Oct CAHN
--	-----------------------	--------	---------	-----	--------------	----------

DROSPIRENONE

TABLET, CHEWABLE;ORAL

DROSPIRENONE

	+! EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022	Jun NEWA
--	--------------------	-------	---------	-----	--------------	----------

DROXIDOPACAPSULE;ORAL
DROXIDOPA

>D>	AB	CELLTRION	100MG	A214217	001	May 05, 2022	Dec	DISC
>A>	@		100MG	A214217	001	May 05, 2022	Dec	DISC
	AB		100MG	A214217	001	May 05, 2022	Apr	NEWA
>D>	AB		200MG	A214217	002	May 05, 2022	Dec	DISC
>A>	@		200MG	A214217	002	May 05, 2022	Dec	DISC
	AB		200MG	A214217	002	May 05, 2022	Apr	NEWA
>D>	AB		300MG	A214217	003	May 05, 2022	Dec	DISC
>A>	@		300MG	A214217	003	May 05, 2022	Dec	DISC
	AB		300MG	A214217	003	May 05, 2022	Apr	NEWA
>D>	@	SLATE RUN PHARMA	100MG	A215265	001	Nov 01, 2021	Dec	CMFD
>A>	AB		100MG	A215265	001	Nov 01, 2021	Dec	CMFD
	@		100MG	A215265	001	Nov 01, 2021	May	DISC
>D>	@		200MG	A215265	002	Nov 01, 2021	Dec	CMFD
>A>	AB		200MG	A215265	002	Nov 01, 2021	Dec	CMFD
	@		200MG	A215265	002	Nov 01, 2021	May	DISC
>D>	@		300MG	A215265	003	Nov 01, 2021	Dec	CMFD
>A>	AB		300MG	A215265	003	Nov 01, 2021	Dec	CMFD
	@		300MG	A215265	003	Nov 01, 2021	May	DISC
	AB	UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Aug	CAHN
	AB		200MG	A213661	002	Feb 18, 2021	Aug	CAHN
	AB		300MG	A213661	003	Feb 18, 2021	Aug	CAHN

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL
DRIZALMA SPRINKLE

+	@	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Nov	DISC
+			EQ 20MG BASE	N212516	001	Jul 19, 2019	Feb	CAHN
+			EQ 30MG BASE	N212516	002	Jul 19, 2019	Feb	CAHN
+	!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Feb	CAHN

DUVELISIBCAPSULE;ORAL
COPIKTRA

+		SECURA	15MG	N211155	001	Sep 24, 2018	May	CMFD
+	@		15MG	N211155	001	Sep 24, 2018	Apr	DISC
+			25MG	N211155	002	Sep 24, 2018	May	CMFD
+	@		25MG	N211155	002	Sep 24, 2018	Apr	DISC

ECONAZOLE NITRATECREAM;TOPICAL
SPECTAZOLE

+	@	ALVOGEN	1%	N018751	001	Dec 23, 1982	Aug	DISC
---	---	---------	----	---------	-----	--------------	-----	------

EDARAVONESUSPENSION;ORAL
RADICAVA ORS

+	!	mitsubishi tanabe	105MG/5ML	N215446	001	May 12, 2022	May	NEWA
---	---	-------------------	-----------	---------	-----	--------------	-----	------

EFAVIRENZTABLET;ORAL
EFAVIRENZ

	@	AUROBINDO PHARMA	600MG	A205322	001	Aug 30, 2018	Apr	DISC
AB	!	HETERO LABS LTD III	600MG	A078886	001	Apr 27, 2018	Sep	CHRS
		SUSTIVA						
	+	@ BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Sep	DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

		EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE						
AB		HETERO LABS LTD V	600MG;200MG;300MG	A203053	001	Jan 24, 2022	Jan	NEWA

EFINACONAZOLESOLUTION;TOPICAL
EFINACONAZOLE

	@	LUPIN LTD	10%	A212169	001	Mar 02, 2022	May	DISC
AB			10%	A212169	001	Mar 02, 2022	Feb	NEWA
AB		NIVAGEN PHARMS INC	10%	A211969	001	Jun 21, 2021	Aug	CAHN
>D>	AB	ZYDUS	10%	A212178	001	Jul 15, 2022	Dec	DISC

SOLUTION; TOPICAL							
EFINACONAZOLE							
>A>	@	10%	A212178	001	Jul 15, 2022	Dec	DISC
AB		10%	A212178	001	Jul 15, 2022	Jul	NEWA
<u>EFLORNITHINE HYDROCHLORIDE</u>							
CREAM; TOPICAL							
VANIQA							
	+ @ SKINMEDICA	13.9%	N021145	001	Jul 27, 2000	Feb	DISC
<u>ELBASVIR; GRAZOPREVRIS</u>							
TABLET; ORAL							
ZEPATIER							
	+! MSD SUB MERCK	50MG; 100MG	N208261	001	Jan 28, 2016	Jun	CAHN
<u>ELETRIPTAN HYDROBROMIDE</u>							
TABLET; ORAL							
ELETRIPTAN HYDROBROMIDE							
AB	BEXIMCO PHARMS USA	EQ 20MG BASE	A215467	001	Jul 13, 2022	Jul	NEWA
AB		EQ 40MG BASE	A215467	002	Jul 13, 2022	Jul	NEWA
<u>ELIGLUSTAT TARTRATE</u>							
CAPSULE; ORAL							
ELIGLUSTAT TARTRATE							
AB	AIZANT	EQ 84MG BASE	A212463	001	Sep 08, 2021	Feb	CAHN
	@ DR REDDYS	EQ 84MG BASE	A212449	001	Aug 17, 2022	Oct	DISC
AB		EQ 84MG BASE	A212449	001	Aug 17, 2022	Aug	NEWA
	@ TEVA PHARMS USA INC	EQ 84MG BASE	A212474	001	Dec 27, 2021	Jun	DISC
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE</u>							
TABLET; ORAL							
EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE							
>D>	ZYDUS PHARMS	5MG; 500MG	A212198	001	Jul 07, 2022	Dec	DISC
>A>	@	5MG; 500MG	A212198	001	Jul 07, 2022	Dec	DISC
AB		5MG; 500MG	A212198	001	Jul 07, 2022	Jul	NFTG
>D>	AB	5MG; 1GM	A212198	002	Jul 07, 2022	Dec	DISC
>A>	@	5MG; 1GM	A212198	002	Jul 07, 2022	Dec	DISC
AB		5MG; 1GM	A212198	002	Jul 07, 2022	Jul	NFTG
>D>	AB	12.5MG; 500MG	A212198	003	Jul 07, 2022	Dec	DISC
>A>	@	12.5MG; 500MG	A212198	003	Jul 07, 2022	Dec	DISC
AB		12.5MG; 500MG	A212198	003	Jul 07, 2022	Jul	NFTG
>D>	AB	12.5MG; 1GM	A212198	004	Jul 07, 2022	Dec	DISC
>A>	@	12.5MG; 1GM	A212198	004	Jul 07, 2022	Dec	DISC
AB		12.5MG; 1GM	A212198	004	Jul 07, 2022	Jul	NFTG
SYNJARDY							
>D>	AB + BOEHRINGER INGELHEIM	5MG; 500MG	N206111	001	Aug 26, 2015	Dec	CTEC
>A>	+	5MG; 500MG	N206111	001	Aug 26, 2015	Dec	CTEC
AB	+	5MG; 500MG	N206111	001	Aug 26, 2015	Jul	CFTG
>D>	AB +	5MG; 1GM	N206111	002	Aug 26, 2015	Dec	CTEC
>A>	+	5MG; 1GM	N206111	002	Aug 26, 2015	Dec	CTEC
AB	+	5MG; 1GM	N206111	002	Aug 26, 2015	Jul	CFTG
>D>	AB +	12.5MG; 500MG	N206111	003	Aug 26, 2015	Dec	CTEC
>A>	+	12.5MG; 500MG	N206111	003	Aug 26, 2015	Dec	CTEC
AB	+	12.5MG; 500MG	N206111	003	Aug 26, 2015	Jul	CFTG
>D>	AB +!	12.5MG; 1GM	N206111	004	Aug 26, 2015	Dec	CTEC
>A>	+	12.5MG; 1GM	N206111	004	Aug 26, 2015	Dec	CTEC
AB	+	12.5MG; 1GM	N206111	004	Aug 26, 2015	Jul	CFTG
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>							
TABLET; ORAL							
DESCOVY							
	+ GILEAD SCIENCES INC	120MG; EQ 15MG BASE	N208215	002	Jan 07, 2022	Jan	NEWA
<u>ENALAPRIL MALEATE</u>							
SOLUTION; ORAL							
ENALAPRIL MALEATE							
AB	ALKEM LABS LTD	1MG/ML	A213714	001	Mar 30, 2022	Mar	NEWA
	@ AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Oct	DISC
AB		1MG/ML	A212894	001	Jun 29, 2022	Jun	NEWA
AB	ANNORA PHARMA	1MG/ML	A214467	001	Feb 24, 2022	Feb	NEWA

TABLET; ORAL							
ENALAPRIL MALEATE							
	@ AIPING PHARM INC	2.5MG	A075178	002	Mar 23, 2001	Jun	CAHN
	@	5MG	A075178	001	Mar 23, 2001	Jun	CAHN
	@	10MG	A075178	003	Mar 23, 2001	Jun	CAHN
	@	20MG	A075178	004	Mar 23, 2001	Jun	CAHN
AB	PRINSTON INC	2.5MG	A213273	001	Jul 07, 2022	Jul	NEWA
AB		5MG	A213273	002	Jul 07, 2022	Jul	NEWA
AB		10MG	A213273	003	Jul 07, 2022	Jul	NEWA
AB		20MG	A213273	004	Jul 07, 2022	Jul	NEWA
<u>ENALAPRILAT</u>							
INJECTABLE; INJECTION							
ENALAPRILAT							
AP	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jan	CHRS
AP	CHARTWELL INJECTABLE	1.25MG/ML	A075634	001	Aug 22, 2000	Mar	CAHN
AP	! HIKMA FARMACEUTICA	1.25MG/ML	A078687	001	Dec 23, 2008	Jan	CHRS
AP	HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Jan	CHRS
<u>ENASIDENIB MESYLATE</u>							
TABLET; ORAL							
IDHIFA							
	+ BRISTOL MYERS SQUIBB	EQ 50MG BASE	N209606	001	Aug 01, 2017	Oct	CAHN
	+!	EQ 100MG BASE	N209606	002	Aug 01, 2017	Oct	CAHN
<u>ENOXAPARIN SODIUM</u>							
INJECTABLE; INTRAVENOUS, SUBCUTANEOUS							
ENOXAPARIN SODIUM							
AB	NANJING KING-FRIEND	300MG/3ML (100MG/ML)	A214856	001	Jun 14, 2022	Jun	NEWA
<u>ENTACAPONE</u>							
TABLET; ORAL							
ENTACAPONE							
AB	WOCKHARDT BIO AG	200MG	A078941	001	Aug 16, 2012	Nov	CAHN
<u>ENTECAVIR</u>							
TABLET; ORAL							
ENTECAVIR							
	@ ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Apr	DISC
	@	1MG	A205824	002	Aug 25, 2017	Apr	DISC
	@ YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	May	DISC
	@	1MG	A208195	002	Nov 10, 2021	May	DISC
<u>ENZALUTAMIDE</u>							
CAPSULE; ORAL							
ENZALUTAMIDE							
	@ ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	Feb	DISC
	@ APOTEX	40MG	A209645	001	Apr 22, 2022	Nov	DISC
AB		40MG	A209645	001	Apr 22, 2022	Apr	NEWA
	XTANDI						
	+! ASTELLAS	40MG	N203415	001	Aug 31, 2012	Nov	CTEC
AB	+!	40MG	N203415	001	Aug 31, 2012	Apr	CTEC
	+!	40MG	N203415	001	Aug 31, 2012	Feb	CTEC
<u>EPHEDRINE HYDROCHLORIDE</u>							
SOLUTION; INTRAVENOUS							
REZIPRES							
	+! DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun	CAHN
	+ @	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun	CAHN
	+ @	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun	CAHN
<u>EPHEDRINE SULFATE</u>							
SOLUTION; INTRAVENOUS							
EPHEDRINE SULFATE							
AP	AGGREGA	50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Apr	NEWA
	+! ENDO VENTURES	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	May	NEWA
	+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb	CMFD
AP	GLAND PHARMA LTD	50MG/ML (50MG/ML)	A216146	001	Feb 25, 2022	Feb	NEWA
AP	MANKIND PHARMA	50MG/ML (50MG/ML)	A216129	001	Apr 14, 2022	Apr	NEWA
AP	XIROMED	50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Sep	CAHN

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC							
ELESTAT							
	+ @ ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Aug	DISC
EPINASTINE HYDROCHLORIDE							
	@ AKORN	0.05%	A204055	001	May 05, 2017	Aug	DISC
AT	! SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Aug	CHRS

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
ADRENALIN							
AP	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Oct	CTEC
EPINEPHRINE							
AP	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Nov	CDFR
	+! BELCHER	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Mar	NEWA
	+! BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Oct	CAHN
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS							
EPINEPHRINE							
AP	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Oct	CMFD
SOLUTION;INTRAVENOUS							
EPINEPHRINE							
	+! INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	N211363	001	Aug 15, 2022	Aug	NEWA
SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS							
EPINEPHRINE							
	+! BELCHER	1MG/ML (1MG/ML)	N205029	001	Jul 29, 2014	Mar	CDFR
	+! BPI LABS	1MG/ML (1MG/ML)	N205029	001	Jul 29, 2014	Oct	CAHN

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION							
LIGNOSPAN FORTE							
	+! DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985	Feb	CRLD
LIGNOSPAN STANDARD							
	+! DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985	Jan	CRLD

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION							
EPIRUBICIN HYDROCHLORIDE							
>D> AP	ACTAVIS TOTOWA	50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008	Dec	DISC
>A>	@	50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008	Dec	DISC
>D> AP		200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008	Dec	DISC
>A>	@	200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008	Dec	DISC

EPLERENONE

TABLET;ORAL							
EPLERENONE							
AB	KARTHA	25MG	A214663	001	Mar 23, 2022	Mar	NEWA
AB		50MG	A214663	002	Mar 23, 2022	Mar	NEWA
AB	PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Sep	CMFD
AB		50MG	A212765	002	Aug 10, 2020	Sep	CMFD

EPTIFIBATIDE

INJECTABLE;INJECTION							
EPTIFIBATIDE							
	@ AKORN	2MG/ML	A204589	001	Apr 18, 2017	Aug	DISC
	@	75MG/100ML	A204589	002	Apr 18, 2017	Aug	DISC
	@ BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Sep	DISC
AP	SHUANGCHENG	75MG/100ML	A213081	002	Apr 20, 2022	Apr	NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL							
ERLOTINIB HYDROCHLORIDE							
>D> AB	EUGIA PHARMA	EQ 25MG BASE	A216342	001	Jun 22, 2022	Dec	DISC
>A>	@	EQ 25MG BASE	A216342	001	Jun 22, 2022	Dec	DISC
AB		EQ 25MG BASE	A216342	001	Jun 22, 2022	Jun	NEWA
>D> AB		EQ 100MG BASE	A216342	002	Jun 22, 2022	Dec	DISC
>A>	@	EQ 100MG BASE	A216342	002	Jun 22, 2022	Dec	DISC
AB		EQ 100MG BASE	A216342	002	Jun 22, 2022	Jun	NEWA
>D> AB		EQ 150MG BASE	A216342	003	Jun 22, 2022	Dec	DISC
>A>	@	EQ 150MG BASE	A216342	003	Jun 22, 2022	Dec	DISC
AB		EQ 150MG BASE	A216342	003	Jun 22, 2022	Jun	NEWA

ERTAPENEM SODIUMINJECTABLE; INTRAMUSCULAR, INTRAVENOUS
INVANZ

AP	+!	MSD SUB MERCK	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Jun CAHN
----	----	---------------	------------------	---------	-----	--------------	----------

ERTUGLIFLOZINTABLET; ORAL
STEGLATRO

+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Jun CAHN
+	!	15MG	N209803	002	Dec 19, 2017	Jun CAHN

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDETABLET; ORAL
SEGLUROMET

+	MSD SUB MERCK	2.5MG; 500MG	N209806	001	Dec 19, 2017	Jun CAHN
+		2.5MG; 1GM	N209806	002	Dec 19, 2017	Jun CAHN
+		7.5MG; 500MG	N209806	003	Dec 19, 2017	Jun CAHN
+	!	7.5MG; 1GM	N209806	004	Dec 19, 2017	Jun CAHN

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATETABLET; ORAL
STEGLUJAN

+	MSD SUB MERCK	5MG; EQ 100MG BASE	N209805	001	Dec 19, 2017	Jun CAHN
+	!	15MG; EQ 100MG BASE	N209805	002	Dec 19, 2017	Jun CAHN

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS; ORAL
ERYC

AB	+!	MAYNE PHARMA	250MG	N050536	001		Nov CAHN
----	----	--------------	-------	---------	-----	--	----------

SOLUTION; TOPICAL
ERYTHRA-DERM

AT		MICRO LABS	2%	A062687	001	Feb 05, 1988	Aug CAHN
----	--	------------	----	---------	-----	--------------	----------

ERYTHROMYCIN

@	BAUSCH	2%	A064039	001	Jan 27, 1994	Jul CAHN
---	--------	----	---------	-----	--------------	----------

>D>	AT	WOCKHARDT BIO AG	2%	A062825	001	Oct 23, 1987	Dec CAHN
-----	----	------------------	----	---------	-----	--------------	----------

>A>	AT	XTTRIUM LABS INC	2%	A062825	001	Oct 23, 1987	Dec CAHN
-----	----	------------------	----	---------	-----	--------------	----------

TABLET; ORAL

ERYTHROMYCIN

AB		ALKEM LABS LTD	250MG	A216066	001	Jul 13, 2022	Jul NEWA
AB			500MG	A216066	002	Jul 13, 2022	Jul NEWA
>D>	BX	AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Dec CTEC
>A>	AB		250MG	A209720	001	Mar 09, 2018	Dec CTEC
>D>	BX		500MG	A209720	002	Mar 09, 2018	Dec CTEC
>A>	AB		500MG	A209720	002	Mar 09, 2018	Dec CTEC

TABLET, COATED PARTICLES; ORAL
PCE

+	@	AZURITY	333MG	N050611	001	Sep 09, 1986	May CAHN
+	@		500MG	N050611	002	Aug 22, 1990	May CAHN

ERYTHROMYCIN ETHYLSUCCINATEGRANULE; ORAL
E.E.S.

AB	+	AZURITY	EQ 200MG BASE/5ML	N050207	001		May CAHN
----	---	---------	-------------------	---------	-----	--	----------

ERYPED

AB	+	AZURITY	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	May CAHN
----	---	---------	-------------------	---------	-----	--------------	----------

AB	+!		EQ 400MG BASE/5ML	N050207	002		May CAHN
----	----	--	-------------------	---------	-----	--	----------

ERYTHROMYCIN ETHYLSUCCINATE

AB		CADILA PHARMS LTD	EQ 200MG BASE/5ML	A216212	001	Nov 21, 2022	Nov NEWA
----	--	-------------------	-------------------	---------	-----	--------------	----------

AB			EQ 400MG BASE/5ML	A216212	002	Nov 21, 2022	Nov NEWA
----	--	--	-------------------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

E.E.S.

@	AZURITY	EQ 200MG BASE	N050297	002		May CAHN
---	---------	---------------	---------	-----	--	----------

ERYPED

@	AZURITY	EQ 200MG BASE	N050297	003	Jul 05, 1988	May CAHN
---	---------	---------------	---------	-----	--------------	----------

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE

AP	NEXUS PHARMS	EQ 500MG BASE/VIAL	A215290	001	Feb 14, 2022	Feb NEWA
----	--------------	--------------------	---------	-----	--------------	----------

ESCITALOPRAM OXALATE

TABLET; ORAL
ESCITALOPRAM OXALATE

>D>	AB	TEVA PHARMS USA	EQ 5MG BASE	A076765	001	Mar 14, 2012	Dec DISC
>A>		@	EQ 5MG BASE	A076765	001	Mar 14, 2012	Dec DISC
>D>	AB		EQ 10MG BASE	A076765	002	Mar 14, 2012	Dec DISC
>A>		@	EQ 10MG BASE	A076765	002	Mar 14, 2012	Dec DISC
>D>	AB		EQ 20MG BASE	A076765	003	Mar 14, 2012	Dec DISC
>A>		@	EQ 20MG BASE	A076765	003	Mar 14, 2012	Dec DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
ESMOLOL HYDROCHLORIDE

>A>	AP	AMNEAL	10MG/ML	A216603	001	Dec 13, 2022	Dec NEWA
>A>	AP		20MG/ML	A216603	002	Dec 13, 2022	Dec NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
ESOMEPRAZOLE MAGNESIUM

@	GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Nov CAHN
@		EQ 40MG BASE	A213859	002	Nov 18, 2020	Nov CAHN

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	ACTAVIS LABS FL INC	EQ 20MG BASE; 375MG	A204470	001	Aug 24, 2022	Aug NEWA
AB		EQ 20MG BASE; 500MG	A204470	002	Aug 24, 2022	Aug NEWA
AB	AJANTA PHARMA LTD	EQ 20MG BASE; 375MG	A213699	001	Oct 06, 2022	Sep NEWA
AB		EQ 20MG BASE; 500MG	A213699	002	Oct 06, 2022	Sep NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	HAINAN POLY	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Feb NEWA
	@ MYLAN	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Apr CAHN
	@	EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Apr CAHN
	@ MYLAN LABS LTD	EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Apr DISC
	@ SUN PHARM	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Feb CAHN
AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Feb CAHN

ESTRADIOL

GEL; TRANSDERMAL
DIVIGEL

AB	+! VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jul CFTG
----	------------------------	------	---------	-----	--------------	----------

AB	CHEMO RESEARCH SL	0.1%	A211783	001	Aug 10, 2022	Jul NFTG
----	-------------------	------	---------	-----	--------------	----------

SYSTEM; TRANSDERMAL
ESTRADIOL

AB1	AMNEAL	0.025MG/24HR	A211293	001	Feb 04, 2019	Sep CTEC
AB		0.025MG/24HR	A211293	001	Feb 04, 2019	Aug CTEC
AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Sep CTEC
AB		0.0375MG/24HR	A211293	002	Feb 04, 2019	Aug CTEC
AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Sep CTEC
AB		0.05MG/24HR	A211293	003	Feb 04, 2019	Aug CTEC
AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Sep CTEC
AB		0.075MG/24HR	A211293	004	Feb 04, 2019	Aug CTEC
AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Sep CTEC
AB		0.1MG/24HR	A211293	005	Feb 04, 2019	Aug CTEC
AB1	ZYDUS NOVELTECH INC	0.025MG/24HR	A206241	001	Dec 01, 2022	Nov NEWA
AB1		0.0375MG/24HR	A206241	002	Dec 01, 2022	Nov NEWA
AB1		0.05MG/24HR	A206241	003	Dec 01, 2022	Nov NEWA
AB1		0.075MG/24HR	A206241	004	Dec 01, 2022	Nov NEWA
AB1		0.1MG/24HR	A206241	005	Dec 01, 2022	Nov NEWA

TABLET; ORAL
ESTRADIOL

@	LANNETT CO INC	0.5MG	A040138	001	Jan 30, 1998	May CAHN
---	----------------	-------	---------	-----	--------------	----------

TABLET;ORAL
ESTRADIOL

@	1MG	A040138	002	Jan 30, 1998	May CAHN
@	2MG	A040138	003	Jan 30, 1998	May CAHN
@ MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Feb DISC
@	1MG	A040114	001	Mar 14, 1996	Feb DISC
@	2MG	A040114	002	Mar 14, 1996	Feb DISC

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL
BIJUVA

>A>	+ @ MAYNE PHARMA	0.5MG;100MG	N210132	002	Dec 28, 2021	Dec CAHN
>A>	+!	1MG;100MG	N210132	001	Oct 28, 2018	Dec CAHN
>D>	+ @ THERAPEUTICSMD INC	0.5MG;100MG	N210132	002	Dec 28, 2021	Dec CAHN
	+ @	0.5MG;100MG	N210132	002	Dec 28, 2021	Apr DISC
>D>	+!	1MG;100MG	N210132	001	Oct 28, 2018	Dec CAHN
	+!	1MG;100MG	N210132	001	Oct 28, 2018	May CTEC
AB	+!	1MG;100MG	N210132	001	Oct 28, 2018	May CFTG

ESTRADIOL AND PROGESTERONE

	@ AMNEAL PHARMS	1MG;100MG	A214293	001	May 16, 2022	May DISC
AB		1MG;100MG	A214293	001	May 16, 2022	May NFTG

ESZOPICLONE

TABLET;ORAL
ESZOPICLONE

@ CHARTWELL RX	1MG	A091165	001	Jul 14, 2011	Jan CAHN
@	2MG	A091165	002	Jul 14, 2011	Jan CAHN
@	3MG	A091165	003	Jul 14, 2011	Jan CAHN

LUNESTA

>D> AB	+ SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Dec CAHN
>D> AB	+	2MG	N021476	002	Dec 15, 2004	Dec CAHN
>D> AB	+!	3MG	N021476	003	Dec 15, 2004	Dec CAHN
>A> AB	+ WOODWARD	1MG	N021476	001	Dec 15, 2004	Dec CAHN
>A> AB	+	2MG	N021476	002	Dec 15, 2004	Dec CAHN
>A> AB	+!	3MG	N021476	003	Dec 15, 2004	Dec CAHN

ETHACRYNIC ACID

TABLET;ORAL
ETHACRYNIC ACID

@ ALVOGEN	25MG	A205709	001	Jul 24, 2018	Aug DISC
-----------	------	---------	-----	--------------	----------

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL
ETHAMBUTOL HYDROCHLORIDE

>D> AB	BARR	400MG	A076057	001	Nov 26, 2001	Dec DISC
>A>	@	400MG	A076057	001	Nov 26, 2001	Dec DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28
ZOVIA 1/35E-28

@ MAYNE PHARMA	0.035MG;1MG	A072721	001	Dec 30, 1991	Jan DISC
----------------	-------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL
HALOETTE

AB	MAYNE PHARMA	0.015MG/24HR;0.12MG/24HR	A211328	001	Aug 05, 2022	Jul NEWA
	NUVARING					
AB	+! ORGANON USA ORGANON	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Jul CAHN
	VERARING					
	@ DR REDDYS LABS SA	0.015MG/24HR;0.12MG/24HR	A207577	001	Dec 09, 2021	Jun DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL
@ MAYNE PHARMA

	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011	Aug DISC
--	-------------------------	---------	-----	--------------	----------

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D> BX	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Dec CTEC
>A> AB1		0.02MG;0.1MG	A091425	001	Jan 18, 2013	Dec CTEC
AB1	NAARI PTE LTD	0.02MG;0.1MG	A207065	001	Aug 17, 2020	Apr CTEC

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL
ETHINYL ESTRADIOL AND NORELGESTROMIN

AB	AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Jul CTEC
----	--------	--------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL
FEMCON FE

	+ @ APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	May CDFR
	NEXESTA FE					
AB	AUROBINDO PHARMA	0.035MG;0.4MG	A207535	001	Feb 02, 2017	May CDFR
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	AMNEAL PHARMS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	May CDFR
AB	BARR	0.035MG;0.4MG	A078965	001	Aug 05, 2010	May CDFR
AB	LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	May CDFR
AB	! MYLAN LABS LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	May CDFR
AB	NAARI PTE LTD	0.035MG;0.4MG	A207066	001	Mar 29, 2017	May CDFR

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

	@ MAYNE PHARMA	0.035MG;0.5MG	A070686	001	Jan 29, 1987	Jan DISC
	RHUZDAH					
AB	AUROBINDO PHARMA	0.035MG;0.4MG	A207585	001	Oct 11, 2022	Sep NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	GLENMARK PHARMS LTD	0.02MG;1MG	A213418	001	Jul 27, 2022	Jul NEWA
	@ MAYNE PHARMA	0.02MG;1MG	A213901	001	Apr 28, 2022	Sep DISC
AB		0.02MG;1MG	A213901	001	Apr 28, 2022	Apr NEWA

TABLET;ORAL

FINZALA

AB	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	May CDFR
	MIBELAS 24 FE					
AB	LUPIN	0.02MG;1MG	A206287	001	May 24, 2016	May CDFR
	MINASTRIN 24 FE					
AB	+! APIL	0.02MG;1MG	N203667	001	May 08, 2013	May CDFR
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	@ AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jun DISC
	@	0.02MG;1MG	A207514	001	Sep 11, 2017	May CDFR
AB	! GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Jun CHRS
AB		0.02MG;1MG	A210369	001	Dec 26, 2017	May CDFR
	@ MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017	May CDFR
AB	XIROMED	0.02MG;1MG	A209609	001	Jul 16, 2018	May CDFR

TABLET;ORAL-21

MICROGESTIN 1.5/30

	@ MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Jan DISC
	MICROGESTIN 1/20					
	@ MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Jan DISC

TABLET;ORAL-28

JUNEL FE 1.5/30

AB	! BARR	0.03MG;1.5MG	A076064	001	Sep 18, 2003	Jun CHRS
	MICROGESTIN FE 1.5/30					
	@ MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Jan DISC
	MICROGESTIN FE 1/20					
	@ MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Jan DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	@ MAYNE PHARMA	0.02MG, 0.03MG, 0.035MG;1MG, 1MG, 1MG	A076629	001	Mar 18, 2010	Jan DISC
AB	MYLAN	0.02MG, 0.03MG, 0.035MG;1MG, 1MG, 1MG	A205069	001	Jun 22, 2018	Feb CMFD
AB		0.02MG, 0.03MG, 0.035MG;1MG, 1MG, 1MG	A205069	001	Jun 22, 2018	Feb CAHN

TABLET, CHEWABLE;ORAL

FINZALA

AB	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Jan CMFD
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	@ AMNEAL PHARMS	0.02MG;1MG	A207514	001	Sep 11, 2017	Jan DISC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28							
TRI-LO-LINYAH							
AB	NOVAST LABS	0.025MG, 0.025MG, 0.025MG, 0.18MG, 0.215MG, 0.25MG	A090541	001	Sep 02, 2022	Aug	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21							
LO/OVRAL							
	+ @ CADENCE HEALTH	0.03MG; 0.3MG	N017612	001		Apr	CRLD
TABLET; ORAL-28							
CRYSELLE							
AB	! DURAMED PHARMS BARR	0.03MG; 0.3MG	A075840	002	Nov 30, 2001	Apr	CHRS
LO/OVRAL-28							
	+ @ WYETH PHARMS	0.03MG; 0.3MG	N017802	001		Apr	CRLD

ETHOSUXIMIDE

CAPSULE; ORAL							
ETHOSUXIMIDE							
>D> BX	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Dec	CTEC
>A> AB		250MG	A200892	001	Sep 25, 2012	Dec	CTEC
AB	PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Nov	CTEC

ETONOGESTREL

IMPLANT; IMPLANTATION							
IMPLANON							
	@ ORGANON	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jan	CAHN
NEXPLANON							
	+! ORGANON	68MG/IMPLANT	N021529	002	May 31, 2011	Jan	CAHN

ETRAVIRINE

TABLET; ORAL							
ETRAVIRINE							
AB	CARNEGIE	100MG	A215402	001	Apr 13, 2022	Apr	NEWA
AB		200MG	A215402	002	Apr 13, 2022	Apr	NEWA

EXEMESTANE

TABLET; ORAL							
EXEMESTANE							
AB	EUGIA PHARMA	25MG	A216454	001	May 20, 2022	May	NEWA

EZETIMIBE

TABLET; ORAL							
EZETIMIBE							
	@ APOTEX	10MG	A208332	001	Jun 12, 2017	Apr	DISC
AB	HETERO LABS LTD III	10MG	A210859	001	Jul 26, 2022	Jul	NEWA
AB	ORIENT PHARMA	10MG	A215693	001	Sep 13, 2022	Sep	NEWA

EZETIMIBE; ROSUVASTATIN CALCIUM

TABLET; ORAL							
ROSZET							
	+ @ ALTHERA PHARMS	10MG; EQ 5MG BASE	N213072	001	Mar 23, 2021	Sep	DISC
	+ @	10MG; EQ 10MG BASE	N213072	002	Mar 23, 2021	Sep	DISC
	+ @	10MG; EQ 20MG BASE	N213072	003	Mar 23, 2021	Sep	DISC
	+ @	10MG; EQ 40MG BASE	N213072	004	Mar 23, 2021	Sep	DISC

FAMCICLOVIR

TABLET; ORAL							
FAMCICLOVIR							
	@ CIPLA	125MG	A078278	001	Mar 21, 2011	Mar	DISC
	@	250MG	A078278	002	Mar 21, 2011	Mar	DISC
	@	500MG	A078278	003	Mar 21, 2011	Mar	DISC

FAMOTIDINE

FOR SUSPENSION; ORAL							
FAMOTIDINE							
AB	AMNEALS PHARMS	40MG/5ML	A216427	001	Aug 04, 2022	Jul	NEWA
INJECTABLE; INJECTION							
FAMOTIDINE							
AP	ZYDUS PHARMS	10MG/ML	A215828	001	Nov 22, 2022	Nov	NEWA

INJECTABLE;INJECTION

FAMOTIDINE PRESERVATIVE FREE

@ AKORN 10MG/ML

A 076324 001 Nov 27, 2002 Feb CAHN

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

@ AKORN 10MG/ML

A 076322 001 Nov 27, 2002 Feb CAHN

TABLET;ORAL

FAMOTIDINE

AB ALKEM LABS LTD 20MG

A 215630 001 Jan 07, 2022 Nov CAHN

AB 40MG

A 215630 002 Jan 07, 2022 Nov CAHN

@ PERRIGO R AND D 20MG

A 077352 002 Jul 27, 2005 Sep DISC

@ 40MG

A 077352 001 Jul 27, 2005 Sep DISC

AB ZYDUS PHARMS 20MG

A 216441 001 Jun 03, 2022 May NEWA

AB 40MG

A 216441 002 Jun 03, 2022 May NEWA

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB PRINSTON INC 40MG

A 206266 001 Mar 28, 2022 Mar NEWA

AB 80MG

A 206266 002 Mar 28, 2022 Mar NEWA

>A> AB ZYDUS PHARMS 40MG

A 205443 001 Jan 09, 2023 Dec NEWA

>A> AB 80MG

A 205443 002 Jan 09, 2023 Dec NEWA

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

+ @ LUPIN 30MG

N 021695 004 Oct 18, 2013 Jul DISC

FENOFIBRATE (MICRONIZED)

>D> AB AJANTA PHARMA LTD 200MG

A 210705 003 Sep 10, 2018 Dec CHRS

>A> AB ! 200MG

A 210705 003 Sep 10, 2018 Dec CHRS

>D> AB IMPAX LABS 67MG

A 075868 001 Oct 27, 2003 Dec DISC

>A> @ 67MG

A 075868 001 Oct 27, 2003 Dec DISC

>D> AB 134MG

A 075868 002 Oct 27, 2003 Dec DISC

>A> @ 134MG

A 075868 002 Oct 27, 2003 Dec DISC

>D> AB ! 200MG

A 075868 003 Oct 27, 2003 Dec DISC

>A> @ 200MG

A 075868 003 Oct 27, 2003 Dec DISC

TABLET;ORAL

FENOFIBRATE

AB AUROBINDO PHARMA 54MG

A 216798 001 Sep 27, 2022 Sep NEWA

AB 160MG

A 216798 002 Sep 27, 2022 Sep NEWA

AB GRAVITI PHARMS 54MG

A 210606 001 Aug 17, 2018 Sep CAHN

AB 160MG

A 210606 002 Aug 17, 2018 Sep CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

+ @ ATHENA 105MG

N 022418 002 Aug 14, 2009 Oct DISC

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AB RISING EQ 400MG BASE

A 214475 001 Jul 18, 2022 Jul NFTG

NALFON

AB +! XSPIRE PHARMA EQ 400MG BASE

N 017604 004 Jul 21, 2009 Jul CFTG

TABLET;ORAL

FENOPROFEN CALCIUM

@ STRIDES PHARMA EQ 600MG BASE

A 072429 001 Aug 17, 1988 Jul CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

@ AVEVA 100MCG/HR

A 077449 004 Oct 20, 2008 Oct DISC

FENTANYL-12

@ AVEVA 12.5MCG/HR

A 077449 005 Sep 11, 2015 Oct DISC

FENTANYL-25

@ AVEVA 25MCG/HR

A 077449 001 Oct 20, 2008 Oct DISC

FENTANYL-37

@ AVEVA 37.5MCG/HR

A 077449 006 Dec 06, 2017 Oct DISC

FENTANYL-50

@ AVEVA 50MCG/HR

A 077449 002 Oct 20, 2008 Oct DISC

FENTANYL-62

@ AVEVA 62.5MCG/HR

A 077449 007 Dec 06, 2017 Oct DISC

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-75

@ AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Oct DISC
FENTANYL-87					
@ AVEVA	87.5MCG/HR	A077449	008	Dec 06, 2017	Oct DISC
MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014	Oct CTEC

FENTANYL CITRATE

TABLET;BUCCAL, SUBLINGUAL
FENTANYL CITRATE

	@ MAYNE PHARMA	EQ 0.1MG BASE	A206329	001	Aug 22, 2022	Oct DISC
AB		EQ 0.1MG BASE	A206329	001	Aug 22, 2022	Aug NEWA
	@	EQ 0.2MG BASE	A206329	002	Aug 22, 2022	Oct DISC
AB		EQ 0.2MG BASE	A206329	002	Aug 22, 2022	Aug NEWA
	@	EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Oct DISC
		EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Aug NEWA
	@	EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Oct DISC
AB		EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Aug NEWA
	@	EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Oct DISC
AB		EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Aug NEWA
	@	EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Oct DISC
AB		EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Aug NEWA
	FENTORA					
	+ CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Oct CTEC
AB		EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Aug CTEC
	+	EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Oct CTEC
AB		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Aug CTEC
	+	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Oct CTEC
AB		EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Aug CTEC
	+	EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Oct CTEC
AB		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Aug CTEC
	+	EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Oct CTEC
AB		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Aug CTEC

FERRIC CARBOXYMALTOS

SOLUTION;INTRAVENOUS
INJECTAFER

+! AM REGENT	100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022	Feb NEWA
--------------	-------------------------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS
TRIFERIC

+ @ ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Oct DISC
SOLUTION;INTRAVENOUS					
TRIFERIC					
+ @ ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Oct DISC
TRIFERIC AVNU					
+ @ ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020	Oct DISC

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

>A> AB	ACCORD HLTHCARE	4MG	A205012	001	Jan 04, 2023	Dec NEWA
>A> AB		8MG	A205012	002	Jan 04, 2023	Dec NEWA
>A> AB	ACTAVIS LABS FL INC	4MG	A204868	001	Jan 04, 2023	Dec NEWA
>A> AB		8MG	A204868	002	Jan 04, 2023	Dec NEWA
>A> AB	ALEMBIC PHARMS	4MG	A204973	001	Jan 04, 2023	Dec NEWA
>A> AB		8MG	A204973	002	Jan 04, 2023	Dec NEWA
AB	ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	May CMFD
AB		8MG	A204827	002	Dec 10, 2015	May CMFD
>A> AB	AMNEAL PHARMS NY	4MG	A205002	001	Jan 04, 2023	Dec NEWA
>A> AB		8MG	A205002	002	Jan 04, 2023	Dec NEWA
>A> AB	ANI PHARMS	4MG	A204504	001	Jan 04, 2023	Dec NEWA
>A> AB		8MG	A204504	002	Jan 04, 2023	Dec NEWA
AB	DR REDDYS	4MG	A204975	001	Aug 13, 2019	Jun CMFD
AB		8MG	A204975	002	Aug 13, 2019	Jun CMFD
>A> AB	LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Dec NEWA
>A> AB		8MG	A204983	002	Jan 05, 2023	Dec NEWA

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL

ALLEGRA

@	CHATTEM SANOFI	60MG	N020625	001	Jul 25, 1996	Jan CAHN
@		60MG	N020625	001	Jul 25, 1996	Jan CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Sep CMFD
AB	APOTEX	EQ 0.5MG BASE	A207993	001	Dec 18, 2020	Oct CMFD
AB	DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Aug CMFD
AB	GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Sep CMFD
AB	HETERO LABS LTD V	EQ 0.5MG BASE	A207933	001	May 18, 2020	Jul CMFD
AB	MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Aug CMFD
	@	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb DISC
AB		EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb CAHN
AB	PRINSTON INC	EQ 0.5MG BASE	A208003	001	Sep 07, 2022	Aug NEWA
AB	SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug CMFD
	@ TEVA PHARMS USA	EQ 0.25MG BASE	A212152	001	Nov 12, 2021	Jun DISC
AB	ZYDUS PHARMS	EQ 0.5MG BASE	A207994	001	Oct 14, 2020	Oct CMFD
	GILENYA					
+	NOVARTIS	EQ 0.25MG BASE	N022527	002	May 11, 2018	Jun CTEC

FINGOLIMOD LAURYL SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

TASCENSO ODT

>D>	+	HANDA	EQ 0.25MG BASE	N214962	001	Dec 23, 2021	Dec CHRS
>A>	+		EQ 0.25MG BASE	N214962	001	Dec 23, 2021	Dec CHRS
	+		EQ 0.25MG BASE	N214962	001	Dec 23, 2021	Nov CMFD
	+	@	EQ 0.25MG BASE	N214962	001	Dec 23, 2021	Sep DISC
>A>	+		EQ 0.5MG BASE	N214962	002	Dec 09, 2022	Dec NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

	@	CHARTWELL	50MG	A079164	001	Jul 09, 2009	Feb CAHN
	@		100MG	A079164	002	Jul 09, 2009	Feb CAHN
	@		150MG	A079164	003	Jul 09, 2009	Feb CAHN
AB		YICHANG HUMANWELL	50MG	A215599	001	Sep 08, 2022	Aug NEWA
AB			100MG	A215599	002	Sep 08, 2022	Aug NEWA
AB			150MG	A215599	003	Sep 08, 2022	Aug NEWA

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

+	LIFE MOLECULAR	1.4-135mCi/ML	N204677	001	Mar 19, 2014	Nov CPOT
---	----------------	---------------	---------	-----	--------------	----------

FLORTAUCIPIR F-18

SOLUTION;INTRAVENOUS

TAUVID

+	AVID RADIOPHARMS INC	50ML (8.1-100mCi/ML)	N212123	003	Jul 01, 2022	Sep NEWA
+		100ML (8.1-100mCi/ML)	N212123	004	Jul 01, 2022	Sep NEWA

FLUCONAZOLE

TABLET;ORAL

FLUCONAZOLE

>D>	AB	IVAX SUB TEVA PHARMS	50MG	A076077	001	Jul 29, 2004	Dec DISC
>A>		@	50MG	A076077	001	Jul 29, 2004	Dec DISC
>D>	AB		100MG	A076077	002	Jul 29, 2004	Dec DISC
>A>		@	100MG	A076077	002	Jul 29, 2004	Dec DISC
>D>	AB		150MG	A076077	003	Jul 29, 2004	Dec DISC
>A>		@	150MG	A076077	003	Jul 29, 2004	Dec DISC
>D>	AB		200MG	A076077	004	Jul 29, 2004	Dec DISC
>A>		@	200MG	A076077	004	Jul 29, 2004	Dec DISC
	AB	THINQ PHARM-CRO PVT	50MG	A076957	001	Sep 28, 2005	Jun CAHN
	AB		100MG	A076957	002	Sep 28, 2005	Jun CAHN
	AB		150MG	A076957	004	Feb 27, 2017	Jun CAHN
	AB		200MG	A076957	003	Sep 28, 2005	Jun CAHN

FLUCYTOSINECAPSULE;ORAL
FLUCYTOSINE

AB	STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Feb CMFD
AB		500MG	A212632	002	Apr 17, 2020	Feb CMFD

FLUDARABINE PHOSPHATEINJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

AP	HIKMA	50MG/VIAL	A076349	001	Aug 28, 2003	Aug CAHN
----	-------	-----------	---------	-----	--------------	----------

FLUDEOXYGLUCOSE F-18INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

>D>	HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014	Dec DISC
>A>	@	4-500mCi/ML	A203937	001	Oct 30, 2014	Dec DISC

FLUDROCORTISONE ACETATETABLET;ORAL
FLUDROCORTISONE ACETATE

AB	HIKMA	0.1MG	A216013	001	Oct 27, 2022	Oct NEWA
AB	NOVITIUM PHARMA	0.1MG	A215279	001	May 31, 2022	May NEWA

FLUNISOLIDESPRAY, METERED;NASAL
FLUNISOLIDE

	@ APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	May DISC
AB	! BAUSCH	0.025MG/SPRAY	A074805	001	Feb 20, 2002	Jun CAHN
AB	RICONPHARMA LLC	0.025MG/SPRAY	A207802	001	Jun 16, 2022	Jun NEWA

FLUOCINOLONE ACETONIDECREAM;TOPICAL
FLUOCINOLONE ACETONIDE

@ MLV	0.025%	A088045	001	Dec 16, 1982	Sep CAHN
-------	--------	---------	-----	--------------	----------

OIL;TOPICAL
FLUOCINOLONE ACETONIDE

@ AMNEAL	0.01%	A201759	001	Oct 17, 2011	Jul DISC
@	0.01%	A201764	001	Oct 17, 2011	Jul DISC

OIL/DROPS;OTIC
FLUOCINOLONE ACETONIDE

@ AMNEAL	0.01%	A091306	001	Oct 17, 2011	Jul DISC
----------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE

@ PAI HOLDINGS PHARM	0.01%	A088312	001	Jan 27, 1984	Apr CAHN
----------------------	-------	---------	-----	--------------	----------

FLUOCINONIDECREAM;TOPICAL
FLUOCINONIDE

@ ENCUBE	0.05%	A211410	001	Oct 16, 2018	Jul CAHN
----------	-------	---------	-----	--------------	----------

LIDEX-E

+ @ ALVOGEN	0.05%	N016908	003		Aug DISC
-------------	-------	---------	-----	--	----------

FLUOROMETHOLONEOINTMENT;OPHTHALMIC
FML

+ @ ALLERGAN	0.1%	N017760	001	Sep 04, 1985	Aug DISC
--------------	------	---------	-----	--------------	----------

FLUOROURACILCREAM;TOPICAL
FLUOROPLEX

+ @ CHARTWELL RX	1%	N016988	001		Jul CAHN
------------------	----	---------	-----	--	----------

INJECTABLE;INJECTION
FLUOROURACIL

@ EUGIA PHARMA SPECILTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Mar CAHN
@	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Mar CAHN
@	2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Mar CAHN
@	5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Mar CAHN
>D> AP	TEVA PHARMS USA	A040333	001	Jan 27, 2000	Dec DISC
>A>	@	A040333	001	Jan 27, 2000	Dec DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1	MICRO LABS	EQ 10MG BASE	A216232	001	Mar 29, 2022	Mar	NEWA
AB1		EQ 20MG BASE	A216232	002	Mar 29, 2022	Mar	NEWA
AB		EQ 40MG BASE	A216232	003	Mar 29, 2022	Mar	NEWA

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA	APTAPHARMA INC	EQ 20MG BASE/5ML	A216953	001	Nov 15, 2022	Nov	NEWA
AA	NOVITIUM PHARMA	EQ 20MG BASE/5ML	A216448	001	Nov 09, 2022	Nov	NEWA

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB	PIRAMAL HLTHCARE UK	EQ 10MG BASE	A211444	001	Sep 13, 2022	Sep	NEWA
AB		EQ 20MG BASE	A211444	002	Sep 13, 2022	Sep	NEWA

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

>A>	AB	AJANTA PHARMA LTD	1MG	A217410	001	Jan 05, 2023	Dec	NEWA
>A>	AB		2.5MG	A217410	002	Jan 05, 2023	Dec	NEWA
>A>	AB		5MG	A217410	003	Jan 05, 2023	Dec	NEWA
>A>	AB		10MG	A217410	004	Jan 05, 2023	Dec	NEWA
	AB	APOTEX	1MG	A216649	001	Jul 15, 2022	Jul	NEWA
	AB		2.5MG	A216649	002	Jul 15, 2022	Jul	NEWA
	AB		5MG	A216649	003	Jul 15, 2022	Jul	NEWA
	AB		10MG	A216649	004	Jul 15, 2022	Jul	NEWA
	AB	PRASCO	1MG	A089804	002	Aug 12, 1988	Jun	CMFD
	@		1MG	A089804	002	Aug 12, 1988	Mar	CAHN
	AB		2.5MG	A089804	003	Aug 12, 1988	Jun	CMFD
	@		2.5MG	A089804	003	Aug 12, 1988	Mar	CAHN
	AB		5MG	A089804	004	Aug 12, 1988	Jun	CMFD
	@		5MG	A089804	004	Aug 12, 1988	Mar	CAHN
	AB		10MG	A089804	001	Aug 12, 1988	Jun	CMFD
	@		10MG	A089804	001	Aug 12, 1988	Mar	CAHN
	AB	SANDOZ INC	1MG	A216891	001	Nov 15, 2022	Nov	NEWA
	AB		2.5MG	A216891	002	Nov 15, 2022	Nov	NEWA
	AB		5MG	A216891	003	Nov 15, 2022	Nov	NEWA
	AB		10MG	A216891	004	Nov 15, 2022	Nov	NEWA
	AB	TARO PHARM INDS LTD	1MG	A215674	001	Apr 14, 2022	Apr	NEWA
	AB		2.5MG	A215674	002	Apr 14, 2022	Apr	NEWA
	AB		5MG	A215674	003	Apr 14, 2022	Apr	NEWA
	AB		10MG	A215674	004	Apr 14, 2022	Apr	NEWA
>A>	AB	TWI PHARMS	1MG	A215848	004	Dec 14, 2022	Dec	NEWA
	AB		2.5MG	A215848	001	Apr 01, 2022	Mar	NEWA
	AB		5MG	A215848	002	Apr 01, 2022	Mar	NEWA
	AB		10MG	A215848	003	Apr 01, 2022	Mar	NEWA
	AB	UPSHER SMITH LABS	1MG	A213784	001	Oct 24, 2022	Nov	CAHN
	AB		2.5MG	A213784	002	Oct 24, 2022	Nov	CAHN
	AB		5MG	A213784	003	Oct 24, 2022	Nov	CAHN
	AB		10MG	A213784	004	Oct 24, 2022	Nov	CAHN
	AB	ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Nov	CAHN
	AB		2.5MG	A215141	002	Oct 20, 2021	Nov	CAHN
	AB		5MG	A215141	003	Oct 20, 2021	Nov	CAHN
	AB		10MG	A215141	004	Oct 20, 2021	Nov	CAHN
	AB	ZENARA	1MG	A213784	001	Oct 24, 2022	Oct	NEWA
	AB		2.5MG	A213784	002	Oct 24, 2022	Oct	NEWA
	AB		5MG	A213784	003	Oct 24, 2022	Oct	NEWA
	AB		10MG	A213784	004	Oct 24, 2022	Oct	NEWA

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

+	@	ALMIRALL	0.05%	N012806	002		Sep	DISC
+	!		0.05%	N012806	002		Feb	CTEC

FLURANDRENOLIDE

@ CINTEX SVCS

LOTION;TOPICAL

FLURANDRENOLIDE

@ CINTEX SVCS

		0.05%	A205342	001	Apr 13, 2016	Feb	DISC
		0.05%	A205343	001	Dec 22, 2016	Feb	DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

RISING

15MG

A070345 002 Nov 27, 1985 Apr CAHN

!

30MG

A070345 001 Nov 27, 1985 Apr CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

@ CHARTWELL RX

125MG

A075818 001 Sep 18, 2001 Jan CAHN

FLUTICASONE PROPIONATE

CREAM; TOPICAL

FLUTICASONE PROPIONATE

>D>

@ ANDA REPOSITORY

0.05%

A076633 001 May 14, 2004 Dec CAHN

>A>

@ ENCUBE

0.05%

A076633 001 May 14, 2004 Dec CAHN

LOTION; TOPICAL

CUTIVATE

+ @ FOUGERA PHARMS

0.05%

N021152 001 Mar 31, 2005 Mar DISC

AB

+

0.05%

N021152 001 Mar 31, 2005 Mar CHRS

FLUTICASONE PROPIONATE

AB

!

GLENMARK GENERICS

0.05%

A090759 001 May 02, 2011 Mar CHRS

POWDER; INHALATION

ARMONAIR DIGIHALER

+ @ TEVA PHARM

0.03MG/INH

N208798 008 Apr 08, 2022 Apr NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB

BIONPHARMA INC

100MG

A212182 002 Sep 16, 2020 Feb CMFD

TABLET; ORAL

FLUVOXAMINE MALEATE

@ CHARTWELL RX

25MG

A075900 001 Feb 23, 2006 Aug CAHN

@

50MG

A075900 002 Feb 23, 2006 Aug CAHN

@

100MG

A075900 003 Feb 23, 2006 Aug CAHN

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

AN

AUCTA

0.02MG/2ML

A216486 001 Nov 25, 2022 Nov NEWA

AN

LUPIN

0.02MG/2ML

A215053 001 Aug 22, 2022 Aug NEWA

>A> AN

SLAYBACK PHARMA LLC

0.02MG/2ML

A215621 001 Dec 13, 2022 Dec NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

@ APOTEX

EQ 150MG BASE/VIAL

A205020 001 Sep 05, 2019 Nov DISC

@ ARTHUR GRP

EQ 150MG BASE/VIAL

A211624 001 Sep 05, 2019 Mar CAHN

@

EQ 150MG BASE/VIAL

A213199 001 Oct 04, 2021 Mar CAHN

@ PRAXGEN

EQ 150MG BASE/VIAL

A211624 001 Sep 05, 2019 Feb DISC

@

EQ 150MG BASE/VIAL

A213199 001 Oct 04, 2021 Feb DISC

@ SANDOZ INC

EQ 150MG BASE/VIAL

A203939 001 Dec 08, 2020 Oct DISC

FOSDENOPTERIN HYDROBROMIDE

POWDER; INTRAVENOUS

NULIBRY

+! SENTYNL THERAPS INC

EQ 9.5MG BASE/VIAL

N214018 001 Feb 26, 2021 Mar CAHN

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSFOMYCIN TROMETHAMINE

AA

CIPLA

EQ 3GM BASE/PACKET

A211881 001 Jan 26, 2022 Jan NEWA

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB

RENATA

EQ 2.5MG BASE

A213891 001 Apr 06, 2022 May CAHN

AB

ZENARA

EQ 2.5MG BASE

A213891 001 Apr 06, 2022 Mar NEWA

FULVESTRANTINJECTABLE; INTRAMUSCULAR
FULVESTRANT

	@ APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jan DISC
AO	JIANGSU HANSON PHARM	50MG/ML	A214682	001	Feb 10, 2022	Feb NEWA
AO	ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Feb CMFD

SOLUTION; INTRAMUSCULAR
FASLODEX

AO	+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002	Oct CDFR
	+	@	125MG/2.5ML (50MG/ML)	N021344	002	Apr 25, 2002	Oct DISC
	+		125MG/2.5ML (50MG/ML)	N021344	002	Apr 25, 2002	Oct NEWA
AO	+	!	250MG/5ML (50MG/ML)	N021344	001	Apr 25, 2002	Oct CPOT

FULVESTRANT

AO		ACCORD HLTHCARE	50MG/ML	A211689	001	Nov 17, 2020	Oct CDFR
AO			250MG/5ML (50MG/ML)	A211689	001	Nov 17, 2020	Oct CPOT
>A>	AO	ALEMBIC PHARMS	250MG/5ML (50MG/ML)	A215077	001	Dec 22, 2022	Dec NEWA
AO		AMNEAL	50MG/ML	A210044	001	Mar 04, 2019	Oct CDFR
AO			250MG/5ML (50MG/ML)	A210044	001	Mar 04, 2019	Oct CPOT
		@ APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Oct CDFR
		@	250MG/5ML (50MG/ML)	A211730	001	Jun 11, 2021	Oct CPOT
AO		CHIA TAI TIANQING	50MG/ML	A211422	001	Feb 07, 2020	Oct CDFR
AO			250MG/5ML (50MG/ML)	A211422	001	Feb 07, 2020	Oct CPOT
AO		DR REDDYS	50MG/ML	A209246	001	Aug 07, 2020	Oct CDFR
AO			250MG/5ML (50MG/ML)	A209246	001	Aug 07, 2020	Oct CPOT
AO		EUGIA PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Oct CDFR
AO			250MG/5ML (50MG/ML)	A208811	001	Jul 23, 2019	Oct CPOT
AO		GLENMARK PHARMS INC	50MG/ML	A207754	001	Aug 22, 2019	Oct CDFR
AO			250MG/5ML (50MG/ML)	A207754	001	Aug 22, 2019	Oct CPOT
AO		HBT LABS INC	50MG/ML	A209714	001	Nov 21, 2019	Oct CDFR
AO			250MG/5ML (50MG/ML)	A209714	001	Nov 21, 2019	Oct CPOT
AO		JIANGSU HANSON PHARM	50MG/ML	A214682	001	Feb 10, 2022	Oct CDFR
AO			250MG/5ML (50MG/ML)	A214682	001	Feb 10, 2022	Oct CPOT
AO		SAGENT PHARMS INC	50MG/ML	A205871	001	Aug 22, 2019	Oct CDFR
AO			250MG/5ML (50MG/ML)	A205871	001	Aug 22, 2019	Oct CPOT
AO		SANDOZ INC	50MG/ML	A205935	001	May 14, 2019	Oct CDFR
AO			250MG/5ML (50MG/ML)	A205935	001	May 14, 2019	Oct CPOT
AO		XIROMED	50MG/ML	A213553	001	Aug 13, 2021	Oct CDFR
AO			250MG/5ML (50MG/ML)	A213553	001	Aug 13, 2021	Oct CPOT
AO		ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Oct CDFR
AO			250MG/5ML (50MG/ML)	A215234	001	Jul 29, 2021	Oct CPOT

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

AP		HONG KONG	10MG/ML	A212803	001	Jan 27, 2022	Jan NEWA
>A>	AP	MANKIND PHARMA	10MG/ML	A216860	001	Dec 16, 2022	Dec NEWA
AP		MEITHEAL	10MG/ML	A212803	001	Jan 27, 2022	Mar CAHN

SOLUTION; ORAL
FUROSEMIDE

!	HIKMA	10MG/ML	A070434	001	Apr 22, 1987	May CTEC
@	WOCKHARDT BIO AG	10MG/ML	A070655	001	Oct 02, 1987	May DISC

SOLUTION; SUBCUTANEOUS
FUROSCIX

+	!	SCPHARMACEUTICALS	80MG/10ML (8MG/ML)	N209988	001	Oct 07, 2022	Oct NEWA
---	---	-------------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

FUROSEMIDE

	@	EPIC PHARMA LLC	40MG	N018750	002	Jul 30, 1984	Mar CAHN
AB		GRAVITI PHARMS	20MG	A216629	001	Oct 17, 2022	Oct NEWA
AB			40MG	A216629	002	Oct 17, 2022	Oct NEWA
AB			80MG	A216629	003	Oct 17, 2022	Oct NEWA

FUTIBATINIBTABLET; ORAL
LYTGOBI

+	!	TAIHO ONCOLOGY	4MG	N214801	001	Sep 30, 2022	Sep NEWA
---	---	----------------	-----	---------	-----	--------------	----------

GABAPENTIN

CAPSULE; ORAL							
GABAPENTIN							
	@ CHARTWELL RX	100MG	A091008	001	Oct 26, 2017	Jun	CAHN
	@	300MG	A091008	002	Oct 26, 2017	Jun	CAHN
	@	400MG	A091008	003	Oct 26, 2017	Jun	CAHN
NEURONTIN							
AB	+ VIATRIS	100MG	N020235	001	Dec 30, 1993	Feb	CAHN
AB	+	300MG	N020235	002	Dec 30, 1993	Feb	CAHN
AB	+	400MG	N020235	003	Dec 30, 1993	Feb	CAHN
SOLUTION; ORAL							
GABAPENTIN							
AA	BELCHER	250MG/5ML	A091286	001	Mar 14, 2016	Jun	CAHN
	@ PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb	CAHN
	@ VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb	CAHN
NEURONTIN							
AA	+! VIATRIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CAHN
TABLET; ORAL							
NEURONTIN							
AB	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Feb	CAHN
AB	+	800MG	N020882	002	Oct 09, 1998	Feb	CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL							
HORIZANT							
	+ AZURITY	300MG	N022399	002	Dec 13, 2011	Mar	CAHN
	+	600MG	N022399	001	Apr 06, 2011	Mar	CAHN

GADOBUTROL

SOLUTION; INTRAVENOUS							
GADAVIST							
AP	+! BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006	Dec 18, 2013	Nov	CFTG
AP	+!	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011	Nov	CFTG
AP	+!	6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011	Nov	CFTG
AP	+!	9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011	Nov	CFTG
GADOBUTROL							
AP	HENGHUI PHARMA	1.20944GM/2ML (604.72MG/ML)	A215061	001	Nov 17, 2022	Nov	NFTG
AP		4.5354GM/7.5ML (604.72MG/ML)	A215061	002	Nov 17, 2022	Nov	NFTG
AP		6.0472GM/10ML (604.72MG/ML)	A215061	003	Nov 17, 2022	Nov	NFTG
AP		9.0708GM/15ML (604.72MG/ML)	A215061	004	Nov 17, 2022	Nov	NFTG

GADOPICLENOL

SOLUTION; INTRAVENOUS							
ELUCIREM							
	+! GUERBET	1.4553GM/3ML (485.1MG/ML)	N216986	001	Sep 21, 2022	Sep	NEWA
	+!	3.63825GM/7.5ML (485.1MG/ML)	N216986	002	Sep 21, 2022	Sep	NEWA
	+!	4.851GM/10ML (485.1MG/ML)	N216986	003	Sep 21, 2022	Sep	NEWA
	+!	7.2765GM/15ML (485.1MG/ML)	N216986	004	Sep 21, 2022	Sep	NEWA
	+!	14.553GM/30ML (485.1MG/ML)	N216986	005	Sep 21, 2022	Sep	NEWA
	+!	24.255GM/50ML (485.1MG/ML)	N216986	006	Sep 21, 2022	Sep	NEWA
	+!	48.51GM/100ML (485.1MG/ML)	N216986	007	Sep 21, 2022	Sep	NEWA

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS							
GADOTERATE MEGLUMINE							
AP	HENGHUI PHARMA	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Jun	CAHN
AP		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Jun	CAHN
AP		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Jun	CAHN
AP		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Jun	CAHN
AP		37.69GM/100ML (376.9MG/ML)	A215982	001	Apr 15, 2022	Jun	CAHN
AP	JIANGSU HENGHUI MED	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Apr	NEWA
AP		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Apr	NEWA
AP		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Apr	NEWA
AP		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Apr	NEWA
AP		37.69GM/100ML (376.9MG/ML)	A215982	001	Apr 15, 2022	Apr	NEWA

GALLIUM GA 68 DOTATOCSOLUTION;INTRAVENOUS
GALLIUM GA 68 DOTATOC

+! UIHC PET IMAGING 0.5-4mCi/ML N210828 001 Aug 21, 2019 Sep CTNA

GALLIUM GA-68 DOTATOCSOLUTION;INTRAVENOUS
GALLIUM GA 68 DOTATOC

+! UIHC PET IMAGING 0.5-4mCi/ML N210828 001 Aug 21, 2019 Sep CAIN

GALLIUM GA-68 GOZETOTIDEPOWDER;INTRAVENOUS
ILLUCCIX

+! TELIX N/A N214032 001 Dec 17, 2021 Mar CPOT

LOCAMETZ

+! AAA USA NOVARTIS N/A N215841 001 Mar 23, 2022 Mar NEWA

SOLUTION;INTRAVENOUS
GALLIUM GA 68 GOZETOTIDE

+! UNIV CA LOS ANGELES 0.5-5mCi/mL N212642 001 Dec 01, 2020 Jul CPOT

+! 30ML (0.5-5mCi/mL) N212642 001 Dec 01, 2020 Jun CTNA

+! 30ML (0.5-5mCi/mL) N212642 001 Dec 01, 2020 Jun CAIN

+! UNIV OF CA SAN FRAN 0.5-5mCi/mL N212643 001 Dec 01, 2020 Jul CPOT

+! 20ML (0.5-5mCi/mL) N212643 001 Dec 01, 2020 Jun CTNA

+! 20ML (0.5-5mCi/mL) N212643 001 Dec 01, 2020 Jun CAIN

GANAXOLONESUSPENSION;ORAL
ZTALMY

+! MARINUS 50MG/ML N215904 001 Jun 01, 2022 Jun NEWA

GANCICLOVIR SODIUMINJECTABLE;INJECTION
GANCICLOVIR SODIUM

@ STERISCIENCE EQ 500MG BASE/VIAL A204560 001 Nov 17, 2017 Feb CAHN

GANIRELIX ACETATEINJECTABLE;INJECTION
FYREMADEL

AP SUN PHARM 250MCG/0.5ML A204246 001 Nov 30, 2018 May CTNA

GANIRELIX ACETATE

AP AMPHASTAR PHARMS INC 250MCG/0.5ML A212613 001 Apr 07, 2022 Apr NEWA

AP HONG KONG 250MCG/0.5ML A214996 001 Jun 06, 2022 May NEWA

AP MEITHEAL 250MCG/0.5ML A214996 001 Jun 06, 2022 Nov CAHN

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

@ RISING 0.5% A206446 001 Jun 08, 2018 Jun CAHN

@ TORRENT 0.5% A213542 001 Nov 03, 2021 Nov DISC

GEFITINIBTABLET;ORAL
GEFITINIB

AB APOTEX 250MG A209532 001 Sep 23, 2022 Sep NFTG

IRESSA

AB +! ASTRAZENECA 250MG N206995 001 Jul 13, 2015 Sep CFTG

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

AP TEYRO LABS EQ 200MG BASE/VIAL A078759 001 Jul 25, 2011 Apr CAHN

AP EQ 1GM BASE/VIAL A078759 002 Jul 25, 2011 Apr CAHN

GEMFIBROZILTABLET;ORAL
GEMFIBROZIL

@ CADILA 600MG A204189 001 Aug 28, 2018 Oct DISC

@ CHARTWELL RX 600MG A074615 001 Sep 29, 1995 Feb CAHN

GEMIFLOXACIN MESYLATETABLET; ORAL
FACTIVE

+ @ LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jan DISC
GEMIFLOXACIN MESYLATE					
@ ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jan DISC

GENTAMICIN SULFATESOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

@ AKORN	EQ 0.3% BASE	A062635	001	Jan 08, 1987	Aug DISC
---------	--------------	---------	-----	--------------	----------

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

>D> PRED-G

>D> +! ALLERGAN	EQ 0.3% BASE; 1%	N050586	001	Jun 10, 1988	Dec DISC
-----------------	------------------	---------	-----	--------------	----------

>A> + @	EQ 0.3% BASE; 1%	N050586	001	Jun 10, 1988	Dec DISC
---------	------------------	---------	-----	--------------	----------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB CHARTWELL MOLECULAR	1MG	A077295	001	Oct 06, 2005	Nov CAHN
AB	2MG	A077295	002	Oct 06, 2005	Nov CAHN
AB	4MG	A077295	003	Oct 06, 2005	Nov CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB ! APOTEX	10MG	A075795	002	Jun 13, 2001	May CHRS
AB AUROBINDO PHARMA USA	5MG	A074226	001	May 10, 1994	Feb CAHN
AB	10MG	A074226	002	May 10, 1994	Feb CAHN
@ CHARTWELL RX	5MG	A074542	001	Jun 20, 1995	Sep CAHN
@	10MG	A074542	002	Jun 20, 1995	Sep CAHN
GLUCOTROL					
+ @ PFIZER	5MG	N017783	001	May 08, 1984	May DISC
+ @	10MG	N017783	002	May 08, 1984	May DISC

GLYBURIDE

TABLET; ORAL

GLYBURIDE

@ CHARTWELL RX	1.25MG	A203581	001	Apr 14, 2016	Jul CAHN
@	2.5MG	A203581	002	Apr 14, 2016	Jul CAHN
@	5MG	A203581	003	Apr 14, 2016	Jul CAHN
@ SUNNY	1.25MG	A203581	001	Apr 14, 2016	Mar DISC
@	2.5MG	A203581	002	Apr 14, 2016	Mar DISC
@	5MG	A203581	003	Apr 14, 2016	Mar DISC
GLYBURIDE (MICRONIZED)					
@ CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998	Feb CAHN
@	3MG	A075174	002	Jun 22, 1998	Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP ALEMBIC PHARMS	0.2MG/ML	A214635	001	Oct 26, 2022	Oct NEWA
AP AMNEAL	0.2MG/ML	A215333	001	Oct 21, 2022	Oct NEWA
AP ASPEN	0.2MG/ML	A212871	001	Nov 29, 2022	Nov NEWA
@ EUGIA PHARMA	0.2MG/ML	A210244	001	Nov 28, 2018	Jul DISC
@ ZYDUS PHARMS	0.2MG/ML	A214213	001	Nov 09, 2021	May DISC

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYCOPYRROLATE

+! FRESENIUS KABI USA	0.6MG/3ML (0.2MG/ML)	N214919	001	Apr 21, 2022	Apr NEWA
-----------------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

GLYCOPYRROLATE

AA ANNORA PHARMA	1MG/5ML	A213698	001	Jul 05, 2022	Jun NEWA
AA SUVEN PHARMS	1MG/5ML	A212467	001	Jul 05, 2022	Jun NEWA

TABLET; ORAL

GLYCOPYRROLATE

@ CHARTWELL RX	1MG	A040568	001	Dec 22, 2004	Jul CAHN
@	2MG	A040568	002	Dec 22, 2004	Jul CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

	@ AKORN	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A079119	001	Sep 10, 2009	Jul	DISC
AP	AMNEAL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May	CAHN
	@ EUGIA PHARMA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jul	DISC
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jul	DISC

GRISEOFULVIN, MICROCRYSTALLINE

TABLET;ORAL

FULVICIN-U/F

	CHARTWELL RX	250MG	A060569	002		Nov	CTEC
		500MG	A060569	001		Nov	CTEC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

	CHARTWELL RX	125MG	A061996	001		Nov	CTEC
		250MG	A061996	002		Nov	CTEC

FULVICIN P/G 165

	CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Nov	CTEC
--	--------------	-------	---------	-----	--------------	-----	------

FULVICIN P/G 330

	CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Nov	CTEC
--	--------------	-------	---------	-----	--------------	-----	------

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

	@ CHARTWELL RX	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	Oct	CAHN
--	----------------	---------------------	---------	-----	--------------	-----	------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

	+ @ CHARTWELL RX	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Oct	CAHN
--	------------------	------------------------------	---------	-----	--------------	-----	------

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB	TWI PHARMS	EQ 1MG BASE	A216399	001	Jun 08, 2022	May	NEWA
AB		EQ 2MG BASE	A216399	002	Jun 08, 2022	May	NEWA

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB	YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May	CMFD
AB		EQ 2MG BASE	A213428	002	Nov 25, 2020	May	CMFD
AB		EQ 3MG BASE	A213428	003	Nov 25, 2020	May	CMFD
AB		EQ 4MG BASE	A213428	004	Nov 25, 2020	May	CMFD

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	MSN	0.5MG	A216004	001	Nov 18, 2022	Nov	NEWA
AB		1MG	A216004	002	Nov 18, 2022	Nov	NEWA
AB		2MG	A216004	003	Nov 18, 2022	Nov	NEWA
AB		5MG	A216004	004	Nov 18, 2022	Nov	NEWA
AB		10MG	A216004	005	Nov 18, 2022	Nov	NEWA
AB		20MG	A216004	006	Nov 18, 2022	Nov	NEWA
AB	SANDOZ	0.5MG	A071209	002	Nov 17, 1986	Mar	CMS1
AB		1MG	A071209	003	Nov 17, 1986	Mar	CMS1
	@	2MG	A071209	004	Nov 17, 1986	Mar	CMS1

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

	@ AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug	DISC
--	---------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	+ @	HIKMA	1,000 UNITS/ML	N017007	001		Jul	CAHN
	+ @		2,500 UNITS/ML	N017007	007		Jul	CAHN
	+ @		5,000 UNITS/ML	N017007	002		Jul	CAHN
	+ @		5,000 UNITS/0.5ML	N017007	010		Jul	CAHN
	+ @		7,500 UNITS/ML	N017007	003		Jul	CAHN
	+ @		10,000 UNITS/ML	N017007	004		Jul	CAHN
	+ @		15,000 UNITS/ML	N017007	005		Jul	CAHN
	+ @		20,000 UNITS/ML	N017007	006		Jul	CAHN
		HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+!	B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992	Mar	CTEC
		HEPARIN SODIUM PRESERVATIVE FREE						
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Jul	CMFD

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

>D>	AA	AVANTHI INC	1.5MG; 5MG	A207176	001	Aug 07, 2017	Dec	CHRS
>A>	AA	!	1.5MG; 5MG	A207176	001	Aug 07, 2017	Dec	CHRS
>D>	AA	!	NOVEL LABS INC	A091528	001	Apr 20, 2011	Dec	DISC
>A>		@	1.5MG; 5MG	A091528	001	Apr 20, 2011	Dec	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		AUSEIC PHARMS	20MG/ML	A203110	001	Jun 29, 2015	Sep	CAHN
AP		BEOWULF ASSET	20MG/ML	A203110	001	Jun 29, 2015	Sep	CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

AB	+!	AZURITY	37.5MG; 20MG	N020727	001	Jun 23, 2005	Mar	CFTG
	+!		37.5MG; 20MG	N020727	001	Jun 23, 2005	Mar	CAHN
		ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE						
AB		RICONPHARMA LLC	37.5MG; 20MG	A215586	001	Apr 06, 2022	Mar	NFTG

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

	@	MYLAN	12.5MG	A075640	001	Jan 28, 2000	Nov	DISC
		TABLET; ORAL						
		HYDROCHLOROTHIAZIDE						
	@	CHARTWELL RX	25MG	A087565	001	Mar 09, 1982	Feb	CAHN
	@		50MG	A084912	001		Feb	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

	@	UNICHEM	12.5MG; 150MG	A207018	001	Sep 19, 2017	Nov	DISC
	@		12.5MG; 300MG	A207018	002	Sep 19, 2017	Nov	DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	CHARTWELL RX	25MG; 40MG	A071060	001	Aug 26, 1987	Feb	CAHN
	@		25MG; 80MG	A071061	001	Aug 26, 1987	Jan	CAHN
	@	RISING	25MG; 40MG	A070947	002	Mar 04, 1987	Jul	CAHN
	@		25MG; 80MG	A070947	001	Apr 01, 1987	Jul	CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

>D>	AB	+	PFIZER PHARMS	12.5MG; EQ 10MG BASE	N020125	001	Dec 28, 1999	Dec	DISC
>A>		+	@	12.5MG; EQ 10MG BASE	N020125	001	Dec 28, 1999	Dec	DISC
>D>	AB	+		12.5MG; EQ 20MG BASE	N020125	002	Dec 28, 1999	Dec	DISC
>A>		+	@	12.5MG; EQ 20MG BASE	N020125	002	Dec 28, 1999	Dec	DISC
>D>	AB	+!		25MG; EQ 20MG BASE	N020125	003	Dec 28, 1999	Dec	DISC
>A>		+	@	25MG; EQ 20MG BASE	N020125	003	Dec 28, 1999	Dec	DISC

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	AUROBINDO PHARMA	25MG;EQ 20MG BASE	A078450	003	Aug 24, 2007	Dec CHRS
>A>	AB	!	25MG;EQ 20MG BASE	A078450	003	Aug 24, 2007	Dec CHRS
		@ LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Jun CTNA
		@	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May DISC
	AB		12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May CTNA
		@	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Jun CTNA
		@	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May DISC
	AB		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May CTNA
		@	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Jun CTNA
		@	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May DISC
	AB		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May CTNA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ MYLAN 25MG;37.5MG

A074701 001 Jun 07, 1996 Jun DISC

TABLET; ORAL

MAXZIDE

AB +! AUROBINDO PHARMA USA 50MG;75MG
MAXZIDE-25

N019129 001 Oct 22, 1984 Feb CAHN

AB + AUROBINDO PHARMA USA 25MG;37.5MG
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

N019129 003 May 13, 1988 Feb CAHN

AB RUBICON 25MG;37.5MG

A216211 001 Feb 23, 2022 Feb NEWA

AB 50MG;75MG

A216211 002 Feb 23, 2022 Feb NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

AB ALVOGEN 20MG
AB 30MG
AB 40MG
AB 60MG
AB 80MG
AB 100MG
AB 120MG

A208269 001 Mar 01, 2021 May CAHN
A208269 002 Mar 01, 2021 May CAHN
A208269 003 Mar 01, 2021 May CAHN
A208269 004 Mar 01, 2021 May CAHN
A208269 005 Mar 01, 2021 May CAHN
A208269 006 Mar 01, 2021 May CAHN
A208269 007 Mar 01, 2021 May CAHN

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT +! ENCUBE 2.5%
FOUGERA PHARMS INC 1%

A203810 001 Jul 23, 2018 Jul CAHN
A080693 003 Oct CRLD

LOTION; TOPICAL

ALA-SCALP

DERM RX 2%

A083231 001 Jun CAHN

HYDROCORTISONE ACETATE

CREAM; TOPICAL

U-CORT

@ TARO 1%

A089472 001 Jun 13, 1988 Nov DISC

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL

HYDROCORTISONE BUTYRATE

AB THE J MOLNER 0.1%

A209556 001 Nov 21, 2017 Oct CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

HOSPIRA INC 0.5MG/0.5ML

N200403 004 Jun 13, 2022 Jun NEWA

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ ANDA REPOSITORY 5MG/5ML

A207108 001 Apr 22, 2020 Sep CAHN

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ ANDA REPOSITORY 2MG
@ 4MG
@ 8MG
@ HIKMA 4MG
@ 8MG

A077471 002 Dec 09, 2009 Sep CAHN
A077471 003 Dec 09, 2009 Sep CAHN
A077471 001 Dec 09, 2009 Sep CAHN
A074597 003 May 29, 2009 Aug DISC
A074597 001 Jul 29, 1998 Aug DISC

HYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT@ BTG INTL 2.5GM/VIAL (5GM/KIT)
+! 5GM/VIAL (5GM/KIT)N022041 002 Dec 15, 2006 Mar CAHN
N022041 001 Apr 08, 2011 Mar CAHNHYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	ACCORD HLTHCARE	100MG	A213342	002	Aug 18, 2021	Sep	CTEC
AB		300MG	A213342	003	Aug 18, 2021	Sep	CTEC
AB	!	400MG	A213342	004	Aug 18, 2021	Sep	CTEC
	!	400MG	A213342	004	Aug 18, 2021	Jan	CHRS
	!	400MG	A213342	004	Aug 18, 2021	Jan	CHRS
AB	APPCO	100MG	A210441	002	Sep 19, 2022	Sep	NEWA
AB		300MG	A210441	003	Sep 19, 2022	Sep	NEWA
AB		400MG	A210441	004	Sep 19, 2022	Sep	NEWA
AB	AUROBINDO PHARMA USA	200MG	A040274	001	May 29, 1998	May	CAHN
	+ NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022	Jan	NEWA
	+!	300MG	N214581	002	Jan 14, 2022	Jan	NEWA
AB	RISE PHARMA	200MG	A212902	001	May 14, 2020	Sep	CAHN
>D> AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	Dec	DISC
>A>	@	200MG	A040133	001	Nov 30, 1995	Dec	DISC

HYDROXYUREA

CAPSULE; ORAL

DROXIA

	+ CHEPLAPHARM	200MG	N016295	002	Feb 25, 1998	Oct	CAHN
	+	300MG	N016295	003	Feb 25, 1998	Oct	CAHN
	+	400MG	N016295	004	Feb 25, 1998	Oct	CAHN
	HYDREA						
AB	+! CHEPLAPHARM	500MG	N016295	001		Oct	CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ AKORN 10MG/5ML
@ PAI HOLDINGS PHARM 10MG/5MLA040010 001 Oct 28, 1994 Aug DISC
A040391 001 Apr 10, 2002 Jan CAHN

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	AIPING LIFE SCI	10MG	A040804	001	Jun 30, 2008	Oct	CAHN
AB		25MG	A040804	002	Jun 30, 2008	Oct	CAHN
AB		50MG	A040804	003	Jun 30, 2008	Oct	CAHN
AB	AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May	CMFD
AB		25MG	A087871	003	Dec 20, 1982	May	CMFD
AB		50MG	A087871	001	Dec 20, 1982	May	CMFD

IBRUTINIB

SUSPENSION; ORAL

IMBRUVICA

+! PHARMACYCLICS INC 70MG/ML

N217003 001 Aug 24, 2022 Aug NEWA

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

	@ AKORN	100MG/5ML	A205647	001	Nov 03, 2016	Sep	DISC
AB	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	May	CTEC
	@ STRIDES PHARMA	100MG/5ML	A215311	001	May 27, 2022	Nov	DISC
AB		100MG/5ML	A215311	001	May 27, 2022	May	NEWA

TABLET; ORAL

IBUPROFEN

	@ L PERRIGO CO	400MG	A077114	001	Jul 18, 2005	Sep	DISC
	@	600MG	A077114	002	Jul 18, 2005	Sep	DISC
	@	800MG	A077114	003	Jul 18, 2005	Sep	DISC
	@ SUNSHINE	400MG	A204062	001	Sep 10, 2018	Mar	CAHN
	@	600MG	A204062	002	Sep 10, 2018	Mar	CAHN
	@	800MG	A204062	003	Sep 10, 2018	Mar	CAHN
AB	YICHANG HUMANWELL	400MG	A215318	001	Mar 30, 2022	Mar	NEWA
AB		600MG	A215318	002	Mar 30, 2022	Mar	NEWA
AB		800MG	A215318	003	Mar 30, 2022	Mar	NEWA

ICATIBANT ACETATEINJECTABLE;SUBCUTANEOUS
FIRAZYR

AP	+	TAKEDA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CAHN
		ICATIBANT ACETATE					
	@	GLENMARK PHARMS LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213222	001	May 21, 2021	Oct DISC

ICOSAPENT ETHYLCAPSULE;ORAL
ICOSAPENT ETHYL

AB		TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Jul CMFD
AB			1GM	A209525	002	Sep 11, 2020	Nov CMFD
		VASCEPA					
AB	+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Oct CTEC

ILOPERIDONETABLET;ORAL
FANAPT

	+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jul CTEC
AB	+		1MG	N022192	001	May 06, 2009	Apr CTEC
	+		2MG	N022192	002	May 06, 2009	Jul CTEC
AB	+		2MG	N022192	002	May 06, 2009	Apr CTEC
	+		4MG	N022192	003	May 06, 2009	Jul CTEC
AB	+		4MG	N022192	003	May 06, 2009	Apr CTEC
	+		6MG	N022192	004	May 06, 2009	Jul CTEC
AB	+		6MG	N022192	004	May 06, 2009	Apr CTEC
	+		8MG	N022192	005	May 06, 2009	Jul CTEC
AB	+		8MG	N022192	005	May 06, 2009	Apr CTEC
	+		10MG	N022192	006	May 06, 2009	Jul CTEC
AB	+		10MG	N022192	006	May 06, 2009	Apr CTEC
	+		12MG	N022192	007	May 06, 2009	Jul CTEC
AB	+		12MG	N022192	007	May 06, 2009	Apr CTEC

ILOPERIDONE

	@	LUPIN LTD	1MG	A206890	001	May 05, 2022	Jul DISC
AB			1MG	A206890	001	May 05, 2022	Apr NEWA
	@		2MG	A206890	002	May 05, 2022	Jul DISC
AB			2MG	A206890	002	May 05, 2022	Apr NEWA
	@		4MG	A206890	003	May 05, 2022	Jul DISC
AB			4MG	A206890	003	May 05, 2022	Apr NEWA
	@		6MG	A206890	004	May 05, 2022	Jul DISC
AB			6MG	A206890	004	May 05, 2022	Apr NEWA
	@		8MG	A206890	005	May 05, 2022	Jul DISC
AB			8MG	A206890	005	May 05, 2022	Apr NEWA
	@		10MG	A206890	006	May 05, 2022	Jul DISC
AB			10MG	A206890	006	May 05, 2022	Apr NEWA
	@		12MG	A206890	007	May 05, 2022	Jul DISC
AB			12MG	A206890	007	May 05, 2022	Apr NEWA

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB		QILU PHARM HAINAN	EQ 100MG BASE	A212135	001	Jun 21, 2022	Jun NEWA
AB			EQ 400MG BASE	A212135	002	Jun 21, 2022	Jun NEWA

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

>D>	@	ANDA REPOSITORY	5%	A091044	001	Feb 28, 2011	Dec CAHN
>A>	@	ENCUBE	5%	A091044	001	Feb 28, 2011	Dec CAHN

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

@ CHARTWELL RX

@

1.25MG

2.5MG

A074594	001	May 23, 1996	Feb CAHN
A074594	002	May 23, 1996	Feb CAHN

INDIGOTINDISULFONATE SODIUMSOLUTION; INTRAVENOUS
BLUDIGO

+!	PROVEPHARM SAS	40MG/5ML (8MG/ML)	N216264	001	Jul 08, 2022	Jul NEWA
----	----------------	-------------------	---------	-----	--------------	----------

INDOMETHACINCAPSULE; ORAL
INDOMETHACIN

>D>	@ CHARTWELL MOLECULES	50MG	A070651	001	Mar 05, 1986	Dec CMFD
>A>	AB	50MG	A070651	001	Mar 05, 1986	Dec CMFD

IODIXANOLINJECTABLE; INJECTION
IODIXANOL

AP	HENGRUI PHARMA	55%	A214271	001	May 19, 2022	May NFTG
AP		65.2%	A214271	002	May 19, 2022	May NFTG
	VISIPAQUE 270					
AP	+! GE HEALTHCARE	55%	N020351	001	Mar 22, 1996	May CFTG
	VISIPAQUE 320					
AP	+! GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996	May CFTG

IOFLUPANE I-123SOLUTION; INTRAVENOUS
DATSCAN

AP	+! GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454	001	Jan 14, 2011	Mar CFTG
AP	IOFLUPANE I-123					
AP	CURIUM	5mCi/2.5ML (2mCi/ML)	A213792	001	Mar 30, 2022	Mar NFTG

IPRATROPIUM BROMIDESOLUTION; INHALATION
IPRATROPIUM BROMIDE

	@ BAUSCH	0.02%	A075835	001	Oct 15, 2001	Jun CAHN
	SPRAY, METERED; NASAL					
	IPRATROPIUM BROMIDE					
AB	AMNEAL	0.021MG/SPRAY	A215104	001	Aug 16, 2022	Aug NEWA
AB		0.042MG/SPRAY	A215105	001	Aug 16, 2022	Aug NEWA
AB	BAUSCH	0.021MG/SPRAY	A076025	001	Mar 31, 2003	Jun CAHN
AB		0.042MG/SPRAY	A076103	001	Mar 31, 2003	Jun CAHN

IRBESARTANTABLET; ORAL
IRBESARTAN

>A>	@ APPCO	75MG	A200461	001	Sep 27, 2012	Dec CAHN
>A>	@	150MG	A200461	002	Sep 27, 2012	Dec CAHN
>A>	@	300MG	A200461	003	Sep 27, 2012	Dec CAHN
>D>	@ MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012	Dec CAHN
>D>	@	150MG	A200461	002	Sep 27, 2012	Dec CAHN
>D>	@	300MG	A200461	003	Sep 27, 2012	Dec CAHN
	@ UNICHEM	75MG	A203020	001	Dec 07, 2015	Nov DISC
	@	150MG	A203020	002	Dec 07, 2015	Nov DISC
	@	300MG	A203020	003	Dec 07, 2015	Nov DISC

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP	EUGIA PHARMA	500MG/25ML (20MG/ML)	A213278	004	Apr 11, 2022	Apr NEWA	
>D>	AP	TEVA PHARMS USA	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008	Dec DISC
>A>	@	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008	Dec DISC	
>D>	AP	100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008	Dec DISC	
>A>	@	100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008	Dec DISC	

ISAVUCONAZONIUM SULFATECAPSULE; ORAL
CRESEMBA

>A>	+	ASTELLAS	74.5MG	N207500	002	Nov 22, 2022	Dec NEWA
-----	---	----------	--------	---------	-----	--------------	----------

ISONIAZID

SYRUP; ORAL							
ISONIAZID							
	@ CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Mar	CAHN
TABLET; ORAL							
ISONIAZID							
	+ @ EPIC PHARMA LLC	100MG	N008678	002		Jul	CAHN
	+ @	300MG	N008678	003		Jul	CAHN
AA	MIKART	100MG	A040090	001	Jun 26, 1997	Mar	CAHN
AA		300MG	A040090	002	Jun 26, 1997	Mar	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION							
ISOPROTERENOL HYDROCHLORIDE							
AP	AM REGENT	0.2MG/ML	A214775	001	Oct 19, 2022	Oct	NEWA
AP	MYLAN LABS LTD	0.2MG/ML	A212573	001	Sep 06, 2022	Aug	NEWA
AP	STI PHARMA LLC	0.2MG/ML	A215542	001	Sep 20, 2022	Sep	NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL							
ISOSORBIDE DINITRATE							
AB	RUBICON	5MG	A215723	001	Jul 08, 2022	Jul	NEWA
AB		10MG	A215723	002	Jul 08, 2022	Jul	NEWA
AB		20MG	A215723	003	Jul 08, 2022	Jul	NEWA
AB		30MG	A215723	004	Jul 08, 2022	Jul	NEWA
AB		40MG	A215723	005	Jul 08, 2022	Jul	NEWA

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL							
ISOSORBIDE MONONITRATE							
AB	AUROBINDO PHARMA	30MG	A216557	001	Nov 07, 2022	Oct	NEWA
AB		60MG	A216557	002	Nov 07, 2022	Oct	NEWA
AB		120MG	A216557	003	Nov 07, 2022	Oct	NEWA
AB	SHANDONG	120MG	A214115	001	Apr 29, 2022	Apr	NEWA
>A>	AB ZYDUS HLTHCARE	30MG	A075395	001	Mar 16, 2000	Dec	CAHN
>A>	AB	60MG	A075395	002	Mar 16, 2000	Dec	CAHN
>A>	AB	120MG	A075395	003	Mar 16, 2000	Dec	CAHN
>D>	AB ZYDUS PHARMS	30MG	A075395	001	Mar 16, 2000	Dec	CAHN
	AB	30MG	A075395	001	Mar 16, 2000	Mar	CAHN
>D>	AB	60MG	A075395	002	Mar 16, 2000	Dec	CAHN
	AB	60MG	A075395	002	Mar 16, 2000	Mar	CAHN
>D>	AB	120MG	A075395	003	Mar 16, 2000	Dec	CAHN
	AB	120MG	A075395	003	Mar 16, 2000	Mar	CAHN

ISOSULFAN BLUE

INJECTABLE; INJECTION							
ISOSULFAN BLUE							
	@ EUGIA PHARMA	1%	A206831	001	Feb 02, 2016	Jul	DISC
	@ FRESENIUS KABI USA	1%	A211869	001	Sep 08, 2022	Oct	DISC
AP		1%	A211869	001	Sep 08, 2022	Sep	NEWA
AP	MSN	1%	A216090	001	Sep 16, 2022	Sep	NEWA

ITRACONAZOLE

CAPSULE; ORAL							
ITRACONAZOLE							
	@ JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	May	DISC
TOLSURA							
	+! MAYNE PHARMA	65MG	N208901	001	Dec 11, 2018	Nov	CAHN

IVABRADINE HYDROCHLORIDE

TABLET; ORAL							
CORLANOR							
AB	+ AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Sep	CTEC
	+	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan	CTEC
AB	+!	EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Sep	CTEC
	+!	EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan	CTEC
IVABRADINE HYDROCHLORIDE							
AB	ANNORA PHARMA	EQ 5MG BASE	A213366	001	Oct 05, 2022	Sep	NEWA
AB		EQ 7.5MG BASE	A213366	002	Oct 05, 2022	Sep	NEWA
	@ CENTAUR PHARMS PVT	EQ 5MG BASE	A214051	001	Dec 30, 2021	Jan	DISC
	@	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan	DISC

TABLET;ORAL									
IVABRADINE HYDROCHLORIDE									
	@ INGENUS PHARMS LLC	EQ 5MG BASE	A214051	001	Dec 30, 2021	Sep	CAHN		
	@	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Sep	CAHN		
<u>IVACAFTOR; LUMACAFTOR</u>									
GRANULE;ORAL									
ORKAMBI									
+	VERTEX PHARMS INC	94MG/PACKET;75MG/PACKET	N211358	003	Sep 02, 2022	Sep	NEWA		
<u>KETOCONAZOLE</u>									
GEL;TOPICAL									
XOLEGEL									
+	@ ALMIRALL	2%	N021946	001	Jul 28, 2006	Sep	DISC		
<u>KETOPROFEN</u>									
CAPSULE;ORAL									
KETOPROFEN									
	@ RISING	50MG	A074035	002	Dec 31, 1996	Oct	CAHN		
	@	75MG	A074035	003	Dec 31, 1996	Oct	CAHN		
<u>KETOROLAC TROMETHAMINE</u>									
INJECTABLE;INJECTION									
KETOROLAC TROMETHAMINE									
AP	ALEMBIC PHARMS	15MG/ML	A214456	001	Nov 02, 2022	Oct	NEWA		
AP		30MG/ML	A214456	002	Nov 02, 2022	Oct	NEWA		
	@ STERISCIENCE	15MG/ML	A078299	001	Jul 16, 2007	Feb	CAHN		
	@	15MG/ML	A201155	001	Aug 04, 2014	Feb	CAHN		
	@	30MG/ML	A078299	002	Jul 16, 2007	Feb	CAHN		
	@	30MG/ML	A201155	002	Aug 04, 2014	Feb	CAHN		
AP	SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008	Sep	CMFD		
AP		30MG/ML	A078737	002	Oct 06, 2008	Sep	CMFD		
	@ WOCKHARDT BIO AG	30MG/ML	A077943	001	Mar 27, 2007	Nov	CAHN		
SOLUTION/DROPS;OPHTHALMIC									
KETOROLAC TROMETHAMINE									
	@ AKORN	0.4%	A078399	001	Nov 05, 2009	Jun	DISC		
TABLET;ORAL									
KETOROLAC TROMETHAMINE									
AB	ATNAHS PHARMA US	10MG	A216407	001	Oct 21, 2022	Oct	NEWA		
AB	HAVIX	10MG	A215788	001	Mar 23, 2022	Mar	NEWA		
AB	HETERO LABS LTD III	10MG	A216651	001	Aug 25, 2022	Aug	NEWA		
AB	SENORES PHARMS	10MG	A215788	001	Mar 23, 2022	Mar	CAHN		
AB	ZYDUS	10MG	A217038	001	Oct 21, 2022	Oct	NEWA		
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE</u>									
SOLUTION;IRRIGATION									
OMIDRIA									
AT	+! RAYNER SURGICAL	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Feb	CAHN		
<u>KETOTIFEN FUMARATE</u>									
DRUG-ELUTING CONTACT LENS;OPHTHALMIC									
ACUVUE THERAVISION WITH KETOTIFEN									
+	! JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	Feb	NEWA		
<u>LABETALOL HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
LABETALOL HYDROCHLORIDE									
	@ STERISCIENCE	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN		
SOLUTION;INTRAVENOUS									
LABETALOL HYDROCHLORIDE									
+	! HIKMA	10MG/2ML (5MG/ML)	N213330	005	Mar 18, 2022	Aug	NEWA		
TABLET;ORAL									
LABETALOL HYDROCHLORIDE									
	@ UNICHEM	100MG	A212719	001	Aug 08, 2022	Nov	DISC		
AB		100MG	A212719	001	Aug 08, 2022	Jul	NEWA		
	@	200MG	A212719	002	Aug 08, 2022	Nov	DISC		
AB		200MG	A212719	002	Aug 08, 2022	Jul	NEWA		
	@	300MG	A212719	003	Aug 08, 2022	Nov	DISC		
AB		300MG	A212719	003	Aug 08, 2022	Jul	NEWA		

LACOSAMIDE

SOLUTION; INTRAVENOUS

LACOSAMIDE

AP	ASPIRO	200MG/20ML (10MG/ML)	A216335	001	Sep 14, 2022	Sep NEWA
AP	FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A214677	001	May 03, 2022	Apr NEWA
AP	GLAND PHARMA LTD	200MG/20ML (10MG/ML)	A215628	001	Sep 19, 2022	Sep NEWA
AP	INDOCO	200MG/20ML (10MG/ML)	A214301	001	Apr 07, 2022	Apr NFTG
AP	ZYDUS PHARMS	200MG/20ML (10MG/ML)	A209465	001	Jun 29, 2022	Jun NEWA

VIMPAT

AP	+! UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008	Apr CFTG
----	------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LACOSAMIDE

AA	ALKEM LABS LTD	10MG/ML	A214672	001	May 19, 2022	May NFTG
AA	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Sep NEWA
AA	HETERO LABS LTD III	10MG/ML	A209301	001	May 31, 2022	May NEWA
AA	NOVITIUM PHARMA	10MG/ML	A216151	001	Aug 26, 2022	Aug NEWA

VIMPAT

AA	+! UCB INC	10MG/ML	N022255	001	Apr 20, 2010	May CFTG
----	------------	---------	---------	-----	--------------	----------

TABLET; ORAL

LACOSAMIDE

AB	ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022	Jul NEWA
AB		100MG	A205011	002	Jul 12, 2022	Jul NEWA
AB		150MG	A205011	003	Jul 12, 2022	Jul NEWA
AB		200MG	A205011	004	Jul 12, 2022	Jul NEWA
>A>	AB ACTAVIS LABS FL INC	50MG	A204855	001	Jan 05, 2023	Dec NEWA
>A>	AB	100MG	A204855	002	Jan 05, 2023	Dec NEWA
>A>	AB	150MG	A204855	003	Jan 05, 2023	Dec NEWA
>A>	AB	200MG	A204855	004	Jan 05, 2023	Dec NEWA
AB	ALEMBIC PHARMS	50MG	A204974	001	Mar 17, 2022	Mar NFTG
AB		100MG	A204974	002	Mar 17, 2022	Mar NFTG
AB		150MG	A204974	003	Mar 17, 2022	Mar NFTG
AB		200MG	A204974	004	Mar 17, 2022	Mar NFTG
AB	ALKEM LABS LTD	50MG	A214695	001	Mar 31, 2022	Mar NEWA
AB		100MG	A214695	002	Mar 31, 2022	Mar NEWA
AB		150MG	A214695	003	Mar 31, 2022	Mar NEWA
AB		200MG	A214695	004	Mar 31, 2022	Mar NEWA
AB	AMNEAL PHARMS	50MG	A204857	001	Mar 17, 2022	Mar NFTG
AB		100MG	A204857	002	Mar 17, 2022	Mar NFTG
AB		150MG	A204857	003	Mar 17, 2022	Mar NFTG
AB		200MG	A204857	004	Mar 17, 2022	Mar NFTG
AB	APOTEX	50MG	A214567	001	Sep 23, 2022	Sep NEWA
AB		100MG	A214567	002	Sep 23, 2022	Sep NEWA
AB		150MG	A214567	003	Sep 23, 2022	Sep NEWA
AB		200MG	A214567	004	Sep 23, 2022	Sep NEWA
>A>	AB AUROBINDO PHARMA LTD	50MG	A204994	001	Jan 05, 2023	Dec NEWA
>A>	AB	100MG	A204994	002	Jan 05, 2023	Dec NEWA
>A>	AB	150MG	A204994	003	Jan 05, 2023	Dec NEWA
>A>	AB	200MG	A204994	004	Jan 05, 2023	Dec NEWA
AB	GLENMARK PHARMS LTD	50MG	A205006	001	Mar 17, 2022	Mar NFTG
AB		100MG	A205006	002	Mar 17, 2022	Mar NFTG
AB		150MG	A205006	003	Mar 17, 2022	Mar NFTG
AB		200MG	A205006	004	Mar 17, 2022	Mar NFTG
AB	HETERO LABS LTD V	50MG	A204787	001	Mar 17, 2022	Mar NFTG
AB		100MG	A204787	002	Mar 17, 2022	Mar NFTG
AB		150MG	A204787	003	Mar 17, 2022	Mar NFTG
AB		200MG	A204787	004	Mar 17, 2022	Mar NFTG
AB	INDOCO	50MG	A208308	001	Mar 17, 2022	Mar NFTG
AB		100MG	A208308	002	Mar 17, 2022	Mar NFTG
AB		150MG	A208308	003	Mar 17, 2022	Mar NFTG
AB		200MG	A208308	004	Mar 17, 2022	Mar NFTG
AB	MSN LABS PVT LTD	50MG	A204921	001	Mar 17, 2022	Mar NFTG
AB		100MG	A204921	002	Mar 17, 2022	Mar NFTG
AB		150MG	A204921	003	Mar 17, 2022	Mar NFTG
AB		200MG	A204921	004	Mar 17, 2022	Mar NFTG
AB	SCIEGEN PHARMS INC	50MG	A205237	001	Mar 17, 2022	Mar NFTG
AB		100MG	A205237	002	Mar 17, 2022	Mar NFTG
AB		150MG	A205237	003	Mar 17, 2022	Mar NFTG
AB		200MG	A205237	004	Mar 17, 2022	Mar NFTG
AB	SUN PHARM	50MG	A205031	001	Mar 17, 2022	Mar NFTG
AB		100MG	A205031	002	Mar 17, 2022	Mar NFTG
AB		150MG	A205031	003	Mar 17, 2022	Mar NFTG
AB		200MG	A205031	004	Mar 17, 2022	Mar NFTG

TABLET;ORAL							
VIMPAT							
AB	+	UCB INC	50MG	N022253	001	Oct 28, 2008	Mar CFTG
AB	+		100MG	N022253	002	Oct 28, 2008	Mar CFTG
AB	+		150MG	N022253	003	Oct 28, 2008	Mar CFTG
AB	+	!	200MG	N022253	004	Oct 28, 2008	Mar CFTG
<u>LACTULOSE</u>							
SOLUTION;ORAL							
LACTULOSE							
	@	TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jun DISC
	@	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Nov DISC
SOLUTION;ORAL, RECTAL							
LACTULOSE							
	@	TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jun DISC
<u>LAMIVUDINE</u>							
TABLET;ORAL							
LAMIVUDINE							
AB		UPSHER SMITH LABS	150MG	A206974	001	Nov 21, 2016	Sep CAHN
AB			300MG	A206974	002	Nov 21, 2016	Sep CAHN
<u>LAMIVUDINE; ZIDOVUDINE</u>							
TABLET;ORAL							
LAMIVUDINE AND ZIDOVUDINE							
	@	CHARTWELL RX	150MG;300MG	A079081	001	May 25, 2011	Mar CAHN
<u>LAMOTRIGINE</u>							
TABLET, EXTENDED RELEASE;ORAL							
LAMOTRIGINE							
	@	TORRENT	200MG	A203370	004	Dec 23, 2013	Aug DISC
AB		WOCKHARDT BIO AG	25MG	A202498	001	Jan 04, 2013	Nov CAHN
AB			50MG	A202498	002	Jan 04, 2013	Nov CAHN
AB			100MG	A202498	003	Jan 04, 2013	Nov CAHN
AB			200MG	A202498	004	Jan 04, 2013	Nov CAHN
AB			300MG	A202498	005	Jan 04, 2013	Nov CAHN
TABLET, FOR SUSPENSION;ORAL							
LAMICTAL CD							
AB	+	GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Jan CDFR
AB	+		5MG	N020764	001	Aug 24, 1998	Jan CDFR
AB	+	!	25MG	N020764	002	Aug 24, 1998	Jan CDFR
	@		100MG	N020764	003	Aug 24, 1998	Jan CDFR
LAMOTRIGINE							
AB		ALEMBIC PHARMS	5MG	A201168	001	Jun 12, 2014	Jan CDFR
AB			25MG	A201168	002	Jun 12, 2014	Jan CDFR
AB		AUROBINDO PHARMA	5MG	A090401	002	Nov 04, 2009	Jan CDFR
AB			25MG	A090401	003	Nov 04, 2009	Jan CDFR
AB		DR REDDYS LABS LTD	5MG	A076701	001	Jan 22, 2009	Jan CDFR
AB			25MG	A076701	002	Jan 22, 2009	Jan CDFR
AB		GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	Jan CDFR
AB			25MG	A079099	002	Feb 19, 2009	Jan CDFR
	@	JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jan CDFR
	@		25MG	A200220	002	Feb 28, 2011	Jan CDFR
	@	MYLAN	5MG	A076630	001	Jan 22, 2009	Jan CDFR
	@		25MG	A076630	002	Jan 22, 2009	Jan CDFR
	@	SANDOZ	5MG	A078409	002	Jan 22, 2009	Jan CDFR
	@		25MG	A078409	003	Jan 22, 2009	Jan CDFR
AB		TARO	5MG	A079204	001	Feb 04, 2009	Jan CDFR
AB			25MG	A079204	002	Feb 04, 2009	Jan CDFR
	@	TEVA	5MG	A076420	001	Jun 21, 2006	Jan CDFR
	@		25MG	A076420	002	Jun 21, 2006	Jan CDFR
AB		WATSON LABS	2MG	A076928	001	Jan 22, 2009	Jan CDFR
AB			5MG	A076928	002	Jan 22, 2009	Jan CDFR
AB			25MG	A076928	003	Jan 22, 2009	Jan CDFR
AB		ZYDUS PHARMS USA INC	5MG	A078009	002	Jan 22, 2009	Jan CDFR
AB			25MG	A078009	003	Jan 22, 2009	Jan CDFR
TABLET, ORALLY DISINTEGRATING;ORAL							
LAMOTRIGINE							
AB		AMRING PHARMS	25MG	A214124	001	Feb 03, 2022	Jan NEWA
AB			50MG	A214124	002	Feb 03, 2022	Jan NEWA
AB			100MG	A214124	003	Feb 03, 2022	Jan NEWA
AB			200MG	A214124	004	Feb 03, 2022	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

@ IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Jun DISC
@	50MG	A200828	002	Jul 15, 2013	Jun DISC
@	100MG	A200828	003	Jul 15, 2013	Jun DISC
@	200MG	A200828	004	Jul 15, 2013	Jun DISC

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL
LANTHANUM CARBONATE

AB	BARR	EQ 500MG BASE	A090977	001	Jan 27, 2022	Jan NEWA
AB		EQ 750MG BASE	A090977	002	Jan 27, 2022	Jan NEWA
AB		EQ 1GM BASE	A090977	003	Jan 27, 2022	Jan NEWA
AB	INVAGEN PHARMS	EQ 500MG BASE	A206868	001	Jan 24, 2022	Jan NEWA
AB		EQ 750MG BASE	A206868	002	Jan 24, 2022	Jan NEWA
AB		EQ 1GM BASE	A206868	003	Jan 24, 2022	Jan NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
IYUZEH

>A>	+!	THEA PHARMA	0.005%	N216472	001	Dec 13, 2022	Dec NEWA
-----	----	-------------	--------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET;ORAL
LEFLUNOMIDE

AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jan CMFD
AB		20MG	A213497	002	May 10, 2021	Jan CMFD
AB	WANBANG BIOPHARMS	10MG	A077087	001	Sep 13, 2005	Jun CAHN
AB		20MG	A077087	002	Sep 13, 2005	Jun CAHN

>A> LENACAPAVIR SODIUM

>A> SOLUTION;SUBCUTANEOUS
>A> SUNLENCA

>A>	+!	GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N215973	001	Dec 22, 2022	Dec NEWA
-----	----	---------------------	--	---------	-----	--------------	----------

>A> TABLET;ORAL
>A> SUNLENCA

>A>	+!	GILEAD SCIENCES INC	EQ 300MG BASE	N215974	001	Dec 22, 2022	Dec NEWA
-----	----	---------------------	---------------	---------	-----	--------------	----------

LENALIDOMIDE

CAPSULE;ORAL
LENALIDOMIDE

AB	APOTEX	5MG	A211022	001	Aug 30, 2022	Aug NEWA
AB		10MG	A211022	002	Aug 30, 2022	Aug NEWA
AB		15MG	A211022	003	Aug 30, 2022	Aug NEWA
AB		25MG	A211022	004	Aug 30, 2022	Aug NEWA
AB	CIPLA	5MG	A210435	001	Sep 06, 2022	Aug NEWA
AB		10MG	A210435	002	Sep 06, 2022	Aug NEWA
AB		15MG	A210435	003	Sep 06, 2022	Aug NEWA
AB		25MG	A210435	004	Sep 06, 2022	Aug NEWA
AB	DR REDDYS	5MG	A209348	003	Aug 30, 2022	Aug NEWA
AB		10MG	A209348	004	Aug 30, 2022	Aug NEWA
AB		15MG	A209348	005	Aug 30, 2022	Aug NEWA
AB		25MG	A209348	006	Aug 30, 2022	Aug NEWA
AB	LOTUS PHARM CO LTD	5MG	A210480	001	Aug 31, 2022	Aug NEWA
AB		10MG	A210480	002	Aug 31, 2022	Aug NEWA
AB		15MG	A210480	003	Aug 31, 2022	Aug NEWA
AB		25MG	A210480	004	Aug 31, 2022	Aug NEWA
AB	MYLAN	5MG	A213912	001	Aug 30, 2022	Aug NEWA
AB		5MG	A213912	001	Aug 30, 2022	Aug CAHN
AB		5MG	A213912	001	Aug 30, 2022	Aug NEWA
AB		10MG	A213912	002	Aug 30, 2022	Aug NEWA
AB		15MG	A213912	003	Aug 30, 2022	Aug NEWA
AB		25MG	A213912	004	Aug 30, 2022	Aug NEWA
AB	ZYDUS PHARMS	5MG	A210154	001	Sep 12, 2022	Sep NEWA
AB		10MG	A210154	002	Sep 12, 2022	Sep NEWA
AB		15MG	A210154	003	Sep 12, 2022	Sep NEWA
AB		25MG	A210154	004	Sep 12, 2022	Sep NEWA

LEUPROLIDE ACETATEFOR SUSPENSION; INTRAMUSCULAR
LUTRATE DEPOT KIT

+	!	GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	May CMFD
+	!	INVAGEN PHARMS	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun CAHN
INJECTABLE; INJECTION							
LEUPROLIDE ACETATE							
AP		AMNEAL	1MG/0.2ML	A215336	001	Oct 28, 2022	Oct NEWA
AP		EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	May NEWA

LEUPROLIDE MESYLATEEMULSION; SUBCUTANEOUS
CAMCEVI KIT

+	!	ACCORD	EQ 42MG BASE	N211488	001	May 25, 2021	Jan CAHN
---	---	--------	--------------	---------	-----	--------------	----------

LEVALBUTEROL TARTRATEAEROSOL, METERED; INHALATION
XOPENEX HFA

+	!	LUPIN	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005	Nov CAHN
---	---	-------	---------------------	---------	-----	--------------	----------

LEVETIRACETAMINJECTABLE; INTRAVENOUS
LEVETIRACETAM

AP		AUSEIC PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Sep CAHN
AP		BEOWULF ASSET	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Sep CAHN
AP		MSN	500MG/5ML (100MG/ML)	A215980	001	Nov 15, 2022	Nov NEWA
AP		PRINSTON INC	500MG/5ML (100MG/ML)	A209474	001	Mar 28, 2022	Mar NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA		AIPING PHARM INC	100MG/ML	A090079	001	Apr 11, 2012	Jun CAHN
AA		BELCHER	100MG/ML	A090461	001	Sep 30, 2010	Jun CAHN
AA		MSN	100MG/ML	A214757	001	Jul 15, 2022	Jul NEWA
		@ WOCKHARDT BIO AG	100MG/ML	A090028	001	Mar 03, 2010	Apr DISC

TABLET; ORAL

LEVETIRACETAM

AB		ALKEM LABS LTD	250MG	A216375	001	May 27, 2022	May NEWA
AB			500MG	A216375	002	May 27, 2022	May NEWA
AB			750MG	A216375	003	May 27, 2022	May NEWA
AB			1GM	A216375	004	May 27, 2022	May NEWA
AB		MSN	250MG	A214815	001	Oct 07, 2022	Sep NEWA
AB			500MG	A214815	002	Oct 07, 2022	Sep NEWA
AB			750MG	A214815	003	Oct 07, 2022	Sep NEWA
AB			1GM	A214815	004	Oct 07, 2022	Sep NEWA
AB		SCIEGEN PHARMS INC	250MG	A215069	003	May 27, 2022	May NEWA
AB			500MG	A215069	004	May 27, 2022	May NEWA
AB			750MG	A215069	001	Jun 11, 2021	Jun CMFD
		@	750MG	A215069	001	Jun 11, 2021	Apr DISC
AB			1GM	A215069	002	Jun 11, 2021	Jun CMFD
		@	1GM	A215069	002	Jun 11, 2021	Apr DISC
		@ SECAN PHARMS	500MG	A205102	004	Dec 16, 2015	Jan DISC
		@	1GM	A205102	003	Dec 16, 2015	Jan DISC
AB		STALLION LABS	250MG	A079042	001	Jan 15, 2009	Mar CAHN
AB			500MG	A079042	002	Jan 15, 2009	Mar CAHN
AB			750MG	A079042	003	Jan 15, 2009	Mar CAHN
AB			1GM	A079042	004	Jan 15, 2009	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB		AIPING PHARM INC	500MG	A204754	001	Aug 26, 2016	Aug CAHN
AB			750MG	A204754	002	Aug 26, 2016	Aug CAHN
		@ ANDA REPOSITORY	500MG	A091291	001	Sep 12, 2011	Sep CAHN
		@	750MG	A091291	002	Sep 12, 2011	Sep CAHN
>D>	AB	DEXCEL	500MG	A202167	001	Sep 04, 2015	Dec DISC
>A>		@	500MG	A202167	001	Sep 04, 2015	Dec DISC
	AB		500MG	A202167	001	Sep 04, 2015	Nov CAHN
>D>	AB		750MG	A202167	002	Sep 04, 2015	Dec DISC
>A>		@	750MG	A202167	002	Sep 04, 2015	Dec DISC
	AB		750MG	A202167	002	Sep 04, 2015	Nov CAHN

LEVOCARNITINE

TABLET; ORAL

LEVOCARNITINE

>A>	AB	NOVITIUM PHARMA	330MG	A216384	001	Dec 09, 2022	Dec NEWA
-----	----	-----------------	-------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		CHARTWELL MOLECULAR	2.5MG/5ML	A204599	001	May 15, 2017	Jun CAHN
----	--	---------------------	-----------	---------	-----	--------------	----------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	!	AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644	001	Jun 20, 2011	Jul CHRS
AP	!		EQ 750MG/30ML (EQ 25MG/ML)	A091644	002	Jun 20, 2011	Jul CHRS
	@	EUGIA PHARMA	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jul DISC
	@		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jul DISC
		LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@	EUGIA PHARMA	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jul DISC
	@		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jul DISC
	@		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jul DISC

TABLET; ORAL

LEVOFLOXACIN

AB		CHARTWELL MOLECULAR	250MG	A076890	001	Mar 30, 2012	Mar CAHN
AB			500MG	A076890	002	Mar 30, 2012	Mar CAHN
AB			750MG	A076890	003	Mar 30, 2012	Mar CAHN

LEVOLEUCOVORIN

POWDER; INTRAVENOUS

KHAPZORY

+	!	ACROTECH BIOPHARMA	175MG/VIAL	N211226	001	Oct 19, 2018	Jul CAHN
+	!		300MG/VIAL	N211226	002	Oct 19, 2018	Jul CAHN

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

AP	+	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Oct CAHN
		LEVOLEUCOVORIN CALCIUM					
	@	HIKMA	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jul DISC

SOLUTION; INTRAVENOUS

FUSILEV

+	@	ACROTECH BIOPHARMA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Oct CAHN
+	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Oct CAHN

LEVOLEUCOVORIN CALCIUM

AP		GLAND PHARMA LTD	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210892	001	Sep 14, 2018	Nov CHRS
	!		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	Nov CTEC
AP	!	MEITHEAL	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A211002	001	Aug 16, 2019	Nov CHRS
	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002	002	Aug 16, 2019	Nov DISC
	@	PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Feb DISC

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

>D>	+	ALLERGAN	EQ 20MG BASE	N204168	001	Jul 25, 2013	Dec CTEC
>A>	AB		EQ 20MG BASE	N204168	001	Jul 25, 2013	Dec CTEC
>D>	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Dec CTEC
>A>	AB		EQ 40MG BASE	N204168	002	Jul 25, 2013	Dec CTEC
>D>	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Dec CTEC
>A>	AB		EQ 80MG BASE	N204168	003	Jul 25, 2013	Dec CTEC
>D>	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Dec CTEC
>A>	AB		EQ 120MG BASE	N204168	004	Jul 25, 2013	Dec CTEC

LEVOMILNACIPRAN HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023	Dec NEWA
>A>	AB		EQ 40MG BASE	A210826	002	Jan 06, 2023	Dec NEWA
>A>	AB		EQ 80MG BASE	A210826	003	Jan 06, 2023	Dec NEWA

CAPSULE, EXTENDED RELEASE;ORAL
LEVOMILNACIPRAN HYDROCHLORIDE

>A> AB	EQ 120MG BASE	A210826	004	Jan 06, 2023	Dec NEWA
--------	---------------	---------	-----	--------------	----------

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

@ L PERRIGO CO

0.75MG

A090740	001	Dec 30, 2010	May DISC
---------	-----	--------------	----------

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

>A>	@ HIKMA	1MG	A074278	002	Jun 18, 2018	Dec CAHN
>A>	@	2MG	A074278	001	Mar 31, 2000	Dec CAHN
>A>	@	3MG	A074278	003	Jun 18, 2018	Dec CAHN
>D> AB	NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Dec CTEC
>A>	!	3MG	A213479	002	Jan 12, 2021	Dec CTEC
>D>	@ SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Dec CAHN
>D> AB	!	2MG	A074278	001	Mar 31, 2000	Dec CAHN
>D> AB	!	3MG	A074278	003	Jun 18, 2018	Dec CAHN

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

@ TEVA PHARMS USA INC

0.112MG

A211369	003	Apr 16, 2021	Jan DISC
---------	-----	--------------	----------

AB		0.2MG	A211369	004	Nov 09, 2022	Nov CPOT
----	--	-------	---------	-----	--------------	----------

AB		0.200MG	A211369	004	Nov 09, 2022	Nov NFTG
----	--	---------	---------	-----	--------------	----------

TIROSINT

+	INSTITUT BIOCHIMIQUE	0.0375MG	N021924	014	Jun 22, 2022	Jun NEWA
+		0.044MG	N021924	015	Jun 22, 2022	Jun NEWA
+		0.0625MG	N021924	016	Jun 22, 2022	Jun NEWA
+		0.112MG	N021924	008	Oct 02, 2009	Jan CTEC
AB	+	0.2MG	N021924	012	Apr 25, 2017	Nov CPOT
AB	+	0.200MG	N021924	012	Apr 25, 2017	Nov CFTG

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

+! HIKMA 100MCG/ML

N214253	001	May 17, 2021	Aug CAHN
---------	-----	--------------	----------

SOLUTION;ORAL

ERMEZA

+! MYLAN 150MCG/5ML

N215809	001	Apr 29, 2022	Apr NEWA
---------	-----	--------------	----------

THYQUIDITY

+! AZURITY 100MCG/5ML

N214047	001	Nov 30, 2020	Jul CAHN
---------	-----	--------------	----------

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOLET

AB1,	GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003	Aug CTEC
AB2,						
AB3,						
AB4						
AB1,		0.025MG	N021137	001	Jun 06, 2003	Jan CMFD
AB3,						
AB4						
AB1,		0.05MG	N021137	002	Jun 06, 2003	Aug CTEC
AB2,						
AB3,						
AB4						
AB1,		0.05MG	N021137	002	Jun 06, 2003	Jan CMFD
AB3,						
AB4						
AB1,		0.075MG	N021137	003	Jun 06, 2003	Aug CTEC
AB2,						
AB3,						
AB4						
AB1,		0.075MG	N021137	003	Jun 06, 2003	Jan CMFD
AB3,						
AB4						
AB1,		0.088MG	N021137	004	Jun 06, 2003	Aug CTEC
AB2,						
AB3,						
AB4						
AB1,		0.088MG	N021137	004	Jun 06, 2003	Jan CMFD
AB3,						
AB4						

TABLET;ORAL						
LEVOLET						
AB1, AB2, AB3, AB4	0.1MG	N021137	005	Jun 06, 2003	Aug	CTEC
AB1, AB3, AB4	0.1MG	N021137	005	Jun 06, 2003	Jan	CMFD
AB1, AB2, AB3, AB4	0.112MG	N021137	006	Jun 06, 2003	Aug	CTEC
AB1, AB3, AB4	0.112MG	N021137	006	Jun 06, 2003	Jan	CMFD
AB1, AB2, AB3, AB4	0.125MG	N021137	007	Jun 06, 2003	Aug	CTEC
AB1, AB3, AB4	0.125MG	N021137	007	Jun 06, 2003	Jan	CMFD
AB1, AB2, AB3, AB4	0.137MG	N021137	008	Jun 06, 2003	Aug	CTEC
AB1, AB3, AB4	0.137MG	N021137	008	Jun 06, 2003	Jan	CMFD
AB1, AB2, AB3, AB4	0.15MG	N021137	009	Jun 06, 2003	Aug	CTEC
AB1, AB3, AB4	0.15MG	N021137	009	Jun 06, 2003	Jan	CMFD
AB1, AB2, AB3, AB4	0.175MG	N021137	010	Jun 06, 2003	Aug	CTEC
AB1, AB3, AB4	0.175MG	N021137	010	Jun 06, 2003	Jan	CMFD
AB1, AB2, AB3, AB4	0.2MG	N021137	011	Jun 06, 2003	Aug	CTEC
AB1, AB3, AB4	0.2MG	N021137	011	Jun 06, 2003	Jan	CMFD
AB1, AB2, AB3, AB4	0.3MG	N021137	012	Jun 06, 2003	Aug	CTEC
AB1, AB3, AB4	0.3MG	N021137	012	Jun 06, 2003	Jan	CMFD
LEVOTHYROXINE SODIUM						
AB1, AB2, AB3, AB4	0.025MG	A212399	001	Oct 19, 2020	Nov	CTEC
AB2, AB3, AB4	0.025MG	A212399	001	Oct 19, 2020	Sep	CTEC
AB1, AB2, AB3, AB4	0.05MG	A212399	002	Oct 19, 2020	Nov	CTEC
AB2, AB3, AB4	0.05MG	A212399	002	Oct 19, 2020	Sep	CTEC
AB1, AB2, AB3, AB4	0.075MG	A212399	003	Oct 19, 2020	Nov	CTEC
AB2, AB3, AB4	0.075MG	A212399	003	Oct 19, 2020	Sep	CTEC
AB1, AB2,	0.088MG	A212399	004	Oct 19, 2020	Nov	CTEC

TABLET;ORAL
LEVOTHYROXINE SODIUM

AB3, AB4 AB2,	0.088MG	A212399	004	Oct 19, 2020	Sep CTEC
AB3, AB4 AB1,	0.1MG	A212399	005	Oct 19, 2020	Nov CTEC
AB2, AB3, AB4 AB2,	0.1MG	A212399	005	Oct 19, 2020	Sep CTEC
AB3, AB4 AB1,	0.112MG	A212399	006	Oct 19, 2020	Nov CTEC
AB2, AB3, AB4 AB2,	0.112MG	A212399	006	Oct 19, 2020	Sep CTEC
AB3, AB4 AB1,	0.125MG	A212399	007	Oct 19, 2020	Nov CTEC
AB2, AB3, AB4 AB2,	0.125MG	A212399	007	Oct 19, 2020	Sep CTEC
AB3, AB4 AB1,	0.137MG	A212399	008	Oct 19, 2020	Nov CTEC
AB2, AB3, AB4 AB2,	0.137MG	A212399	008	Oct 19, 2020	Sep CTEC
AB3, AB4 AB1,	0.15MG	A212399	009	Oct 19, 2020	Nov CTEC
AB2, AB3, AB4 AB2,	0.15MG	A212399	009	Oct 19, 2020	Sep CTEC
AB3, AB4 AB1,	0.175MG	A212399	010	Oct 19, 2020	Nov CTEC
AB2, AB3, AB4 AB2,	0.175MG	A212399	010	Oct 19, 2020	Sep CTEC
AB3, AB4 AB1,	0.2MG	A212399	011	Oct 19, 2020	Nov CTEC
AB2, AB3, AB4 AB2,	0.2MG	A212399	011	Oct 19, 2020	Sep CTEC
AB3, AB4 AB1,	0.3MG	A212399	012	Oct 19, 2020	Nov CTEC
AB2, AB3, AB4 AB2,	0.3MG	A212399	012	Oct 19, 2020	Sep CTEC
AB3, AB4 >A> AB1,	0.025MG	A211417	001	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.025MG	A211417	001	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.05MG	A211417	002	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.05MG	A211417	002	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.075MG	A211417	003	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.075MG	A211417	003	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.088MG	A211417	004	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.088MG	A211417	004	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.1MG	A211417	005	Dec 21, 2022	Dec NEWA
AB2 >A> AB1,	0.1MG	A211417	005	Dec 21, 2022	Dec NEWA

TABLET;ORAL
THYRO-TABS

AB1, +	0.088MG	N021116	010	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.1MG	N021116	004	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.112MG	N021116	011	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.125MG	N021116	005	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.137MG	N021116	012	Dec 07, 2004	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.15MG	N021116	006	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.175MG	N021116	007	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.2MG	N021116	008	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.3MG	N021116	009	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC
AKTEN

+! THEA PHARMA	3.5%	N022221	001	Oct 07, 2008	Apr CAHN
INJECTABLE;INJECTION					
LIDOCAINE HYDROCHLORIDE					
AP AFAXYS	1%	A215132	001	Jun 09, 2022	Jun NEWA
AP SINTETICA SA	1%	A214267	001	Sep 19, 2022	Sep NEWA
AP	2%	A214267	002	Sep 19, 2022	Sep NEWA
AP	4%	A214269	001	May 05, 2022	Apr NEWA
AP SINTETICA US	1%	A214267	001	Sep 19, 2022	Nov CAHN
AP	2%	A214267	002	Sep 19, 2022	Nov CAHN
AP	4%	A214269	001	May 05, 2022	Nov CAHN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
AP ! HOSPIRA	4%	A088295	001	May 17, 1984	Apr CTEC
INJECTABLE;SPINAL					
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%					
+! HOSPIRA	5%	A083914	001		Jul CRLD
SOLUTION;TOPICAL					
LIDOCAINE HYDROCHLORIDE					
AT NOVITIUM PHARMA	4%	A216250	001	Mar 23, 2022	Mar NEWA

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL
EMLA

+ @ TEVA BRANDED PHARM	2.5%;2.5%	N019941	001	Dec 30, 1992	Jul DISC
LIDOCAINE AND PRILOCAINE					
@ ACRUX DDS PTY	2.5%;2.5%	A212482	001	Jul 27, 2021	Jan DISC
! AKORN	2.5%;2.5%	A076290	001	Sep 25, 2003	Jul CHRS
>A> AB ENCUBE	2.5%;2.5%	A076320	001	Aug 27, 2003	Dec CAHN
AB PADAGIS US	2.5%;2.5%	A212482	001	Jul 27, 2021	Nov CMFD
@	2.5%;2.5%	A212482	001	Jul 27, 2021	Jun CAHN
>D> AB TOLMAR	2.5%;2.5%	A076320	001	Aug 27, 2003	Dec CAHN

LIDOCAINE; TETRACAINEPATCH; TOPICAL
SYNERA

+ @ GALEN SPECIALTY 70MG; 70MG N021623 001 Jun 23, 2005 Sep DISC

LINCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION
LINCOMYCIN HYDROCHLORIDE

	@ ATHENEX INC	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Sep CAHN
AP	GLAND PHARMA LTD	EQ 300MG BASE/ML	A215657	001	Sep 26, 2022	Sep NEWA
>A> AP	HAINAN POLY	EQ 300MG BASE/ML	A216662	001	Dec 21, 2022	Dec NEWA
AP	MICRO LABS	EQ 300MG BASE/ML	A215082	001	Nov 08, 2021	Nov CTNA
AP		EQ 300MG BASE/ML	A215082	001	Nov 08, 2021	Nov CAIN
AP	XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Nov CTNA

LINDANESHAMPOO; TOPICAL
LINDANE

@ WOCKHARDT BIO AG 1% A088191 001 Sep 18, 1984 Jul DISC

LINEZOLIDFOR SUSPENSION; ORAL
LINEZOLID

AB	HETERO LABS	100MG/5ML	A211813	001	Oct 31, 2022	Oct NEWA
	SOLUTION; INTRAVENOUS					
	LINEZOLID					
AP	HIKMA	600MG/300ML (2MG/ML)	A206454	001	Aug 22, 2022	Aug NEWA
	@ HOSPIRA	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	May DISC
>D> AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	Dec DISC
>A>	@	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	Dec DISC
	TABLET; ORAL					
	LINEZOLID					
	@ AMNEAL PHARMS	600MG	A204536	001	Dec 21, 2015	Jul DISC

LISINOPRILTABLET; ORAL
LISINOPRIL

	@ GRAVITI PHARMS	2.5MG	A075999	001	Jul 01, 2002	Apr CAHN
	@	5MG	A075999	002	Jul 01, 2002	Apr CAHN
	@	10MG	A075999	003	Jul 01, 2002	Apr CAHN
	@	20MG	A075999	004	Jul 01, 2002	Apr CAHN
	@	30MG	A075999	005	Jul 01, 2002	Apr CAHN
	@	40MG	A075999	006	Jul 01, 2002	Apr CAHN
	@ STRIDES PHARMA	2.5MG	A076071	001	Jul 01, 2002	Jan CAHN
	@	5MG	A076071	002	Jul 01, 2002	Jan CAHN
	@	10MG	A076071	003	Jul 01, 2002	Jan CAHN
	@	20MG	A076071	004	Jul 01, 2002	Jan CAHN
	@	30MG	A076071	005	Jul 01, 2002	Jan CAHN
	@	40MG	A076071	006	Jul 01, 2002	Jan CAHN
AB	WOCKHARDT BIO AG	2.5MG	A078402	001	Apr 19, 2007	Nov CAHN
AB		5MG	A078402	002	Apr 19, 2007	Nov CAHN
AB		10MG	A078402	003	Apr 19, 2007	Nov CAHN
AB		20MG	A078402	004	Apr 19, 2007	Nov CAHN
AB		30MG	A078402	005	Apr 19, 2007	Nov CAHN
AB		40MG	A078402	006	Apr 19, 2007	Nov CAHN

LITHIUM CITRATESYRUP; ORAL
LITHIUM CITRATE

	+ @ HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Apr DISC
	! PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Apr CAHN
	! WOCKHARDT BIO AG	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Apr CTEC
AA	!	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Apr CHRS

LOPERAMIDE HYDROCHLORIDECAPSULE; ORAL
LOPERAMIDE HYDROCHLORIDE

@ CHARTWELL RX 2MG A072993 001 Aug 28, 1992 Mar CAHN

LOPINAVIR; RITONAVIR

TABLET; ORAL

LOPINAVIR AND RITONAVIR

AB	LAURUS	100MG; 25MG	A213857	001	Mar 21, 2022	Mar NEWA
AB		200MG; 50MG	A213857	002	Mar 21, 2022	Mar NEWA

LORAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

LOREEV XR

+	ALMATICA	1.5MG	N214826	004	Feb 16, 2022	Feb NEWA
---	----------	-------	---------	-----	--------------	----------

TABLET; ORAL

LORAZEPAM

@	STRIDES PHARMA	0.5MG	A071591	002	Oct 13, 1987	Nov CAHN
@		1MG	A071591	003	Oct 13, 1987	Nov CAHN
@		2MG	A071591	001	Oct 13, 1987	Nov CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

@	HIKMA	25MG	A077459	001	Oct 06, 2010	Jul DISC
@		50MG	A077459	002	Oct 06, 2010	Oct DISC
@		100MG	A077459	003	Oct 06, 2010	Oct DISC

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

EYSUVIS

+	ALCON LABS INC	0.25%	N210933	001	Oct 26, 2020	Aug CAHN
+	ALCON LABS INC	1%	N210565	001	Aug 22, 2018	Aug CAHN

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	CHARTWELL RX	10MG	A075300	001	Dec 17, 2001	Aug CAHN
AB		20MG	A075300	002	Dec 17, 2001	Aug CAHN
AB		40MG	A075300	003	Dec 17, 2001	Aug CAHN

LUBIPROSTONE

CAPSULE; ORAL

LUBIPROSTONE

@	ANCHEN PHARMS	8MCG	A201442	001	Jun 27, 2022	Oct DISC
AB		8MCG	A201442	001	Jun 27, 2022	Jun NEWA
@		24MCG	A201442	002	Jun 27, 2022	Oct DISC
AB		24MCG	A201442	002	Jun 27, 2022	Jun NEWA
AB	DR REDDYS	8MCG	A206994	001	Feb 08, 2022	Jan NEWA
AB		24MCG	A206994	002	Feb 08, 2022	Jan NEWA
AB	TEVA PHARMS USA INC	8MCG	A209920	001	Jan 18, 2022	Nov CMFD
@		8MCG	A209920	001	Jan 18, 2022	Aug DISC
AB		8MCG	A209920	001	Jan 18, 2022	Jan NEWA
AB		24MCG	A209920	002	Jan 18, 2022	Nov CMFD
@		24MCG	A209920	002	Jan 18, 2022	Aug DISC
AB		24MCG	A209920	002	Jan 18, 2022	Jan NEWA

LUMATEPERONE TOSYLATE

CAPSULE; ORAL

CAPLYTA

+	INTRA-CELLULAR	EQ 10.5MG BASE	N209500	002	Apr 22, 2022	May NEWA
+		EQ 21MG BASE	N209500	003	Apr 22, 2022	May NEWA

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	20MG	A212244	001	Dec 13, 2022	Dec NEWA
>A>	AB		40MG	A212244	002	Dec 13, 2022	Dec NEWA
>A>	AB		60MG	A212244	003	Dec 13, 2022	Dec NEWA
>A>	AB		80MG	A212244	004	Dec 13, 2022	Dec NEWA
>A>	AB		120MG	A212244	005	Dec 13, 2022	Dec NEWA
	AB	INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Aug CMFD
	AB		40MG	A208028	002	Jan 03, 2019	Aug CMFD
	AB		60MG	A208028	003	Jan 03, 2019	Aug CMFD
	AB		80MG	A208028	004	Jan 03, 2019	Aug CMFD

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB		120MG	A208028	005	Jan 03, 2019	Aug CMFD
AB	MSN	20MG	A208037	001	Sep 09, 2022	Sep NEWA
AB		40MG	A208037	002	Sep 09, 2022	Sep NEWA
AB		60MG	A208037	003	Sep 09, 2022	Sep NEWA
AB		80MG	A208037	004	Sep 09, 2022	Sep NEWA
AB		120MG	A208037	005	Sep 09, 2022	Sep NEWA
>D>	@ ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019	Dec CMFD
>A> AB		20MG	A208052	001	Mar 19, 2019	Dec CMFD
>D>	@	40MG	A208052	002	Mar 19, 2019	Dec CMFD
>A> AB		40MG	A208052	002	Mar 19, 2019	Dec CMFD
>D>	@	60MG	A208052	003	Mar 19, 2019	Dec CMFD
>A> AB		60MG	A208052	003	Mar 19, 2019	Dec CMFD
>D>	@	80MG	A208052	004	Mar 19, 2019	Dec CMFD
>A> AB		80MG	A208052	004	Mar 19, 2019	Dec CMFD
>D>	@	120MG	A208052	005	Mar 19, 2019	Dec CMFD
>A> AB		120MG	A208052	005	Mar 19, 2019	Dec CMFD

LUTETIUM LU 177 DOTATATE

SOLUTION; INTRAVENOUS

LUTATHERA

+	!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jun CAIN
---	---	-------------	----------	---------	-----	--------------	----------

LUTETIUM LU-177 VIPIVOTIDE TETRAKETAN

SOLUTION; INTRAVENOUS

PLUVICTO

+	!	AAA USA NOVARTIS	27mCi/ML	N215833	001	Mar 23, 2022	Mar NEWA
---	---	------------------	----------	---------	-----	--------------	----------

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE

>D> AT	NOVAST LABS	5%	A206716	001	Jul 31, 2017	Dec CTEC
>A>	!	5%	A206716	001	Jul 31, 2017	Dec CTEC
>D> AT	! PAR FORM	5%	A201511	001	Feb 12, 2013	Dec DISC
>A>	@	5%	A201511	001	Feb 12, 2013	Dec DISC
AT	!	5%	A201511	001	Feb 12, 2013	Feb CHRS
	SULFAMYLON					
+	@ MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Nov DISC
+	@	5%	N019832	003	Jun 05, 1998	Feb DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

>D>	MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5						
>D> AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Dec DISC	
>A>	@	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Dec DISC	
AP		30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Jun NFTG	
>D>	MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4						
>D> AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Dec DISC	
>A>	@	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Dec DISC	
AP		30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Jun CTNA	
AP		30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	May NFTG	
	PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER						
>D> AP	++ BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Dec CTEC	
>A>	++	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Dec CTEC	
AP	++	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Jun CFTG	
	PLASMA-LYTE A IN PLASTIC CONTAINER						
>D> AP	++ BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Dec CTEC	
>A>	++	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Dec CTEC	
AP	++	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	May CFTG	

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

>D>	@ MILLA PHARMS	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Dec CMFD
>A>	AP	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Dec CMFD
	@	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Jul DISC
	AP	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Jun CAHN
	AP	4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Nov CMFD
	@	4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Jul DISC
	AP	4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Jun CAHN
	AP	4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Nov CMFD
	@	4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Jul DISC
	AP	4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Jun CAHN

MARAVIROC

TABLET;ORAL

MARAVIROC

AB	HETERO LABS LTD III	150MG	A203347	001	Feb 07, 2022	Jan NFTG
AB		300MG	A203347	002	Feb 07, 2022	Jan NFTG
	SELZENTRY					
AB	+ VIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007	Jan CFTG
AB	+!	300MG	N022128	002	Aug 06, 2007	Jan CFTG

MAVACAMTEN

CAPSULE;ORAL

CAMZYOS

+	BRISTOL	2.5MG	N214998	001	Apr 28, 2022	Sep CAHN
+		5MG	N214998	002	Apr 28, 2022	Sep CAHN
+		10MG	N214998	003	Apr 28, 2022	Sep CAHN
+		15MG	N214998	004	Apr 28, 2022	Sep CAHN
+	MYOKARDIA	2.5MG	N214998	001	Apr 28, 2022	Apr NEWA
+		5MG	N214998	002	Apr 28, 2022	Apr NEWA
+		10MG	N214998	003	Apr 28, 2022	Apr NEWA
+		15MG	N214998	004	Apr 28, 2022	Apr NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA	APNAR PHARMA LP	12.5MG	A087128	002		Apr CAHN
AA		25MG	A087128	001		Apr CAHN
AA	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Feb NEWA
AA		25MG	A200432	002	Feb 17, 2022	Feb NEWA
AA		50MG	A200432	003	Feb 17, 2022	Feb NEWA
AA	LUPIN LTD	12.5MG	A203003	001	Aug 11, 2022	Aug NEWA
AA		25MG	A203003	002	Aug 11, 2022	Aug NEWA
AA		50MG	A203003	003	Aug 11, 2022	Aug NEWA

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

AA	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Feb NEWA
----	----------------	------	---------	-----	--------------	----------

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB	EUGIA PHARMA	150MG/ML	A212824	001	Aug 22, 2022	Aug NEWA
AB		150MG/ML	A212844	001	Aug 31, 2022	Aug NEWA
>A>	AB	HIKMA	A214309	001	Jan 05, 2023	Dec NEWA
	@ SUN PHARM	150MG/ML	A210760	001	May 01, 2019	Jul DISC
	@	150MG/ML	A210761	001	Apr 24, 2019	Jul DISC

MELOXICAM

CAPSULE;ORAL

VIVLODEX

+	@ ICEUTICA OPERATIONS	5MG	N207233	001	Oct 22, 2015	Mar CAHN
+	@	10MG	N207233	002	Oct 22, 2015	Mar CAHN

SOLUTION;INTRAVENOUS

>D>	ANJESO					
>D>	+! BAUDAX	30MG/ML (30MG/ML)	N210583	001	Feb 20, 2020	Dec DISC
>A>	+ @	30MG/ML (30MG/ML)	N210583	001	Feb 20, 2020	Dec DISC
	SUSPENSION;ORAL					
	MELOXICAM					
	+! AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	May CTNA

SUSPENSION;ORAL
MELOXICAM

+! 7.5MG/5ML N021530 001 Jun 01, 2004 May CMFD

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION
MELPHALAN HYDROCHLORIDE

AP	ARTHUR GRP	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep CAHN
AP	NANJING	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep CMFD
	@	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Apr CAHN

POWDER;INTRAVENOUS
EVOMELA

+!	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Oct CAHN
----	--------------------	-------------------	---------	-----	--------------	----------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

	@ ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017	Oct DISC
	@	14MG	A205784	002	Jun 09, 2017	Oct DISC
	@	21MG	A205784	003	Jun 09, 2017	Oct DISC
	@	28MG	A205784	004	Jun 09, 2017	Oct DISC
	@ ANI PHARMS	7MG	A205365	001	Feb 28, 2020	Nov DISC
	@	14MG	A205365	002	Feb 28, 2020	Apr DISC
	@	21MG	A205365	003	Feb 28, 2020	Oct DISC
AB	XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Sep NEWA
AB		14MG	A213985	002	Oct 11, 2022	Sep NEWA
AB		28MG	A213985	003	Oct 11, 2022	Sep NEWA

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA	! CHARTWELL MOLECULAR	2MG/ML	A204033	001	Oct 13, 2015	Oct CAHN
----	-----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	ALLIED	5MG	A209527	001	May 07, 2018	Feb CAHN
AB		10MG	A209527	002	May 07, 2018	Feb CAHN
AB	ESKAYEF	5MG	A209527	001	May 07, 2018	Aug CAHN
AB		10MG	A209527	002	May 07, 2018	Aug CAHN
AB	HETERO LABS LTD V	5MG	A204389	001	Sep 26, 2022	Sep NEWA
AB		10MG	A204389	002	Sep 26, 2022	Sep NEWA
>D> AB	LANNETT CO INC	5MG	A207236	001	Nov 10, 2016	Dec DISC
>A>	@	5MG	A207236	001	Nov 10, 2016	Dec DISC
>D> AB		10MG	A207236	002	Nov 10, 2016	Dec DISC
>A>	@	10MG	A207236	002	Nov 10, 2016	Dec DISC
AB	RENATA	5MG	A209527	001	May 07, 2018	Nov CAHN
AB		5MG	A209527	001	May 07, 2018	Jul CAHN
AB		10MG	A209527	002	May 07, 2018	Nov CAHN
AB		10MG	A209527	002	May 07, 2018	Jul CAHN
	@ RISING	5MG	A079225	001	Jan 30, 2015	Jan CAHN
	@	10MG	A079225	002	Jan 30, 2015	Jan CAHN

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

@	ANDA REPOSITORY	50MG	A040893	001	Jun 24, 2009	Sep CAHN
@		75MG	A040893	002	Jun 24, 2009	Sep CAHN
@		100MG	A040893	003	Jun 24, 2009	Sep CAHN
@		150MG	A040893	004	Jun 24, 2009	Sep CAHN
@	GENUS	50MG	A040893	001	Jun 24, 2009	Apr CAHN
@		75MG	A040893	002	Jun 24, 2009	Apr CAHN
@		100MG	A040893	003	Jun 24, 2009	Apr CAHN
@		150MG	A040893	004	Jun 24, 2009	Apr CAHN
@	MIKART	50MG	A040893	001	Jun 24, 2009	Mar CAHN
@		75MG	A040893	002	Jun 24, 2009	Mar CAHN
@		100MG	A040893	003	Jun 24, 2009	Mar CAHN
@		150MG	A040893	004	Jun 24, 2009	Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

@	HIKMA	25MG/ML;25MG/ML	N011730	001		Jul CAHN
---	-------	-----------------	---------	-----	--	----------

MEROPENEMINJECTABLE; INJECTION
MEROPENEM

AP	BROOKS STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Sep CAHN
AP		1GM/VIAL	A216154	002	Aug 18, 2022	Sep CAHN
AP	STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Aug NEWA
AP		1GM/VIAL	A216154	002	Aug 18, 2022	Aug NEWA

MESALAMINECAPSULE, EXTENDED RELEASE; ORAL
MESALAMINE

AB	ALEMBIC PHARMS	375MG	A216967	001	Oct 28, 2022	Oct NEWA
AB	SUN PHARM	500MG	A214585	001	May 11, 2022	Apr NFTG
	@ TEVA PHARMS USA	375MG	A209970	001	May 06, 2022	Nov DISC
AB		375MG	A209970	001	May 06, 2022	Apr NEWA
	PENTASA					
AB	+! TAKEDA PHARMS USA	500MG	N020049	002	Jul 08, 2004	Apr CFTG
	SUPPOSITORY; RECTAL					
	MESALAMINE					
	@ AMNEAL	1GM	A210509	001	Jan 02, 2020	Sep DISC
	TABLET, DELAYED RELEASE; ORAL					
	ASACOL HD					
	+ @ APIL	800MG	N021830	001	May 29, 2008	May DISC
	MESALAMINE					
	! ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017	May CTEC
AB	!	800MG	A203286	001	Jul 21, 2017	May CHRS

METAPROTERENOL SULFATESYRUP; ORAL
METAPROTERENOL SULFATE

!	ANDA REPOSITORY	10MG/5ML	A073632	001	Jul 22, 1992	Sep CAHN
---	-----------------	----------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDESOLUTION; ORAL
METFORMIN HYDROCHLORIDE

AB	!	SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Oct CHRS
AB		VISTAPHARM	500MG/5ML	A212677	001	Aug 19, 2022	Aug NEWA
		RIOMET					
	+ @	RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Oct DISC
		TABLET, EXTENDED RELEASE; ORAL					
		METFORMIN HYDROCHLORIDE					
AB1		AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Feb CTEC
AB			750MG	A078596	002	Jan 03, 2008	Feb CTEC
	@	AMTA	500MG	A213394	001	Aug 03, 2021	Jan DISC
	@		1GM	A213394	002	Aug 03, 2021	Jan DISC
>A>	AB3	MICRO LABS	500MG	A212448	001	Jan 10, 2023	Dec NEWA
>A>	AB3		1GM	A212448	002	Jan 10, 2023	Dec NEWA
	AB3	PRINSTON INC	500MG	A212681	001	Jun 09, 2022	Jun NEWA
	AB3		1GM	A212681	002	Jun 09, 2022	Jun NEWA
	AB2	SCIEGEN PHARMS INC	500MG	A214629	001	Feb 22, 2022	Feb NEWA
	AB2		1GM	A214629	002	Feb 22, 2022	Feb NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDETABLET; ORAL
ACTOPLUS MET

+ @	TAKEDA PHARMS USA	500MG; EQ 15MG BASE	N021842	001	Aug 29, 2005	May DISC
-----	-------------------	---------------------	---------	-----	--------------	----------

METHADONE HYDROCHLORIDETABLET; ORAL
METHADONE HYDROCHLORIDE

@	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Feb DISC
@		10MG	A210484	002	Aug 02, 2018	Feb DISC

METHAMPHETAMINE HYDROCHLORIDETABLET; ORAL
DESOXYN

AA	+!	KEY THERAP	5MG	N005378	002		Aug CAHN
		TABLET, EXTENDED RELEASE; ORAL					
		DESOXYN					
	@	KEY THERAP	5MG	N005378	004		Aug CAHN
	@		10MG	N005378	003		Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
DESOXYN

@ 15MG N005378 005 Aug CAHN

METHAZOLAMIDE

TABLET;ORAL
METHAZOLAMIDE

AB	BAUSCH AND LOMB INC	25MG	A207438	001	Oct 05, 2018	Apr CAHN
AB		50MG	A207438	002	Oct 05, 2018	Apr CAHN
>A>	AB TAGI	25MG	A215615	001	Oct 18, 2022	Dec CAHN
>A>	AB	50MG	A215615	002	Oct 18, 2022	Dec CAHN
>D>	AB ZENARA	25MG	A215615	001	Oct 18, 2022	Dec CAHN
	AB	25MG	A215615	001	Oct 18, 2022	Oct NEWA
>D>	AB	50MG	A215615	002	Oct 18, 2022	Dec CAHN
	AB	50MG	A215615	002	Oct 18, 2022	Oct NEWA

METHENAMINE HIPPURATE

TABLET;ORAL
HIPREX

AB + VALIDUS PHARMS 1GM N017681 001 Apr CMFD

METHIMAZOLE

TABLET;ORAL
METHIMAZOLE

AB	AIPING LIFE SCI	5MG	A040547	001	Feb 18, 2005	Oct CAHN
AB		10MG	A040547	002	Feb 18, 2005	Oct CAHN
	@	20MG	A040547	004	Feb 18, 2005	Oct CAHN

METHOCARBAMOL

SOLUTION;IM-IV
METHOCARBAMOL

AP	BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Jul NEWA
AP	HAINAN POLY	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Aug CAHN
	@ MYLAN INSTITUTIONAL	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Nov DISC

TABLET;ORAL

METHOCARBAMOL

AA	ACME LABS	500MG	A203550	001	Feb 08, 2017	Sep CAHN
AA		750MG	A203550	002	Feb 08, 2017	Sep CAHN
	@ CHARTWELL MOLECULAR	500MG	A084756	002	Mar 31, 2003	Aug CAHN
	@	750MG	A084756	001		Aug CAHN
AA	PRINSTON INC	500MG	A086988	002		Oct CMS1

METHOTREXATE

SOLUTION;ORAL
JYLAMVO

+! THERAKIND 2MG/ML N212479 001 Nov 29, 2022 Nov NEWA

SOLUTION;SUBCUTANEOUS
REDITREX

>D>	+ @ CUMBERLAND PHARMS	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019	Dec CAHN
	+ @	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019	Sep DISC
>D>	+ @	10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019	Dec CAHN
	+ @	10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019	Sep DISC
>D>	+ @	12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019	Dec CAHN
	+ @	12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019	Sep DISC
>D>	+!	15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019	Dec CAHN
>D>	+ @	17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019	Dec CAHN
	+ @	17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019	Sep DISC
>D>	+!	20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019	Dec CAHN
>D>	+ @	22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019	Dec CAHN
	+ @	22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019	Sep DISC
>D>	+!	25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019	Dec CAHN
>A>	+ @ NORDIC GRP	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019	Dec CAHN
>A>	+ @	10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019	Dec CAHN
>A>	+ @	12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019	Dec CAHN
>A>	+!	15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019	Dec CAHN
>A>	+ @	17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019	Dec CAHN
>A>	+!	20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019	Dec CAHN
>A>	+ @	22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019	Dec CAHN
>A>	+!	25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019	Dec CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION							
METHOTREXATE LPF							
+ @	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982	Jan	CRLD
METHOTREXATE PRESERVATIVE FREE							
+ @	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005	Jan	CRLD
+ @		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005	Jan	CRLD
METHOTREXATE SODIUM							
+ @	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004		Jan	CRLD
+ @		EQ 20MG BASE/VIAL	N011719	001		Jan	CRLD
+ @		EQ 25MG BASE/ML	N011719	005		Jan	CRLD
+ @		EQ 50MG BASE/VIAL	N011719	003		Jan	CRLD
+ @		EQ 100MG BASE/VIAL	N011719	006		Jan	CRLD
METHOTREXATE SODIUM PRESERVATIVE FREE							
@	EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar	CAHN
@		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar	CAHN
@		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar	CAHN
@		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar	CAHN
AP	HIKMA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Jan	CHRS
+ @	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988	Jan	CRLD
MEXATE-AQ							
+ @	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985	Jan	CRLD

METHYLDOPA

TABLET; ORAL							
METHYLDOPA							
@	ACCORD HLTHCARE	250MG	A070084	001	Oct 15, 1985	Sep	DISC
@		500MG	A070085	001	Oct 15, 1985	Aug	DISC

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL							
DAYTRANA							
AB	+ NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006	Mar	CFTG
AB	+	15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006	Mar	CFTG
AB	+	20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006	Mar	CFTG
AB	+!	30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006	Mar	CFTG
METHYLPHENIDATE							
AB	MYLAN TECH VIATRIS	10MG/9HR (1.1MG/HR)	A206497	001	Mar 14, 2022	Mar	NFTG
AB		15MG/9HR (1.6MG/HR)	A206497	002	Mar 14, 2022	Mar	NFTG
AB		20MG/9HR (2.2MG/HR)	A206497	003	Mar 14, 2022	Mar	NFTG
AB		30MG/9HR (3.3MG/HR)	A206497	004	Mar 14, 2022	Mar	NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL							
METADATE CD							
AB2	+ AYU BIOPHARMA	10MG	N021259	003	May 27, 2003	May	CAHN
AB2	+	20MG	N021259	001	Apr 03, 2001	May	CAHN
AB2	+	30MG	N021259	002	Jun 19, 2003	May	CAHN
AB2	+	40MG	N021259	004	Feb 19, 2006	May	CAHN
AB2	+	50MG	N021259	005	Feb 19, 2006	May	CAHN
AB2	+!	60MG	N021259	006	Feb 19, 2006	May	CAHN
TABLET, EXTENDED RELEASE; ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
AB	ACTAVIS LABS FL	72MG	A076655	002	Feb 28, 2022	Feb	NEWA
>D>	AB	ALVOGEN	A204772	001	Feb 29, 2016	Dec	DISC
>A>	@	10MG	A204772	001	Feb 29, 2016	Dec	DISC
>D>	AB	18MG	A210818	001	Nov 30, 2018	Dec	DISC
>A>	@	18MG	A210818	001	Nov 30, 2018	Dec	DISC
>D>	AB	20MG	A204772	002	Feb 29, 2016	Dec	DISC
>A>	@	20MG	A204772	002	Feb 29, 2016	Dec	DISC
>D>	AB	27MG	A210818	002	Nov 30, 2018	Dec	DISC
>A>	@	27MG	A210818	002	Nov 30, 2018	Dec	DISC
>D>	AB	36MG	A210818	003	Nov 30, 2018	Dec	DISC
>A>	@	36MG	A210818	003	Nov 30, 2018	Dec	DISC
>D>	AB	54MG	A210818	004	Nov 30, 2018	Dec	DISC
>A>	@	54MG	A210818	004	Nov 30, 2018	Dec	DISC
AB	! OSMOTICA	72MG	A205327	005	Jul 28, 2017	Feb	CTEC
	@ RHODES PHARMS	18MG	A214111	001	May 31, 2022	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB		18MG	A214111	001	May 31, 2022	May NEWA
	@	27MG	A214111	002	May 31, 2022	Jun DISC
AB		27MG	A214111	002	May 31, 2022	May NEWA
	@	36MG	A214111	003	May 31, 2022	Jun DISC
AB		36MG	A214111	003	May 31, 2022	May NEWA
	@	54MG	A214111	004	May 31, 2022	Jun DISC
AB		54MG	A214111	004	May 31, 2022	May NEWA

RELEXXII

+	OSMOTICA PHARM US	18MG	N216117	001	Jun 23, 2022	Jun NEWA
+		27MG	N216117	002	Jun 23, 2022	Jun NEWA
+		36MG	N216117	003	Jun 23, 2022	Jun NEWA
+		45MG	N216117	004	Jun 23, 2022	Jun NEWA
+		54MG	N216117	005	Jun 23, 2022	Jun NEWA
+		63MG	N216117	006	Jun 23, 2022	Jun NEWA
+	!	72MG	N216117	007	Jun 23, 2022	Jun NEWA

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

@	AMNEAL	4MG	A207481	001	Sep 21, 2021	Mar DISC
@		8MG	A207481	002	Sep 21, 2021	Mar DISC
@		16MG	A207481	003	Sep 21, 2021	Mar DISC
@		32MG	A207481	004	Sep 21, 2021	Mar DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

+	PFIZER	20MG/ML	N011757	002		Nov CTEC
AB	+	40MG/ML	N011757	001		Jul CHRS
AB	+	80MG/ML	N011757	004		Jul CHRS

METHYLPREDNISOLONE ACETATE

AB	!	AMNEAL	40MG/ML	A210043	001	May 20, 2019	Jul CHRS
AB	!		80MG/ML	A210043	002	May 20, 2019	Jul CHRS
	@	PAR STERILE PRODUCTS	40MG/ML	A214297	001	Jan 21, 2022	Jul DISC
AB			40MG/ML	A214297	001	Jan 21, 2022	Jan NEWA
AB			80MG/ML	A214297	002	Jan 21, 2022	Jan NEWA
	@	SAGENT PHARMS INC	20MG/ML	A201835	001	Jun 27, 2018	Nov DISC
AB	!		40MG/ML	A201835	002	Jun 27, 2018	Nov CHRS
AB	!		80MG/ML	A201835	003	Jun 27, 2018	Sep CHRS
>A>	AB	SLAYBACK PHARMA LLC	80MG/ML	A214870	001	Jan 03, 2023	Dec NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

@	EUGIA PHARMA	EQ 40MG BASE/VIAL	A207667	001	Dec 15, 2015	Jul DISC
@		EQ 125MG BASE/VIAL	A207667	002	Dec 15, 2015	Jul DISC
@		EQ 500MG BASE/VIAL	A207667	003	Dec 15, 2015	Jul DISC
@		EQ 2GM BASE/VIAL	A207667	004	Dec 15, 2015	Jul DISC
AP	HIKMA	EQ 40MG BASE/VIAL	A203125	001	Sep 26, 2022	Sep NEWA
AP		EQ 125MG BASE/VIAL	A203125	002	Sep 26, 2022	Sep NEWA
AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Jan CMFD
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Jan CMFD
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Jan CMFD
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Jan CMFD
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Jan CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

AB	!	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Feb CTEC
AB		NOVITIUM PHARMA	10MG	A215270	001	Feb 18, 2022	Feb NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	CHARTWELL RX	EQ 5MG BASE	A074478	001	Oct 05, 1995	Mar CAHN
@		EQ 10MG BASE	A072215	001	Jan 30, 1990	Mar CAHN
@		EQ 10MG BASE	A074478	002	Oct 05, 1995	Mar CAHN

METOLAZONETABLET; ORAL
METOLAZONE

AB	AACE PHARMS	2.5MG	A216216	001	Oct 25, 2022	Oct	NEWA
AB		5MG	A216216	002	Oct 25, 2022	Oct	NEWA
AB		10MG	A216216	003	Oct 25, 2022	Oct	NEWA
AB	ESKAYEF	2.5MG	A215616	001	Oct 24, 2022	Oct	NEWA
AB		5MG	A215616	002	Oct 24, 2022	Oct	NEWA
AB		10MG	A215616	003	Oct 24, 2022	Oct	NEWA
AB	RENATA	2.5MG	A215616	001	Oct 24, 2022	Nov	CAHN
AB		5MG	A215616	002	Oct 24, 2022	Nov	CAHN
AB		10MG	A215616	003	Oct 24, 2022	Nov	CAHN
	ZAROXOLYN						
	+ @ I3 PHARMS	2.5MG	N017386	001		Nov	CAHN
	+ @	5MG	N017386	002		Nov	CAHN
	+ @	10MG	N017386	003		Nov	CAHN

METOPROLOL SUCCINATETABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

AB	ACCORD HLTHCARE	EQ 25MG TARTRATE	A215637	001	Oct 18, 2022	Oct	NEWA
AB		EQ 50MG TARTRATE	A215637	002	Oct 18, 2022	Oct	NEWA
AB		EQ 100MG TARTRATE	A215637	003	Oct 18, 2022	Oct	NEWA
AB		EQ 200MG TARTRATE	A215637	004	Oct 18, 2022	Oct	NEWA
	@ PRINSTON INC	EQ 100MG TARTRATE	A210597	001	Jan 04, 2022	Aug	DISC
	@	EQ 200MG TARTRATE	A210597	002	Jan 04, 2022	Aug	DISC
AB	SUNSHINE	EQ 50MG TARTRATE	A214004	001	Sep 26, 2022	Sep	NEWA
AB		EQ 100MG TARTRATE	A214004	002	Sep 26, 2022	Sep	NEWA
AB		EQ 200MG TARTRATE	A214004	003	Sep 26, 2022	Sep	NEWA
AB	YICHANG HUMANWELL	EQ 25MG TARTRATE	A213854	004	Aug 01, 2022	Jul	NEWA

METOPROLOL TARTRATEINJECTABLE; INJECTION
METOPROLOL TARTRATE

@ STERISCIENCE 1MG/ML

A090317 001 Apr 19, 2010 Feb CAHN

TABLET; ORAL

METOPROLOL TARTRATE

@ CHARTWELL RX 50MG
@ 100MGA073288 001 Mar 25, 1994 Mar CAHN
A073289 001 Mar 25, 1994 Mar CAHNMETRONIDAZOLECREAM; TOPICAL
NORITATE

+! BAUSCH 1%

N020743 001 Sep 26, 1997 Jul CAHN

GEL; TOPICAL

METRONIDAZOLE

>A> AB ENCUBE 0.75%
>D> AB TOLMAR 0.75%A077547 001 Jul 13, 2006 Dec CAHN
A077547 001 Jul 13, 2006 Dec CAHN

GEL; VAGINAL

METRONIDAZOLE

AB GLENMARK PHARMS LTD 0.75%
@ TOLMAR 0.75%A215794 001 Jan 27, 2022 Jan NEWA
A077264 001 Oct 31, 2006 Nov DISC

INJECTABLE; INJECTION

METRONIDAZOLE

@ HIKMA 500MG/100ML
METRONIDAZOLE IN PLASTIC CONTAINER
@ RISING 500MG/100MLN018907 001 Mar 30, 1984 Jul CAHN
A205531 001 May 09, 2017 Jan CAHNMETYROSINECAPSULE; ORAL
DEMSERAB +! BAUSCH 250MG
METYROSINE

N017871 001 Oct CTEC

AB AMNEAL 250MG

A213734 001 Jul 24, 2020 Oct CTEC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	ANNORA PHARMA	150MG	A216463	001	Nov 09, 2022	Nov NEWA
AB		200MG	A216463	002	Nov 09, 2022	Nov NEWA
AB		250MG	A216463	003	Nov 09, 2022	Nov NEWA
AB	AUCTA	150MG	A215315	001	Aug 26, 2022	Sep CAHN
AB		200MG	A215315	002	Aug 26, 2022	Sep CAHN
AB		250MG	A215315	003	Aug 26, 2022	Sep CAHN
AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Aug NEWA
AB		200MG	A215315	002	Aug 26, 2022	Aug NEWA
AB		250MG	A215315	003	Aug 26, 2022	Aug NEWA

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

AP	MEITHEAL	EQ 50MG BASE/VIAL	A215381	001	Sep 28, 2022	Nov CAHN
AP		EQ 100MG BASE/VIAL	A215381	002	Sep 28, 2022	Nov CAHN
AP	NANJING KING-FRIEND	EQ 50MG BASE/VIAL	A215381	001	Sep 28, 2022	Sep NEWA
AP		EQ 100MG BASE/VIAL	A215381	002	Sep 28, 2022	Sep NEWA
AP	ZYDUS PHARMS	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Oct NEWA
AP		EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Oct NEWA

MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	MYLAN	0.25%; 81.35%; 15%	N021026	001	Feb 16, 2006	Jul CAIN
---	-------	--------------------	---------	-----	--------------	----------

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

+	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	Jul NEWA
+		100MG/100ML (1MG/ML)	N215868	002	Jul 20, 2022	Jul NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

@	WOCKHARDT BIO AG	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Nov CAHN
@		EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Nov CAHN
@		EQ 5MG BASE/ML	A078141	002	May 30, 2008	Nov CAHN
@		EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Nov CAHN
	MIDAZOLAM HYDROCHLORIDE	PRESERVATIVE FREE				
@	STERISCIENCE	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan CAHN
@		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan CAHN
	MIDOZALAM HYDROCHLORIDE					
@	STERISCIENCE	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Feb CAHN
@		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Feb CAHN

SOLUTION; INTRAMUSCULAR

MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)

+	@ RAFA LABS LTD	EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Sep DISC
+		EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Aug NEWA

SEIZALAM

+	MMT	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018	May CAHN
---	-----	------------------------------------	---------	-----	--------------	----------

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

@	AKORN	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Aug DISC
---	-------	----------------	---------	-----	--------------	----------

MIGLITOL

TABLET; ORAL

MIGLITOL

AB	WESTMINSTER PHARMS	25MG	A203965	001	Feb 24, 2015	Aug CAHN
AB		50MG	A203965	002	Feb 24, 2015	Aug CAHN
AB		100MG	A203965	003	Feb 24, 2015	Aug CAHN

MIGLUSTATCAPSULE;ORAL
MIGLUSTAT

AB	BRECKENRIDGE	100MG	A209325	001	Feb 03, 2022	Jan NEWA
----	--------------	-------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDEAEROSOL, FOAM;TOPICAL
AMZEEQ

+	JOURNEY	EQ 4% BASE	N212379	001	Oct 18, 2019	Jan CAHN
---	---------	------------	---------	-----	--------------	----------

+	JOURNEY	EQ 1.5% BASE	N213690	001	May 28, 2020	Jan CAHN
---	---------	--------------	---------	-----	--------------	----------

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	TORRENT	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

INJECTABLE;INJECTION
MINOCIN

AP	+	REMPEX	EQ 100MG BASE/VIAL	N050444	001	Jul CFTG
----	---	--------	--------------------	---------	-----	----------

MINOCYCLINE HYDROCHLORIDE

AP		NEXUS PHARMS	EQ 100MG BASE/VIAL	A214934	001	Jul 22, 2022	Jul NFTG
----	--	--------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	BEXIMCO PHARMS USA	EQ 50MG BASE	A215466	001	May 27, 2022	May NEWA
AB		EQ 75MG BASE	A215466	002	May 27, 2022	May NEWA
AB		EQ 100MG BASE	A215466	003	May 27, 2022	May NEWA
AB	TORRENT	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SIDMAK LABS INDIA	EQ 55MG BASE	A204394	002	Oct 07, 2022	Sep NEWA
AB		EQ 65MG BASE	A204394	003	Oct 07, 2022	Sep NEWA
AB		EQ 115MG BASE	A204394	006	Oct 07, 2022	Sep NEWA

MIRABEGRONTABLET, EXTENDED RELEASE;ORAL
MIRABEGRON

AB	LUPIN LTD	25MG	A209485	001	Sep 28, 2022	Sep NEWA	
AB		50MG	A209485	002	Sep 28, 2022	Sep NFTG	
AB	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Sep NEWA	
AB		50MG	A209488	002	Sep 29, 2022	Sep NEWA	
AB	MYRBETRIQ						
AB	+	APGDI	25MG	N202611	001	Jun 28, 2012	Sep CTEC
AB	+		50MG	N202611	002	Jun 28, 2012	Sep CFTG

MIRTAZAPINETABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

AB	SQUARE PHARMS	15MG	A205798	001	Jun 01, 2017	Jan CAHN
AB		30MG	A205798	002	Jun 01, 2017	Jan CAHN
AB		45MG	A205798	003	Jun 01, 2017	Jan CAHN

MISOPROSTOLTABLET;ORAL
CYTOTECH

AB	+	PFIZER	0.1MG	N019268	003	Sep 21, 1990	Mar CTEC
AB	+		0.2MG	N019268	001	Dec 27, 1988	Mar CTEC

MISOPROSTOL

AB	ANI PHARMS	0.1MG	A076095	001	Jul 10, 2002	Mar CMFD
AB		0.2MG	A076095	002	Jul 10, 2002	Mar CMFD
AB	MICRO LABS	0.1MG	A216872	001	Oct 17, 2022	Oct NEWA
AB		0.2MG	A216872	002	Oct 17, 2022	Oct NEWA

MITAPIVAT SULFATETABLET;ORAL
PYRUKYND

+	AGIOS PHARMS INC	EQ 5MG BASE	N216196	001	Feb 17, 2022	Feb NEWA
+		EQ 20MG BASE	N216196	002	Feb 17, 2022	Feb NEWA
+		EQ 50MG BASE	N216196	003	Feb 17, 2022	Feb NEWA

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN

AP	GLAND PHARMA LTD	40MG/VIAL	A216648	001	Nov 22, 2022	Nov CMS1
AP		40MG/VIAL	A216648	001	Nov 15, 2022	Nov NEWA
AP	HONG KONG	5MG/VIAL	A214505	001	Sep 08, 2022	Sep NEWA
AP		20MG/VIAL	A214505	002	Sep 08, 2022	Sep NEWA
AP		40MG/VIAL	A214504	001	Sep 06, 2022	Aug NEWA
AP	MEITHEAL	5MG/VIAL	A214505	001	Sep 08, 2022	Oct CAHN
AP		20MG/VIAL	A214505	002	Sep 08, 2022	Oct CAHN
AP		40MG/VIAL	A214504	001	Sep 06, 2022	Oct CAHN

MOMETASONE FUROATE

LOTION;TOPICAL
MOMETASONE FUROATE

>D>	@ ANDA REPOSITORY	0.1%	A076499	001	Nov 21, 2007	Dec CAHN
>A>	@ ENCUBE	0.1%	A076499	001	Nov 21, 2007	Dec CAHN

OINTMENT;TOPICAL
MOMETASONE FUROATE

>D>	@ ANDA REPOSITORY	0.1%	A076481	001	Nov 14, 2003	Dec CAHN
>A>	@ ENCUBE	0.1%	A076481	001	Nov 14, 2003	Dec CAHN

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL
RYALTRIS

+	!	GLENMARK SPECIALTY	0.025MG/SPRAY;0.665MG/SPRAY	N211746	001	Jan 13, 2022	Jan NEWA
---	---	--------------------	-----------------------------	---------	-----	--------------	----------

MONTELUKAST SODIUM

GRANULE;ORAL
SINGULAIR

AB	+	!	ORGANON	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002	Mar CAHN
----	---	---	---------	--------------------	---------	-----	--------------	----------

TABLET;ORAL
MONTELUKAST SODIUM

AB			GRAVITI PHARMS	EQ 10MG BASE	A209012	001	Apr 24, 2017	Sep CAHN
			@ L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017	Sep DISC

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM

AB			GRAVITI PHARMS	EQ 4MG BASE	A209011	001	Apr 18, 2017	Sep CAHN
AB				EQ 5MG BASE	A209011	002	Apr 18, 2017	Sep CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	@	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Jul DISC
	@		30MG	A200411	002	Apr 12, 2016	Jul DISC
	@		40MG	A200411	007	Jul 25, 2018	Jul DISC
	@		50MG	A200411	003	Apr 12, 2016	Jul DISC
	@		60MG	A200411	004	Apr 12, 2016	Jul DISC
	@		80MG	A200411	005	Apr 12, 2016	Jul DISC
	@		100MG	A200411	006	Apr 12, 2016	Jul DISC
	@	NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jan DISC
	@		30MG	A203158	002	Aug 04, 2021	Jan DISC
	@		50MG	A203158	003	Aug 04, 2021	Jan DISC
	@		60MG	A203158	004	Aug 04, 2021	Jan DISC
	@		80MG	A203158	005	Aug 04, 2021	Jan DISC
	@		100MG	A203158	006	Aug 04, 2021	Jan DISC
		UPSHER SMITH LABS	20MG	A202104	002	Jun 03, 2013	Jul CTEC
			30MG	A202104	003	Jun 03, 2013	Jul CTEC
			50MG	A202104	004	Jun 03, 2013	Jul CTEC
			60MG	A202104	005	Jun 03, 2013	Jul CTEC
			80MG	A202104	006	Jun 03, 2013	Jul CTEC
			100MG	A202104	007	Jun 03, 2013	Jul CTEC

INJECTABLE;INJECTION
MORPHINE SULFATE

+	!	HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	May CMFD
+	@		50MG/ML	N202515	006	Apr 29, 2021	Jan DISC
		INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021	Jan CMFD

TABLET;ORAL

MORPHINE SULFATE

	@	INGENUS PHARMS NJ	15MG	A215584	001	Feb 07, 2022	Sep CAHN
	@		30MG	A215584	002	Feb 07, 2022	Sep CAHN

TABLET;ORAL

MORPHINE SULFATE

	@ NOVAST LABS	15MG	A215584	001	Feb 07, 2022	Aug CAHN
	@	30MG	A215584	002	Feb 07, 2022	Aug CAHN
	@ RICONPHARMA LLC	15MG	A215584	001	Feb 07, 2022	Feb DISC
AB		15MG	A215584	001	Feb 07, 2022	Jan NEWA
	@	30MG	A215584	002	Feb 07, 2022	Feb DISC
AB		30MG	A215584	002	Feb 07, 2022	Jan NEWA

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXEZA

AT2	+! IMPRIMIS PHARMS USA	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun CAHN
	MOXIFLOXACIN HYDROCHLORIDE					
AT1	INDOCO	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Apr CAHN

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB	AMNEAL	EQ 2% BASE	A214811	001	Nov 15, 2022	Nov NEWA
AB	PADAGIS ISRAEL	EQ 2% BASE	A212465	001	Aug 03, 2022	Jul NEWA

MYCOPHENOLATE MOFETILFOR SUSPENSION;ORAL
MYCOPHENOLATE MOFETIL

AB	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Jan NEWA
	TABLET;ORAL					
	MYCOPHENOLATE MOFETIL					
AB	AMNEAL	500MG	A090606	001	Jul 16, 2010	Jun CMFD

MYCOPHENOLATE MOFETIL HYDROCHLORIDEINJECTABLE;INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

>A> AP	STERISCIENCE	500MG/VIAL	A216390	001	Dec 23, 2022	Dec NEWA
--------	--------------	------------	---------	-----	--------------	----------

MYCOPHENOLIC SODIUMTABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC SODIUM

AB	BIOCON PHARMA	EQ 180MG BASE	A214630	001	Nov 29, 2021	Nov CTNA
AB		EQ 180MG BASE	A214630	001	Nov 29, 2021	Nov CAIN
AB		EQ 360MG BASE	A214630	002	Nov 29, 2021	Nov CTNA
AB		EQ 360MG BASE	A214630	002	Nov 29, 2021	Nov CAIN

NADOLOL

TABLET;ORAL

NADOLOL

AB	AUROBINDO PHARMA	20MG	A201893	003	Jun 07, 2022	Jun NEWA
AB	CHARTWELL RX	20MG	A209309	001	Oct 05, 2017	Nov CAHN
AB		40MG	A209309	002	Oct 05, 2017	Nov CAHN
AB		80MG	A209309	003	Oct 05, 2017	Nov CAHN

NAFCILLIN SODIUMINJECTABLE;INJECTION
NAFCILLIN SODIUM

@ STERISCIENCE EQ 1GM BASE/VIAL
@ EQ 2GM BASE/VIAL

A200002	001	Apr 07, 2014	Feb CAHN
A200002	002	Apr 07, 2014	Feb CAHN

NALMEFENE HYDROCHLORIDEINJECTABLE;INJECTION
REVEX

+ @	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CPOT
+ @		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CPOT
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS					
	NALMEFENE HYDROCHLORIDE					
!	PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jan NEWA
	REVEX					
+ @	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CDFR
+ @		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CDFR
+ @	HIKMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jul CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
REVEX							
	+ @	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jul	CAHN
<u>NALOXONE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
NALOXONE HYDROCHLORIDE							
AP	ACCORD HLTHCARE	0.4MG/ML	A216624	001	Oct 26, 2022	Oct	NEWA
AP		1MG/ML	A216624	002	Oct 26, 2022	Oct	NEWA
	@ ANDA REPOSITORY	0.4MG/ML	A207846	001	Dec 17, 2018	Sep	CAHN
AP	BAXTER HLTHCARE CORP	0.4MG/ML	A214792	001	Nov 07, 2022	Oct	NEWA
AP	HIKMA	1MG/ML	A212300	001	Jun 10, 2022	Jun	NEWA
AP	MYLAN LABS LTD	1MG/ML	A213843	001	Jun 09, 2022	Jun	NEWA
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS							
NALOXONE HYDROCHLORIDE (AUTOINJECTOR)							
	+ @ KALEO INC	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	May	DISC
	+!	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	Feb	NEWA
SPRAY, METERED;NASAL							
NALOXONE HYDROCHLORIDE							
AB	PADAGIS ISRAEL	4MG/SPRAY	A211951	001	Jun 21, 2022	Jun	NEWA
<u>NANDROLONE DECANOATE</u>							
INJECTABLE;INJECTION							
DECA-DURABOLIN							
	@ WOODWARD SPECL	50MG/ML	N013132	001	Jun 12, 1986	Apr	CAHN
	@	100MG/ML	N013132	002	Jun 12, 1986	Apr	CAHN
	+ @	200MG/ML	N013132	003	Jun 12, 1986	Apr	CAHN
<u>NAPROXEN</u>							
SUSPENSION;ORAL							
NAPROXEN							
AB	HETERO LABS LTD III	25MG/ML	A215776	001	Jun 07, 2022	May	NEWA
TABLET;ORAL							
NAPROXEN							
	@ L PERRIGO CO	250MG	A077339	001	Apr 27, 2005	Oct	DISC
	@	375MG	A077339	002	Apr 27, 2005	Oct	DISC
	@	500MG	A077339	003	Apr 27, 2005	Oct	DISC
<u>NEBIVOLOL HYDROCHLORIDE</u>							
TABLET;ORAL							
NEBIVOLOL HYDROCHLORIDE							
	@ AJANTA PHARMA LTD	EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Sep	DISC
AB		EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Mar	NEWA
	@	EQ 5MG BASE	A213349	002	Mar 31, 2022	Sep	DISC
AB		EQ 5MG BASE	A213349	002	Mar 31, 2022	Mar	NEWA
	@	EQ 10MG BASE	A213349	003	Mar 31, 2022	Sep	DISC
AB		EQ 10MG BASE	A213349	003	Mar 31, 2022	Mar	NEWA
	@	EQ 20MG BASE	A213349	004	Mar 31, 2022	Sep	DISC
AB		EQ 20MG BASE	A213349	004	Mar 31, 2022	Mar	NEWA
AB	MANKIND PHARMA	EQ 2.5MG BASE	A216172	001	Nov 14, 2022	Nov	NEWA
AB		EQ 5MG BASE	A216172	002	Nov 14, 2022	Nov	NEWA
AB		EQ 10MG BASE	A216172	003	Nov 14, 2022	Nov	NEWA
AB		EQ 20MG BASE	A216172	004	Nov 14, 2022	Nov	NEWA
AB	PRINSTON INC	EQ 2.5MG BASE	A212682	001	Apr 07, 2022	Apr	NEWA
AB		EQ 5MG BASE	A212682	002	Apr 07, 2022	Apr	NEWA
AB		EQ 10MG BASE	A212682	003	Apr 07, 2022	Apr	NEWA
AB		EQ 20MG BASE	A212682	004	Apr 07, 2022	Apr	NEWA
AB	REYOUNG	EQ 2.5MG BASE	A212917	001	Dec 17, 2021	May	CAHN
AB		EQ 5MG BASE	A212917	002	Dec 17, 2021	May	CAHN
AB		EQ 10MG BASE	A212917	003	Dec 17, 2021	May	CAHN
AB		EQ 20MG BASE	A212917	004	Dec 17, 2021	May	CAHN
	@ UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Nov	DISC
AB		EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Mar	NEWA
	@	EQ 5MG BASE	A213830	002	Mar 15, 2022	Nov	DISC
AB		EQ 5MG BASE	A213830	002	Mar 15, 2022	Mar	NEWA
	@	EQ 10MG BASE	A213830	003	Mar 15, 2022	Nov	DISC
AB		EQ 10MG BASE	A213830	003	Mar 15, 2022	Mar	NEWA
	@	EQ 20MG BASE	A213830	004	Mar 15, 2022	Nov	DISC
AB		EQ 20MG BASE	A213830	004	Mar 15, 2022	Mar	NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

VYDUO

PRINSTON INC

EQ 5MG BASE; 80MG

A210596 001 Sep 19, 2022 Sep NFTG

>D> NEDOCROMIL SODIUM

>D> SOLUTION/DROPS; OPHTHALMIC

>D> ALOCRI

>D> +! ALLERGAN 2%

N021009 001 Dec 08, 1999 Dec DISC

>A> + @ 2%

N021009 001 Dec 08, 1999 Dec DISC

+! 2%

N021009 001 Dec 08, 1999 Jul CTC

NEDOCROMIL SODIUM

@ AKORN 2%

A090638 001 Aug 22, 2012 Jul DISC

NELARABINE

INJECTABLE; INTRAVENOUS

NELARABINE

>A> AP DR REDDYS 250MG/50ML (5MG/ML)

A216934 001 Dec 23, 2022 Dec NEWA

>A> AP KINDOS 250MG/50ML (5MG/ML)

A216038 001 Jan 10, 2023 Dec NEWA

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

@ CHARTWELL MOLECULAR 500MG

A204435 001 Jun 10, 2016 Aug CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

@ AM REGENT 5MG/10ML (0.5MG/ML)

A209182 001 May 04, 2018 Apr DISC

@ 10MG/10ML (1MG/ML)

A209182 002 May 04, 2018 Apr DISC

AP DR REDDYS 3MG/3ML (1MG/ML)

A216291 001 Jul 06, 2022 Jul CPOT

AP 3MG/ML (1MG/ML)

A216291 001 Jul 06, 2022 Jun NFTG

AP +! FRESENIUS KABI USA 3MG/3ML (1MG/ML)

N203629 003 Sep 18, 2018 Jun CFTG

AP HIKMA 3MG/3ML (1MG/ML)

A216206 001 Jul 13, 2022 Jul NEWA

AP NIVAGEN PHARMS INC 5MG/10ML (0.5MG/ML)

A212627 001 Nov 03, 2022 Oct NEWA

AP 10MG/10ML (1MG/ML)

A212627 002 Nov 03, 2022 Oct NEWA

NEOSTIGMINE METHYLSULFATE

AP AVET LIFESCIENCES 5MG/10ML (0.5MG/ML)

A208230 001 Nov 25, 2022 Nov NEWA

AP 10MG/10ML (1MG/ML)

A208230 002 Nov 25, 2022 Nov NEWA

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

>D> AB MACLEODS PHARMS LTD 200MG

A090688 001 Jan 14, 2019 Dec CHRS

>A> AB ! 200MG

A090688 001 Jan 14, 2019 Dec CHRS

@ PRINSTON INC 200MG

A078644 001 May 22, 2012 Sep DISC

>D> VIRAMUNE

>D> AB +! BOEHRINGER INGELHEIM 200MG

N020636 001 Jun 21, 1996 Dec DISC

>A> + @ 200MG

N020636 001 Jun 21, 1996 Dec DISC

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

@ ALVOGEN 100MG

A204621 002 Nov 09, 2015 Sep DISC

@ 400MG

A204621 001 Jul 10, 2015 Nov DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

@ BEIJING 500MG

A214428 001 Nov 22, 2021 May DISC

@ 1GM

A214428 002 Nov 22, 2021 May DISC

AB MACLEODS PHARMS LTD 500MG

A204934 001 Mar 03, 2022 Feb NEWA

AB 1GM

A204934 002 Mar 03, 2022 Feb NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

>A> AB GLENMARK PHARMS LTD 20MG

A216357 001 Dec 16, 2022 Dec NEWA

>A> AB 30MG

A216357 002 Dec 16, 2022 Dec NEWA

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

+! HIKMA INTL PHARMS 25MG/10ML (2.5MG/ML)

N022276 001 Jul 24, 2008 Apr CAHN

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

+	!	HIKMA INTL PHARMS	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Apr CAHN
+	!		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Apr CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB2		ALEMBIC PHARMS	30MG	A216896	001	Nov 18, 2022	Nov NEWA
AB2			60MG	A216896	002	Nov 18, 2022	Nov NEWA
AB2			90MG	A216896	003	Nov 18, 2022	Nov NEWA
AB2		ALKEM LABS LTD	30MG	A216067	001	Mar 29, 2022	Mar NEWA
AB2			60MG	A216067	002	Mar 29, 2022	Mar NEWA
AB2			90MG	A216067	003	Mar 29, 2022	Mar NEWA
AB2		PHARMADAX INC	30MG	A216019	001	Nov 18, 2022	Nov NEWA
AB2			60MG	A216019	002	Nov 18, 2022	Nov NEWA
	@	RISING	30MG	A090602	001	Sep 13, 2010	Oct CAHN
	@		30MG	A201071	001	Dec 03, 2010	Aug CAHN
	@		60MG	A090602	002	Sep 13, 2010	Oct CAHN
	@		60MG	A201071	002	Dec 03, 2010	Aug CAHN
	@		90MG	A090602	003	Sep 13, 2010	Oct CAHN
	@		90MG	A201071	003	Dec 03, 2010	Aug CAHN

NIMODIPINE

SOLUTION;ORAL

NYMALIZE

+	@	AZURITY	3MG/ML	N203340	001	May 10, 2013	Mar CAHN
+	!		6MG/ML	N203340	002	Apr 08, 2020	Mar CAHN

NITISINONE

CAPSULE;ORAL

NITISINONE

AB	DIPHARMA	2MG	A212390	001	May 26, 2022	May NEWA
AB		5MG	A212390	002	May 26, 2022	May NEWA
AB		10MG	A212390	003	May 26, 2022	May NEWA
AB	MEDUNIK	2MG	A212390	001	May 26, 2022	Jun CAHN
AB		5MG	A212390	002	May 26, 2022	Jun CAHN
AB		10MG	A212390	003	May 26, 2022	Jun CAHN
>A> AB	TORRENT	2MG	A215908	001	Jan 09, 2023	Dec NEWA
>A> AB		5MG	A215908	002	Jan 09, 2023	Dec NEWA
>A> AB		10MG	A215908	003	Jan 09, 2023	Dec NEWA
>A> AB		20MG	A215908	004	Jan 09, 2023	Dec NFTG
	ORFADIN					
>D>	+! SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Dec CFTG
>A> AB	+!	20MG	N021232	004	Jun 13, 2016	Dec CFTG

NITRIC OXIDE

GAS;INHALATION

NOXIVENT

		LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr CAHN
AA			800PPM	A207141	002	Oct 02, 2018	Apr CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

	@	AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Jul DISC
--	---	---------------	----------	---------	-----	--------------	----------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

	@	ATHEM	25MG	A074336	001	Jan 25, 1995	Sep CAHN
	@		50MG	A074336	002	Jan 25, 1995	Sep CAHN
	@		100MG	A074336	003	Jan 25, 1995	Sep CAHN
	@	AUROBINDO PHARMA USA	100MG	A077025	001	Aug 18, 2004	Apr CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		INVENTIA	75MG;25MG	A211013	001	Feb 18, 2022	Feb NEWA
----	--	----------	-----------	---------	-----	--------------	----------

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL
NITROGLYCERIN

AB2	ZYDUS PHARMS	0.1MG/HR	A089885	002	Oct 30, 2017	Aug CAHN
AB2		0.2MG/HR	A089884	001	Oct 30, 1998	Aug CAHN
AB2		0.4MG/HR	A089885	001	Oct 30, 1998	Aug CAHN
AB2		0.6MG/HR	A089886	001	Oct 30, 1998	Aug CAHN

TABLET;SUBLINGUAL
NITROGLYCERIN

AB	NATCO	0.3MG	A211604	001	Apr 30, 2019	Sep CAHN
AB		0.4MG	A211604	002	Apr 30, 2019	Sep CAHN
AB		0.6MG	A211604	003	Apr 30, 2019	Sep CAHN
	@ ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022	Aug DISC
AB		0.3MG	A210153	001	Mar 08, 2022	Feb NEWA
	@	0.4MG	A210153	002	Mar 08, 2022	Aug DISC
AB		0.4MG	A210153	002	Mar 08, 2022	Feb NEWA
	@	0.6MG	A210153	003	Mar 08, 2022	Aug DISC
AB		0.6MG	A210153	003	Mar 08, 2022	Feb NEWA
	NITROSTAT					
AB	+ VIATRIS	0.3MG	N021134	001	May 01, 2000	Jan CAHN
AB	+	0.4MG	N021134	002	May 01, 2000	Jan CAHN
AB	+!	0.6MG	N021134	003	May 01, 2000	Jan CAHN

NIZATIDINESOLUTION;ORAL
NIZATIDINE

@ AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Jun DISC
-----------------	---------	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATEINJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

>D> AP	ZYDUS PHARMS	EQ 1MG BASE/ML	A216341	001	Jul 19, 2022	Dec DISC
>A>	@	EQ 1MG BASE/ML	A216341	001	Jul 19, 2022	Dec DISC
AP		EQ 1MG BASE/ML	A216341	001	Jul 19, 2022	Jul NEWA
	SOLUTION;INTRAVENOUS					
	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE					
+!	INFORLIFE	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N215700	001	Sep 15, 2022	Sep NEWA
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N215700	002	Sep 15, 2022	Sep NEWA
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N215700	003	Sep 15, 2022	Sep NEWA
+!	NEVAKAR INJECTABLES	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Oct NEWA
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Oct NEWA
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Oct NEWA

NORETHINDRONE

TABLET;ORAL-28

>A>	EMZAHH					
>A> AB2	AUROBINDO PHARMA	0.35MG	A216796	001	Jan 06, 2023	Dec NEWA
	NORETHINDRONE					
	@ AMNEAL PHARMS	0.35MG	A202260	001	Aug 01, 2013	Sep DISC

NORTRIPTYLINE HYDROCHLORIDECAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
@	EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
@	EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
@	EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN

SOLUTION;ORAL
NORTRIPTYLINE HYDROCHLORIDE

!	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 23, 2000	Nov CTEC
AA	!	EQ 10MG BASE/5ML	A075606	001	Aug 23, 2000	Oct CMS1
	@ TARO	EQ 10MG BASE/5ML	A077965	001	Jun 20, 2006	Nov DISC

NYSTATIN

	SUSPENSION;ORAL						
	NILSTAT						
	+ @ GLENMARK PHARMS LTD	100,000 UNITS/ML	N050299	001		Apr	CAHN
	NYSTATIN						
	@ AKORN	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Sep	DISC
AA	LEADING	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Aug	CAHN
AA	MEDLEY PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Feb	NEWA
AA	VISTAPHARM	100,000 UNITS/ML	A064142	002	Mar 07, 2011	May	CMS1

NYSTATIN; TRIAMCINOLONE ACETONIDE

	CREAM;TOPICAL						
	NYSTATIN AND TRIAMCINOLONE ACETONIDE						
AT	MACLEODS PHARMS LTD	100,000 UNITS/GM;0.1%	A214181	001	Jul 13, 2022	Jul	NEWA
	OINTMENT;TOPICAL						
	NYSTATIN AND TRIAMCINOLONE ACETONIDE						
	@ CHARTWELL RX	100,000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	Sep	CAHN

OCTREOTIDE ACETATE

	CAPSULE, DELAYED RELEASE;ORAL						
	MYCAPSSA						
	+! AMRYT	EQ 20MG BASE	N208232	001	Jun 26, 2020	Jan	CAHN
	INJECTABLE;INJECTION						
	OCTREOTIDE ACETATE						
AP	HERITAGE PHARMS	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr	CMFD
AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr	CMFD
AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Apr	CMFD
AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr	CMFD
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Apr	CMFD

OFLOXACIN

	SOLUTION/DROPS;OPHTHALMIC						
	OFLOXACIN						
	@ AKORN	0.3%	A076615	001	May 14, 2004	Sep	DISC
AT	MANKIND PHARMA	0.3%	A215886	001	Nov 23, 2022	Nov	NEWA
	SOLUTION/DROPS;OTIC						
	OFLOXACIN						
	@ FDC LTD	0.3%	A215038	001	Jan 19, 2022	Jun	DISC
AT		0.3%	A215038	001	Jan 19, 2022	Jan	NEWA
AT	MANKIND PHARMA	0.3%	A216130	001	Jul 14, 2022	Jul	NEWA

OLANZAPINE

	TABLET;ORAL						
	OLANZAPINE						
AB	CHARTWELL MOLECULAR	2.5MG	A203333	001	Mar 15, 2016	Mar	CAHN
AB		5MG	A203333	002	Mar 15, 2016	Mar	CAHN
AB		7.5MG	A203333	003	Mar 15, 2016	Mar	CAHN
AB		10MG	A203333	004	Mar 15, 2016	Mar	CAHN
AB		15MG	A203333	005	Mar 15, 2016	Mar	CAHN
AB		20MG	A203333	006	Mar 15, 2016	Mar	CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL						
	OLANZAPINE						
AB	CHARTWELL MOLECULAR	5MG	A203456	001	Mar 16, 2016	Mar	CAHN
AB		10MG	A203456	002	Mar 16, 2016	Mar	CAHN
AB		15MG	A203456	003	Mar 16, 2016	Mar	CAHN
AB		20MG	A203456	004	Mar 16, 2016	Mar	CAHN

OLMESARTAN MEDOXOMIL

	TABLET;ORAL						
	OLMESARTAN MEDOXOMIL						
AB	PRINSTON INC	5MG	A206720	001	Dec 02, 2022	Nov	NEWA
AB		20MG	A206720	002	Dec 02, 2022	Nov	NEWA
AB		40MG	A206720	003	Dec 02, 2022	Nov	NEWA
	@ SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Nov	DISC
	@	20MG	A090237	002	Apr 13, 2020	Nov	DISC
	@	40MG	A090237	003	Apr 13, 2020	Nov	DISC

>A>	<u>OLUTASIDENIB</u>							
>A>	CAPSULE;ORAL							
>A>	REZLIDHIA							
>A>	+!	RIGEL PHARMS INC	150MG	N215814	001	Dec 01, 2022	Dec	NEWA
	<u>OMEGA-3-ACID ETHYL ESTERS</u>							
	CAPSULE;ORAL							
	OMEGA-3-ACID ETHYL ESTERS							
AB	GLW	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Jun	CAHN	
	<u>OMEPRAZOLE</u>							
	CAPSULE, DELAYED REL PELLETS;ORAL							
	OMEPRAZOLE							
	@	STRIDES PHARMA	10MG	A075876	001	May 29, 2003	Jan	CAHN
	@		20MG	A075876	002	May 29, 2003	Jan	CAHN
	@		40MG	A075876	003	Jan 21, 2009	Jan	CAHN
	<u>OMEPRAZOLE; SODIUM BICARBONATE</u>							
	FOR SUSPENSION;ORAL							
	KONVOMEF							
	+!	AZURITY	2MG/ML;84MG/ML	N213593	001	Aug 30, 2022	Aug	NEWA
	<u>OMIDENEPAG ISOPROPYL</u>							
	SOLUTION;OPHTHALMIC							
	OMLONTI							
	+!	SANTEN	0.002%	N215092	001	Sep 22, 2022	Sep	NEWA
	<u>ONDANSETRON</u>							
	TABLET, ORALLY DISINTEGRATING;ORAL							
	ONDANSETRON							
AB	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006	Apr	CMFD	
AB		8MG	A077406	004	Dec 26, 2006	Apr	CMFD	
		16MG	A077406	001	Dec 26, 2006	Apr	CMFD	
		24MG	A077406	002	Dec 26, 2006	Apr	CMFD	
	<u>ONDANSETRON HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	ONDANSETRON HYDROCHLORIDE							
	@	EUGIA PHARMA	EQ 2MG BASE/ML	A202599	001	Dec 21, 2012	Jun	DISC
	@	STERISCIENCE	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Feb	CAHN
>D> AP	TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006	Dec	DISC	
>A>	@	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006	Dec	DISC	
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
	@	EUGIA PHARMA	EQ 2MG BASE/ML	A202600	001	Dec 21, 2012	Jul	DISC
	@	STERISCIENCE	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Feb	CAHN
	SOLUTION;ORAL							
	ONDANSETRON HYDROCHLORIDE							
>D> AA	HIKMA	EQ 4MG BASE/5ML	A076960	001	Dec 26, 2006	Dec	CHRS	
>A> AA	!	EQ 4MG BASE/5ML	A076960	001	Dec 26, 2006	Dec	CHRS	
>D>	ZOFRAN							
>D> AA	+!	NOVARTIS	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Dec	DISC
>A>	+ @	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Dec	DISC	
	TABLET;ORAL							
	ONDANSETRON HYDROCHLORIDE							
	@	AUROBINDO PHARMA	EQ 24MG BASE	A078539	003	Jul 31, 2007	Feb	DISC
	@	CASI PHARMS INC	EQ 24MG BASE	A077517	003	Jun 25, 2007	Feb	DISC
AB	CHARTWELL MOLECULES	EQ 4MG BASE	A077303	001	Jun 25, 2007	May	CMFD	
AB		EQ 8MG BASE	A077303	002	Jun 25, 2007	May	CMFD	
AB	!	EQ 24MG BASE	A077303	004	Jun 25, 2007	May	CMFD	
	@	DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006	Mar	DISC
	@	EQ 24MG BASE	A076183	001	Dec 26, 2006	Feb	DISC	
AB	GLENMARK GENERICS	EQ 8MG BASE	A077535	002	Jun 25, 2007	May	CHRS	
AB	!	EQ 8MG BASE	A077535	002	Jun 25, 2007	Feb	CHRS	
	@	EQ 24MG BASE	A077535	003	Jun 25, 2007	Feb	DISC	
	@	TEVA	EQ 4MG BASE	A076252	001	Jun 25, 2007	Feb	DISC
	@	EQ 8MG BASE	A076252	002	Jun 25, 2007	Feb	DISC	
	@	EQ 24MG BASE	A076252	003	Jun 25, 2007	Feb	DISC	
	ZOFRAN							
	+ @	NOVARTIS	EQ 4MG BASE	N020103	001	Dec 31, 1992	Feb	DISC

TABLET;ORAL
ZOFTRAN

+ @ EQ 8MG BASE
+ @ EQ 24MG BASE

N020103 002 Dec 31, 1992 Feb DISC
N020103 003 Aug 27, 1999 Feb DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE

AB BAYSHORE PHARMS LLC 100MG

A091158 001 Jul 27, 2012 Aug CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB ACCORD HLTHCARE EQ 30MG BASE
AB EQ 45MG BASE
AB EQ 75MG BASE

A214726 001 Jul 25, 2022 Jul NEWA
A214726 002 Jul 25, 2022 Jul NEWA
A214726 003 Jul 25, 2022 Jul NEWA

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB ALVOGEN EQ 6MG BASE/ML
>D> @ APTAPHARMA INC EQ 6MG BASE/ML
>A> AB EQ 6MG BASE/ML
@ EQ 6MG BASE/ML
AB HETERO LABS LTD V EQ 6MG BASE/ML
@ LEADING EQ 6MG BASE/ML
AB EQ 6MG BASE/ML
AB MSN EQ 6MG BASE/ML
AB STRIDES PHARMA EQ 6MG BASE/ML
@ EQ 6MG BASE/ML
AB EQ 6MG BASE/ML

A208823 001 Oct 31, 2017 May CAHN
A212858 001 Aug 30, 2021 Dec CMFD
A212858 001 Aug 30, 2021 Dec CMFD
A212858 001 Aug 30, 2021 Mar DISC
A209590 001 Mar 28, 2022 Mar NEWA
A214949 001 Feb 28, 2022 Sep DISC
A214949 001 Feb 28, 2022 Feb NEWA
A215313 001 May 02, 2022 Apr NEWA
A211894 001 Jan 13, 2022 Oct CMFD
A211894 001 Jan 13, 2022 Jul DISC
A211894 001 Jan 13, 2022 Jan NEWA

OTEFSECONAZOLE

CAPSULE;ORAL
VIVJOA

+! MYCOVIA PHARMS 150MG

N215888 001 Apr 26, 2022 Apr NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION
OXACILLIN SODIUM

@ PIRAMAL CRITICAL EQ 1GM BASE/VIAL
@ EQ 2GM BASE/VIAL
@ STERISCIENCE EQ 1GM BASE/VIAL
AP EQ 2GM BASE/VIAL
@ EQ 2GM BASE/VIAL

A206681 001 Sep 11, 2017 Aug DISC
A206681 002 Sep 11, 2017 Aug DISC
A091486 001 Aug 25, 2014 Feb CAHN
A091486 002 Aug 25, 2014 Oct CMFD
A091486 002 Aug 25, 2014 Feb CAHN

OXALIPLATIN

INJECTABLE;INTRAVENOUS
OXALIPLATIN

@ CHARTWELL MOLECULAR 50MG/10ML (5MG/ML)
@ 100MG/20ML (5MG/ML)

A208523 001 Feb 10, 2017 Mar CAHN
A208523 002 Feb 10, 2017 Mar CAHN

OXAZEPAM

CAPSULE;ORAL
OXAZEPAM

AB UNITED RES LABS 10MG
AB 15MG
AB 30MG
SERAX
+ @ ALPHARMA US PHARMS 10MG
+ @ 15MG
+ @ 30MG

A071026 002 Aug 10, 1987 Apr CAHN
A071026 003 Aug 10, 1987 Apr CAHN
A071026 001 Aug 10, 1987 Apr CAHN
N015539 002 Jan CRLD
N015539 004 Jan CRLD
N015539 006 Jan CRLD

OXCARBAZEPINE

SUSPENSION;ORAL
OXCARBAZEPINE

AB AUCTA 300MG/5ML
AB BIONPHARMA INC 300MG/5ML
AB RUBICON 300MG/5ML

A215332 001 Nov 30, 2022 Nov NEWA
A209652 001 Nov 04, 2022 Oct NEWA
A215726 001 Aug 30, 2022 Aug NEWA

OXYBUTYNIN CHLORIDE

SYRUP; ORAL							
OXYBUTYNIN CHLORIDE							
AA	!	@ CHARTWELL RX	5MG/5ML	A075039	001	Jan 29, 1999	Mar CAHN
	!	LANNETT CO INC	5MG/5ML	A074520	001	Mar 29, 1996	Mar CHRS
	!	@ WOCKHARDT BIO AG	5MG/5ML	A074868	001	Feb 12, 1997	Mar DISC
TABLET; ORAL							
OXYBUTYNIN CHLORIDE							
AB		BEXIMCO PHARMS USA	5MG	A213550	001	Jul 14, 2022	Jul NEWA
AB		STRIDES PHARMA	5MG	A208165	001	Dec 17, 2020	Jul CMFD

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL							
OXYCODONE HYDROCHLORIDE							
>D>	!	@ NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Feb DISC
	!	@ WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Dec CAHN
	!	@	5MG/5ML	A206456	001	Jun 16, 2015	Apr DISC
>A>	!	@ XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Dec CAHN
TABLET; ORAL							
ROXYBOND							
		PROTEGA PHARMS	5MG	N209777	001	Apr 20, 2017	Mar CMFD
		@	5MG	N209777	001	Apr 20, 2017	Feb CAHN
			15MG	N209777	002	Apr 20, 2017	Mar CMFD
		@	15MG	N209777	002	Apr 20, 2017	Feb CAHN
			30MG	N209777	003	Apr 20, 2017	Mar CMFD
		@	30MG	N209777	003	Apr 20, 2017	Feb CAHN

PACLITAXEL

INJECTABLE; INJECTION							
PACLITAXEL							
AP		ALEMBIC PHARMS	6MG/ML	A216874	001	Oct 20, 2022	Oct NEWA
AP		GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Feb CTNA
POWDER; INTRAVENOUS							
ABRAXANE							
+	!	BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Nov CAHN
PACLITAXEL							
+	!	HBT LABS INC	100MG/VIAL	N211875	001	Jul 27, 2022	Jul NEWA

PACRITINIB CITRATE

CAPSULE; ORAL							
VONJO							
+	!	CTI BIOPHARMA CORP	EQ 100MG BASE	N208712	001	Feb 28, 2022	Feb NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL							
PALIPERIDONE							
AB		AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019	Sep CTEC
AB			3MG	A204707	002	Sep 23, 2019	Sep CTEC
AB			6MG	A204707	003	Sep 23, 2019	Sep CTEC
AB			9MG	A204707	004	Sep 23, 2019	Sep CTEC
AB		LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Jun NEWA
AB			3MG	A208643	002	Jun 29, 2022	Jun NEWA
AB			6MG	A208643	003	Jun 29, 2022	Jun NEWA
AB			9MG	A208643	004	Jun 29, 2022	Jun NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS							
PALONOSETRON HYDROCHLORIDE							
!	!	EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jul CMFD
	!	@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jan DISC
	!		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jul CMFD
AP	!	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jan DISC

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS
PANTOPRAZOLE SODIUM

AP	ASPIRO	EQ 40MG BASE/VIAL	A213778	001	May 18, 2022	May NEWA
AP	BE PHARMS	EQ 40MG BASE/VIAL	A216171	001	May 18, 2022	May NEWA
AP	GLAND PHARMA LTD	EQ 40MG BASE/VIAL	A204400	001	May 18, 2022	May NEWA
	@ KNACK	EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	Nov DISC
AP		EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	May NEWA
AP	MEITHEAL	EQ 40MG BASE/VIAL	A215860	001	Aug 29, 2022	Nov CAHN
AP	NANJING KING-FRIEND	EQ 40MG BASE/VIAL	A215860	001	Aug 29, 2022	Aug NEWA
TABLET, DELAYED RELEASE;ORAL						
PANTOPRAZOLE SODIUM						
	@ L PERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014	Sep DISC
AB	MANKIND PHARMA	EQ 40MG BASE	A215880	001	Jul 26, 2022	Jul NEWA
AB	WOCKHARDT BIO AG	EQ 20MG BASE	A091231	001	Jan 19, 2011	Nov CAHN
AB		EQ 40MG BASE	A091231	002	Jan 19, 2011	Nov CAHN

PARICALCITOL

SOLUTION;INTRAVENOUS
PARICALCITOL

	@ AKORN	0.005MG/ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Aug DISC
	@	0.01MG/2ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Aug CPOT
	@ RISING	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Mar DISC

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

+	@ APOTEX	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
+	@	EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
+	@	EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
+	@	EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION;ORAL

PAXIL

AB	+! APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN
----	-----------	------------------	---------	-----	--------------	----------

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

AB	CHARTWELL RX	EQ 10MG BASE	A076618	001	Aug 15, 2005	Mar CAHN
AB		EQ 20MG BASE	A076618	002	Aug 15, 2005	Mar CAHN
AB		EQ 30MG BASE	A076618	003	Aug 15, 2005	Mar CAHN
AB		EQ 40MG BASE	A076618	004	Aug 15, 2005	Mar CAHN

PAXIL

AB	+	APOTEX	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb CAHN
AB	+		EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb CAHN
AB	+		EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb CAHN
AB	+!		EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb CAHN
	@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

	@ SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan DISC
	@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan DISC
	@	EQ 37.5MG BASE	A213612	003	May 26, 2022	Nov DISC
AB		EQ 37.5MG BASE	A213612	003	May 26, 2022	May NEWA

PAXIL CR

AB	+	APOTEX	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB	+		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+!		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PAROXETINE MESYLATE

TABLET;ORAL

PEXEVA

+	@ SEBELA IRELAND LTD	EQ 40MG BASE	N021299	004	Jul 03, 2003	Jun DISC
---	----------------------	--------------	---------	-----	--------------	----------

PEGAPTANIB SODIUM

INJECTABLE;INTRAVITREAL
MACUGEN

+	@ BAUSCH AND LOMB INC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	Jun CAHN
---	-----------------------	----------------------	---------	-----	--------------	----------

PEMETREXEDSOLUTION; INTRAVENOUS
PEMETREXED

+	!	ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	May CMFD
+	!		500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	May CMFD
+	!		1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	May CMFD

PEMETREXED DISODIUMPOWDER; INTRAVENOUS
ALIMTA

AP	+	!	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	May CFTG
AP	+	!		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	May CFTG

PEMETREXED DISODIUM

AP			ACCORD HLTHCARE	EQ 100MG BASE/VIAL	A203485	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A203485	002	May 25, 2022	May NFTG
AP				EQ 1GM BASE/VIAL	A203485	003	May 25, 2022	May NEWA
AP			AMNEAL	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jul NEWA
AP			APOTEX	EQ 100MG BASE/VIAL	A203774	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A203774	002	May 25, 2022	May NFTG
AP				EQ 750MG BASE/VIAL	A209851	001	May 25, 2022	May NEWA
AP				EQ 1GM BASE/VIAL	A209085	001	May 25, 2022	May NEWA
AP			BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022	Aug NEWA
AP				EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022	Aug NEWA
		@	BIOCON PHARMA	EQ 1GM BASE/VIAL	A211090	001	May 25, 2022	Nov DISC
AP				EQ 1GM BASE/VIAL	A211090	001	May 25, 2022	May NEWA
AP			DR REDDYS	EQ 100MG BASE/VIAL	A202596	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A202596	002	May 25, 2022	May NFTG
AP				EQ 1GM BASE/VIAL	A202596	003	May 25, 2022	May NEWA
AP			EUGIA PHARMA	EQ 100MG BASE/VIAL	A214632	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A214632	002	May 25, 2022	May NFTG
AP				EQ 1GM BASE/VIAL	A214632	003	May 25, 2022	May NEWA
AP			FRESENIUS KABI USA	EQ 100MG BASE/VIAL	A090384	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A090384	002	May 25, 2022	May NFTG
AP		!		EQ 750MG BASE/VIAL	A090384	003	May 25, 2022	May NEWA
AP		!		EQ 1GM BASE/VIAL	A090384	004	May 25, 2022	May NEWA
>A>	AP		HONG KONG	EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Dec NEWA
>A>	AP			EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Dec NEWA
>A>	AP			EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Dec NEWA
>A>	AP			EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Dec NEWA
		@	HOSPIRA	EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	Nov DISC
AP				EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	Aug CAHN
AP				EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	May NFTG
		@		EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	Nov DISC
AP				EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	Aug CAHN
AP				EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	May NFTG
		@		EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	Nov DISC
AP				EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	Aug CAHN
AP				EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	May NEWA
AP			JIANGSU HANSON PHARM	EQ 100MG BASE/VIAL	A208696	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A208696	002	May 25, 2022	May NFTG
AP			NANG KUANG PHARM CO	EQ 100MG BASE/VIAL	A207352	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A207352	002	May 25, 2022	May NFTG
AP			QILU PHARM HAINAN	EQ 100MG BASE/VIAL	A204890	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A204890	002	May 25, 2022	May NFTG
AP			WAVERLEY PHARMA INC	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	May NFTG
AP			ZYDUS PHARMS	EQ 100MG BASE/VIAL	A214073	001	May 25, 2022	May NFTG
AP				EQ 500MG BASE/VIAL	A214073	002	May 25, 2022	May NFTG
AP				EQ 1GM BASE/VIAL	A214073	003	May 25, 2022	May NEWA

SOLUTION; INTRAVENOUS
PEMETREXED DISODIUM

+	!	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022	Jul NEWA
+	!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jul NEWA
+	!		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jul NEWA
+	!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jul NEWA
+	!	HOSPIRA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Aug CTNA
+	!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Aug CTNA
+	!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Aug CTNA

SOLUTION; INTRAVENOUS
PEMETREXED DISODIUM

+	!	HOSPIRA INC	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Jun NEWA
+	!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Jun NEWA
+	!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Jun NEWA
+	!	SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	Aug CTNA
+	!		EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	May NEWA
+	!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	Aug CTNA
+	!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	May NEWA
+	!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	Aug CTNA
+	!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	May NEWA

PEMETREXED DITROMETHAMINE

POWDER; INTRAVENOUS
PEMETREXED DITROMETHAMINE

+	!	HOSPIRA	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Aug CAHN
+	!		EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Aug CTNA
+	!		EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Jun NEWA
+	!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Aug CAHN
+	!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Aug CTNA
+	!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Jun NEWA
+	!	@	EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Sep DISC
+	!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Aug CAHN
+	!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Aug CTNA
+	!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Jun NEWA

PENCICLOVIR

CREAM; TOPICAL
DENA VIR

AB	+	!	MYLAN	1%	N020629	001	Sep 24, 1996	Nov CFTG
AB			TEVA PHARMS USA	1%	A212710	001	Nov 09, 2022	Nov NFTG

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTAMIDINE ISETHIONATE

AP			XGEN PHARMS	300MG/VIAL	A206982	001	Mar 17, 2022	Mar NEWA
----	--	--	-------------	------------	---------	-----	--------------	----------

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION
PENTOBARBITAL SODIUM

AP			HIKMA	50MG/ML	A203619	001	Nov 13, 2017	Aug CAHN
----	--	--	-------	---------	---------	-----	--------------	----------

PERINDOPRIL ERBUMINE

TABLET; ORAL
PERINDOPRIL ERBUMINE
AUROBINDO PHARMA

			2MG	A079070	001	Nov 10, 2009	Sep CTEC
			4MG	A079070	002	Nov 10, 2009	Sep CTEC
		!	8MG	A079070	003	Nov 10, 2009	Nov CTEC
		@	HIKMA	A090072	001	Nov 10, 2009	Sep DISC
		@	4MG	A090072	002	Nov 10, 2009	Sep DISC
		@	8MG	A090072	003	Nov 10, 2009	Nov DISC

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE

AB			APPCO	2MG	A210163	001	May 18, 2022	May NEWA
AB				4MG	A210163	002	May 18, 2022	May NEWA
AB				8MG	A210163	003	May 18, 2022	May NEWA
AB				16MG	A210163	004	May 18, 2022	May NEWA
		@	MYLAN	2MG	A206691	001	Apr 14, 2017	Mar DISC
		@		4MG	A206691	002	Apr 14, 2017	Mar DISC
		@		8MG	A206691	003	Apr 14, 2017	Mar DISC
		@		16MG	A206691	004	Apr 14, 2017	Mar DISC

PEXIDARTINIB HYDROCHLORIDECAPSULE;ORAL
TURALIO

+ DAIICHI SANKYO INC EQ 125MG BASE

N211810 002 Oct 14, 2022 Oct NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

AA CHARTWELL 35MG

A089452 001 Oct 30, 1991 Apr CAHN

PHENOBARBITAL SODIUMPOWDER;INTRAVENOUS
SEZABY

>D> +! SPARC 100MG/VIAL

N215910 001 Nov 17, 2022 Dec CAHN

+! 100MG/VIAL

N215910 001 Nov 17, 2022 Nov NEWA

>A> +! SUN PHARM INDS INC 100MG/VIAL

N215910 001 Nov 17, 2022 Dec CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB NOVITIUM PHARMA 10MG

A215042 001 Jul 19, 2022 Jul NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

@ LANNETT CO INC 37.5MG

A201961 001 Jul 20, 2011 Nov DISC

AA +! SANDOZ 30MG

A087190 001 Feb CRLD

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

@ LANNETT 37.5MG

A040555 001 Apr 15, 2005 Jul DISC

PHENYLEPHRINE HYDROCHLORIDESOLUTION;INTRAVENOUS
BIORPHEN

+! DR REDDYS LABS SA 0.5MG/5ML (0.1MG/ML)

N212909 001 Oct 21, 2019 Jun CAHN

+ @ 10MG/ML (10MG/ML)

N212909 002 Mar 11, 2021 Jun CAHN

PHENYLEPHRINE HYDROCHLORIDE

AP1 ACCORD HLTHCARE 10MG/ML (10MG/ML)

A213237 001 Jul 01, 2020 Feb CMFD

AP1 50MG/5ML (10MG/ML)

A213237 002 Jul 01, 2020 Feb CMFD

AP1 100MG/10ML (10MG/ML)

A213237 003 Jul 01, 2020 Feb CMFD

AP1 MANKIND PHARMA 10MG/ML (10MG/ML)

A217069 001 Aug 30, 2022 Aug NEWA

AP1 50MG/5ML (10MG/ML)

A217069 002 Aug 30, 2022 Aug NEWA

AP1 100MG/10ML (10MG/ML)

A217069 003 Aug 30, 2022 Aug NEWA

@ PAR STERILE PRODUCTS 10MG/ML (10MG/ML)

A210025 001 Dec 21, 2018 Jan DISC

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT MANKIND PHARMA 2.5%

A216859 001 Sep 29, 2022 Sep NEWA

>A> AT 10%

A216496 001 Jan 11, 2023 Dec NFTG

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB +! VIATRIS 125MG/5ML

N008762 001 Feb CAHN

DILANTIN-30

@ VIATRIS 30MG/5ML

N008762 002 Feb CAHN

PHENYTOIN

AB PAI HOLDINGS PHARM 125MG/5ML

A040420 001 Apr 19, 2002 Apr CAHN

AB VISTAPHARM 125MG/5ML

A040342 002 Aug 18, 2005 May CMS1

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

+! VIATRIS 30MG EXTENDED

A084349 001 Feb CAHN

AB +! 100MG EXTENDED

A084349 002 Feb CAHN

EXTENDED PHENYTOIN SODIUM

AB UNICHEM 100MG EXTENDED

A213834 001 Oct 13, 2022 Oct NEWA

PHYTONADIONEINJECTABLE; INJECTION
PHYTONADIONE

	@	CIPLA	1MG/0.5ML	A212424	001	Apr 22, 2022	Jul	DISC
AB2	!		1MG/0.5ML	A212424	001	Apr 22, 2022	Apr	NFTG
	!		1MG/0.5ML	A214596	001	Apr 22, 2022	Jul	CTEC
AB2	!		1MG/0.5ML	A214596	001	Apr 22, 2022	Jul	CHRS
AB2			1MG/0.5ML	A214596	001	Apr 22, 2022	Apr	NFTG
	@		10MG/ML	A212424	002	Apr 22, 2022	Jul	DISC
AB2	!		10MG/ML	A212424	002	Apr 22, 2022	Apr	NFTG
	!		10MG/ML	A214596	002	Apr 22, 2022	Jul	CTEC
AB2	!		10MG/ML	A214596	002	Apr 22, 2022	Jul	CHRS
AB2			10MG/ML	A214596	002	Apr 22, 2022	Apr	NFTG
AB1		DR REDDYS	10MG/ML	A207719	001	May 22, 2019	Apr	CTEC
		VITAMIN K1						
AB1	+	HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	Apr	CTEC

PILOCARPINE HYDROCHLORIDESOLUTION; OPHTHALMIC
ISOPTO CARPINE

AT	+	NOVARTIS	1%	N200890	001	Jun 22, 2010	May	CHRS
AT	+		2%	N200890	002	Jun 22, 2010	May	CHRS

PINDOLOLTABLET; ORAL
PINDOLOL

AB		AUROBINDO PHARMA USA	5MG	A074019	001	Sep 03, 1992	Oct	CAHN
AB	!		10MG	A074019	002	Sep 03, 1992	Oct	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP		STERISCIENCE	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	May	CMFD
	@		EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Feb	CAHN
AP			EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	May	CMFD
	@		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Feb	CAHN
AP			EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	May	CMFD
	@		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Feb	CAHN

PIRFENIDONECAPSULE; ORAL
PIRFENIDONE

AB		ACCORD HLTHCARE	267MG	A212731	001	Jan 20, 2022	Jan	NEWA
AB		AMNEAL	267MG	A212569	001	Jan 03, 2022	May	CMFD
	@		267MG	A212569	001	Jan 03, 2022	Jan	DISC
AB		LAURUS	267MG	A212724	001	Jul 19, 2022	Jul	NEWA
AB		SANDOZ INC	267MG	A212600	001	Jun 13, 2022	Jun	NEWA
AB		SCIEGEN PHARMS INC	267MG	A212077	001	Aug 01, 2022	Jul	NEWA

TABLET; ORAL
ESBRIET

AB	+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan	CFTG
AB	+		801MG	N208780	003	Jan 11, 2017	Jan	CFTG

PIRFENIDONE

AB		ACCORD HLTHCARE	267MG	A212730	001	Jan 25, 2022	Jan	NFTG
AB			801MG	A212730	002	Jan 25, 2022	Jan	NFTG
AB		AIZANT	267MG	A212747	001	Jul 21, 2022	Jul	NEWA
AB			534MG	A212747	002	Jul 21, 2022	Jul	NEWA
AB			801MG	A212747	003	Jul 21, 2022	Jul	NEWA
AB		ALEMBIC PHARMS	267MG	A212708	001	May 20, 2022	May	NEWA
AB			801MG	A212708	002	May 20, 2022	May	NEWA
AB		AMNEAL	267MG	A212570	001	Mar 25, 2022	Mar	NEWA
AB			801MG	A212570	002	Mar 25, 2022	Mar	NEWA
AB		HETERO LABS LTD V	267MG	A212674	001	Sep 21, 2022	Sep	NEWA
AB			801MG	A212674	002	Sep 21, 2022	Sep	NEWA
AB		LAURUS	267MG	A212722	001	Jul 19, 2022	Jul	NEWA
AB			534MG	A212722	002	Jul 19, 2022	Jul	CTEC
			534MG	A212722	002	Jul 19, 2022	Jul	NEWA

TABLET;ORAL							
PIRFENIDONE							
AB		801MG	A212722	003	Jul 19, 2022	Jul	NEWA
AB	MICRO LABS	267MG	A212680	001	May 18, 2022	May	NEWA
AB		801MG	A212680	002	May 18, 2022	May	NEWA
AB	MSN	267MG	A212772	001	May 24, 2022	May	NEWA
AB		801MG	A212772	002	May 24, 2022	May	NEWA
AB	SANDOZ INC	267MG	A212560	001	Apr 28, 2022	Apr	NEWA
AB		801MG	A212560	002	Apr 28, 2022	Apr	NEWA
AB	SCIEGEN PHARMS INC	267MG	A212078	001	Aug 01, 2022	Jul	NEWA
AB		801MG	A212078	002	Aug 01, 2022	Jul	NEWA
AB	TEVA PHARMS USA	267MG	A212759	001	Jan 25, 2022	Jan	NFTG
AB		801MG	A212759	002	Jan 25, 2022	Jan	NFTG
<u>POLIDOCANOL</u>							
SOLUTION;INTRAVENOUS							
VARITHENA							
+ @ PROVENISIS							
		77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Sep	DISC
<u>POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE</u>							
FOR SOLUTION;ORAL							
LAX-LYTE WITH FLAVOR PACKS							
@ L PERRIGO CO							
		420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A079232	001	Feb 25, 2010	Oct	DISC
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE							
@ NOVEL LABS INC							
		420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090019	001	May 27, 2009	Feb	DISC
<u>POLYMYXIN B SULFATE</u>							
INJECTABLE;INJECTION							
POLYMYXIN B SULFATE							
AP	GLAND	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Nov	CMFD
<u>POMALIDOMIDE</u>							
CAPSULE;ORAL							
POMALIDOMIDE							
@ MYLAN							
		1MG	A210275	001	Jan 26, 2022	Feb	CAHN
@							
		1MG	A210275	001	Jan 26, 2022	Feb	DISC
AB		1MG	A210275	001	Jan 26, 2022	Jan	NEWA
@							
		2MG	A210275	002	Jan 26, 2022	Feb	CAHN
@							
		2MG	A210275	002	Jan 26, 2022	Feb	DISC
AB		2MG	A210275	002	Jan 26, 2022	Jan	NEWA
@							
		3MG	A210275	003	Jan 26, 2022	Feb	CAHN
@							
		3MG	A210275	003	Jan 26, 2022	Feb	DISC
AB		3MG	A210275	003	Jan 26, 2022	Jan	NEWA
@							
		4MG	A210275	004	Jan 26, 2022	Feb	CAHN
@							
		4MG	A210275	004	Jan 26, 2022	Feb	DISC
AB		4MG	A210275	004	Jan 26, 2022	Jan	NEWA
@ TEVA PHARMS USA							
		1MG	A209956	001	May 04, 2022	Nov	DISC
AB		1MG	A209956	001	May 04, 2022	Apr	NEWA
@							
		2MG	A209956	002	May 04, 2022	Nov	DISC
AB		2MG	A209956	002	May 04, 2022	Apr	NEWA
@							
		3MG	A209956	003	May 04, 2022	Nov	DISC
AB		3MG	A209956	003	May 04, 2022	Apr	NEWA
@							
		4MG	A209956	004	May 04, 2022	Nov	DISC
AB		4MG	A209956	004	May 04, 2022	Apr	NEWA
POMALYST							
+ CELGENE							
		1MG	N204026	001	Feb 08, 2013	Nov	CTEC
AB	+	1MG	N204026	001	Feb 08, 2013	Apr	CTEC
+							
		1MG	N204026	001	Feb 08, 2013	Feb	CTEC
AB	+	1MG	N204026	001	Feb 08, 2013	Jan	CTEC
+							
		2MG	N204026	002	Feb 08, 2013	Nov	CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Apr	CTEC
+							
		2MG	N204026	002	Feb 08, 2013	Feb	CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Jan	CTEC
+							
		3MG	N204026	003	Feb 08, 2013	Nov	CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Apr	CTEC
+							
		3MG	N204026	003	Feb 08, 2013	Feb	CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Jan	CTEC
+!							
		4MG	N204026	004	Feb 08, 2013	Nov	CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	Apr	CTEC
+!							
		4MG	N204026	004	Feb 08, 2013	Feb	CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	Jan	CTEC

PONESIMODTABLET; ORAL
PONVORY

+	!	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	Aug CHRS
+			20MG	N213498	010	Mar 18, 2021	Aug CHRS

POSACONAZOLEFOR SUSPENSION, DELAYED RELEASE; ORAL
NOXAFIL POWDERMIX KIT

+	!	MSD MERCK CO	300MG	N214770	001	May 31, 2021	Oct CMFD
+	@		300MG	N214770	001	May 31, 2021	Jan DISC

SOLUTION; INTRAVENOUS
NOXAFIL

AP	+	!	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	May CFTG
AP			POSACONAZOLE		A208768	001	May 25, 2022	May NFTG

PAR STERILE PRODUCTS 300MG/16.7ML (18MG/ML)
SUSPENSION; ORAL
NOXAFIL

>D>	+	!	SCHERING	40MG/ML	N022003	001	Sep 15, 2006	Dec CTEC
>A>	AB	+		40MG/ML	N022003	001	Sep 15, 2006	Dec CTEC

POSACONAZOLE

>D>	@	HIKMA	40MG/ML	A208773	001	May 15, 2020	Dec CMFD
>A>	AB		40MG/ML	A208773	001	May 15, 2020	Dec CMFD

TABLET, DELAYED RELEASE; ORAL
POSACONAZOLE

AB		ACTAVIS LABS FL INC	100MG	A207355	001	Nov 30, 2022	Nov NEWA
>A>	AB	AMNEAL	100MG	A216626	001	Dec 22, 2022	Dec NEWA
AB		BIOCON PHARMA	100MG	A214476	001	Feb 04, 2022	Jan NEWA
AB		DR REDDYS	100MG	A212500	001	Apr 07, 2022	Apr NEWA
>A>	AB	HETERO LABS LTD III	100MG	A214321	001	Dec 08, 2022	Dec NEWA
AB		SPECGX LLC	100MG	A212226	001	May 10, 2022	Apr NEWA

POTASSIUM ACETATEINJECTABLE; INJECTION
POTASSIUM ACETATE

@	EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Mar DISC
---	--------------	---------	---------	-----	--------------	----------

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

@	LANNETT CO INC	8MEQ	A204210	001	Mar 28, 2016	Mar DISC
@		10MEQ	A204210	002	Mar 28, 2016	Mar DISC

FOR SOLUTION; ORAL
POTASSIUM CHLORIDE

@	GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jul DISC
AA		20MEQ	A213467	001	Jan 27, 2022	Jan NEWA
AA	RUBICON	20MEQ	A214108	001	Mar 24, 2022	Mar NEWA
AA	STRIDES PHARMA	20MEQ	A211667	001	Mar 11, 2021	Oct CMFD

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	+	!	HOSPIRA	2MEQ/ML	A080205	001	Sep CRLD
AP			POTASSIUM CHLORIDE 10MEQ				

AP			FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar CMFD
AP				746MG/100ML	A211087	002	Sep 09, 2020	Mar CMFD

POTASSIUM CHLORIDE 20MEQ

AP			FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar CMFD
AP				1.49GM/100ML	A211087	005	May 07, 2021	Mar CMFD

POTASSIUM CHLORIDE 40MEQ

AP			FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar CMFD
----	--	--	--------------------	--------------	---------	-----	--------------	----------

SOLUTION; ORAL

POTASSIUM CHLORIDE

>A>	AA		GUARDIAN DRUG	20MEQ/15ML	A214892	001	Dec 30, 2022	Dec NEWA
>A>	AA			40MEQ/15ML	A214892	002	Dec 30, 2022	Dec NEWA
AA			RUBICON	20MEQ/15ML	A214656	001	Jan 13, 2022	Jan NEWA
AA				40MEQ/15ML	A214656	002	Jan 13, 2022	Jan NEWA
AA			STRIDES PHARMA	40MEQ/15ML	A211665	001	Nov 17, 2022	Nov NEWA
AA		@	TRIS PHARMA INC	20MEQ/15ML	A214076	001	Jan 26, 2022	Apr DISC
AA				20MEQ/15ML	A214076	001	Jan 26, 2022	Jan NEWA
AA		@		40MEQ/15ML	A214076	002	Jan 26, 2022	Apr DISC
AA				40MEQ/15ML	A214076	002	Jan 26, 2022	Jan NEWA
AA			WES PHARMA INC	20MEQ/15ML	A213062	001	Jun 06, 2022	May NEWA

SOLUTION; ORAL

POTASSIUM CHLORIDE						
AA	40MEQ/15ML	A213062	002	Jun 06, 2022	May	NEWA
TABLET, EXTENDED RELEASE; ORAL						
K-TAB						
+ @ ABBVIE		8MEQ	N018279	002	Aug 01, 1988	Mar DISC
POTASSIUM CHLORIDE						
AB1	AMTA	10MEQ	A214395	001	Jan 28, 2021	Jul CMFD
AB1		20MEQ	A214395	002	Jan 28, 2021	Jul CMFD
AB1	GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Nov CAHN
AB1		20MEQ	A214395	002	Jan 28, 2021	Nov CAHN
AB3	RUBICON	10MEQ	A215725	001	Jul 25, 2022	Jul NEWA
AB3		20MEQ	A215725	002	Jul 25, 2022	Jul NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%						
AP	+! BAXTER HLTHCARE	150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Aug CTEC
AP	FRESENIUS KABI USA	150MG/100ML; 450MG/100ML	A212347	001	Sep 17, 2020	Aug CMFD
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%						
AP	FRESENIUS KABI USA	150MG/100ML; 900MG/100ML	A212347	003	Jun 02, 2021	Aug CMFD
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%						
AP	+! BAXTER HLTHCARE	300MG/100ML; 900MG/100ML	N017648	002		Aug CTEC
AP	FRESENIUS KABI USA	300MG/100ML; 900MG/100ML	A212347	002	Sep 17, 2020	Aug CMFD

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN						
+ ACROTECH BIOPHARMA		20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Oct CAHN
+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Oct CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE						
AB	! GLENMARK GENERICS	0.25MG	A090781	002	Oct 08, 2010	Mar CHRS
AB	RISING	0.25MG	A211088	001	Oct 03, 2018	Sep CAHN
AB		0.5MG	A211088	002	Oct 03, 2018	Sep CAHN
AB		0.75MG	A211088	003	Oct 03, 2018	Sep CAHN
AB		1MG	A211088	004	Oct 03, 2018	Sep CAHN
AB		1.5MG	A211088	005	Oct 03, 2018	Sep CAHN
AB	ZYDUS PHARMS USA INC	0.75MG	A078920	006	Nov 23, 2022	Nov NEWA

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE						
AB	ALEMBIC PHARMS	0.375MG	A204518	001	Jan 02, 2019	Apr CMFD
AB		0.75MG	A204518	002	Jan 02, 2019	Apr CMFD
AB		1.5MG	A204518	003	Jan 02, 2019	Apr CMFD
AB		2.25MG	A204518	004	Jan 02, 2019	Apr CMFD
AB		3MG	A204518	005	Jan 02, 2019	Apr CMFD
AB		3.75MG	A204518	006	Jan 02, 2019	Apr CMFD
AB		4.5MG	A204518	007	Jan 02, 2019	Apr CMFD
@ ANCHEN PHARMS		0.375MG	A202206	001	Feb 06, 2014	Oct DISC
@		0.75MG	A202206	002	Feb 06, 2014	Oct DISC
@		1.5MG	A202206	003	Feb 06, 2014	Oct DISC
@		2.25MG	A202206	004	Feb 06, 2014	Oct DISC
@		3MG	A202206	005	Feb 06, 2014	Oct DISC
@		3.75MG	A202206	006	Feb 06, 2014	Oct DISC
@		4.5MG	A202206	007	Feb 06, 2014	Oct DISC
AB	NOVAST LABS	0.375MG	A213444	001	Feb 03, 2022	Jan NEWA
AB		0.75MG	A213444	002	Feb 03, 2022	Jan NEWA
AB		1.5MG	A213444	003	Feb 03, 2022	Jan NEWA
AB		2.25MG	A213444	004	Feb 03, 2022	Jan NEWA
AB		3MG	A213444	005	Feb 03, 2022	Jan NEWA
AB		3.75MG	A213444	006	Feb 03, 2022	Jan NEWA
AB		4.5MG	A213444	007	Feb 03, 2022	Jan NEWA

PRASUGREL

TABLET; ORAL

PRASUGREL HYDROCHLORIDE							
>A>	AB	LUPIN LTD	EQ 5MG BASE	A205930	001	Jan 09, 2023	Dec NEWA
>A>	AB		EQ 10MG BASE	A205930	002	Jan 09, 2023	Dec NEWA

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

@ CHARTWELL RX	EQ 5MG BASE	A205790	001	Oct 16, 2017	Aug CAHN
@	EQ 10MG BASE	A205790	002	Oct 16, 2017	Aug CAHN
@ USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Apr DISC
@	EQ 10MG BASE	A205790	002	Oct 16, 2017	Apr DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Aug DISC
@	EQ 2MG BASE	A072577	001	May 16, 1989	Aug DISC
@	EQ 5MG BASE	A072577	003	May 16, 1989	Feb DISC
AB APPCO	EQ 1MG BASE	A213406	001	Oct 21, 2022	Oct NEWA
AB	EQ 2MG BASE	A213406	002	Oct 21, 2022	Oct NEWA
AB	EQ 5MG BASE	A213406	003	Oct 21, 2022	Oct NEWA
>A> AB MANKIND PHARMA	EQ 1MG BASE	A215697	001	Dec 30, 2022	Dec NEWA
>A> AB	EQ 2MG BASE	A215697	002	Dec 30, 2022	Dec NEWA
>A> AB	EQ 5MG BASE	A215697	003	Dec 30, 2022	Dec NEWA

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

+! WATSON LABS	5MG	A080354	001		Mar CRLD
----------------	-----	---------	-----	--	----------

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

@ ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986	Sep DISC
------------	----------	---------	-----	--------------	----------

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+ @ ALLERGAN	0.2%;10%	N012813	002		Aug DISC
--------------	----------	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA AMNEAL	EQ 15MG BASE/5ML	A216715	001	Oct 25, 2022	Oct NEWA
-----------	------------------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING; ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ RISING	EQ 10MG BASE	A202179	001	Apr 10, 2013	Jul CAHN
@	EQ 15MG BASE	A202179	002	Apr 10, 2013	Jul CAHN
@	EQ 30MG BASE	A202179	003	Apr 10, 2013	Jul CAHN

PREDNISONE

SOLUTION; ORAL

PREDNISONE

+! HIKMA	5MG/5ML	A088703	001	Nov 08, 1984	May CRLD
----------	---------	---------	-----	--------------	----------

TABLET; ORAL

PREDNISONE

AB AUROBINDO PHARMA LTD	2.5MG	A215672	001	Mar 28, 2022	Mar NEWA
AB	5MG	A215672	002	Mar 28, 2022	Mar NEWA
AB	10MG	A215672	003	Mar 28, 2022	Mar NEWA
AB	20MG	A215672	004	Mar 28, 2022	Mar NEWA
AB	50MG	A215672	005	Mar 28, 2022	Mar NEWA
+ @ ROXANE	25MG	A087833	001	May 04, 1982	Nov CRLD

TABLET, DELAYED RELEASE; ORAL

PREDNISONE

AB ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Oct CMFD
AB	2MG	A204867	002	Apr 25, 2017	Oct CMFD
AB	5MG	A204867	003	Apr 25, 2017	Oct CMFD
AB RAYOS					
AB + HORIZON	1MG	N202020	001	Jul 26, 2012	Oct CTEC
AB +	2MG	N202020	002	Jul 26, 2012	Oct CTEC
AB +!	5MG	N202020	003	Jul 26, 2012	Oct CTEC

PREGABALINCAPSULE;ORAL
PREGABALIN

AB	ALLIED	50MG	A210585	001	Dec 26, 2019	Feb CAHN
AB		75MG	A210585	002	Dec 26, 2019	Feb CAHN
AB		100MG	A210585	003	Dec 26, 2019	Feb CAHN
AB		150MG	A210585	004	Dec 26, 2019	Feb CAHN
AB		200MG	A210585	005	Dec 26, 2019	Feb CAHN
AB		300MG	A210585	006	Dec 26, 2019	Feb CAHN
AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022	Feb NEWA
AB		50MG	A212988	002	Mar 08, 2022	Feb NEWA
AB		75MG	A212988	003	Mar 08, 2022	Feb NEWA
AB		100MG	A212988	004	Mar 08, 2022	Feb NEWA
AB		150MG	A212988	005	Mar 08, 2022	Feb NEWA
AB		200MG	A212988	006	Mar 08, 2022	Feb NEWA
AB		225MG	A212988	007	Mar 08, 2022	Feb NEWA
AB		300MG	A212988	008	Mar 08, 2022	Feb NEWA
	@ LUPIN LTD	25MG	A091040	001	May 03, 2022	Jul DISC
AB		25MG	A091040	001	May 03, 2022	Apr NEWA
	@	50MG	A091040	002	May 03, 2022	Jul DISC
AB		50MG	A091040	002	May 03, 2022	Apr NEWA
	@	75MG	A091040	003	May 03, 2022	Jul DISC
AB		75MG	A091040	003	May 03, 2022	Apr NEWA
	@	100MG	A091040	004	May 03, 2022	Jul DISC
AB		100MG	A091040	004	May 03, 2022	Apr NEWA
	@	150MG	A091040	005	May 03, 2022	Jul DISC
AB		150MG	A091040	005	May 03, 2022	Apr NEWA
	@	200MG	A091040	006	May 03, 2022	Jul DISC
AB		200MG	A091040	006	May 03, 2022	Apr NEWA
	@	225MG	A091040	007	May 03, 2022	Jul DISC
AB		225MG	A091040	007	May 03, 2022	Apr NEWA
	@	300MG	A091040	008	May 03, 2022	Jul DISC
AB		300MG	A091040	008	May 03, 2022	Apr NEWA
AB	MARKSANS PHARMA	25MG	A216197	001	Jul 18, 2022	Jul NEWA
AB		50MG	A216197	002	Jul 18, 2022	Jul NEWA
AB		75MG	A216197	003	Jul 18, 2022	Jul NEWA
AB		100MG	A216197	004	Jul 18, 2022	Jul NEWA
AB		150MG	A216197	005	Jul 18, 2022	Jul NEWA
AB		200MG	A216197	006	Jul 18, 2022	Jul NEWA
AB		225MG	A216197	007	Jul 18, 2022	Jul NEWA
AB		300MG	A216197	008	Jul 18, 2022	Jul NEWA
AB	PRINSTON INC	25MG	A207883	001	Sep 01, 2022	Aug NEWA
AB		50MG	A207883	002	Sep 01, 2022	Aug NEWA
AB		75MG	A207883	003	Sep 01, 2022	Aug NEWA
AB		100MG	A207883	004	Sep 01, 2022	Aug NEWA
AB		150MG	A207883	005	Sep 01, 2022	Aug NEWA
AB		200MG	A207883	006	Sep 01, 2022	Aug NEWA
AB		225MG	A207883	007	Sep 01, 2022	Aug NEWA
AB		300MG	A207883	008	Sep 01, 2022	Aug NEWA
AB	RENATA	50MG	A210585	001	Dec 26, 2019	Jul CAHN
AB		75MG	A210585	002	Dec 26, 2019	Jul CAHN
AB		100MG	A210585	003	Dec 26, 2019	Jul CAHN
AB		150MG	A210585	004	Dec 26, 2019	Jul CAHN
AB		200MG	A210585	005	Dec 26, 2019	Jul CAHN
AB		300MG	A210585	006	Dec 26, 2019	Jul CAHN
>A> AB	ZYDUS PHARMS	25MG	A206752	001	Dec 09, 2022	Dec NEWA
>A> AB		50MG	A206752	002	Dec 09, 2022	Dec NEWA
>A> AB		75MG	A206752	003	Dec 09, 2022	Dec NEWA
>A> AB		100MG	A206752	004	Dec 09, 2022	Dec NEWA
>A> AB		150MG	A206752	005	Dec 09, 2022	Dec NEWA
>A> AB		200MG	A206752	006	Dec 09, 2022	Dec NEWA
>A> AB		225MG	A206752	007	Dec 09, 2022	Dec NEWA
>A> AB		300MG	A206752	008	Dec 09, 2022	Dec NEWA
	SOLUTION;ORAL					
	PREGABALIN					
AA	INVATECH	20MG/ML	A212604	001	Feb 18, 2022	Feb NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	PREGABALIN					
	@ MYLAN	82.5MG	A211948	001	Apr 13, 2021	Mar DISC
AB		82.5MG	A211948	001	Apr 13, 2021	Mar CAHN
	@	165MG	A211967	001	Nov 04, 2021	Mar DISC
AB	RUBICON	82.5MG	A215249	001	Mar 22, 2022	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

AB		165MG	A215249	002	Mar 22, 2022	Mar NEWA
AB		330MG	A215249	003	Mar 22, 2022	Mar NEWA
AB	SCIEGEN PHARMS INC	82.5MG	A215675	001	Sep 14, 2022	Sep NEWA
AB		165MG	A215675	002	Sep 14, 2022	Sep NEWA
AB		330MG	A215675	003	Sep 14, 2022	Sep NEWA

PRIMIDONE

TABLET;ORAL
PRIMIDONE

AB	RUBICON	50MG	A214896	001	Jun 28, 2022	Jun NEWA
>A> AB		125MG	A214896	003	Dec 28, 2022	Dec NEWA
AB		250MG	A214896	002	Jun 28, 2022	Jun NEWA

PROBENECID

TABLET;ORAL
PROBENECID

@ AUROBINDO PHARMA USA	500MG	A084211	002			Jul CAHN
------------------------	-------	---------	-----	--	--	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	AMNEAL	EQ 5MG BASE/ML	A214192	001	Nov 28, 2022	Nov NEWA
AP	EUGIA PHARMA	EQ 5MG BASE/ML	A213873	001	Jul 14, 2022	Jul NEWA
AP	HIKMA	EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Nov NEWA

PROCHLORPERAZINE MALEATE

TABLET;ORAL
PROCHLORPERAZINE MALEATE

@ CHARTWELL RX	EQ 5MG BASE	A040101	001	Jul 19, 1996	Nov CAHN	
@	EQ 10MG BASE	A040101	002	Jul 19, 1996	Nov CAHN	
@	EQ 25MG BASE	A040101	003	Jul 19, 1996	Nov CAHN	
@ MYLAN	EQ 5MG BASE	A040185	002	Oct 28, 1996	Sep DISC	
@	EQ 10MG BASE	A040185	001	Oct 28, 1996	Sep DISC	
AB	NOVITIUM PHARMA	EQ 5MG BASE	A216202	001	Jun 13, 2022	Jul CAHN
AB		EQ 10MG BASE	A216202	002	Jun 13, 2022	Jul CAHN
AB	ZENARA	EQ 5MG BASE	A216202	001	Jun 13, 2022	Jun NEWA
AB		EQ 10MG BASE	A216202	002	Jun 13, 2022	Jun NEWA
AB	ZYDUS	EQ 5MG BASE	A216495	001	Aug 08, 2022	Jul NEWA
AB		EQ 10MG BASE	A216495	002	Aug 08, 2022	Jul NEWA

PROGESTERONE

INJECTABLE;INJECTION
PROGESTERONE

>D> AO	+! ACTAVIS LABS UT INC	50MG/ML	N017362	002		Dec DISC
>A>	+ @	50MG/ML	N017362	002		Dec DISC
>D> AO	EUGIA PHARMA	50MG/ML	A210965	001	Dec 06, 2018	Dec CHRS
>A> AO	!	50MG/ML	A210965	001	Dec 06, 2018	Dec CHRS

PROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
SPARINE

@ HIKMA	25MG/ML	N010349	008		Jul CAHN
@	50MG/ML	N010349	006		Jul CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+! WEST-WARD PHARMS INT	25MG/ML	A083312	001		Apr CRLD
AP	+!	50MG/ML	A083312	002		Apr CRLD

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

AB	ANNORA PHARMA	12.5MG	A216446	001	Nov 02, 2022	Oct NEWA
AB		25MG	A216446	002	Nov 02, 2022	Oct NEWA

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
LARGON

@ HIKMA	20MG/ML	N012382	002		Jul CAHN
---------	---------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION							
PROPRANOLOL HYDROCHLORIDE							
	@ ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Feb	DISC
	@ CHARTWELL INJECTABLE	1MG/ML	A075792	001	Aug 29, 2000	Mar	CAHN
AP	! HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008	Feb	CTEC
SOLUTION; ORAL							
PROPRANOLOL HYDROCHLORIDE							
	@ PAI HOLDINGS PHARM	20MG/5ML	A071984	001	Mar 03, 1989	Apr	CAHN
	@	40MG/5ML	A071985	001	Mar 03, 1989	Apr	CAHN
TABLET; ORAL							
PROPRANOLOL HYDROCHLORIDE							
	@ CHARTWELL RX	10MG	A070663	001	Jun 13, 1986	Mar	CAHN
	@	20MG	A070664	001	Jun 13, 1986	Mar	CAHN
	@	40MG	A070665	001	Jun 13, 1986	Mar	CAHN
	@	60MG	A070666	001	Oct 10, 1986	Mar	CAHN
	@	80MG	A070667	001	Jun 13, 1986	Mar	CAHN
AB	IMPAX LABS INC	80MG	A071976	001	Apr 06, 1988	Nov	CMFD

PROPYLTHIOURACIL

TABLET; ORAL							
PROPYLTHIOURACIL							
	@ CHARTWELL MOLECULAR	50MG	A080016	001		Aug	CAHN

PYRIDOSTIGMINE BROMIDE

SYRUP; ORAL							
PYRIDOSTIGMINE BROMIDE							
>D>	@ MILLA PHARMS	60MG/5ML	A212405	001	Apr 19, 2022	Dec	CMFD
>A> AA		60MG/5ML	A212405	001	Apr 19, 2022	Dec	CMFD
	@	60MG/5ML	A212405	001	Apr 19, 2022	Oct	DISC
AA		60MG/5ML	A212405	001	Apr 19, 2022	Apr	NEWA
TABLET; ORAL							
PYRIDOSTIGMINE BROMIDE							
AB	EYWA	30MG	A211181	002	May 14, 2019	Jun	CTEC
AB	IMPAX LABS	30MG	A040502	002	Jun 28, 2022	Jun	NEWA

PYRIMETHAMINE

TABLET; ORAL							
PYRIMETHAMINE							
AB	AUROBINDO PHARMA LTD	25MG	A216983	001	Oct 25, 2022	Oct	NEWA

QUETIAPINE FUMARATE

TABLET; ORAL							
QUETIAPINE FUMARATE							
AB	HETERO LABS LTD V	EQ 25MG BASE	A204316	001	Jun 16, 2022	Jun	NEWA
AB		EQ 50MG BASE	A204316	002	Jun 16, 2022	Jun	NEWA
AB		EQ 100MG BASE	A204316	003	Jun 16, 2022	Jun	NEWA
AB		EQ 200MG BASE	A204316	004	Jun 16, 2022	Jun	NEWA
AB		EQ 300MG BASE	A204316	005	Jun 16, 2022	Jun	NEWA
AB		EQ 400MG BASE	A204316	006	Jun 16, 2022	Jun	NEWA
AB	PRINSTON INC	EQ 25MG BASE	A206954	001	Aug 24, 2022	Aug	NEWA
AB		EQ 50MG BASE	A206954	002	Aug 24, 2022	Aug	NEWA
AB		EQ 100MG BASE	A206954	003	Aug 24, 2022	Aug	NEWA
AB		EQ 200MG BASE	A206954	004	Aug 24, 2022	Aug	NEWA
AB		EQ 300MG BASE	A206954	005	Aug 24, 2022	Aug	NEWA
AB		EQ 400MG BASE	A206954	006	Aug 24, 2022	Aug	NEWA
TABLET, EXTENDED RELEASE; ORAL							
QUETIAPINE FUMARATE							
AB	PRINSTON INC	EQ 50MG BASE	A208781	001	Apr 26, 2022	Apr	NEWA
AB		EQ 150MG BASE	A208781	002	Apr 26, 2022	Apr	NEWA
AB		EQ 200MG BASE	A208781	003	Apr 26, 2022	Apr	NEWA
AB		EQ 300MG BASE	A208781	004	Apr 26, 2022	Apr	NEWA
AB	SCIEGEN PHARMS INC	EQ 50MG BASE	A209635	005	Nov 16, 2018	Nov	CTEC
AB		EQ 150MG BASE	A209635	001	Nov 29, 2017	Nov	CTEC
AB		EQ 200MG BASE	A209635	002	Nov 29, 2017	Nov	CTEC
AB		EQ 300MG BASE	A209635	003	Nov 29, 2017	Nov	CTEC
AB		EQ 400MG BASE	A209635	004	Nov 29, 2017	Nov	CTEC
AB	UNICHEM	EQ 50MG BASE	A215478	001	Aug 15, 2022	Aug	NEWA
AB		EQ 150MG BASE	A215478	002	Aug 15, 2022	Aug	NEWA
AB		EQ 200MG BASE	A215478	003	Aug 15, 2022	Aug	NEWA
AB		EQ 300MG BASE	A215478	004	Aug 15, 2022	Aug	NEWA

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

AB EQ 400MG BASE A215478 005 Aug 15, 2022 Aug NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

>D> ACCUPRIL

>D> AB + PFIZER PHARMS EQ 5MG BASE N019885 001 Nov 19, 1991 Dec DISC

>A> + @ EQ 5MG BASE N019885 001 Nov 19, 1991 Dec DISC

>D> AB + EQ 10MG BASE N019885 002 Nov 19, 1991 Dec DISC

>A> + @ EQ 10MG BASE N019885 002 Nov 19, 1991 Dec DISC

>D> AB + EQ 20MG BASE N019885 003 Nov 19, 1991 Dec DISC

>A> + @ EQ 20MG BASE N019885 003 Nov 19, 1991 Dec DISC

>D> AB +! EQ 40MG BASE N019885 004 Nov 19, 1991 Dec DISC

>A> + @ EQ 40MG BASE N019885 004 Nov 19, 1991 Dec DISC

QUINAPRIL HYDROCHLORIDE

@ CHARTWELL RX EQ 5MG BASE A076803 001 Mar 02, 2005 Mar CAHN

@ EQ 10MG BASE A076803 002 Mar 02, 2005 Mar CAHN

@ EQ 20MG BASE A076803 003 Mar 02, 2005 Mar CAHN

@ EQ 40MG BASE A076803 004 Mar 02, 2005 Mar CAHN

>D> AB LUPIN EQ 40MG BASE A077690 004 Jun 20, 2006 Dec CHRS

>A> AB ! EQ 40MG BASE A077690 004 Jun 20, 2006 Dec CHRS

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE GLUCONATE

AB EYWA 324MG A212589 001 Sep 17, 2021 Aug CMFD

@ 324MG A212589 001 Sep 17, 2021 Mar DISC

AB ! SUN PHARM INDUSTRIES 324MG A089338 001 Feb 11, 1987 Aug CTEC

! 324MG A089338 001 Feb 11, 1987 Mar CTEC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

>D> AB TEVA PHARMS USA 20MG A076822 001 Nov 08, 2013 Dec DISC

>A> @ 20MG A076822 001 Nov 08, 2013 Dec DISC

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

+! MSD SUB MERCK EQ 100MG BASE/PACKET N205786 001 Dec 20, 2013 Jun CAHN

TABLET;ORAL

ISENTRESS

+! MSD SUB MERCK EQ 400MG BASE N022145 001 Oct 12, 2007 Jun CAHN

ISENTRESS HD

+! MSD SUB MERCK EQ 600MG BASE N022145 002 May 26, 2017 Jun CAHN

TABLET, CHEWABLE;ORAL

ISENTRESS

+ MSD SUB MERCK EQ 25MG BASE N203045 001 Dec 21, 2011 Jun CAHN

+! EQ 100MG BASE N203045 002 Dec 21, 2011 Jun CAHN

RAMELTEON

TABLET;ORAL

RAMELTEON

AB UPSHER SMITH LABS 8MG A213815 001 Oct 26, 2020 Sep CAHN

AB XIROMED 8MG A216209 001 Nov 25, 2022 Nov NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@ CHARTWELL RX 1.25MG A077514 001 Jun 18, 2008 Mar CAHN

@ 2.5MG A077514 002 Jun 18, 2008 Mar CAHN

@ 5MG A077514 003 Jun 18, 2008 Mar CAHN

@ 10MG A077514 004 Jun 18, 2008 Mar CAHN

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@ LANNETT CO INC EQ 15MG BASE/ML A078890 001 Jul 01, 2010 Jul DISC

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL
ASPRUZYO SPRINKLE

+ SPIL 500MG
+! 1GM
+ SUN PHARMA GLOBAL 500MG
+! 1GM

N216018 001 Feb 28, 2022 Mar CAHN
N216018 002 Feb 28, 2022 Mar CAHN
N216018 001 Feb 28, 2022 Feb NEWA
N216018 002 Feb 28, 2022 Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

>A> AB AUROBINDO PHARMA 500MG
>A> AB 1GM
AB HETERO LABS LTD III 500MG
AB 1GM
AB I3 PHARMS 500MG
AB 1GM
AB VKT PHARMA 500MG
AB 1GM

A209081 001 Dec 23, 2022 Dec NEWA
A209081 002 Dec 23, 2022 Dec NEWA
A212788 001 May 05, 2022 Apr NEWA
A212788 002 May 05, 2022 Apr NEWA
A213517 001 Apr 27, 2022 Apr NEWA
A213517 002 Apr 27, 2022 Apr NEWA
A214035 001 Jan 19, 2022 Jan NEWA
A214035 002 Jan 19, 2022 Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL
RASAGILINE MESYLATE

AB CHARTWELL RX EQ 0.5MG BASE
AB EQ 1MG BASE
@ DR REDDYS EQ 0.5MG BASE
@ EQ 1MG BASE

A201892 001 Jul 27, 2018 Nov CAHN
A201892 002 Jul 27, 2018 Nov CAHN
A201942 001 Nov 18, 2021 Jan DISC
A201942 002 Nov 18, 2021 Jan DISC

REGADENOSON

SOLUTION;INTRAVENOUS
LEXISCAN

AP +! ASTELLAS 0.4MG/5ML (0.08MG/ML)
RAGADENOSON
AP IMS LTD 0.4MG/5ML (0.08MG/ML)
REGADENOSON
AP ACCORD HLTHCARE 0.4MG/5ML (0.08MG/ML)
@ 0.4MG/5ML (0.08MG/ML)
AP 0.4MG/5ML (0.08MG/ML)
AP APOTEX 0.4MG/5ML (0.08MG/ML)
AP DR REDDYS 0.4MG/5ML (0.08MG/ML)
AP EUGIA PHARMA 0.4MG/5ML (0.08MG/ML)
AP GLAND PHARMA LTD 0.4MG/5ML (0.08MG/ML)
AP HONG KONG 0.4MG/5ML (0.08MG/ML)
AP HOSPIRA 0.4MG/5ML (0.08MG/ML)
@ IMS LTD 0.4MG/5ML (0.08MG/ML)
AP 0.4MG/5ML (0.08MG/ML)
AP MEITHEAL 0.4MG/5ML (0.08MG/ML)

N022161 001 Apr 10, 2008 Apr CFTG
A214252 001 May 23, 2022 May NEWA
A213236 001 Apr 11, 2022 Nov CMFD
A213236 001 Apr 11, 2022 Oct DISC
A213236 001 Apr 11, 2022 Apr NFTG
A207604 001 Apr 11, 2022 Apr NFTG
A213210 001 Apr 11, 2022 Apr NFTG
A216437 001 Oct 26, 2022 Oct NEWA
A207320 001 Jul 12, 2022 Jul NEWA
A212806 001 Apr 11, 2022 Apr NFTG
A214349 001 Aug 31, 2022 Aug NEWA
A214252 001 May 23, 2022 Nov DISC
A214252 001 May 23, 2022 May CMS1
A212806 001 Apr 11, 2022 Nov CAHN

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION
REMIFENTANIL HYDROCHLORIDE

AP HIKMA EQ 1MG BASE/VIAL
AP EQ 2MG BASE/VIAL
AP EQ 5MG BASE/VIAL

A210594 001 Oct 13, 2020 Jul CAHN
A210594 002 Oct 13, 2020 Jul CAHN
A210594 003 Oct 13, 2020 Jul CAHN

REPAGLINIDE

TABLET;ORAL
REPAGLINIDE

@ BOSCOGEN 0.5MG
@ 1MG
@ 2MG

A091517 001 Apr 24, 2015 Aug DISC
A091517 002 Apr 24, 2015 Aug DISC
A091517 003 Apr 24, 2015 Aug DISC

RIBAVIRIN

CAPSULE;ORAL
REBETOL

>D> AB +! MERCK SHARP DOHME 200MG
>A> + @ 200MG
RIBAVIRIN
>D> AB AUROBINDO PHARMA 200MG
>A> AB ! 200MG

N020903 002 Jul 25, 2001 Dec DISC
N020903 002 Jul 25, 2001 Dec DISC
A079117 001 Sep 17, 2009 Dec CHRS
A079117 001 Sep 17, 2009 Dec CHRS

RIFAMPINCAPSULE;ORAL
RIFAMPIN

AB	CHARTWELL MOLECULAR	150MG	A065390	001	Mar 28, 2008	Jun CAHN
AB		300MG	A065390	002	Mar 28, 2008	Jun CAHN

RILUZOLEFILM;ORAL
EXSERVAN

+	AQUESTIVE	50MG	N212640	001	Nov 22, 2019	Aug CAHN
---	-----------	------	---------	-----	--------------	----------

SUSPENSION;ORAL
TIGLUTIK KIT

+	ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Jun CAHN
---	----------------	-----------	---------	-----	--------------	----------

RIOCIGUATTABLET;ORAL
ADEMPAS

AB	+	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013	Aug CFTG
AB	+		1MG	N204819	002	Oct 08, 2013	Aug CFTG
AB	+		1.5MG	N204819	003	Oct 08, 2013	Aug CFTG
AB	+		2MG	N204819	004	Oct 08, 2013	Aug CFTG
AB	+		2.5MG	N204819	005	Oct 08, 2013	Aug CFTG

RIOCIGUAT

AB		MSN	0.5MG	A211135	001	Sep 01, 2022	Aug NFTG
AB			1MG	A211135	002	Sep 01, 2022	Aug NFTG
AB			1.5MG	A211135	003	Sep 01, 2022	Aug NFTG
AB			2MG	A211135	004	Sep 01, 2022	Aug NFTG
AB			2.5MG	A211135	005	Sep 01, 2022	Aug NFTG

RISEDRONATE SODIUMTABLET;ORAL
ACTONEL

+	@ APIL	5MG	N020835	002	Apr 14, 2000	Aug DISC
+	@	30MG	N020835	001	Mar 27, 1998	Aug DISC

RISPERIDONESOLUTION;ORAL
RISPERIDONE

AA		CHARTWELL MOLECULAR	1MG/ML	A202386	001	Jan 12, 2015	Aug CMFD
	@		1MG/ML	A202386	001	Jan 12, 2015	May CAHN
AA		LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	May CAHN

RITONAVIRTABLET;ORAL
RITONAVIR

AB		CIPLA	100MG	A202573	001	Jan 15, 2015	Mar CAHN
AB			100MG	A203759	001	May 10, 2022	Apr NEWA

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB		ZYDUS PHARMS	4.6MG/24HR	A206318	001	Mar 04, 2019	Aug CAHN
AB			9.5MG/24HR	A206318	002	Mar 04, 2019	Aug CAHN
AB			13.3MG/24HR	A206318	003	Mar 04, 2019	Aug CAHN

RIZATRIPTAN BENZOATETABLET;ORAL
MAXALT

+	@ ORGANON LLC	EQ 5MG BASE	N020864	001	Jun 29, 1998	Jul CAHN
AB	+	EQ 10MG BASE	N020864	002	Jun 29, 1998	Jul CAHN

RIZATRIPTAN BENZOATE

AB		CREEKWOOD PHARMS	EQ 5MG BASE	A202047	001	Dec 31, 2012	May CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	May CAHN
	@	JUBILANT GENERICS	EQ 5MG BASE	A203252	001	Dec 31, 2014	May DISC
	@		EQ 10MG BASE	A203252	002	Dec 31, 2014	May DISC
AB		PHARMGEN	EQ 5MG BASE	A202047	001	Dec 31, 2012	Sep CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	Sep CAHN
	@	SANDOZ	EQ 5MG BASE	A079230	001	Dec 31, 2012	Sep DISC
	@		EQ 10MG BASE	A079230	002	Dec 31, 2012	Sep DISC

TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

@ SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Sep DISC
@	EQ 10MG BASE	A078739	002	Jul 01, 2013	Sep DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	PRINSTON INC	50MG/5ML (10MG/ML)	A212668	001	May 26, 2022	May NEWA
AP		100MG/10ML (10MG/ML)	A212668	002	May 26, 2022	May NEWA

ROFLUMILAST

CREAM;TOPICAL
ZORYVE

+	ARCUTIS	0.3%	N215985	001	Jul 29, 2022	Jul NEWA
---	---------	------	---------	-----	--------------	----------

TABLET;ORAL
DALIRESP

AB	+	ASTRAZENECA	250MCG	N022522	002	Jan 23, 2018	Aug CFTG
		ROFLUMILAST					
AB		MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Aug CMFD
AB		MSN	250MCG	A208256	001	Sep 07, 2022	Aug NFTG
AB			500MCG	A208256	002	Sep 07, 2022	Aug NEWA
AB		MYLAN	500MCG	A208257	001	Jul 13, 2018	Aug CMFD
AB		PRINSTON INC	500MCG	A208299	001	May 10, 2022	Apr NEWA
AB		ZYDUS PHARMS	500MCG	A208303	001	Feb 10, 2022	Sep CMFD
	@		500MCG	A208303	001	Feb 10, 2022	Jul DISC
AB			500MCG	A208303	001	Feb 10, 2022	Feb NEWA

ROMIDEPSIN

SOLUTION;INTRAVENOUS
ROMIDEPSIN

+	@ TEVA PHARMS USA INC	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020	Jul DISC
---	-----------------------	-----------------------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

AB		PRINSTON INC	EQ 2MG BASE	A204413	001	May 11, 2022	Apr NEWA
AB			EQ 4MG BASE	A204413	002	May 11, 2022	Apr NEWA
AB			EQ 6MG BASE	A204413	003	May 11, 2022	Apr NEWA
AB			EQ 8MG BASE	A204413	004	May 11, 2022	Apr NEWA
AB			EQ 12MG BASE	A204413	005	May 11, 2022	Apr NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	GLAND PHARMA LTD	200MG/100ML (2MG/ML)	A210102	001	Aug 18, 2022	Aug NEWA
AP		400MG/200ML (2MG/ML)	A210102	002	Aug 18, 2022	Aug NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL
ROSUVASTATIN CALCIUM

AB		SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24, 2019	Oct CMFD
AB			EQ 10MG BASE	A206381	002	Apr 24, 2019	Oct CMFD
AB			EQ 20MG BASE	A206381	003	Apr 24, 2019	Oct CMFD
AB			EQ 40MG BASE	A206381	004	Apr 24, 2019	Oct CMFD
	@	STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jan CAHN
	@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Jan CAHN
	@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Jan CAHN
	@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Jan CAHN
	@	ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	Mar CAHN
	@		EQ 10MG BASE	A206513	002	Mar 01, 2019	Mar CAHN
	@		EQ 20MG BASE	A206513	003	Mar 01, 2019	Mar CAHN
	@		EQ 40MG BASE	A206513	004	Mar 01, 2019	Mar CAHN

RUFINAMIDE

SUSPENSION;ORAL
RUFINAMIDE

AB		AUROBINDO PHARMA	40MG/ML	A216549	001	Oct 26, 2022	Oct NEWA
AB		GLASSHOUSE PHARMS	40MG/ML	A214009	001	Nov 07, 2022	Oct NEWA
>D>	@	LUPIN LTD	40MG/ML	A213457	001	Dec 18, 2020	Dec CMFD
>A>	AB		40MG/ML	A213457	001	Dec 18, 2020	Dec CMFD
	@		40MG/ML	A213457	001	Dec 18, 2020	Apr DISC

TABLET;ORAL
RUFINAMIDE

	LUPIN LTD	100MG	A204964	001	Aug 17, 2022	Aug NFTG
AB		200MG	A204964	002	Aug 17, 2022	Aug NEWA
AB		400MG	A204964	003	Aug 17, 2022	Aug NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL
SAPROPTERIN DIHYDROCHLORIDE

AB	ANNORA PHARMA	100MG/PACKET	A215420	001	Aug 18, 2022	Aug NEWA
AB		500MG/PACKET	A215420	002	Aug 18, 2022	Aug NEWA
AB	DR REDDYS	500MG/PACKET	A215798	001	May 13, 2022	May NEWA

TABLET;ORAL
SAPROPTERIN DIHYDROCHLORIDE

AB	ANNORA PHARMA	100MG	A215534	001	Aug 23, 2022	Aug NEWA
----	---------------	-------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

TABLET;ORAL
SELEGILINE HYDROCHLORIDE
@ BOSCOGEN

5MG

A074912	001	Apr 30, 1998	Apr DISC
---------	-----	--------------	----------

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL
SELENIUM SULFIDE

! PADAGIS US 2.5%
@ WOCKHARDT BIO AG 2.5%

A089996	001	Jan 10, 1991	Jun CTEC
A088228	001	Sep 01, 1983	Jun DISC

SELEXIPAG

TABLET;ORAL

>A> SELEXIPAG

>A> AB	ZYDUS	0.2MG	A214302	001	Dec 21, 2022	Dec NFTG
>A> AB		0.4MG	A214302	002	Dec 21, 2022	Dec NFTG
>A> AB		0.6MG	A214302	003	Dec 21, 2022	Dec NFTG
>A> AB		0.8MG	A214302	004	Dec 21, 2022	Dec NFTG
>A> AB		1MG	A214302	005	Dec 21, 2022	Dec NFTG
>A> AB		1.2MG	A214302	006	Dec 21, 2022	Dec NFTG
>A> AB		1.4MG	A214302	007	Dec 21, 2022	Dec NFTG
>A> AB		1.6MG	A214302	008	Dec 21, 2022	Dec NFTG

UPTRAVI

>D>	+	ACTELION	0.2MG	N207947	001	Dec 21, 2015	Dec CFTG
>A> AB	+		0.2MG	N207947	001	Dec 21, 2015	Dec CFTG
>D>	+	!	0.4MG	N207947	002	Dec 21, 2015	Dec CFTG
>A> AB	+	!	0.4MG	N207947	002	Dec 21, 2015	Dec CFTG
>D>	+		0.6MG	N207947	003	Dec 21, 2015	Dec CFTG
>A> AB	+		0.6MG	N207947	003	Dec 21, 2015	Dec CFTG
>D>	+		0.8MG	N207947	004	Dec 21, 2015	Dec CFTG
>A> AB	+		0.8MG	N207947	004	Dec 21, 2015	Dec CFTG
>D>	+		1MG	N207947	005	Dec 21, 2015	Dec CFTG
>A> AB	+		1MG	N207947	005	Dec 21, 2015	Dec CFTG
>D>	+		1.2MG	N207947	006	Dec 21, 2015	Dec CFTG
>A> AB	+		1.2MG	N207947	006	Dec 21, 2015	Dec CFTG
>D>	+		1.4MG	N207947	007	Dec 21, 2015	Dec CFTG
>A> AB	+		1.4MG	N207947	007	Dec 21, 2015	Dec CFTG
>D>	+		1.6MG	N207947	008	Dec 21, 2015	Dec CFTG
>A> AB	+		1.6MG	N207947	008	Dec 21, 2015	Dec CFTG

SELINEXOR

TABLET;ORAL
XPOVIO

+ KARYOPHARM THERAPS 20MG
+! 60MG

N212306	001	Jul 03, 2019	Mar CHRS
N212306	004	Apr 15, 2021	Mar CHRS

SELPERCATINIB

CAPSULE;ORAL
RETEVMO

+ LOXO ONCOL ELI LILLY 40MG
+! 80MG

N213246	001	May 08, 2020	Sep CAHN
N213246	002	May 08, 2020	Sep CAHN

SEMAGLUTIDESOLUTION;SUBCUTANEOUS
OZEMPIC+! NOVO 2MG/3ML (0.68MG/ML)
+! 8MG/3ML (2.68MG/ML)N209637 004 Oct 06, 2022 Oct NEWA
N209637 003 Mar 28, 2022 Apr NEWASERTRALINE HYDROCHLORIDECONCENTRATE;ORAL
ZOLOFTAA +! VIATRIS EQ 20MG BASE/ML
TABLET;ORAL
ZOLOFT

N020990 001 Dec 07, 1999 Jan CAHN

AB + VIATRIS EQ 25MG BASE
AB + EQ 50MG BASE
AB +! EQ 100MG BASE
+ @ EQ 150MG BASE
+ @ EQ 200MG BASEN019839 005 Mar 06, 1996 Jan CAHN
N019839 001 Dec 30, 1991 Jan CAHN
N019839 002 Dec 30, 1991 Jan CAHN
N019839 003 Dec 30, 1991 Jan CAHN
N019839 004 Dec 30, 1991 Jan CAHNSEVELAMER CARBONATEFOR SUSPENSION;ORAL
SEVELAMER CARBONATE@ LUPIN LTD 800MG/PACKET
@ 2.4GM/PACKETA201513 001 Dec 23, 2021 Jul DISC
A201513 002 Dec 23, 2021 Jul DISC

TABLET;ORAL

SEVELAMER CARBONATE

AB ARTHUR GRP 800MG
@ LUPIN LTD 800MG
AB MICRO LABS 800MG
@ STRIDES PHARMA 800MGA200959 001 Mar 20, 2018 Sep CAHN
A204600 001 Jan 14, 2021 May DISC
A215537 001 Feb 07, 2022 Jan NEWA
A201069 001 Aug 05, 2020 Jan CAHNSILDENAFIL CITRATEFOR SUSPENSION;ORAL
REVATIOAB +! VIATRIS EQ 10MG BASE/ML
SILDENAFIL CITRATE

N203109 001 Aug 30, 2012 Feb CAHN

>A> AB AUROBINDO PHARMA LTD EQ 10MG BASE/ML
AB LUPIN LTD EQ 10MG BASE/ML
AB MSN EQ 10MG BASE/ML
@ TRIS PHARMA INC EQ 10MG BASE/ML
AB ZYDUS EQ 10MG BASE/MLA214773 001 Dec 23, 2022 Dec NEWA
A211638 001 Mar 23, 2022 Mar NEWA
A214641 001 Feb 08, 2022 Jan NEWA
A212312 001 Nov 17, 2021 Apr DISC
A215708 001 Sep 29, 2022 Sep NEWASOLUTION;INTRAVENOUS
REVATIOAP +! VIATRIS EQ 10MG BASE/12.5ML (EQ 0.8MG
BASE/ML)

N022473 001 Nov 18, 2009 Feb CAHN

TABLET;ORAL
REVATIOAB +! VIATRIS EQ 20MG BASE
VIAGRA

N021845 001 Jun 03, 2005 Feb CAHN

AB + VIATRIS EQ 25MG BASE
AB + EQ 50MG BASE
AB +! EQ 100MG BASEN020895 001 Mar 27, 1998 Feb CAHN
N020895 002 Mar 27, 1998 Feb CAHN
N020895 003 Mar 27, 1998 Feb CAHNSILODOSINCAPSULE;ORAL
SILODOSIN@ UPSHER SMITH LABS 4MG
@ 8MGA213230 001 Jan 03, 2022 Feb DISC
A213230 002 Jan 03, 2022 Feb DISC

>A> AB ZYDUS PHARMS 4MG

A204816 001 Dec 08, 2022 Dec NEWA

>A> AB 8MG

A204816 002 Dec 08, 2022 Dec NEWA

SIMVASTATINTABLET;ORAL
SIMVASTATIN@ CHARTWELL RX 5MG
@ 10MG
@ 20MG
@ 40MG
@ 80MGA077766 001 Dec 20, 2006 Mar CAHN
A077766 002 Dec 20, 2006 Mar CAHN
A077766 003 Dec 20, 2006 Mar CAHN
A077766 004 Dec 20, 2006 Mar CAHN
A077766 005 Dec 20, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
SIMVASTATIN

+ @ SYNTHON PHARMS	10MG	N021961	001	Oct 09, 2007	Nov CRLD
+ @	20MG	N021961	002	Oct 09, 2007	Nov CRLD
+ @	40MG	N021961	003	Oct 09, 2007	Nov CRLD
+ @	80MG	N021961	004	Oct 09, 2007	Nov CRLD

SINCALIDE

POWDER;INTRAVENOUS
SINCALIDE

+! MAIA PHARMS INC	0.005MG/VIAL	N210850	001	Nov 22, 2022	Nov NEWA
--------------------	--------------	---------	-----	--------------	----------

SIROLIMUS

GEL;TOPICAL
HYFTOR

+! NOBELPHARMA	0.2%	N213478	001	Mar 22, 2022	Mar NEWA
----------------	------	---------	-----	--------------	----------

SOLUTION;ORAL
SIROLIMUS

@ TORRENT	1MG/ML	A215016	001	Dec 27, 2021	Jun DISC
-----------	--------	---------	-----	--------------	----------

SODIUM BICARBONATE

INJECTABLE;INJECTION
SODIUM BICARBONATE

AP ! HOSPIRA	0.5MEQ/ML	A202981	001	Mar 04, 2016	Apr CHRS
--------------	-----------	---------	-----	--------------	----------

SODIUM CHLORIDE

INJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

+ B BRAUN	9MG/10ML	N019635	005	Aug 08, 2016	Nov CMS1
-----------	----------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS
SODIUM CHLORIDE 23.4%

AP FRESenius KABI USA	400MEQ/100ML (4MEQ/ML)	A212070	003	Feb 14, 2022	Feb NFTG
AP +! HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Feb CFTG

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F 18

+ @ NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Mar CRLD
------------------	--------------	---------	-----	--------------	----------

AP BAMF	10-200mCi/ML	A216126	001	Dec 06, 2022	Nov NEWA
---------	--------------	---------	-----	--------------	----------

SODIUM IODIDE I-123

CAPSULE;ORAL
SODIUM IODIDE I 123

@ GE HEALTHCARE	200uCi	N017630	003	Jan 08, 1993	Aug NEWA
-----------------	--------	---------	-----	--------------	----------

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION
NITROPRESS

>D> AP ! HOSPIRA	25MG/ML	A071961	001	Aug 01, 1988	Dec DISC
------------------	---------	---------	-----	--------------	----------

>A> @ VPNA	25MG/ML	A071961	001	Aug 01, 1988	Dec DISC
------------	---------	---------	-----	--------------	----------

SODIUM NITROPRUSSIDE

@ AKORN	25MG/ML	A208635	001	May 04, 2017	Jun DISC
---------	---------	---------	-----	--------------	----------

@ ANDA REPOSITORY	25MG/ML	A209834	001	Jun 26, 2018	Sep CAHN
-------------------	---------	---------	-----	--------------	----------

@ AVET LIFESCIENCES	25MG/ML	A208923	001	Nov 08, 2022	Nov DISC
---------------------	---------	---------	-----	--------------	----------

AP	25MG/ML	A208923	001	Nov 08, 2022	Oct NEWA
----	---------	---------	-----	--------------	----------

AP BE PHARMS	25MG/ML	A214971	001	Jul 12, 2021	Apr CMFD
--------------	---------	---------	-----	--------------	----------

@	25MG/ML	A214971	001	Jul 12, 2021	Jan DISC
---	---------	---------	-----	--------------	----------

AP CAPLIN	25MG/ML	A211016	001	Nov 29, 2019	Mar CAHN
-----------	---------	---------	-----	--------------	----------

>D> AP MICRO LABS	25MG/ML	A209352	001	Dec 08, 2017	Dec CHRS
-------------------	---------	---------	-----	--------------	----------

>A> AP !	25MG/ML	A209352	001	Dec 08, 2017	Dec CHRS
----------	---------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

AP +! EXELA PHARMA	20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018	Aug CFTG
--------------------	-----------------------	---------	-----	--------------	----------

AP +!	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Aug CFTG
-------	-----------------------	---------	-----	--------------	----------

SODIUM NITROPRUSSIDE

AP HAINAN POLY	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Aug NFTG
----------------	----------------------	---------	-----	--------------	----------

AP	20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Aug NFTG
----	-----------------------	---------	-----	--------------	----------

AP	50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Aug NFTG
----	-----------------------	---------	-----	--------------	----------

>A>	<u>SODIUM PHENYL BUTYRATE</u>									
>A>	FOR SUSPENSION; ORAL									
>A>	OLPRUVA									
>A>	+	ACER	2GM/PACKET	N214860	001	Dec 22, 2022	Dec	NEWA		
>A>	+		3GM/PACKET	N214860	002	Dec 22, 2022	Dec	NEWA		
>A>	+		4GM/PACKET	N214860	003	Dec 22, 2022	Dec	NEWA		
>A>	+		5GM/PACKET	N214860	004	Dec 22, 2022	Dec	NEWA		
>A>	+		6GM/PACKET	N214860	005	Dec 22, 2022	Dec	NEWA		
>A>	+		6.67GM/PACKET	N214860	006	Dec 22, 2022	Dec	NEWA		
	PELLETS; ORAL									
	PHEBURANE									
	+	MEDUNIK	84GM/BOT	N216513	001	Jun 17, 2022	Jun	NEWA		
	TABLET; ORAL									
	SODIUM PHENYL BUTYRATE									
AB		GLENMARK PHARMS LTD	500MG	A216462	001	Nov 01, 2022	Oct	NEWA		
	<u>SODIUM PHENYL BUTYRATE; TAURURSODIOL</u>									
	FOR SUSPENSION; ORAL									
	RELYVRIO									
	+	AMYLYX	3GM/PACKET; 1GM/PACKET	N216660	001	Sep 29, 2022	Sep	NEWA		
	<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</u>									
	TABLET; ORAL									
	VISICOL									
	@	SALIX PHARMS	0.398GM; 1.102GM	N021097	001	Sep 21, 2000	Aug	CAIN		
	<u>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</u>									
	INJECTABLE; INJECTION									
	SODIUM PHOSPHATES									
AP		FRESENIUS KABI USA	142MG/ML; 276MG/ML	A209997	001	Mar 30, 2022	Mar	NFTG		
	SODIUM PHOSPHATES IN PLASTIC CONTAINER									
AP	+	HOSPIRA	142MG/ML; 276MG/ML	N018892	001	May 10, 1983	Mar	CFTG		
	<u>SODIUM POLYSTYRENE SULFONATE</u>									
	POWDER; ORAL, RECTAL									
	SODIUM POLYSTYRENE SULFONATE									
AA		AIPING LIFE SCI	453.6GM/BOT	A090313	001	Dec 21, 2011	Oct	CAHN		
	+	@ PAI HOLDINGS PHARM	453.6GM/BOT	A088786	001	Sep 11, 1984	Apr	CAHN		
	SUSPENSION; ORAL, RECTAL									
	KIONEX									
AA		ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CMFD		
	SPS									
AA	+	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Mar	CTEC		
	<u>SODIUM TETRADECYL SULFATE</u>									
	INJECTABLE; INJECTION									
	SODIUM TETRADECYL SULFATE									
AP		HIKMA	60MG/2ML (30MG/ML)	A209937	001	Dec 09, 2019	Aug	CAHN		
	<u>SODIUM THIOSULFATE</u>									
	SOLUTION; INTRAVENOUS									
	PEDMARK									
	+	FENNEC PHARMS INC	12.5GM/100ML (125MG/ML)	N212937	001	Sep 20, 2022	Sep	NEWA		
	<u>SOFOSBUVIR</u>									
	TABLET; ORAL									
	SOFOSBUVIR									
	@	TEVA PHARMS USA INC	400MG	A211353	001	Jan 27, 2022	Jul	DISC		
AB			400MG	A211353	001	Jan 27, 2022	Jan	NFTG		
	SOVALDI									
	+	GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013	Jul	CTEC		
AB	+		400MG	N204671	001	Dec 06, 2013	Jan	CFTG		
	<u>SOLIFENACIN SUCCINATE</u>									
	TABLET; ORAL									
	SOLIFENACIN SUCCINATE									
	@	ACCORD HLTHCARE	5MG	A207477	001	Jan 04, 2022	Jul	DISC		
	@		10MG	A207477	002	Jan 04, 2022	Jul	DISC		
	@	AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	Jan	DISC		
	@		10MG	A209719	002	May 20, 2019	Jan	DISC		

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	ANNORA PHARMA	5MG	A215761	001	Jun 15, 2022	Jun NEWA
AB		10MG	A215761	002	Jun 15, 2022	Jun NEWA
>A> AB	AUROBINDO PHARMA	5MG	A206817	001	Dec 27, 2022	Dec NEWA
>A> AB		10MG	A206817	002	Dec 27, 2022	Dec NEWA

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SUNOSI

+	AXSOME MALTA	EQ 75MG BASE	N211230	001	Jun 17, 2019	May CAHN
+	!	EQ 150MG BASE	N211230	002	Jun 17, 2019	May CAHN

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

+	!	SUN PHARM	EQ 200MG BASE	N205266	001	Jul 24, 2015	Feb CAHN
---	---	-----------	---------------	---------	-----	--------------	----------

SORAFENIB TOSYLATE

TABLET;ORAL

NEXAVAR

AB	+	!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	Apr CTEC
			SORAFENIB TOSYLATE					
AB			DR REDDYS	EQ 200MG BASE	A216073	001	Jun 07, 2022	May NEWA
AB			MYLAN	EQ 200MG BASE	A207012	001	Sep 10, 2020	Apr CMFD
AB			TEVA PHARMS USA INC	EQ 200MG BASE	A209567	001	Nov 12, 2020	Oct CMFD
AB			YABAO PHARM	EQ 200MG BASE	A209050	001	Nov 09, 2022	Nov NEWA

SOTALOL HYDROCHLORIDE

SOLUTION;ORAL

SOTYLIZE

+	!	AZURITY	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014	Mar CAHN
---	---	---------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

BETAPACE

AB	+		LEGACY PHARMA	80MG	N019865	001	Oct 30, 1992	Nov CAHN
AB	+			120MG	N019865	005	Apr 20, 1994	Nov CAHN
AB	+	!		160MG	N019865	002	Oct 30, 1992	Nov CAHN
AB	+			240MG	N019865	003	Oct 30, 1992	Nov CAHN
			@	320MG	N019865	004	Oct 30, 1992	Nov CAHN
			BETAPACE AF					
			@ LEGACY PHARMA	40MG	N021151	006	Apr 02, 2003	Nov CAHN
			@	60MG	N021151	007	Apr 02, 2003	Nov CAHN
AB	+			80MG	N021151	001	Feb 22, 2000	Nov CAHN
			@	100MG	N021151	005	Mar 14, 2003	Nov CAHN
AB	+			120MG	N021151	002	Feb 22, 2000	Nov CAHN
AB	+	!		160MG	N021151	003	Feb 22, 2000	Nov CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB			OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Oct CMFD
AB				50MG	A040750	002	Aug 29, 2006	Oct CMFD
AB				100MG	A040750	003	Aug 29, 2006	Oct CMFD

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP	!		MEDEFIL INC	100% (5ML)	A211188	004	Dec 02, 2019	Feb CTEC
AP			NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Feb CMFD

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

			@ BE PHARMS	20MG/ML	A216003	001	Feb 07, 2022	Aug DISC
AP				20MG/ML	A216003	001	Feb 07, 2022	Jan NEWA
AP			MEITHEAL	20MG/ML	A214514	001	Oct 19, 2021	Mar CAHN

SUCRALFATESUSPENSION;ORAL
SUCRALFATE

AB	MYLAN	1GM/10ML	A212913	001	Sep 12, 2022	Sep NEWA
AB	VISTAPHARM	1GM/10ML	A211884	001	Mar 15, 2022	Mar NEWA

TABLET;ORAL
SUCRALFATE

AB	AMNEAL PHARMS	1GM	A215576	001	Apr 15, 2022	Apr NEWA
----	---------------	-----	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIMSUSPENSION;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

	@ LUPIN LTD	200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021	May DISC
AB	NOVITIUM PHARMA	200MG/5ML;40MG/5ML	A214330	001	Feb 08, 2022	Jan NEWA

SULINDACTABLET;ORAL
SULINDAC

>A>	@ ANI PHARMS	150MG	A072973	002	Feb 28, 1992	Dec CMS1
	@ RISING	150MG	A073039	002	Jun 22, 1993	Jul CAHN
	@	200MG	A073039	001	Jun 22, 1993	Jul CAHN

SUMATRIPTANSPRAY;NASAL
SUMATRIPTAN

AB	PADAGIS ISRAEL	5MG/SPRAY	A213465	002	Sep 21, 2020	Nov CAIN
----	----------------	-----------	---------	-----	--------------	----------

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

	@ STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb CAHN
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb CAHN

SUNITINIB MALATECAPSULE;ORAL
SUNITINIB MALATE

AB	DR REDDYS	EQ 12.5MG BASE	A215843	001	Apr 11, 2022	Apr NEWA
AB		EQ 25MG BASE	A215843	002	Apr 11, 2022	Apr NEWA
AB		EQ 37.5MG BASE	A215843	003	Apr 11, 2022	Apr NEWA
AB		EQ 50MG BASE	A215843	004	Apr 11, 2022	Apr NEWA

TACROLIMUSINJECTABLE;INJECTION
PROGRAF

+	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Nov CTEC
	TACROLIMUS					
	@ HOSPIRA	EQ 5MG BASE/ML	A203900	001	Aug 25, 2017	Nov DISC

TADALAFILSUSPENSION;ORAL
TADLIQ

+	CMP DEV LLC	20MG/5ML	N214522	001	Jun 17, 2022	Jun NEWA
---	-------------	----------	---------	-----	--------------	----------

TABLET;ORAL
ALYQ

AB2	TEVA PHARMS INC	20MG	A216932	001	Oct 12, 2022	Sep NEWA
	TADALAFIL					
AB1	AUSTARPHARMA	2.5MG	A208824	001	Oct 27, 2020	Mar CAHN
AB1		5MG	A208824	002	Oct 27, 2020	Mar CAHN
AB1		10MG	A208824	003	Oct 27, 2020	Mar CAHN
AB1		20MG	A208824	004	Oct 27, 2020	Mar CAHN
	@ CHARTWELL RX	2.5MG	A210716	001	Dec 29, 2020	May CAHN
	@	5MG	A210716	002	Dec 29, 2020	May CAHN
	@	10MG	A210716	003	Dec 29, 2020	May CAHN
	@	20MG	A210716	004	Dec 29, 2020	May CAHN
AB1	PRINSTON INC	2.5MG	A210609	001	Aug 11, 2022	Aug NEWA
AB1		5MG	A210609	002	Aug 11, 2022	Aug NEWA
AB1		10MG	A210609	003	Aug 11, 2022	Aug NEWA
AB2		20MG	A210608	001	Aug 11, 2022	Aug NEWA
AB1		20MG	A210609	004	Aug 11, 2022	Aug NEWA

TAFENOQUINE SUCCINATE

TABLET; ORAL

ARAKODA

+! 60 DEGREES PHARMS EQ 100MG BASE

N210607 001 Aug 08, 2018 Jul CAHN

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

TAFLUPROST

AT SANDOZ INC 0.0015%

A209040 001 Jan 28, 2022 Jan NEWA

ZIOPTAN

AT +! THEA PHARMA 0.0015%

N202514 001 Feb 10, 2012 Apr CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

@ ACME LABS 0.4MG

A214730 001 May 04, 2022 Nov DISC

AB 0.4MG

A214730 001 May 04, 2022 Apr NEWA

TAPINAROF

CREAM; TOPICAL

VTAMA

+! DERMAVANT SCI 1%

N215272 001 May 23, 2022 May NEWA

TASIMELTEON

CAPSULE; ORAL

HETLIOZ

>D> +! VANDA PHARMS INC 20MG

N205677 001 Jan 31, 2014 Dec CFTG

>A> AB +! 20MG

N205677 001 Jan 31, 2014 Dec CFTG

TASIMELTEON

>A> AB APOTEX CORP 20MG

A211607 001 Dec 20, 2022 Dec NEWA

>A> AB TEVA PHARMS USA INC 20MG

A211601 001 Dec 12, 2022 Dec NFTG

TAVABOROLE

SOLUTION; TOPICAL

TAVABOROLE

AB CHARTWELL RX 5%

A211963 001 Feb 03, 2021 Mar CAHN

AB IDENTIRX 5%

A211963 001 Feb 03, 2021 Mar CMFD

TAZAROTENE

GEL; TOPICAL

TAZAROTENE

AB COSETTE 0.05%

A215433 001 Sep 13, 2022 Sep NFTG

AB 0.1%

A214136 001 Sep 13, 2022 Sep NFTG

TAZORAC

AB +! ALLERGAN 0.05%

N020600 001 Jun 13, 1997 Sep CFTG

AB +! 0.1%

N020600 002 Jun 13, 1997 Sep CFTG

LOTION; TOPICAL

ARAZLO

+! BAUSCH 0.045%

N211882 001 Dec 18, 2019 May CAHN

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNETIUM TC99M MERTIATIDE KIT

AP MEDI-RADIOPHARMA N/A

A206489 001 Feb 06, 2020 Nov CAHN

TECHNETIUM TC-99M SUCCIMER

POWDER; INTRAVENOUS

NEPHROSCAN

+! THERAGNOSTICS N/A

N214993 001 Feb 18, 2022 Mar CAIN

TECHNETIUM TC-99M SUCCIMER KIT

POWDER; INTRAVENOUS

NEPHROSCAN

+! THERAGNOSTICS N/A

N214993 001 Feb 18, 2022 Feb NEWA

TECHNETIUM TC-99M TETROFOSMIN KITINJECTABLE; INJECTION
MYOVUE

+! GE HEALTHCARE N/A N020372 001 Feb 09, 1996 Feb CMFD

TECOVIRIMATSOLUTION; INTRAVENOUS
TPOXX

+! SIGA TECHNOLOGIES 200MG/20ML (10MG/ML) N214518 001 May 18, 2022 May NEWA

TEDUGLUTIDE RECOMBINANTPOWDER; SUBCUTANEOUS
GATTEX KIT

+! TAKEDA PHARMS USA 5MG/VIAL N203441 001 Dec 21, 2012 Apr CAHN

TEMOZOLOMIDECAPSULE; ORAL
TEMODAR

>D>							
>D>	AB	+	MERCK SHARP DOHME	5MG	N021029	001	Aug 11, 1999 Dec DISC
>A>		+	@	5MG	N021029	001	Aug 11, 1999 Dec DISC
>D>	AB	+		20MG	N021029	002	Aug 11, 1999 Dec DISC
>A>		+	@	20MG	N021029	002	Aug 11, 1999 Dec DISC
>D>	AB	+		100MG	N021029	003	Aug 11, 1999 Dec DISC
>A>		+	@	100MG	N021029	003	Aug 11, 1999 Dec DISC
>D>	AB	+		140MG	N021029	005	Oct 19, 2006 Dec DISC
>A>		+	@	140MG	N021029	005	Oct 19, 2006 Dec DISC
>D>	AB	+		180MG	N021029	006	Oct 19, 2006 Dec DISC
>A>		+	@	180MG	N021029	006	Oct 19, 2006 Dec DISC
>D>	AB	+	!	250MG	N021029	004	Aug 11, 1999 Dec DISC
>A>		+	@	250MG	N021029	004	Aug 11, 1999 Dec DISC

TEMOZOLOMIDE

>D>	AB		ACCORD HLTHCARE	250MG	A201528	006	Feb 27, 2017 Dec CHRS
>A>	AB	!		250MG	A201528	006	Feb 27, 2017 Dec CHRS
		@	ANI PHARMS	5MG	A203490	001	Jul 13, 2016 Jun DISC
		@		20MG	A203490	002	Jul 13, 2016 Jun DISC
		@		100MG	A203490	003	Jul 13, 2016 Jun DISC
		@		140MG	A203490	004	Jul 13, 2016 Jun DISC
		@		180MG	A203490	005	Jul 13, 2016 Jun DISC
		@		250MG	A203490	006	Jul 13, 2016 Mar DISC
AB			HERITAGE	5MG	A078879	001	Mar 01, 2010 Jan CMFD
AB				20MG	A078879	002	Mar 01, 2010 Jan CMFD
AB				100MG	A078879	003	Mar 01, 2010 Jan CMFD
AB				140MG	A078879	005	Mar 01, 2010 Jan CMFD
AB				180MG	A078879	006	Mar 01, 2010 Jan CMFD
AB				250MG	A078879	004	Mar 01, 2010 Jan CMFD

TENAPANOR HYDROCHLORIDETABLET; ORAL
IBSRELA

+! ARDELYX INC EQ 50MG BASE N211801 001 Sep 12, 2019 Feb CMFD

TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB CHARTWELL 300MG A206481 001 Jul 26, 2018 Jul CMFD

TERBINAFINE HYDROCHLORIDETABLET; ORAL
TERBINAFINE HYDROCHLORIDE

AB			CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007 Mar CMFD
		@	HERITAGE PHARMA AVET	EQ 250MG BASE	A076377	001	Jul 02, 2007 Jul DISC

TERBUTALINE SULFATEINJECTABLE; INJECTION
TERBUTALINE SULFATE

		@	AKORN	1MG/ML	A078151	001	Jan 07, 2008 Aug DISC
AP	!		CHARTWELL INJECTABLE	1MG/ML	A076770	001	Apr 23, 2004 Mar CAHN

TERLIPRESSIN ACETATEPOWDER; INTRAVENOUS
TERLIVAZ

+	!	MALLINCKRODT IRELAND	EQ 0.85MG BASE/VIAL	N022231	001	Sep 14, 2022	Sep NEWA
---	---	----------------------	---------------------	---------	-----	--------------	----------

TESTOSTERONEGEL; TRANSDERMAL
ANDROGEL

+	@	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jan DISC
+	@		1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jan DISC
+	@		25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan DISC
+	@		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan DISC

TESTOSTERONE

AB1	!	ACTAVIS LABS UT INC	50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jan CHRS
AB2	!	PADAGIS ISRAEL	1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jan CHRS

TESTOSTERONE CYPIONATESOLUTION; INTRAMUSCULAR
TESTOSTERONE CYPIONATE

+	@	SLAYBACK PHARMA LLC	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Sep DISC
+	!		200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jun NEWA

TESTOSTERONE UNDECANOATECAPSULE; ORAL
JATENZO

+		TOLMAR	158MG	N206089	001	Mar 27, 2019	Nov CAHN
+			198MG	N206089	002	Mar 27, 2019	Nov CAHN
+	!		237MG	N206089	003	Mar 27, 2019	Nov CAHN

KYZATREX

+		MARIUS PHARMS LLC	100MG	N213953	001	Jul 27, 2022	Jul NEWA
+			150MG	N213953	002	Jul 27, 2022	Jul NEWA
+	!		200MG	N213953	003	Jul 27, 2022	Jul NEWA

TLANDO

+	!	ANTARES PHARMA INC	112.5MG	N208088	001	Mar 28, 2022	Mar NEWA
---	---	--------------------	---------	---------	-----	--------------	----------

TETRABENAZINETABLET; ORAL
TETRABENAZINE

@	HIKMA	12.5MG
@		25MG

A209739	001	Apr 08, 2019	Feb DISC
A209739	002	Apr 08, 2019	Feb DISC

THEOPHYLLINETABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

AB		TEVA PHARMS INC	300MG	A216961	001	Oct 12, 2022	Sep NEWA
AB			450MG	A216961	002	Oct 12, 2022	Sep NEWA

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

AP		EUGIA PHARMA	100MG/ML	A208703	001	Apr 20, 2022	Apr NEWA
----	--	--------------	----------	---------	-----	--------------	----------

THIOGUANINETABLET; ORAL
THIOGUANINE

+	!	WOODWARD SPECL	40MG	N012429	001		Apr CAHN
---	---	----------------	------	---------	-----	--	----------

THIOTHIXENECAPSULE; ORAL
THIOTHIXENE

AB		AMNEAL	1MG	A215456	001	Feb 28, 2022	Feb NEWA
AB			2MG	A215456	002	Feb 28, 2022	Feb NEWA
AB			5MG	A215456	003	Feb 28, 2022	Feb NEWA
AB			10MG	A215456	004	Feb 28, 2022	Feb NEWA

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

TIAGABINE HYDROCHLORIDE

@ AMNEAL PHARMS CO	2MG	A208181	001	Dec 08, 2017	Jul DISC
@	4MG	A208181	002	Dec 08, 2017	Jul DISC
@	12MG	A208181	003	Dec 08, 2017	Jul DISC
@	16MG	A208181	004	Dec 08, 2017	Jul DISC

TICAGRELOR

TABLET; ORAL

BRILINTA

+ ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Feb CTEC
TICAGRELOR					
@ MYLAN	60MG	A208597	001	Jul 09, 2021	Feb DISC
@	90MG	A208597	002	Jul 09, 2021	Feb DISC

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

@ XELLIA PHARMS APS	50MG/VIAL	A205722	001	Oct 18, 2019	Jun DISC
---------------------	-----------	---------	-----	--------------	----------

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

AT	+	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Apr CAHN
AT	+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Apr CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB		DR REDDYS	EQ 0.25% BASE	A215733	001	Sep 22, 2022	Sep NEWA
AB			EQ 0.5% BASE	A215733	002	Sep 22, 2022	Sep NEWA
AB		GLAND PHARMA LTD	EQ 0.25% BASE	A214645	001	Jun 24, 2022	Jun NEWA
TIMOPTIC-XE							
AB	+	BAUSCH	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr CAHN
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr CAHN
AB	+	BAUSCH AND LOMB INC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Jul CAHN
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Jul CAHN
SOLUTION/DROPS; OPHTHALMIC							
TIMOLOL MALEATE							
		@ AKORN	EQ 0.5% BASE	A074516	001	Mar 25, 1997	Jul DISC
		@	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Sep DISC
AT3		INGENUS PHARMS LLC	EQ 0.25% BASE	A216533	001	Sep 13, 2022	Sep NEWA
AT3			EQ 0.5% BASE	A216533	002	Sep 13, 2022	Sep NEWA
AT3		MICRO LABS	EQ 0.5% BASE	A216596	001	Sep 07, 2022	Aug NEWA
TIMOPTIC							
AT1	+	BAUSCH	EQ 0.25% BASE	N018086	001		Apr CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Apr CAHN
AT1	+	BAUSCH AND LOMB INC	EQ 0.25% BASE	N018086	001		Jul CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Jul CAHN
TIMOPTIC IN OCUDOSE							
AT3	+	BAUSCH AND LOMB INC	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Feb CAHN
AT3	+		EQ 0.5% BASE	N019463	002	Nov 05, 1986	Feb CAHN

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

@ HIKMA	250MG	A201172	001	Apr 30, 2012	Sep DISC
@	500MG	A201172	002	Apr 30, 2012	Sep DISC

TIOPRONIN

TABLET; ORAL

TIOPRONIN

AB		PAR PHARM INC	100MG	A216198	001	Jun 02, 2022	May NEWA
----	--	---------------	-------	---------	-----	--------------	----------

TIPRANAVIR

>D> SOLUTION; ORAL

>D> APTIVUS

>D>	+	BOEHRINGER INGELHEIM	100MG/ML	N022292	001	Jun 23, 2008	Dec DISC
-----	---	----------------------	----------	---------	-----	--------------	----------

>A>	+	@	100MG/ML	N022292	001	Jun 23, 2008	Dec DISC
-----	---	---	----------	---------	-----	--------------	----------

TIRZEPATIDESOLUTION; SUBCUTANEOUS
MOUNJARO

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	May NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	May NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	May NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	May NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	May NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	May NEWA

TIZANIDINE HYDROCHLORIDECAPSULE; ORAL
ZANAFLEX

AB	+	LEGACY PHARMA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Nov CAHN
AB	+		EQ 4MG BASE	N021447	002	Aug 29, 2002	Nov CAHN
AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Nov CAHN

TABLET; ORAL
ZANAFLEX

	+	@ LEGACY PHARMA	EQ 2MG BASE	N020397	002	Feb 04, 2000	Nov CAHN
AB	+		EQ 4MG BASE	N020397	001	Nov 27, 1996	Nov CAHN

TOBRAMYCINSOLUTION; INHALATION
TOBRAMYCIN

AN		MANKIND PHARMA	300MG/4ML	A216725	001	Sep 22, 2022	Sep NEWA
----	--	----------------	-----------	---------	-----	--------------	----------

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

		@ AKORN	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014	Aug DISC
>D> AP		TEVA PHARMS USA	EQ 40MG BASE/ML	A063100	001	Jan 30, 1992	Dec DISC
>A>		@	EQ 40MG BASE/ML	A063100	001	Jan 30, 1992	Dec DISC

TOFACITINIB CITRATETABLET, EXTENDED RELEASE; ORAL
TOFACITINIB

		@ ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Jan DISC
		@	EQ 22MG BASE	A214264	002	Aug 19, 2021	Jan DISC
		XELJANZ XR					
	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jan CTEC
	+		EQ 22MG BASE	N208246	002	Dec 12, 2019	Jan CTEC

TOLVAPTANTABLET; ORAL
SAMSCA

AB	+	OTSUKA	15MG	N022275	001	May 19, 2009	Feb CFTG
		TOLVAPTAN					
AB		ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Aug NEWA
AB		APOTEX	15MG	A207605	002	Sep 06, 2022	Aug NEWA
AB		HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Aug NEWA
AB		PAR PHARM INC	15MG	A206119	001	Feb 15, 2022	Feb NFTG
AB			30MG	A206119	002	Feb 15, 2022	Feb NEWA

TOPIRAMATECAPSULE; ORAL
TOPIRAMATE

		@ STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009	Nov CAHN
		@	25MG	A078418	002	Oct 14, 2009	Nov CAHN

CAPSULE, EXTENDED RELEASE; ORAL
TOPIRAMATE

AB2		ZYDUS PHARMS	25MG	A208949	001	Nov 29, 2022	Nov NEWA
AB2			50MG	A208949	002	Nov 29, 2022	Nov NEWA
AB2			100MG	A208949	003	Nov 29, 2022	Nov NEWA
AB2			150MG	A208949	004	Nov 29, 2022	Nov NEWA
AB2			200MG	A208949	005	Nov 29, 2022	Nov NEWA

TABLET; ORAL
TOPIRAMATE

		@ UPSHER SMITH LABS	25MG	A078499	001	Jan 07, 2010	Mar DISC
		@	50MG	A078499	002	Jan 07, 2010	Mar DISC
		@	100MG	A078499	003	Jan 07, 2010	Mar DISC
		@	200MG	A078499	004	Jan 07, 2010	Mar DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION							
TOPOTECAN HYDROCHLORIDE							
AP	TEYRO LABS	EQ 4MG BASE/VIAL	A091199	001	Dec 01, 2010	Apr	CAHN
SOLUTION; INTRAVENOUS							
TOPOTECAN HYDROCHLORIDE							
	@ MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	DISC

TRAMADOL HYDROCHLORIDE

TABLET; ORAL							
TRAMADOL HYDROCHLORIDE							
	@ MYLAN	50MG	A075986	001	Jun 21, 2002	Sep	DISC
AB	! SUN PHARM INDS INC	50MG	A075964	001	Jun 19, 2002	Sep	CHRS
ULTRAM							
	+ @ JANSSEN PHARMS	50MG	N020281	002	Mar 03, 1995	Sep	DISC
	+ @	100MG	N020281	001	Mar 03, 1995	Aug	CRLD
TABLET, EXTENDED RELEASE; ORAL							
TRAMADOL HYDROCHLORIDE							
	@ MYLAN	100MG	A205257	001	Dec 22, 2015	Sep	DISC
	@	200MG	A205257	002	Dec 22, 2015	Jun	DISC
	@	300MG	A205257	003	Dec 22, 2015	Jun	DISC

TRANDOLAPRIL

TABLET; ORAL							
TRANDOLAPRIL							
	@ CHARTWELL MOLECULAR	1MG	A077307	002	Jun 12, 2007	Nov	CAHN
	@	2MG	A077307	001	Jun 12, 2007	Nov	CAHN
	@	4MG	A077307	003	Jun 12, 2007	Nov	CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION							
TRANEXAMIC ACID							
	@ AKORN	100MG/ML	A206594	001	Sep 28, 2017	Jun	DISC
	@	100MG/ML	A206634	001	Jun 09, 2016	Jun	DISC
	@ ANDA REPOSITORY	100MG/ML	A202755	001	Feb 25, 2016	Sep	CAHN

TRANLYCYPROMINE SULFATE

TABLET; ORAL							
TRANLYCYPROMINE SULFATE							
AB	CROSSMEDIKA SA	EQ 10MG BASE	A213503	001	Jun 27, 2022	Jun	NEWA

TREPROSTINIL

POWDER; INHALATION							
TYVASO DPI							
	+ UNITED THERAP	0.016MG/INH	N214324	001	May 23, 2022	May	NEWA
	+	0.032MG/INH	N214324	002	May 23, 2022	May	NEWA
	+	0.048MG/INH	N214324	003	May 23, 2022	May	NEWA
	+!	0.064MG/INH	N214324	004	May 23, 2022	May	NEWA

TRETINOIN

CREAM; TOPICAL							
TRETINOIN							
>A> AB	TARO PHARMS	0.025%	A215713	001	Jan 05, 2023	Dec	NEWA

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL							
NASACORT							
	@ CHATTEM SANOFI	0.055MG/INH	N019798	001	Jul 11, 1991	Jan	CAHN
	@	0.055MG/INH	N019798	001	Jul 11, 1991	Jan	CAHN
CREAM; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	ENCUBE	0.1%	A208848	001	Sep 18, 2017	Jul	CAHN
FOR SUSPENSION, EXTENDED RELEASE; INTRA-ARTICULAR							
ZILRETTA							
	+! PACIRA PHARMS INC	32MG/VIAL	N208845	001	Oct 06, 2017	Feb	CAHN
INJECTABLE; INJECTION							
TRIAMCINOLONE ACETONIDE							
>D> BX	AMNEAL	40MG/ML	A207550	001	Dec 11, 2017	Dec	CTEC
>A> AB		40MG/ML	A207550	001	Dec 11, 2017	Dec	CTEC
AB	CUSTOPHARM INC	40MG/ML	A213543	001	Jan 19, 2022	Jan	NEWA

INJECTABLE;INJECTION							
TRIAMCINOLONE ACETONIDE							
AB	EUGIA PHARMA	40MG/ML	A212400	001	Jul 05, 2022	Jun	NEWA
AB	LONG GROVE PHARMS	40MG/ML	A213543	001	Jan 19, 2022	Jan	CAHN
AB	MYLAN LABS LTD	40MG/ML	A212567	001	Nov 02, 2022	Oct	NEWA
OINTMENT;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	ENCUBE	0.1%	A205373	001	May 13, 2016	Jul	CAHN
PASTE;DENTAL							
TRIAMCINOLONE ACETONIDE							
>A> AT	QUAGEN	0.1%	A214582	001	Dec 09, 2022	Dec	NEWA
SPRAY, METERED;NASAL							
TRIAMCINOLONE ACETONIDE							
@ PERRIGO PHARMA INTL		0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN
<u>TRIAMCINOLONE HEXACETONIDE</u>							
INJECTABLE;INJECTION							
ARISTOSPAN							
+ @ SANDOZ INC		5MG/ML	N016466	001		Jul	DISC
+ @		20MG/ML	N016466	002		Jul	DISC
<u>TRIAZOLAM</u>							
TABLET;ORAL							
TRIAZOLAM							
AB	SANDOZ INC	0.125MG	A216890	001	Nov 08, 2022	Oct	NEWA
AB		0.25MG	A216890	002	Nov 08, 2022	Oct	NEWA
>A> AB	ZYDUS PHARMS	0.125MG	A213003	001	Dec 28, 2022	Dec	NEWA
>A> AB		0.25MG	A213003	002	Dec 28, 2022	Dec	NEWA
<u>TRIENTINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
TRIENTINE HYDROCHLORIDE							
@ ACCORD HLTHCARE		250MG	A212929	001	Aug 30, 2021	Oct	DISC
AB	ECI PHARMS LLC	250MG	A209945	001	Aug 13, 2021	Sep	CAHN
AB	HETERO LABS LTD III	250MG	A216356	001	Jun 23, 2022	Jun	NEWA
@ LUPIN LTD		250MG	A211637	001	May 21, 2020	Apr	DISC
<u>TRIENTINE TETRAHYDROCHLORIDE</u>							
TABLET;ORAL							
CUVRIOR							
+! ORPHALAN		300MG	N215760	001	Apr 28, 2022	Apr	NEWA
<u>TRIFLURIDINE</u>							
SOLUTION/DROPS;OPHTHALMIC							
TRIFLURIDINE							
@ AKORN		1%	A205438	001	Jul 28, 2017	Aug	DISC
<u>TRIMETHOPRIM</u>							
TABLET;ORAL							
TRIMETHOPRIM							
AB	NOVITIUM PHARMA	100MG	A216393	001	Oct 28, 2022	Oct	NEWA
<u>TRIPTORELIN PAMOATE</u>							
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR							
TRIPTODUR KIT							
+! AZURITY		EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun	CAHN
<u>TROSPIMUM CHLORIDE</u>							
TABLET;ORAL							
TROSPIMUM CHLORIDE							
AB	AMICI	20MG	A215781	001	Feb 16, 2022	Feb	NEWA
AB	ENALTEC	20MG	A215781	001	Feb 16, 2022	May	CAHN
AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Jul	CAHN
<u>TRYPAN BLUE</u>							
SOLUTION;OPHTHALMIC							
MEMBRANEBLUE							
+ @ DORC		0.15%	N022278	001	Feb 20, 2009	Jul	DISC

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL
RINVOQ

+	ABBVIE INC	15MG	N211675	001	Aug 16, 2019	Jan CHRS
+		30MG	N211675	002	Jan 14, 2022	Apr CHRS
+	!	30MG	N211675	002	Jan 14, 2022	Jan NEWA
+	!	45MG	N211675	003	Mar 16, 2022	Mar NEWA

URSODIOL

CAPSULE;ORAL
ACTIGALL

	@ TEVA BRANDED PHARM	150MG	N019594	001	Dec 31, 1987	Apr CAHN
AB	+	300MG	N019594	002	Dec 31, 1987	Apr CAHN
	URSODIOL					
AB	AUROBINDO PHARMA LTD	300MG	A214849	001	Nov 28, 2022	Nov NEWA
	@ VGYAAN	300MG	A214329	001	Jul 28, 2021	Feb DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

AB	WOCKHARDT BIO AG	EQ 500MG BASE	A090216	001	May 24, 2010	Nov CAHN
AB		EQ 1GM BASE	A090216	002	May 24, 2010	Nov CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL
VALGANCICLOVIR HYDROCHLORIDE

AB	AIRIS PHARMA PVT LTD	50MG/ML	A210169	001	Feb 17, 2022	Feb NEWA
AB	AUROBINDO PHARMA	50MG/ML	A215124	001	Nov 17, 2022	Nov NEWA
AB	HETERO LABS LTD V	50MG/ML	A211475	001	Oct 04, 2022	Sep NEWA
AB	MSN	50MG/ML	A210169	001	Feb 17, 2022	Aug CAHN

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

	@ MYLAN	EQ 450MG BASE	A205151	001	Mar 03, 2021	Mar DISC
AB		EQ 450MG BASE	A205151	001	Mar 03, 2021	Mar CAHN

VALPROATE SODIUM

INJECTABLE;INJECTION
VALPROATE SODIUM

	@ MYLAN	EQ 100MG BASE/ML	A208120	001	Dec 22, 2021	May DISC
--	---------	------------------	---------	-----	--------------	----------

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

AA	ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Sep CAHN
>D> AA	LANNETT CO INC	250MG/5ML	A077960	001	Oct 13, 2006	Dec DISC
>A>	@	250MG/5ML	A077960	001	Oct 13, 2006	Dec DISC
	@ WOCHHARDT BIO AG	250MG/5ML	A070868	001	Jul 01, 1986	Mar DISC

VALRUBICIN

SOLUTION;INTRAVESICAL
VALRUBICIN

AO	HIKMA	40MG/ML	A206430	001	Apr 19, 2019	Aug CAHN
----	-------	---------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION;ORAL
FIRVANQ KIT

AB	+	AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Nov CFTG
AB	+		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Nov CFTG

VANCOMYCIN HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Nov NFTG
AB		EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Nov NFTG

INJECTABLE;INJECTION

VANCOCIN HYDROCHLORIDE

	@ STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Jan CAHN
	@	EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Jan CAHN
	@	EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Jan CAHN
	@	EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Jan CAHN
	@	EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Jan CAHN
	@	EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Jan CAHN
	@	EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Jan CAHN
	@	EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Jan CAHN

INJECTABLE; INJECTION							
VANCOCIN HYDROCHLORIDE							
	@	EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Jan	CAHN
VANCOMYCIN HYDROCHLORIDE							
AP	ASPIRO	EQ 500MG BASE/VIAL	A216591	001	Jul 06, 2022	Jun	NEWA
AP		EQ 1GM BASE/VIAL	A216591	002	Jul 06, 2022	Jun	NEWA
AP	HOSPIRA	EQ 750MG BASE/VIAL	A062912	002	Jan 07, 2009	Sep	CHRS
AP		EQ 750MG BASE/VIAL	A062933	002	May 27, 2009	Sep	CHRS
	@ KNACK	EQ 500MG BASE/VIAL	A213059	001	Feb 15, 2022	Aug	DISC
AP		EQ 500MG BASE/VIAL	A213059	001	Feb 15, 2022	Feb	NEWA
	@	EQ 750MG BASE/VIAL	A213059	002	Feb 15, 2022	Aug	DISC
AP		EQ 750MG BASE/VIAL	A213059	002	Feb 15, 2022	Feb	NEWA
	@	EQ 1GM BASE/VIAL	A213059	003	Feb 15, 2022	Aug	DISC
AP		EQ 1GM BASE/VIAL	A213059	003	Feb 15, 2022	Feb	NEWA
AP	MEITHEAL	EQ 500MG BASE/VIAL	A215197	001	Jul 28, 2022	Oct	CAHN
AP		EQ 750MG BASE/VIAL	A215195	001	Sep 15, 2022	Oct	CAHN
AP		EQ 1GM BASE/VIAL	A215197	002	Jul 28, 2022	Oct	CAHN
AP		EQ 5GM BASE/VIAL	A215196	001	Jul 27, 2022	Oct	CAHN
AP		EQ 10GM BASE/VIAL	A215196	002	Jul 27, 2022	Oct	CAHN
AP	NANJING KING-FRIEND	EQ 500MG BASE/VIAL	A215197	001	Jul 28, 2022	Jul	NEWA
AP		EQ 750MG BASE/VIAL	A215195	001	Sep 15, 2022	Sep	NEWA
AP		EQ 1GM BASE/VIAL	A215197	002	Jul 28, 2022	Jul	NEWA
AP		EQ 5GM BASE/VIAL	A215196	001	Jul 27, 2022	Jul	NEWA
AP		EQ 10GM BASE/VIAL	A215196	002	Jul 27, 2022	Jul	NEWA
	@ SANDOZ	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Oct	DISC
	@	EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Oct	DISC
POWDER; INTRAVENOUS							
VANCOMYCIN HYDROCHLORIDE							
	+ @ MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481	001	Jul 10, 2018	Feb	DISC
<u>VARDENAFIL HYDROCHLORIDE</u>							
TABLET; ORAL							
LEVITRA							
	+ @ BAYER HLTHCARE	EQ 20MG BASE	N021400	004	Aug 19, 2003	Feb	DISC
VARDENAFIL HYDROCHLORIDE							
AB	! ZYDUS PHARMS	EQ 20MG BASE	A208960	004	Oct 31, 2018	Feb	CHRS
TABLET, ORALLY DISINTEGRATING; ORAL							
STAXYN							
	+ @ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	May	DISC
VARDENAFIL HYDROCHLORIDE							
AB	! ALEMBIC PHARMS	10MG	A208324	001	Nov 16, 2018	May	CHRS
<u>VARENICLINE TARTRATE</u>							
SPRAY; NASAL							
TYRVAYA							
	+! OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY	N213978	001	Oct 15, 2021	Aug	CDFR
TABLET; ORAL							
CHANTIX							
	+ @ PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Apr	DISC
	+ @	EQ 1MG BASE	N021928	002	May 10, 2006	Apr	DISC
AB	+	EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CHRS
VARENICLINE TARTRATE							
	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Apr	CTEC
	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Apr	CTEC
AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Feb	CHRS
<u>VASOPRESSIN</u>							
SOLUTION; INTRAVENOUS							
VASOPRESSIN							
AP	AMNEAL	20UNITS/ML (20UNITS/ML)	A212944	001	Aug 05, 2022	Sep	CPOT
AP		20UNITS/ML (20UNITS/ML)	A212944	001	Aug 05, 2022	Jul	NEWA
AP	AMPHASTAR PHARMS INC	20UNITS/ML (20UNITS/ML)	A211857	001	Jul 18, 2022	Jul	NEWA
AP	EUGIA PHARMA	20UNITS/ML (20UNITS/ML)	A214314	001	Aug 15, 2022	Aug	NEWA
<u>VENLAFAXINE BESYLATE</u>							
TABLET, EXTENDED RELEASE; ORAL							
VENLAFAXINE BESYLATE							
	+! ALMATICA	EQ 112.5MG BASE	N215429	001	Jun 29, 2022	Jun	NEWA

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB	WOCKHARDT BIO AG	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Nov CAHN
AB		EQ 75MG BASE	A078865	002	Apr 14, 2011	Nov CAHN
AB		EQ 150MG BASE	A078865	003	Apr 14, 2011	Nov CAHN
AB	YICHANG HUMANWELL	EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Aug CMFD
	@	EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Jan DISC
AB		EQ 75MG BASE	A214654	002	Aug 06, 2021	Aug CMFD
	@	EQ 75MG BASE	A214654	002	Aug 06, 2021	Jan DISC
AB		EQ 150MG BASE	A214654	003	Aug 06, 2021	Aug CMFD
	@	EQ 150MG BASE	A214654	003	Aug 06, 2021	Jan DISC

TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

>D>	AB	JB CHEMS PHARMS	EQ 37.5MG BASE	A216044	001	Nov 28, 2022	Dec CAHN
	AB		EQ 37.5MG BASE	A216044	001	Nov 28, 2022	Nov NEWA
>D>	AB		EQ 75MG BASE	A216044	002	Nov 28, 2022	Dec CAHN
	AB		EQ 75MG BASE	A216044	002	Nov 28, 2022	Nov NEWA
>D>	AB		EQ 150MG BASE	A216044	003	Nov 28, 2022	Dec CAHN
	AB		EQ 150MG BASE	A216044	003	Nov 28, 2022	Nov NEWA
>D>	AB		EQ 225MG BASE	A216044	004	Nov 28, 2022	Dec CAHN
	AB		EQ 225MG BASE	A216044	004	Nov 28, 2022	Nov NEWA
	@	PHARMADAX INC	EQ 75MG BASE	A214423	001	Jan 04, 2022	Jul DISC
	@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Jul DISC
	@	SUNNY	EQ 75MG BASE	A214423	001	Jan 04, 2022	Sep CAHN
	@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Sep CAHN
>A>	AB	UNIQUE	EQ 37.5MG BASE	A216044	001	Nov 28, 2022	Dec CAHN
>A>	AB		EQ 75MG BASE	A216044	002	Nov 28, 2022	Dec CAHN
>A>	AB		EQ 150MG BASE	A216044	003	Nov 28, 2022	Dec CAHN
>A>	AB		EQ 225MG BASE	A216044	004	Nov 28, 2022	Dec CAHN
	AB	ZYDUS PHARMS	EQ 37.5MG BASE	A215622	001	Aug 30, 2022	Aug NEWA
	AB		EQ 75MG BASE	A215622	002	Aug 30, 2022	Aug NEWA
	AB		EQ 150MG BASE	A215622	003	Aug 30, 2022	Aug NEWA
	AB		EQ 225MG BASE	A215622	004	Aug 30, 2022	Aug NEWA

VERAPAMIL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VERAPAMIL HYDROCHLORIDE

	@	RISING	100MG	A078306	001	Aug 09, 2007	Oct CAHN
	@		200MG	A078306	002	Aug 09, 2007	Oct CAHN
	@		300MG	A078306	003	Aug 09, 2007	Oct CAHN
		VERELAN					
AB	+	SOCIETAL CDMO	120MG	N019614	001	May 29, 1990	Jun CAHN
AB	+		180MG	N019614	003	Jan 09, 1992	Jun CAHN
AB	+		240MG	N019614	002	May 29, 1990	Jun CAHN
	+		360MG	N019614	004	May 10, 1996	Jun CAHN
		VERELAN PM					
	+	SOCIETAL CDMO	100MG	N020943	001	Nov 25, 1998	Jun CAHN
	+		200MG	N020943	002	Nov 25, 1998	Jun CAHN
	+		300MG	N020943	003	Nov 25, 1998	Jun CAHN

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

AP	ACIC PHARMS	2.5MG/ML	A215829	001	Mar 17, 2022	Mar NEWA
AP	MANKIND PHARMA	2.5MG/ML	A214653	001	Jun 15, 2022	Jun NEWA

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

	@	CHARTWELL RX	40MG	A073168	001	Jul 31, 1992	Mar CAHN
	@		80MG	A071423	001	May 24, 1988	Mar CAHN
	@		120MG	A071424	001	May 25, 1988	Mar CAHN

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

>D>	AA	ELITE LABS INC	500MG/PACKET	A214961	001	Jun 24, 2022	Dec CAHN
	AA		500MG/PACKET	A214961	001	Jun 24, 2022	Jun NEWA
	@	GRANULES	500MG/PACKET	A213469	001	Apr 24, 2020	Sep DISC
	@	LUPIN LTD	500MG/PACKET	A211790	001	Mar 10, 2022	Jul DISC
	AA		500MG/PACKET	A211790	001	Mar 10, 2022	Mar NEWA
	AA	MSN	500MG/PACKET	A215363	001	Sep 07, 2022	Aug NEWA
>A>	AA	PYROS PHARMS	500MG/PACKET	A214961	001	Jun 24, 2022	Dec CAHN

TABLET;ORAL

VIGABATRIN

AB	AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Jun NEWA
AB	AUROBINDO PHARMA LTD	500MG	A215601	001	May 10, 2022	Apr NEWA
AB	HIKMA	500MG	A213104	001	Aug 29, 2022	Aug NEWA
AB	ZYDUS	500MG	A215707	001	Jan 19, 2022	Jan NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

AB	INVAGEN PHARMS	20MG	A208200	003	Dec 06, 2022	Nov NEWA
AB	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	May CMFD
AB		20MG	A208212	002	Sep 30, 2019	May CMFD
AB		40MG	A208212	003	Sep 30, 2019	May CMFD

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

AP	!	JIANGSU HANSON PHARM	EQ 10MG BASE/ML	A091106	001	Sep 26, 2012	Apr CHRS
>D>	AP	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003	Dec DISC
>A>	@		EQ 10MG BASE/ML	A076028	001	Feb 03, 2003	Dec DISC

VORICONAZOLE

FOR SUSPENSION;ORAL

VORICONAZOLE

@ RISING

200MG/5ML

A202361 001 May 28, 2013 Aug CAHN

INJECTABLE;INTRAVENOUS

VORICONAZOLE

AP		HONG KONG	200MG/VIAL	A214516	001	May 09, 2022	Apr NEWA
AP		MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022	Jun CAHN
	@	MYLAN LABS LTD	200MG/VIAL	A210849	001	Oct 11, 2022	Oct DISC
AP			200MG/VIAL	A210849	001	Oct 11, 2022	Sep NEWA

VORINOSTAT

CAPSULE;ORAL

ZOLINZA

+! MSD SUB MERCK 100MG

N021991 001 Oct 06, 2006 Jun CAHN

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

+ TAKEDA PHARMS USA EQ 5MG BASE
 + EQ 10MG BASE
 +! EQ 20MG BASE

N204447 001 Sep 30, 2013 Mar CTEC
 N204447 002 Sep 30, 2013 Mar CTEC
 N204447 004 Sep 30, 2013 Mar CTEC

VORTIOXETINE HYDROBROMIDE

@ ZYDUS PHARMS EQ 5MG BASE
 @ EQ 10MG BASE
 @ EQ 20MG BASE

A211146 001 Sep 17, 2021 Mar DISC
 A211146 002 Sep 17, 2021 Mar DISC
 A211146 003 Sep 17, 2021 Mar DISC

VOXELOTOR

TABLET;ORAL

OXBRYTA

+ GLOBAL BLOOD THERAPS 300MG

N213137 002 Oct 14, 2022 Oct NEWA

VUTRISIRAN

SOLUTION;SUBCUTANEOUS

AMVUTTRA

+! ALNYLAM PHARMS INC 25MG/0.5ML (25MG/0.5ML)

N215515 001 Jun 13, 2022 Jun NEWA

ZAFIRLUKAST

TABLET;ORAL

ZAFIRLUKAST

AB		RISING PHARMS	10MG	A204928	001	Aug 25, 2022	Aug NEWA
AB			20MG	A204928	002	Aug 25, 2022	Aug NEWA

ZALEPLON

CAPSULE;ORAL

ZALEPLON

AB		CHARTWELL MOLECULAR	5MG	A077505	001	Jun 20, 2008	Mar CAHN
AB			10MG	A077505	002	Jun 20, 2008	Mar CAHN

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL
ZILEUTON

AB	ANNORA PHARMA	600MG	A215742	001	Oct 11, 2022	Sep NEWA
	@ TEVA PHARMS USA	600MG	A211043	001	May 03, 2022	Oct DISC
	ZINC SULFATE					
AB	TEVA PHARMS USA	600MG	A211043	001	May 03, 2022	Apr NEWA

ZINC CHLORIDE

INJECTABLE;INJECTION
ZINC CHLORIDE

>D>	@ EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Dec CMFD
>A> AP		EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Dec CMFD
	@	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb DISC
	ZINC CHLORIDE IN PLASTIC CONTAINER					
>D>	+! HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Dec CTEC
>A> AP	+!	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Dec CTEC
	+!	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Feb CTEC

ZINC SULFATE

SOLUTION;INTRAVENOUS
ZINC SULFATE

>D>	+! AM REGENT	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020	Dec CFTG
>A> AP	+!	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020	Dec CFTG
AP	+!	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019	Apr CFTG
AP	+!	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Apr CFTG
AP	GLAND PHARMA LTD	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216249	001	May 03, 2022	Apr NFTG
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216249	002	May 03, 2022	Apr NFTG

ZINC SULFATE MONOHYDRATE

SOLUTION;INTRAVENOUS
ZINC SULFATE

>A> AP	FRESENIUS KABI USA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216145	001	Dec 27, 2022	Dec NFTG
>A> AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216145	002	Dec 27, 2022	Dec NEWA
>A> AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216145	003	Dec 27, 2022	Dec NEWA

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL
GEODON

AB	+! VIATRIS	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jan CAHN
AB	+	EQ 40MG BASE	N020825	002	Feb 05, 2001	Jan CAHN
AB	+	EQ 60MG BASE	N020825	003	Feb 05, 2001	Jan CAHN
AB	+	EQ 80MG BASE	N020825	004	Feb 05, 2001	Jan CAHN

ZIPRASIDONE MESYLATE

INJECTABLE;INTRAMUSCULAR
GEODON

AP	+! VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CPOT
AP	+!	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jan CAHN
	ZIPRASIDONE MESYLATE					
AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CPOT
	POWDER;INTRAMUSCULAR					
	GEODON					
AP	+! VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CDFR
	ZIPRASIDONE MESYLATE					
AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CDFR
AP	MSN	EQ 20MG BASE/VIAL	A216091	001	Sep 15, 2022	Sep NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS
ZOLEDRONIC ACID

AP	AMNEAL	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May CAHN
	@ EUGIA PHARMA	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Jul DISC
	@	EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Jul DISC

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

>D>	ZOLPIMIST					
>D>	+! AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008	Dec DISC
>A>	+ @	5MG/SPRAY	N022196	001	Dec 19, 2008	Dec DISC

TABLET;ORAL							
ZOLPIDEM TARTRATE							
AB	CHARTWELL MOLECULAR	5MG	A077388	001	Jul 30, 2012	Mar	CAHN
AB		10MG	A077388	002	Jul 30, 2012	Mar	CAHN
<u>ZONISAMIDE</u>							
SUSPENSION;ORAL							
ZONISADE							
+!	AZURITY	100MG/5ML	N214273	001	Jul 15, 2022	Jul	NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

AUROBINDO PHARMA LTD 250MG; 250MG; 65MG

A211695 001 Feb 02, 2022 Jan NEWA

ADAPALENE

GEL; TOPICAL

ADAPALENE

TARO PHARMS 0.1%

A215940 001 Jan 14, 2022 Jan NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

GAVISCON

+ @ CHATTEM SANOFI 80MG; 20MG

N018685 001 Dec 09, 1983 May DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

BAJAJ 5MG/5ML

A091327 001 Oct 17, 2011 Jun CAHN

@ CHARTWELL RX 5MG/5ML

A090378 002 May 09, 2008 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BAJAJ 5MG/5ML

A091327 002 Oct 17, 2011 Jun CAHN

@ CHARTWELL RX 5MG/5ML

A090378 001 May 09, 2008 Mar CAHN

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

GLENMARK PHARMS INC 5MG

A078427 003 Dec 28, 2007 May CAHN

10MG

A078427 004 Dec 28, 2007 May CAHN

TABLET, CHEWABLE; ORAL

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 2.5MG

N021621 007 Nov 30, 2020 Jun CMFD

+ 10MG

N021621 004 Nov 16, 2007 Jun CMFD

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

@ L PERRIGO CO 1.34MG

A074512 001 Nov 22, 1995 Jul DISC

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

@ PERRIGO 5.2MG/SPRAY

A075427 001 Dec 12, 2001 Sep DISC

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AKORN 1%

A209484 001 Nov 21, 2018 Mar CMKT

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

AUROBINDO PHARMA 38MG; 200MG

A216204 001 May 31, 2022 May NEWA

DOCOSANOL

CREAM; TOPICAL

DOCOSANOL

@ ALEOR DERMACEUTICALS 10%

A215839 001 May 03, 2022 Dec CMFD

10%

A215839 001 May 03, 2022 Dec CMFD

@ 10%

A215839 001 May 03, 2022 Oct DISC

10%

A215839 001 May 03, 2022 Apr NEWA

ENCUBE 10%

A212385 001 Oct 07, 2022 Sep NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

GRAVITI PHARMS EQ 20MG BASE

A216349 001 Jun 24, 2022 Jun NEWA

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

+ @ DEXCEL EQ 20MG BASE

N214278 001 Oct 20, 2020 Jan DISC

>D>

>A>

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE

GLENMARK PHARMS INC	10MG	A077146	001	Mar 07, 2005	Jun CAHN
	20MG	A090837	001	Aug 04, 2010	May CAHN
VKT PHARMA	10MG	A215822	001	Jan 28, 2022	Jan NEWA
	20MG	A215822	002	Jan 28, 2022	Jan NEWA

TABLET, CHEWABLE; ORAL
FAMOTIDINE

@ PERRIGO	10MG	A075715	001	Aug 22, 2003	Oct DISC
-----------	------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

ALLEGRA HIVES

+! CHATTEM SANOFI	180MG	N020872	009	Jan 24, 2011	Oct CMFD
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
@ SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jun DISC
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
@ SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jun DISC
FEXOFENADINE HYDROCHLORIDE ALLERGY					
@ SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jun DISC
FEXOFENADINE HYDROCHLORIDE HIVES					
@ SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jun DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+! CHATTEM SANOFI	60MG; 120MG	N020786	002	Jan 24, 2011	Jan CAHN
+!	60MG; 120MG	N020786	002	Jan 24, 2011	Jan CAHN
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION					
+! CHATTEM SANOFI	180MG; 240MG	N021704	002	Jan 24, 2011	Jan CAHN
+!	180MG; 240MG	N021704	002	Jan 24, 2011	Jan CAHN
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
DR REDDYS	60MG; 120MG	A215434	001	May 31, 2022	May NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

DR REDDYS	600MG	A215932	001	Mar 15, 2022	Mar NEWA
	1.2GM	A215932	002	Mar 15, 2022	Mar NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

GRANULES	600MG; 60MG	A216082	001	Aug 22, 2022	Aug NEWA
	1.2GM; 120MG	A216082	002	Aug 22, 2022	Aug NEWA
L PERRIGO CO	600MG; 60MG	A214407	001	Feb 01, 2022	Jan NEWA
	1.2GM; 120MG	A214407	002	Feb 01, 2022	Jan NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Nov CMFD
----------------	---------------------------------------	---------	-----	--------------	----------

SUSPENSION/DROPS; ORAL

IBUPROFEN

@ STRIDES PHARMA	50MG/1.25ML	A214071	001	Jun 09, 2022	Nov DISC
	50MG/1.25ML	A214071	001	Jun 09, 2022	Jun NEWA

TABLET; ORAL

IBUPROFEN

@ PERRIGO	200MG	A075995	001	Mar 14, 2002	Oct DISC
JUNIOR STRENGTH IBUPROFEN					
@ L PERRIGO CO	100MG	A075367	001	Apr 22, 1999	Nov DISC
TAB-PROFEN					
@ PERRIGO	200MG	A072095	001	Dec 08, 1987	Nov DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ PERRIGO

100MG/5ML;15MG/5ML

A076478 001 Nov 05, 2003 Nov DISC

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

ZURAGARD

+! ZUREX PHARMA

70%

N210872 001 Apr 26, 2019 Jul CMFD

IVERMECTIN

LOTION;TOPICAL

IVERMECTIN

@ TEVA PHARMS USA

0.5%

A212485 001 Mar 21, 2022 Sep DISC

0.5%

A212485 001 Mar 21, 2022 Mar NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH

EQ 0.025% BASE

A208158 001 Sep 24, 2020 Mar CPOT

BAUSCH AND LOMB INC

EQ 0.025% BASE

A208158 001 Sep 24, 2020 Mar CAHN

CHILDREN'S ALAWAY

+ BAUSCH AND LOMB

EQ 0.025% BASE

N021996 002 Feb 11, 2015 Mar CPOT

+

EQ 0.035% BASE

N021996 002 Feb 11, 2015 Mar CTNA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

GLENMARK PHARMS INC

15MG

A202727 001 May 18, 2012 May CAHN

@ LANNETT CO INC

15MG

A207157 001 Sep 29, 2017 Nov DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI

2.5MG/5ML

N209090 001 Jan 31, 2017 Jan CAHN

TABLET;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI

5MG

N209089 001 Jan 31, 2017 Jan CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

@ L PERRIGO CO

0.75MG

A090740 001 Dec 30, 2010 May DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

@ AKORN

1MG/5ML

A074352 001 Nov 17, 1995 Jun DISC

PERRIGO

1MG/5ML

A073243 001 Jan 21, 1992 Dec DISC

@

1MG/5ML

A073243 001 Jan 21, 1992 Dec DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

GRANULES

2MG;125MG

A215981 001 Aug 29, 2022 Aug NEWA

TABLET, CHEWABLE;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ PERRIGO

2MG;125MG

A076029 001 Aug 30, 2002 Oct DISC

LORATADINE

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC

5MG

N021891 001 Aug 23, 2006 Apr CHRS

CLARITIN

+! BAYER HEALTHCARE LLC

10MG

N021891 002 Nov 21, 2018 Apr CHRS

>D>

>A>

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL
MICONAZOLE NITRATE

@ PERRIGO 100MG A074395 001 Mar 20, 1997 Nov DISC

MINOXIDIL

AEROSOL, FOAM;TOPICAL
MINOXIDIL

PERRIGO PHARMA INTL 5% A091344 001 Apr 28, 2011 Jan CAHN

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

@ AKORN 2% A074731 001 Dec 24, 1996 Aug DISC

MINOXIDIL (FOR WOMEN)

@ AKORN 2% A074731 002 May 11, 2005 Aug DISC

MINOXIDIL EXTRA STRENGTH (FOR MEN)

@ PERRIGO NEW YORK 5% A075737 001 Mar 15, 2002 Nov DISC

THEROXIDIL

PURE SOURCE 2% A078176 001 Nov 09, 2007 Jun CAHN

5% A076239 001 Aug 24, 2004 Jun CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL
NASONEX 24HR ALLERGY

+! PERRIGO PHARMA INTL 0.05MG/SPRAY N215712 001 Mar 17, 2022 Mar NEWA

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

>A>

PATHEON SOFTGELS EQ 200MG BASE A214463 001 Jan 10, 2023 Dec NEWA

STRIDES PHARMA EQ 200MG BASE A215472 001 Aug 17, 2022 Aug NEWA

TABLET;ORAL

NAPROXEN SODIUM

HETERO LABS LTD V 220MG A211065 001 Oct 28, 2022 Oct NEWA

YICHANG HUMANWELL 220MG A212033 001 Aug 30, 2019 Jul CMFD

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ @ BAYER 220MG;120MG N021076 001 Nov 29, 1999 Jan DISC

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ AUROBINDO PHARMA 220MG;120MG A211360 001 Jun 01, 2022 Nov DISC

220MG;120MG A211360 001 Jun 01, 2022 May NEWA

! PERRIGO 220MG;120MG A076518 001 Mar 17, 2004 Jan CHRS

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

>A>

FERTIN PHARMA EQ 4MG BASE A214354 001 Dec 21, 2022 Dec NEWA

@ L PERRIGO CO EQ 2MG BASE A076776 001 Sep 16, 2004 Nov DISC

@ EQ 4MG BASE A076778 001 Sep 16, 2004 Nov DISC

@ PERRIGO R AND D EQ 2MG BASE A078967 001 Apr 23, 2008 Nov DISC

@ EQ 4MG BASE A078968 001 Apr 23, 2008 Nov DISC

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

AUROBINDO PHARMA LTD EQ 2MG BASE A215357 001 May 13, 2022 May NEWA

EQ 4MG BASE A215357 002 May 13, 2022 May NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ BAUSCH AND LOMB INC EQ 0.1% BASE A206046 001 Jul 26, 2017 Jun CAHN

@ GLENMARK PHARMS INC EQ 0.1% BASE A200810 001 Jun 28, 2017 May CAHN

@ MYLAN EQ 0.2% BASE A204620 001 Jun 16, 2020 May DISC

@ RISING EQ 0.1% BASE A204392 001 Mar 21, 2018 Jul CAHN

@ EQ 0.2% BASE A204620 001 Jun 16, 2020 Jul CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
OMEPRAZOLE

+! DEXCEL 20MG N209400 001 Jul 05, 2017 Feb CHRS

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

L PERRIGO CO EQ 20MG BASE A216096 001 May 24, 2022 May NEWA

TABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

@ PERRIGO R AND D EQ 20MG BASE A204152 001 Jul 30, 2015 Nov DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

@ CHARTWELL RX 20MG;1.1GM A204137 001 Jul 15, 2016 Jul CAHN
ZEGERID OTC

+! RILEY CONSUMER 20MG;1.1GM N022281 001 Dec 01, 2009 Mar CAHN
FOR SUSPENSION;ORAL
ZEGERID OTC

+! RILEY CONSUMER 20MG/PACKET;1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

POTASSIUM IODIDE

SOLUTION;ORAL
POTASSIUM IODIDE

+ @ ROXANE 1GM/ML N018551 001 Feb 19, 1982 Jan CRLD

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE

! L PERRIGO CO 120MG A075153 001 Feb 26, 1999 Jun CHRS

SUDAFED 12 HOUR
@ MCNEIL CONS 120MG A073585 001 Oct 31, 1991 Jun DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

@ PERRIGO EQ 75MG BASE A076195 001 Aug 30, 2002 Sep DISC

@ PERRIGO R AND D EQ 150MG BASE A091429 001 May 11, 2011 Sep DISC

@ EQ 150MG BASE A091429 002 May 11, 2011 Sep DISC

THINQ PHARM-CRO PVT EQ 75MG BASE A210250 001 Aug 30, 2019 Jul CAHN

EQ 150MG BASE A210228 001 Aug 30, 2019 Jul CAHN

ZANTAC 150

+ @ CHATTEM SANOFI EQ 150MG BASE N021698 001 Aug 31, 2004 Jan CAHN

+ @ EQ 150MG BASE N021698 002 Mar 13, 2007 Jan CAHN

ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE N020520 001 Dec 19, 1995 Jan CAHN

TABLET, EFFERVESCENT;ORAL
ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE N020745 001 Feb 26, 1998 Jan CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL
NASACORT ALLERGY 24 HOUR

+! CHATTEM SANOFI 0.055MG/SPRAY N020468 002 Oct 11, 2013 Jan CAHN

+! 0.055MG/SPRAY N020468 002 Oct 11, 2013 Jan CAHN

TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL 0.055MG/SPRAY A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2022

NO DECEMBER 2022 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2022 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD</u>						
N 215413 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11255842	Jan 10, 2040	U-3322			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	10239883	Jul 11, 2032	U-2666		NCE	Oct 31, 2022
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001 >A>	10689377	May 17, 2037	DS DP U-3490			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	11395889	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	11266796	Feb 22, 2041	DP			
	11344685	Sep 26, 2039	DP			
	11351317	Feb 10, 2038	DP			
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	11433076	Apr 24, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	8357713	Dec 22, 2029	DP U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	8357713	Dec 22, 2029	DP U-2104			
<u>ALPELISIB - VIJOICE</u>						
N 215039 001	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - VIJOICE</u>						
N 215039 002	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - VIJOICE</u>						
N 215039 003	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11197835	Dec 02, 2030	U-2106			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11197835	Dec 02, 2030	U-2106			
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	10626088	Feb 25, 2037	DP		NPP	Sep 29, 2025
	10793893	May 26, 2034	U-2956		ODE-223	Nov 28, 2025
	11268128	Jun 29, 2032	U-2956			
	11274331	Jun 29, 2032	U-2956			
	11274332	Jun 29, 2032	U-2956			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	11446318	May 15, 2035	U-2414			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11235169	Oct 15, 2040	U-3303			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	11357753	Feb 09, 2038	U-2754			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	11357753	Feb 09, 2038	U-2754			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11364230	Oct 06, 2037	DP			
	11471409	Oct 06, 2037	U-3447			
	11471409	Oct 06, 2037	U-3448			
	11484498	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIQVA</u>						
N 214439 001	11253474	Feb 24, 2041	DP U-3309			
	11253474	Feb 24, 2041	DP U-3310			
	11253474	Feb 24, 2041	DP U-3311			
	11458095	Feb 24, 2041	DP U-3309			
	11458095	Feb 24, 2041	DP U-3310			
	11458095	Feb 24, 2041	DP U-3311			
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
<u>AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK</u>						
N 215153 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
<u>AMPHOTERICIN B - AMPHOTERICIN B</u>						
A 212514 001					CGT	Aug 14, 2022
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - APOMORPHINE HYDROCHLORIDE</u>						
A 212025 001					CGT	Aug 24, 2022
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	11419769	Dec 16, 2031	DP U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	11419769	Dec 16, 2031	DP U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	11419769	Dec 16, 2031	DP U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	11419769	Dec 16, 2031	DP U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	11419769	Dec 16, 2031	DP U-2825			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREPITANT - APONVIE</u>						
N 216457 001	10500208	Sep 18, 2035	DP			
	10624850	Sep 18, 2035	U-3440			
	10953018	Sep 18, 2035	U-3440			
	11173118	Sep 18, 2035	DP			
	9561229	Sep 18, 2035	DP U-3440			
	9808465	Sep 18, 2035	U-3440			
	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			
	9974794	Sep 18, 2035	DP U-3440			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
<u>ARIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	11273158	Apr 06, 2039	U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	11407735	May 14, 2040	DS		ODE-381	Oct 29, 2028
	8829195	May 13, 2033	DS	U-1374	ODE-382	Oct 29, 2028
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	11407735	May 14, 2040	DS		ODE-381	Oct 29, 2028
	8829195	May 13, 2033	DS	U-1374	ODE-382	Oct 29, 2028
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUVU</u>						
N 209381 001	>A> 11529368	Mar 09, 2032	DP	U-2310		
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 216120 001					CGT	Jan 29, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 216120 002					CGT	Jan 29, 2023
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001					ODE-377	Oct 07, 2028
<u>AVANAFIL - STENDRA</u>						
N 202276 001					M-282	Oct 18, 2025
<u>AVANAFIL - STENDRA</u>						
N 202276 002					M-282	Oct 18, 2025
<u>AVANAFIL - STENDRA</u>						
N 202276 003					M-282	Oct 18, 2025
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Jan 12, 2037	U-3044			
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Jan 12, 2037	U-3044			
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					I-889	May 20, 2025
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	>A> 11491125	Sep 29, 2041	DP U-3488			
	>A> 11491125	Sep 29, 2041	DP U-3489			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	>A> 11491125	Sep 29, 2041	DP U-3488			
	>A> 11491125	Sep 29, 2041	DP U-3489			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	>A> 11491125	Sep 29, 2041	DP U-3488			
	>A> 11491125	Sep 29, 2041	DP U-3489			
<u>BACLOFEN - FLEQSUVY</u>						
N 215602 001	11324696	Sep 29, 2037	DP			
	11446246	Sep 08, 2037	U-3433			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		I-891	May 10, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	>A> 9737469	Mar 29, 2033	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		I-891	May 10, 2025
	>A> 9737469	Mar 29, 2033	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	8158616	Jun 08, 2030	DS DP		I-891	May 10, 2025
	9089574	Nov 30, 2032	U-3372		NCE	May 31, 2023
	>A> 9737469	Mar 29, 2033	U-3500			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	11395889	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	11395889	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921 001	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921 002	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001	11311541	Apr 09, 2035	U-3369			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
A 205574 001					>A> PC	Jun 05, 2023
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
A 205574 002					>A> PC	Jun 05, 2023
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001					ODE*	Dec 07, 2022
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002					ODE*	Dec 07, 2022
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003					ODE*	Dec 07, 2022
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004					ODE*	Dec 07, 2022
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001					ODE*	Dec 07, 2022
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	10933046	Feb 19, 2040	DP U-3357		NP	Apr 22, 2025
	10945987	Feb 19, 2040	U-3356			
	11426378	Aug 18, 2040	U-3356			
	9687465	Nov 27, 2032	DP U-3356			
	9868103	Aug 08, 2028	DP U-3356			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 212433 001					CGT	Mar 13, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	11230530	Mar 09, 2035	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11230530	Mar 09, 2035	U-3300			
<u>BETAINE - BETAINE</u>						
A 214864 001					CGT	Aug 02, 2022
<u>BEXAROTENE - BEXAROTENE</u>						
A 215398 001					CGT	Nov 13, 2022
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002					NCE ODE-378	Feb 07, 2023 Oct 07, 2028
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001					NPP	Jun 16, 2025
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 001	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 002	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 005	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 006	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Apr 28, 2031	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Apr 28, 2031	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Apr 28, 2031	DS			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					NP	Dec 15, 2024
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	11331442	May 10, 2038	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
	11426348	Jan 22, 2041	DP U-3380			
	11452691	Jan 22, 2041	DP U-3439			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
	11426348	Jan 22, 2041	DP U-3380			
	11452691	Jan 22, 2041	DP U-3439			
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	11400019	Jan 12, 2041	DP			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	11433066	Sep 18, 2032	U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	11433066	Sep 18, 2032	U-3131			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	11433066	Sep 18, 2032	U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	11433066	Sep 18, 2032	U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	11433066	Sep 18, 2032	U-3131			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	10058518	Nov 05, 2034	U-3419		NP	Aug 18, 2025
	10064857	Nov 05, 2034	U-3419			
	10080727	Nov 05, 2034	U-3419			
	10092560	Nov 05, 2034	U-3419			
	10092561	Nov 05, 2034	U-3419			
	10105327	Nov 05, 2034	U-3419			
	10105361	Nov 05, 2034	U-3419			
	10251879	Nov 05, 2034	U-3419			
	10463634	Nov 05, 2034	U-3419			
	10512643	Nov 05, 2034	U-3419			
	10548857	Nov 05, 2034	U-3419			
	10596167	Nov 05, 2034	U-3419			
	10772850	Nov 05, 2034	U-3419			
	10780064	Jan 07, 2040	U-3419			
	10780066	Nov 09, 2034	U-3419			
	10786469	Nov 05, 2034	U-3419			
	10786496	Nov 05, 2034	U-3419			
	10799497	Nov 05, 2034	U-3419			
	10806710	Nov 05, 2034	U-3419			
	10864209	Nov 05, 2034	U-3419			
	10874663	Nov 05, 2034	U-3419			
	10874664	Nov 05, 2034	U-3419			
	10874665	Nov 05, 2034	U-3419			
	10881624	Nov 05, 2034	U-3419			
	10881657	Nov 05, 2034	U-3419			
	10894046	Nov 05, 2034	U-3419			
	10894047	Nov 05, 2034	U-3419			
	10898453	Nov 05, 2034	U-3419			
	10925842	Jan 07, 2040	U-3419			
	10933034	Nov 05, 2034	U-3419			
	10940124	Jan 07, 2040	U-3419			
	10945973	Nov 05, 2034	U-3419			
	10966941	Nov 05, 2034	U-3419			
	10966942	Jan 07, 2040	U-3419			
	10966974	Nov 05, 2034	U-3419			
	11020389	Nov 05, 2034	U-3419			
	11058648	Nov 05, 2034	U-3419			
	11090300	Nov 05, 2034	U-3419			
	11096937	Nov 05, 2034	U-3419			
	11123343	Nov 05, 2034	U-3419			
	11129826	Nov 05, 2034	U-3419			
	11141388	Nov 05, 2034	U-3419			
	11141416	Nov 05, 2034	U-3419			
	11147808	Nov 05, 2034	U-3419			
	11185515	Nov 05, 2034	U-3419			
	11191739	Nov 05, 2034	DP U-3419			
	11197839	Nov 05, 2034	DP U-3419			
	11207281	Nov 05, 2034	U-3419			
	11213521	Nov 05, 2034	U-3419			
	11229640	Nov 05, 2034	U-3419			
	11234946	Nov 05, 2034	U-3419			
	11253491	Nov 05, 2034	U-3419			
	11253492	Nov 05, 2034	U-3419			
	11273133	Nov 05, 2034	U-3419			
	11273134	Nov 05, 2034	U-3419			
	11285118	Nov 05, 2034	U-3419			
	11285146	Nov 05, 2034	U-3419			
	11291638	Nov 05, 2034	U-3419			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11291665	Nov 05, 2034	U-3419			
	11298351	Nov 05, 2034	U-3419			
	11298352	Nov 05, 2034	U-3419			
	11311534	Nov 05, 2034	U-3419			
	11344544	Nov 05, 2034	U-3419			
	11357744	Nov 05, 2034	U-3419			
	11364233	Nov 05, 2034	U-3419			
	11382874	Nov 05, 2034	U-3419			
	11419867	Nov 05, 2034	U-3419			
	11426370	Nov 05, 2034	U-3419			
	11426401	Nov 05, 2034	U-3419			
	11433067	Nov 05, 2034	DP U-3419			
	11439636	Nov 05, 2034	U-3419			
	11478468	Nov 05, 2034	U-3419			
	11497721	Nov 05, 2034	U-3419			
	11510918	Nov 05, 2034	U-3419			
>A>	11517542	Nov 05, 2034	U-3419			
>A>	11517543	Nov 05, 2034	U-3419			
>A>	11524007	Nov 05, 2034	U-3419			
>A>	11524008	Nov 05, 2034	U-3419			
	8569328	Oct 29, 2033	DP U-3419			
	9168234	Nov 05, 2034	U-3419			
	9198905	Nov 05, 2034	U-3419			
	9205083	Nov 05, 2034	U-3419			
	9238032	Nov 05, 2034	U-3419			
	9278095	Nov 05, 2034	U-3419			
	9314462	Nov 05, 2034	U-3419			
	9370513	Nov 05, 2034	U-3419			
	9375429	Nov 05, 2034	U-3419			
	9408815	Nov 05, 2034	U-3419			
	9421176	Nov 05, 2034	U-3419			
	9457023	Nov 05, 2034	U-3419			
	9457025	Nov 05, 2034	U-3419			
	9474731	Nov 05, 2034	U-3419			
	9486450	Nov 05, 2034	U-3419			
	9700528	Nov 05, 2034	U-3419			
	9700553	Nov 05, 2034	U-3419			
	9707191	Nov 05, 2034	U-3419			
	9763932	Nov 05, 2034	U-3419			
	9861595	Nov 05, 2034	U-3419			
	9867819	Nov 05, 2034	U-3419			
	9968568	Nov 05, 2034	U-3419			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	11278544	Apr 21, 2024	U-1583			
	11324741	May 29, 2029	U-1583			
<u>CABOTEGRAVIR - APRETEUDE</u>						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	8410103	Apr 28, 2026	DS DP U-3061		M-273	Jan 31, 2025
	8410103	Apr 28, 2026	DS DP U-3348		NPP	Mar 29, 2025
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11298349	Feb 10, 2032	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11253528	Mar 14, 2034	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE</u>						
A 213071 001					CGT	May 05, 2023
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10213400	Mar 15, 2033	U-2499			
	10213400*PED	Sep 15, 2033				
	10864181	Mar 15, 2033	U-3017			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
	11426373	Sep 19, 2037	U-3432			
	8731963	Dec 17, 2022	U-1110			
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306	Mar 15, 2033	U-3198			
	8772306*PED	Sep 15, 2033				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
	11357741	Jun 17, 2035	U-2862			
	11400055	Oct 13, 2035	U-3071			
	11406623	Mar 01, 2041	U-3233			
	11446258	Jun 17, 2035	U-2780			
	11446258	Jun 17, 2035	U-2781			
	11446258	Jun 17, 2035	U-3071			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
	11357741	Jun 17, 2035	U-2862			
	11400055	Oct 13, 2035	U-3071			
	11406623	Mar 01, 2041	U-3233			
	11446258	Jun 17, 2035	U-2780			
	11446258	Jun 17, 2035	U-2781			
	11446258	Jun 17, 2035	U-3071			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11033521	Mar 28, 2039	DP U-219			
	11033521	Mar 28, 2039	DP U-3304			
	11033521	Mar 28, 2039	DP U-3305			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	RE47954	Oct 21, 2029	U-3449			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	RE47954	Oct 21, 2029	U-3449			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	RE47954	Oct 21, 2029	U-3449			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	RE48960	Jun 28, 2025	DS DP U-3087			
	RE48960	Jun 28, 2025	DS DP U-3088			
<u>CEFAZOLIN SODIUM - CEFZOLIN AND DEXTROSE</u>						
N 050779 001					NPP	Nov 23, 2023
<u>CEFAZOLIN SODIUM - CEFZOLIN AND DEXTROSE</u>						
N 050779 002					NPP	Nov 23, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE</u>						
N 050779 003					NPP	Nov 23, 2023
<u>CEFIDEROCOL SULFATE TOSYLATE - FETROJA</u>						
N 209445 001	9238657	Nov 14, 2033	DS DP U-282			
	9238657	Nov 14, 2033	DS DP U-3470			
	9238657	Nov 14, 2033	DS DP U-3471			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10420841	Mar 14, 2034		U-1672	NPP	Apr 21, 2025
	10420841	Mar 14, 2034		U-2631		
	10420841	Mar 14, 2034		U-3360		
	10420841	Mar 14, 2034		U-3361		
	11278622	Mar 14, 2034		U-3335		
	11278622	Mar 14, 2034		U-3336		
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			
	8968753	Mar 14, 2034		U-1672		
	8968753	Mar 14, 2034		U-1673		
	8968753	Mar 14, 2034		U-3360		
	8968753	Mar 14, 2034		U-3361		
<u>CELECOXIB; TRAMADOL HYDROCHLORIDE - SEGLENTIS</u>						
N 213426 001	11478488	Apr 19, 2030		U-3244		
<u>CETRORELIX ACETATE - CETRORELIX ACETATE</u>						
A 215737 001					CGT	Apr 22, 2023
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001	10792271	Sep 15, 2038	DP U-3457			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	11246863	Nov 27, 2038	DP			
	11369566	Apr 21, 2029	DP			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	11337989	Mar 15, 2033		U-1		
	11439610	Mar 15, 2033	DS DP			
	6706276	Mar 06, 2023	DP			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	10849919	Nov 23, 2038		U-3411		
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11207332	Nov 20, 2028	DP U-3280			
	8865690	Jul 24, 2023		U-2942		
	9211295	Jul 24, 2023	DP			
	9433628	Feb 28, 2029	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE</u>						
A 214668 001					CGT	Feb 01, 2023
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	11129896	Sep 22, 2036		U-3293	NP GAIN	Dec 07, 2024 Dec 07, 2029
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - CLINDAMYCIN PHOSPHATE AND TRETINOIN</u>						
A 212845 001					CGT	Oct 09, 2022
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	>A> 11541002	Sep 05, 2039	DP U-724			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002 >A>	11541002	Sep 05, 2039	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003 >A>	11541002	Sep 05, 2039	DP U-724			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10478400	Jun 29, 2036	DS DP U-1776		>A> I-902	Oct 28, 2025
	10478400*PED	Dec 29, 2036			M-278	Jul 28, 2025
	10590102	Jun 30, 2036	DS DP U-1776		PED	Jan 28, 2026
	10590102*PED	Dec 30, 2036				
	11087354	Jun 22, 2034	U-1776			
	11087354*PED	Dec 22, 2034				
	11254649	Jun 30, 2036	DS DP U-1776			
	11254649*PED	Dec 30, 2036				
	7803839	Nov 10, 2029	DS DP			
	7803839*PED	May 10, 2030				
	8362002	Oct 05, 2026	U-1776			
	8362002*PED	Apr 05, 2027				
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 003	10993952	Feb 15, 2036	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11510941	Jan 15, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-894	Jun 22, 2025
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-894	Jun 22, 2025
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	7758890	Jun 30, 2025	DP			
	8604072	Jul 20, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005					M-238	Feb 22, 2022
<u>DAPSONE - ACZONE</u>						
N 207154 001	11273132	Nov 18, 2033	DP			
<u>DAPTOMYCIN - DAPZURA RT</u>						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11168058	Feb 27, 2038	DS DP		I-900	Aug 05, 2025
<u>DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8501238	Dec 19, 2028	DS DP U-1636			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	11357731	Oct 25, 2038	U-3083			
	11458103	Oct 25, 2038	DP			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11236328	Jun 22, 2032	U-3301			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Jun 19, 2031	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7728143	Jun 19, 2031	DS			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	11419914	Jun 15, 2030	U-3431			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	11419914	Jun 15, 2030	U-3431			
<u>DEUCRAVACITINIB - SOTYKTU</u>						
N 214958 001	10000480	Nov 07, 2033	DS DP		NCE	Sep 09, 2027
	11021475	Nov 07, 2033	U-3434			
	RE47929	Nov 07, 2033	DS DP U-3434			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
<u>DEXAMETHASONE - DEXAMETHASONE</u>						
A 216295 001					CGT	Mar 08, 2023
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	11458041	Nov 16, 2037	U-1680			
	11458041	Nov 16, 2037	U-3455			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	11097061	Jun 23, 2039	DP U-3418			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	11304961	Dec 18, 2037	DP U-3344			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
	11478422	Jun 26, 2039	DP			
	11497711	Jun 26, 2039	DP			
	11517524	Jun 26, 2039	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
	11478422	Jun 26, 2039	DP			
	11497711	Jun 26, 2039	DP			
	11517524	Jun 26, 2039	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	11241414	Mar 27, 2029	DP			
<u>DICLOFENAC EPOLAMINE - LICART</u>						
N 206976 001	11344520	Feb 20, 2035		U-3393		
	11351133	Feb 20, 2035		U-3393		
<u>DICLOXACILLIN SODIUM - DICLOXACILLIN SODIUM</u>						
A 216845 001					CGT	Mar 29, 2023
<u>DICLOXACILLIN SODIUM - DICLOXACILLIN SODIUM</u>						
A 216845 002					CGT	Mar 29, 2023
<u>DIGOXIN - DIGOXIN</u>						
A 214982 001					CGT	Aug 16, 2022
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</u>						
N 213436 001	11266799	Nov 05, 2036	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	11246850	Nov 16, 2035		U-1384		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	11246850	Nov 16, 2035		U-1384		
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	11234985	Jan 24, 2031	DP U-257			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	10016372	Jul 26, 2037		U-3334	NP	Mar 11, 2025
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ADLARTY</u>						
N 212304 002	10016372	Jul 26, 2037	U-3334		NP	Mar 11, 2025
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2630			
	8486975	Oct 07, 2031	DS DP U-3308			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2629			
	8486975	Oct 07, 2031	DS DP U-3307			
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 213796 001					CGT	Oct 29, 2022
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	11234954	Jan 18, 2028	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	11234954	Jan 18, 2028	U-620			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	11253472	Aug 06, 2028	DS DP			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	11439598	Jun 28, 2031	DP			
	11478487	Jun 28, 2031	DP			
>A>	11504334	Jun 28, 2031	DP			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	10179140	Jun 28, 2031	U-2553		NP	Jun 29, 2025
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			
	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	11439598	Jun 28, 2031	DP			
	11478487	Jun 28, 2031	DP			
>A>	11504334	Jun 28, 2031	DP			
	9603860	Jun 28, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	11202772	Apr 13, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	11202772	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	11312718	Jan 10, 2032	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	11312718	Jan 10, 2032	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	10987341	Nov 01, 2039	DP		NP	May 12, 2025
	11241416	Nov 01, 2039	DP			
	11478450	Nov 01, 2039	U-3468			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11213519	Jan 03, 2028	U-2720			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11344551	Mar 14, 2034	U-3388			
	11344551	Mar 14, 2034	U-3389			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11459305	Nov 07, 2028	DP U-2842			
<u>ELBASVIR; GRAZOPREVR - ZEPATIER</u>						
N 208261 001					NPP	Dec 09, 2024
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11426407	Oct 06, 2035	DS DP U-3425			
	11453655	Dec 08, 2037	DS DP			
>A>	11517564	Dec 08, 2037	DP U-3498			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11426407	Oct 06, 2035	DS DP U-3425			
	11453655	Dec 08, 2037	DS DP			
>A>	11517564	Dec 08, 2037	DP U-3498			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	11458119	Nov 24, 2030	DS DP			
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
	11484527	Mar 14, 2033	U-3475			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	9949997	May 17, 2034	U-2292		M-82	Feb 24, 2025
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065*PED	Feb 15, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	9296769	Aug 15, 2032	DS DP U-1663			
	9296769*PED	Feb 15, 2033				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	11173141	Mar 25, 2036	DP			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	9474754	Aug 05, 2033	U-2802			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	11253515	Jul 18, 2038	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	11253515	Jul 18, 2038	DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11241400	May 16, 2040	U-3183			
	11464752	May 16, 2040	DP			
	11478436	May 16, 2040	U-3183			
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	10869845	Jan 22, 2040	DP			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	>A> 10004700	Aug 14, 2034	DP U-2325	Y		
	>A> 10039728	Aug 14, 2034	U-1828	Y		
	9283197	Aug 15, 2034	DP U-1828	Y		
	9283197	Aug 15, 2034	DP U-1829	Y		
	9283197	Aug 15, 2034	DP U-1830	Y		
<u>EPINEPHRINE - SYMJEPPI</u>						
N 207534 001	11141540	Oct 20, 2036	DP U-3379			
<u>EPINEPHRINE - SYMJEPPI</u>						
N 207534 002	11141540	Oct 20, 2036	DP U-3379			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	10961190	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	10961190	Oct 19, 2037	DS			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS		M-280	Sep 13, 2025
	6214865*PED	Jan 20, 2024			PED	Mar 13, 2026
	RE46965	Jan 08, 2027	DP			
	RE46965*PED	Jul 08, 2027				
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002					M-275	Sep 17, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806	003				M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806	004				M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805	001				M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805	002				M-275	Sep 17, 2024
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243	001	11311500	Sep 10, 2035	U-3034		
		11311500	Sep 10, 2035	U-3035		
		11311500	Sep 10, 2035	U-3036		
		11446260	Mar 14, 2034	U-3444		
		11446260	Mar 14, 2034	U-3445		
		11446260	Mar 14, 2034	U-3446		
		8785500	Mar 05, 2033	U-2502		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	001	11364247	May 06, 2025	U-2501		
		11364247	May 06, 2025	U-2831		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	002	11364247	May 06, 2025	U-2501		
		11364247	May 06, 2025	U-2831		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	003	11364247	May 06, 2025	U-2501		
		11364247	May 06, 2025	U-2831		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	004	11364247	May 06, 2025	U-2501		
		11364247	May 06, 2025	U-2831		
<u>ESTRADIOL - ESTRADIOL</u>						
A 211783	001				CGT	Apr 08, 2023
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	001	11241445	Nov 21, 2032	U-2316		
		11241445	Nov 21, 2032	U-2317		
		11246875	Nov 21, 2032	U-2316		
		11246875	Nov 21, 2032	U-2317		
		11266661	Feb 02, 2034	U-2316		
		11266661	Feb 02, 2034	U-2317		
		11304959	Nov 21, 2032	DP		
		11351182	Nov 21, 2032	U-2316		
		11351182	Nov 21, 2032	U-2317		
		11497709	Nov 21, 2032	U-2316		
		11497709	Nov 21, 2032	U-2317		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	002	11241445	Nov 21, 2032	U-2316		
		11241445	Nov 21, 2032	U-2317		
		11246875	Nov 21, 2032	U-2316		
		11246875	Nov 21, 2032	U-2317		
		11266661	Feb 02, 2034	U-2316		
		11266661	Feb 02, 2034	U-2317		
		11304959	Nov 21, 2032	DP		
		11351182	Nov 21, 2032	U-2316		
		11351182	Nov 21, 2032	U-2317		
		11497709	Nov 21, 2032	U-2316		
		11497709	Nov 21, 2032	U-2317		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
	11497709	Nov 21, 2032	U-2316			
	11497709	Nov 21, 2032	U-2317			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	8058280	Jan 28, 2024	DS		I-898	Aug 05, 2025
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001 >A>	11529360	Nov 21, 2032	DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001 >A>	11529308	Jun 21, 2039	DP			
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001	11400092	Sep 24, 2039	U-3409			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001 >A>	10452815	Jun 29, 2038	U-2859	Y	I-887	Mar 25, 2025
	>A> 10452815*PED	Dec 29, 2038			NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860		ODE-312	Jun 25, 2027
	10478441*PED	Nov 03, 2033			PED	Dec 25, 2023
	10478442	May 03, 2033	U-2860		PED	Sep 25, 2025
	10478442*PED	Nov 03, 2033			PED	Dec 25, 2027
	10603290	Aug 02, 2037	U-2861			
	10603290	Aug 02, 2037	U-3347			
	10603290*PED	Feb 02, 2038				
	10947183	Dec 20, 2036	DS DP			
	10947183*PED	Jun 20, 2037				
	11040018	Aug 02, 2037	U-2861			
	11040018	Aug 02, 2037	U-3347			
	11040018*PED	Feb 02, 2038				
	11406606	Aug 02, 2037	U-3406			
	11406606	Aug 02, 2037	U-3407			
	11406606*PED	Feb 02, 2038				
	9549909	May 03, 2033	U-2858			
	9549909*PED	Nov 03, 2033				
	9603814	May 03, 2033	U-2858			
	9603814*PED	Nov 03, 2033				
	9603815	May 03, 2033	U-2858			
	9603815*PED	Nov 03, 2033				
	9610260	May 03, 2033	U-2858			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	9610260*PED	Nov 03, 2033				
<u>FENOPROFEN CALCIUM - FENOPROFEN CALCIUM</u>						
A 214475 001					CGT	Feb 11, 2023
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	11234938	Nov 26, 2034	DP			
	11234938*PED	May 26, 2035				
	11446252	Nov 26, 2034	DP			
	11446252*PED	May 26, 2035				
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	9993483	Jul 02, 2030	DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 001					M-279	Sep 01, 2025
<u>FINERENONE - KERENDIA</u>						
N 215341 002					M-279	Sep 01, 2025
<u>FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE</u>						
A 207971 001					PC	Mar 20, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE</u>						
A 207985	001				PC	Mar 20, 2023
<u>FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE</u>						
A 207991	001				PC	Mar 20, 2023
<u>FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE</u>						
A 208008	001				PC	Mar 20, 2023
<u>FINGOLIMOD LAURYL SULFATE - TASCENSO ODT</u>						
N 214962	002	>A> 10555902	Jan 19, 2036	U-3493		
		>A> 10925829	Jan 19, 2036	DP		
		>A> 9925138	Jan 19, 2036	DP		
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	001				NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	002				NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	003				NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	004				NPP	Mar 22, 2025
<u>FLIBANSERIN - ADDYI</u>						
N 022526	001	7151103	May 09, 2028	U-1734		
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123	003	8932557	May 19, 2029	DS		
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123	004	8932557	May 19, 2029	DS		
<u>FLUOCINOLONE ACETONIDE - YUTIQ</u>						
N 210331	001	7998108	Jan 12, 2028	DP U-3410		
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798	004	11173259	Jul 06, 2040	DP		
		11173259*PED	Jan 06, 2041			
		11266796	Feb 22, 2041	DP		
		11266796*PED	Aug 22, 2041			
		11344685	Sep 26, 2039	DP		
		11344685*PED	Mar 26, 2040			
		11351317	Feb 10, 2038	DP		
		11351317*PED	Aug 10, 2038			
		11357935	Sep 24, 2038	DP		
		11439777	May 24, 2040	DP		
		11464923	Jun 19, 2040	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798	005	11173259	Jul 06, 2040	DP		
		11173259*PED	Jan 06, 2041			
		11266796	Feb 22, 2041	DP		
		11266796*PED	Aug 22, 2041			
		11344685	Sep 26, 2039	DP		
		11344685*PED	Mar 26, 2040			
		11351317	Feb 10, 2038	DP		
		11351317*PED	Aug 10, 2038			
		11357935	Sep 24, 2038	DP		
		11439777	May 24, 2040	DP		
		11464923	Jun 19, 2040	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Nov 08, 2030	DP			
	8714149*PED	May 08, 2031				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001					D-186	May 02, 2025
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-186	May 02, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11312698	May 23, 2032	DS DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11312698	May 23, 2032	DS DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	RE48898	Jan 19, 2026	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	RE48898	Jan 19, 2026	DP			
<u>FUROSEMIDE - FUROSCIX</u>						
N 209988 001	10272064	Apr 03, 2034	DP			
	11433044	Apr 03, 2034	U-3462			
	9884039	Apr 03, 2034	U-3462			
<u>FUTIBATINIB - LYTGobi</u>						
N 214801 001	10434103	Mar 31, 2036	DS DP		NCE	Sep 30, 2027
	9108973	Feb 23, 2033	DS DP U-3456			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GALLIUM GA-68 DOTATOC - GALLIUM GA 68 DOTATOC</u>						
N 210828 001					ODE-383 W	Aug 21, 2026 Aug 21, 2026
<u>GALLIUM GA-68 GOZETOTIDE - ILLUCCIX</u>						
N 214032 001	11027031	Jul 28, 2035		U-3317		
<u>GALLIUM GA-68 GOZETOTIDE - LOCAMETZ</u>						
N 215841 001	11369590	Aug 15, 2028	DS DP	U-3400	NP	Mar 23, 2025
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	10603308	Aug 10, 2037		U-3374	NCE	Jun 01, 2027
	7858609	Nov 28, 2026	DP			
	8022054	Nov 28, 2026	DP			
	8318714	Nov 28, 2026	DP			
	8367651	Nov 28, 2026	DP			
	8618087	Nov 28, 2026		U-3374		
	9029355	Nov 28, 2026	DP			
	9056116	Nov 28, 2026		U-3374		
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	11028392	Oct 03, 2034	DS DP	U-2672		
>A>	11530408	May 18, 2024	DS DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	11246866	Jun 24, 2036		DP		
	11246866*PED	Dec 24, 2036				
	11484534	Mar 14, 2034		U-3237		
	11484534*PED	Sep 14, 2034				
	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	11278683	Aug 16, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001					NPP	Aug 18, 2024
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	11235168	Jan 04, 2038	U-2250			
	11311620	Dec 19, 2036	U-2250			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE</u>						
A 215586 001					CGT	Oct 09, 2022
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	11304962	May 02, 2036	U-2236			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1745			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS DP			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS DP			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2150			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8497277	Dec 28, 2026	U-1947			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031		U-1491		
	8999999	Jun 03, 2031		U-1946		
	8999999	Jun 03, 2031		U-2241		
	8999999	Jun 03, 2031		U-2242		
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031		U-1650		
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034		U-2969		
	9795604	Oct 24, 2034		U-2970		
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031		U-1491		
	9801881	Jun 03, 2031		U-2242		
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031		U-2159		
	9801883	Jun 03, 2031		U-2243		
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031		U-1947		
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10106548	Jun 03, 2033	DS DP		NP	Aug 24, 2025
	10125140	Jun 03, 2033	DS DP		PED	Feb 24, 2026
	10478439	Jun 03, 2031		U-3422		
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8497277	Dec 28, 2026		U-3422		
	8697711	Dec 28, 2026	DS DP			
	8735403	Dec 28, 2026	DS DP			
	8754091	Dec 28, 2026	DP			
	8957079	Dec 28, 2026	DS DP			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034		U-3422		
<u>ICOSAPENT ETHYL - ICOSAPENT ETHYL</u>						
A 209525 001					PC	Mar 08, 2023
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	11213504	Apr 29, 2030		U-3292		
	11298333	Jun 28, 2033		U-3358		
	11369582	Jun 28, 2033		U-2841		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	11213504	Apr 29, 2030		U-3292		
	11298333	Jun 28, 2033		U-3358		
	11369582	Jun 28, 2033		U-2841		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11202752	Apr 30, 2030		U-1455		
	11202752	Apr 30, 2030		U-172		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002	11318130	Dec 11, 2029		U-68		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			
	10273477	Mar 08, 2024	DS			
	10590418	Jul 19, 2022	U-3272			
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-3272			
	11078485	Nov 04, 2023	DS U-3272			
	8106022	Dec 12, 2029	DS DP U-3272			
	8222222	Dec 29, 2027	U-3272			
	8232383	Feb 20, 2023	DS DP			
	8546143	Apr 23, 2022	DS U-3272			
	8809292	May 10, 2027	DS DP U-3272			
	8828956	Dec 04, 2028	DS DP U-3272			
	9074213	Mar 09, 2022	DS U-3272			
	9370582	Dec 04, 2028	DS DP U-3272			
	9708610	Jan 01, 2024	DS DP U-3272			
	9708615	Mar 08, 2024	DS			
<u>INDIGOTINDISULFONATE SODIUM - BLUDIGO</u>						
N 216264 001	10927258	Dec 23, 2037	DS		NCE	Jul 08, 2027
	11499050	Dec 23, 2037	DS			
<u>IODIXANOL - IODIXANOL</u>						
A 214271 001					CGT	Jan 09, 2023
<u>IODIXANOL - IODIXANOL</u>						
A 214271 002					CGT	Jan 09, 2023
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	11369597	Jun 12, 2033	U-1848			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002	>A> 10206879	Sep 14, 2027	DP		>A> NCE	Mar 06, 2020
	>A> 10603280	Sep 14, 2027	DP		>A> ODE*	Mar 06, 2022
	>A> 10812238	Oct 31, 2025	DS		>A> GAIN	Mar 06, 2025
					>A> GAIN	Mar 06, 2027
<u>ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE</u>						
A 211290 001					CGT	Jun 20, 2022
<u>IVACAFITOR - KALYDECO</u>						
N 207925 001	11147770	Feb 27, 2033	DP U-3339			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	11147770	Feb 27, 2033	DP U-3339			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	11147770	Feb 27, 2033	DP U-3339			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 206038 001	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 206038 002	8846718	Jul 02, 2029	U-1908			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 211358 001	8846718	Jul 02, 2029	U-2375		NPP	Sep 02, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	8846718	Jul 02, 2029	U-2375		NPP	Sep 02, 2025
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		NS	Sep 02, 2025
	10646481	Aug 13, 2029	DP			
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-3424			
	8324242	Aug 05, 2027	U-3424			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-3426			
	8741933	Nov 08, 2026	U-3424			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-3427			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-3427			
	9192606	Sep 29, 2029	DP U-3428			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-3429			
	9931334	Dec 28, 2026	DP U-3429			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10610125	Jun 21, 2030	U-2784		I-893	May 25, 2025
	10610125	Jun 21, 2030	U-2785			
	10610125	Jun 21, 2030	U-3385			
	10653710	Oct 18, 2036	U-3387			
	10799490	Mar 13, 2035	DP U-2981			
	10799490	Mar 13, 2035	DP U-2982			
	10799490	Mar 13, 2035	DP U-3384			
	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
	10980788	Jun 07, 2039	U-3214			
	10980788	Jun 07, 2039	U-3383			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9474779	Aug 19, 2033	DS DP U-3386			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-3386			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
	9968595	Mar 13, 2035	DP U-3384			
<u>KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN</u>						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004					NPP	Oct 14, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001					NPP	Oct 14, 2024
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 001					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 002					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 003					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 004					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 209348 001					PC	Mar 06, 2023
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 209348 002					PC	Mar 06, 2023
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					M-272	Dec 19, 2024
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					M-272	Dec 19, 2024
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8357713	Dec 22, 2029	DP U-1801			
	8357713	Dec 22, 2029	DP U-1802			
	8357713	Dec 22, 2029	DP U-1803			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	10098877	Jan 10, 2026	U-3283			
	10517868	Jan 10, 2026	U-3283			
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	11278547	Mar 02, 2040	U-3282			
	11478471	Jan 10, 2026	U-3283			
	9918984	Jan 10, 2026	U-3283			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 013	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 014	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 015	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - ERMEZA</u>						
N 215809 001	9345772	Feb 27, 2035	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	11278623	May 10, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 004	8999393	Jan 08, 2034	DP U-3210			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	11299500	Oct 04, 2038	DS			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	11299500	Oct 04, 2038	DS			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11219596	May 03, 2033	U-2985			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001	11261447	Nov 20, 2038	DS DP U-2995		I-901	Oct 06, 2025
	11401517	Aug 14, 2035	DS DP U-2995			
	11446380	Oct 09, 2035	DS DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	11026951	Dec 03, 2034	U-3274			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO</u>						
N 215833 001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
	10406240	Aug 15, 2028	DS DP U-3345			
	11318121	Aug 15, 2028	DS DP U-3345			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAKETAN - PLUVICTO</u>						
N 215833 001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
	10406240	Aug 15, 2028	DS DP U-3345			
	11318121	Aug 15, 2028	DS DP U-3345			
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB</u>						
N 213135 001	11382864	Aug 04, 2037	U-3164			
<u>MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE</u>						
A 202511 001					PC	Mar 06, 2023
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	11229647	Feb 12, 2040	U-3290		ODE-379	Sep 29, 2028
	11260053	May 26, 2031	U-3290			
	11376251	Oct 26, 2032	U-3290			
	11497745	Feb 12, 2040	U-3290			
<u>MARAVIROC - MARAVIROC</u>						
A 203347 001					PC	Aug 06, 2022
<u>MARAVIROC - MARAVIROC</u>						
A 203347 002					PC	Aug 06, 2022
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					NCE	Nov 23, 2026
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
<u>MELOXICAM - ANJESO</u>						
N 210583 001	11253478	May 26, 2030	DP U-3318			
	11458145	Mar 08, 2039	U-3318			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	11344622	Apr 25, 2032	U-3093			
	6992207	Jun 25, 2023	DS DP U-3093			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	11376237	Apr 06, 2039	U-3421			
<u>MESALAMINE - MESALAMINE</u>						
A 214585 001					CGT	Nov 14, 2022
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	11166947	Jan 25, 2038		U-3299		
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	11166947	Jan 25, 2038		U-3299		
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	11166947	Jan 25, 2038		U-3299		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11241391	Mar 23, 2032		U-2357		
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11241391	Mar 23, 2032		U-2357		
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11241391	Mar 23, 2032		U-2357		
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11241391	Mar 23, 2032		U-2357		
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11241391	Mar 23, 2032		U-2357		
	11241392	Mar 23, 2032	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001				NP		Jun 19, 2023
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 09, 2028	U-2007			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
	11357761	May 30, 2038	U-2371			
	11357762	May 30, 2038	U-2371			
	11357763	May 30, 2038	U-2371			
	11357764	May 30, 2038	DS			
	11357765	May 30, 2038	DS			
	11357784	Feb 06, 2039	U-2371			
	11376244	May 30, 2038	DS			
	11389436	May 30, 2038	U-2371			
	11389437	May 30, 2038	U-2371			
	11426396	May 30, 2038	DS			
	11458128	May 30, 2038	U-2371			
	8592362	Feb 12, 2029	U-2371	Y		
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	10016443	Sep 04, 2034	U-3297		NP	Jan 13, 2025
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP U-3297			
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
	11400101	Sep 04, 2034	U-3297			
	9078923	Sep 04, 2034	DP U-3297			
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP U-3297			
	9937189	Sep 04, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	>A> 9480644	Mar 16, 2035	DP U-1903	Y		
	>A> 9707226	Mar 16, 2035	DP U-1903	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	>A> 9480644	Mar 16, 2035	DP U-1903	Y		
	>A> 9707226	Mar 16, 2035	DP U-1903	Y		
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	11135155	Aug 26, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854 001	11027072	May 24, 2039	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001	10143792	May 24, 2031	U-2476			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	7731690	Jan 15, 2025	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9737669	Nov 23, 2024	DP			
	9814838	Feb 28, 2031	DP			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
<u>NEOSTIGMINE METHYLSULFATE - NEOSTIGMINE METHYLSULFATE</u>						
A 216291 001					CGT	Jan 21, 2023
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11207306	Apr 16, 2038	U-2804			
	11413277	Apr 16, 2038	DP U-2804			
	11517563	Apr 16, 2038	DP			
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	11291793	Aug 18, 2025	DP			
	11383059	Aug 18, 2025	U-3037			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 001	10888534	Apr 26, 2039	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 002	10888534	Apr 26, 2039	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	10888534	Apr 26, 2039	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Feb 21, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Feb 21, 2027	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11338011	Feb 03, 2036	U-2857			
	>A> 11510963	Feb 03, 2036	U-2857			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	>A> 10414752	Sep 18, 2035	DP			
	>A> 10532047	May 16, 2039	DS			
	>A> 10550098	Sep 18, 2035	DP			
	>A> 10959994	May 16, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	>A> 11013733	May 16, 2039	U-3496			
	>A> 11013734	May 16, 2039	U-3495			
	>A> 11376246	May 16, 2039	U-3495			
	>A> 11497743	May 16, 2039	U-3495			
	>A> 11498913	Sep 18, 2035	DP			
	>A> 9834539	Sep 18, 2035	DS DP U-3497			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	10751333	Jul 16, 2039	DP			
	11103492	Jul 16, 2039	DP			
<u>OMIDENEPAG ISOPROPYL - OMLONTI</u>						
N 215092 001	10179127	Jan 08, 2035	DP U-3454		NCE	Sep 22, 2027
	10702511	Jan 08, 2035	DP U-3454			
	10765750	Jan 08, 2035	DP			
	10774072	Jun 10, 2035	DS			
	11197849	Jan 08, 2035	DP U-3454			
	8648097	Oct 13, 2029	DS DP			
	8685986	Oct 13, 2029	DP			
	9415038	Jan 08, 2035	DP U-3454			
	RE48183	Jan 08, 2035	DP U-3454			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	>A> 11524951	Jul 25, 2032	DS DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	>A> 11524951	Jul 25, 2032	DS DP			
<u>OTESECONAZOLE - VIVJOA</u>						
N 215888 001	10414751	Mar 17, 2036	DS DP		NCE	Apr 26, 2027
	11247981	May 09, 2033	U-3366		GAIN	Apr 26, 2032
	8236962	Apr 22, 2031	DS DP			
	8754227	Apr 22, 2031	U-3366			
	9840492	Mar 17, 2036	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	>A> 11517560	Jun 11, 2035	U-3494			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEO</u>						
N 212520 001	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039	U-2849			
	>A> 11541036	Dec 16, 2039	DP			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001	8153632	Jan 17, 2029	DS DP U-3331		NCE	Feb 28, 2027
	8153632	Jan 17, 2029	DS DP U-3332			
	8980873	Mar 25, 2030	DS DP U-3331			
	8980873	Mar 25, 2030	DS DP U-3332			
	9573964	May 05, 2028	U-3331			
	9573964	May 05, 2028	U-3332			
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291			
	9061057	Aug 26, 2033	DS DP U-3291			
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP U-3291			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	>A> 7456168	Jan 16, 2023	U-1998			
	>A> 7456168	Jan 16, 2023	U-2515			
	>A> 7456168	Jan 16, 2023	U-3501			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	>A> 7456168	Jan 16, 2023	U-1998			
	>A> 7456168	Jan 16, 2023	U-2515			
	>A> 7456168	Jan 16, 2023	U-3501			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	>A> 7456168	Jan 16, 2023	U-1998			
	>A> 7456168	Jan 16, 2023	U-2515			
	>A> 7456168	Jan 16, 2023	U-3501			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	>A> 7456168	Jan 16, 2023	U-2515			
	>A> 7456168	Jan 16, 2023	U-3501			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	>A> 7456168	Jan 16, 2023	U-2515			
	>A> 7456168	Jan 16, 2023	U-3501			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	>A> 7456168	Jan 16, 2023	U-2515			
	>A> 7456168	Jan 16, 2023	U-3501			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11292815	Nov 15, 2033	DS DP U-3124			
	11292815	Nov 15, 2033	DS DP U-3354			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	11466004	May 03, 2039	U-3464		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	11466004	May 03, 2039	U-3464		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	11466004	May 03, 2039	U-3464		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11266750	Mar 16, 2037	U-665			
	>A> 11529431	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11266750	Mar 16, 2037	U-665			
	11395856	Dec 28, 2035	DS DP U-665			
	>A> 11529431	Mar 16, 2037	U-665			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	7893075	May 04, 2033	DS			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 002	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
	10435404	Jul 24, 2038	DP		ODE*	Aug 02, 2026
	10730876	May 05, 2036	DS			
	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
	7893075	May 04, 2033	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 001	8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
	8895057	Jun 09, 2028	U-3398			
	9011906	Jun 09, 2028	U-3398			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 002	8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
	8895057	Jun 09, 2028	U-3398			
	9011906	Jun 09, 2028	U-3398			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 003	8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
	8895057	Jun 09, 2028	U-3398			
	9011906	Jun 09, 2028	U-3398			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 004	8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
	8895057	Jun 09, 2028	U-3398			
	9011906	Jun 09, 2028	U-3398			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216859 001					CGT	Apr 05, 2023
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214596 001					CGT	Oct 30, 2022
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214596 002					CGT	Oct 30, 2022
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	11285134	Apr 24, 2039	U-3252			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	11452721	Aug 27, 2038	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	8383150	May 10, 2028	DP U-2361			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8383150	May 10, 2028	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	8383150	May 10, 2028	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8383150	May 10, 2028	DP U-2361			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	8207197	Mar 07, 2030	DS DP			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	8207197	Mar 07, 2030	DS DP			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	11319346	Mar 01, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					I-881	Jun 17, 2024
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001					I-881	Jun 17, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11273160	Apr 03, 2039	U-2952			
<u>PRASTERONE - INTRAROSA</u>						
N 208470 001	8957054	Jan 08, 2030	U-1922			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - ASPRUZYO SPRINKLE</u>						
N 216018 001	11510878	Jan 24, 2038	DP			
<u>RANOLAZINE - ASPRUZYO SPRINKLE</u>						
N 216018 002	10898444	Jan 24, 2038	DP			
	11510878	Jan 24, 2038	DP			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
	11491169	May 28, 2041	U-3484			
	11491169	May 28, 2041	U-3485			
	11492353	Dec 08, 2031	DS			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
	11491169	May 28, 2041	U-3484			
	11491169	May 28, 2041	U-3485			
	11492353	Dec 08, 2031	DS			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	10961250	Jul 10, 2027	DP U-2968			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11247969	Mar 10, 2025	DP			
	11484531	Oct 23, 2039	U-2440			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
<u>RIFAMYCIN SODIUM - AEMCOLO</u>						
N 210910 001					NCE GAIN	Nov 16, 2023 Nov 16, 2028
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOICIGUAT - ADEMPAS</u>						
N 204819 001	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOICIGUAT - ADEMPAS</u>						
N 204819 002	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOICIGUAT - ADEMPAS</u>						
N 204819 003	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOICIGUAT - ADEMPAS</u>						
N 204819 004	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOICIGUAT - ADEMPAS</u>						
N 204819 005	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11266635	Aug 12, 2040	U-3330			
	11344536	Aug 12, 2040	U-3381			
	11395818	Dec 30, 2040	DP			
	11426390	Aug 12, 2040	U-3416			
	11433056	Aug 12, 2040	U-3423			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					NPP	May 27, 2025
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167		>A> M-284	Mar 10, 2023
	9415053	Nov 13, 2024	DP U-2142		>A> PED	Sep 10, 2023
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200		>A> M-284	Mar 10, 2023
	9415053	Nov 13, 2024	DP U-1301		>A> PED	Sep 10, 2023
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200		>A> M-284	Mar 10, 2023
	9415053	Nov 13, 2024	DP U-1301		>A> PED	Sep 10, 2023
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
9539218	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004					>A> M-284 >A> PED	Mar 10, 2023 Sep 10, 2023
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP PED	Dec 20, 2024 Jun 20, 2025
<u>ROFLUMILAST - ROFLUMILAST</u>						
A 208213 001					PC	Apr 17, 2023
<u>ROFLUMILAST - ROFLUMILAST</u>						
A 208247 001					PC	Apr 17, 2023
<u>ROFLUMILAST - ROFLUMILAST</u>						
A 208256 001					PC	Apr 18, 2023
<u>ROFLUMILAST - ROFLUMILAST</u>						
A 208257 001					PC	Apr 17, 2023
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	10940142	Jun 07, 2037	DP		NP	Jul 29, 2025
	11129818	Aug 25, 2037	DP U-3408			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	DP U-3408			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	>A> 10016429	Jun 12, 2028	U-3226		>A> I-872	Sep 22, 2024
	>A> 10016429	Jun 12, 2028	U-3230		>A> ODE-238	May 24, 2026
	>A> 10016429*PED	Dec 12, 2028			>A> ODE-373	Sep 22, 2028
	>A> 7598257	Dec 24, 2027	DS DP U-3227		>A> PED	Mar 22, 2025
	>A> 7598257	Dec 24, 2027	DS DP U-3228		>A> PED	Nov 24, 2026
	>A> 7598257*PED	Jun 24, 2028			>A> PED	Mar 22, 2029
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8722693*PED	Dec 12, 2028				
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8822481*PED	Dec 12, 2028				
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 8829013*PED	Dec 12, 2028				
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9079912*PED	Jun 12, 2027				
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
	>A> 9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	>A> 10016429	Jun 12, 2028	U-3226		>A> I-872	Sep 22, 2024
	>A> 10016429	Jun 12, 2028	U-3230		>A> ODE-238	May 24, 2026
	>A> 10016429*PED	Dec 12, 2028			>A> ODE-373	Sep 22, 2028
	>A> 7598257	Dec 24, 2027	DS DP U-3227		>A> PED	Mar 22, 2025
	>A> 7598257	Dec 24, 2027	DS DP U-3228		>A> PED	Nov 24, 2026
	>A> 7598257*PED	Jun 24, 2028			>A> PED	Mar 22, 2029
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8722693*PED	Dec 12, 2028				
	>A> 8822481	Jun 12, 2028		U-1573		
	>A> 8822481	Jun 12, 2028		U-3226		
	>A> 8822481	Jun 12, 2028		U-3227		
	>A> 8822481	Jun 12, 2028		U-3228		
	>A> 8822481	Jun 12, 2028		U-3230		
	>A> 8822481*PED	Dec 12, 2028				
	>A> 8829013	Jun 12, 2028		U-1201		
	>A> 8829013	Jun 12, 2028		U-1622		
	>A> 8829013	Jun 12, 2028		U-3227		
	>A> 8829013	Jun 12, 2028		U-3228		
	>A> 8829013*PED	Dec 12, 2028				
	>A> 9079912	Dec 12, 2026		U-3226		
	>A> 9079912	Dec 12, 2026		U-3227		
	>A> 9079912	Dec 12, 2026		U-3228		
	>A> 9079912	Dec 12, 2026		U-3230		
	>A> 9079912*PED	Jun 12, 2027				
	>A> 9814722	Dec 12, 2026		U-3226		
	>A> 9814722	Dec 12, 2026		U-3230		
	>A> 9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	>A> 10016429	Jun 12, 2028		U-3226	>A> ODE-238	May 24, 2026
	>A> 10016429	Jun 12, 2028		U-3230	>A> ODE-373	Sep 22, 2028
	>A> 10016429*PED	Dec 12, 2028			>A> PED	Nov 24, 2026
	>A> 7598257	Dec 24, 2027	DS DP	U-3227	>A> PED	Mar 22, 2029
	>A> 7598257	Dec 24, 2027	DS DP	U-3228		
	>A> 7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8722693*PED	Dec 12, 2028				
	>A> 8822481	Jun 12, 2028		U-1573		
	>A> 8822481	Jun 12, 2028		U-3226		
	>A> 8822481	Jun 12, 2028		U-3227		
	>A> 8822481	Jun 12, 2028		U-3228		
	>A> 8822481	Jun 12, 2028		U-3230		
	>A> 8822481*PED	Dec 12, 2028				
	>A> 8829013	Jun 12, 2028		U-1201		
	>A> 8829013	Jun 12, 2028		U-1622		
	>A> 8829013	Jun 12, 2028		U-3227		
	>A> 8829013	Jun 12, 2028		U-3228		
	>A> 8829013*PED	Dec 12, 2028				
	>A> 9079912	Dec 12, 2026		U-3226		
	>A> 9079912	Dec 12, 2026		U-3227		
	>A> 9079912	Dec 12, 2026		U-3228		
	>A> 9079912	Dec 12, 2026		U-3230		
	>A> 9079912*PED	Jun 12, 2027				
	>A> 9814722	Dec 12, 2026		U-3226		
	>A> 9814722	Dec 12, 2026		U-3230		
	>A> 9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	>A> 10016429	Jun 12, 2028		U-3226	>A> ODE-238	May 24, 2026
	>A> 10016429	Jun 12, 2028		U-3230	>A> ODE-373	Sep 22, 2028
	>A> 10016429*PED	Dec 12, 2028			>A> PED	Nov 24, 2026
	>A> 7598257	Dec 24, 2027	DS DP	U-3227	>A> PED	Mar 22, 2029
	>A> 7598257	Dec 24, 2027	DS DP	U-3228		
	>A> 7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8722693*PED	Dec 12, 2028				
	>A> 8822481	Jun 12, 2028		U-1573		
	>A> 8822481	Jun 12, 2028		U-3226		
	>A> 8822481	Jun 12, 2028		U-3227		
	>A> 8822481	Jun 12, 2028		U-3228		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8822481*PED	Dec 12, 2028				
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 8829013*PED	Dec 12, 2028				
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9079912*PED	Jun 12, 2027				
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
	>A> 9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	>A> 10016429	Jun 12, 2028	U-3226		>A> ODE-238	May 24, 2026
	>A> 10016429	Jun 12, 2028	U-3230		>A> ODE-373	Sep 22, 2028
	>A> 10016429*PED	Dec 12, 2028			>A> PED	Nov 24, 2026
	>A> 7598257	Dec 24, 2027	DS DP U-3227		>A> PED	Mar 22, 2029
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8722693*PED	Dec 12, 2028				
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8822481*PED	Dec 12, 2028				
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 8829013*PED	Dec 12, 2028				
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9079912*PED	Jun 12, 2027				
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
	>A> 9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	>A> 10610530	Jun 12, 2028	U-3229		>A> I-896	Jul 18, 2025
	>A> 10610530	Jun 12, 2028	U-3404		>A> NP	Sep 21, 2024
	>A> 10610530*PED	Dec 12, 2028			>A> PED	Mar 21, 2025
	>A> 10639310	Dec 12, 2026	U-3229		>A> PED	Jan 18, 2026
	>A> 10639310*PED	Jun 12, 2027				
	>A> 10758543	May 20, 2031	DP			
	>A> 10758543*PED	Nov 20, 2031				
	>A> 10869870	May 20, 2031	U-3229			
	>A> 10869870	May 20, 2031	U-3404			
	>A> 10869870*PED	Nov 20, 2031				
	>A> 11219624	May 20, 2031	DP U-3229			
	>A> 11219624*PED	Nov 20, 2031				
	>A> 7598257	Dec 24, 2027	DS DP			
	>A> 7598257*PED	Jun 24, 2028				
	>A> 8415362	Dec 24, 2027	DS DP			
	>A> 8415362*PED	Jun 24, 2028				
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8722693*PED	Dec 12, 2028				
	>A> 8822481	Jun 12, 2028	U-3229			
	>A> 8822481	Jun 12, 2028	U-3404			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	>A> 8822481*PED	Dec 12, 2028				
	>A> 9079912	Dec 12, 2026	U-3229			
	>A> 9079912	Dec 12, 2026	U-3404			
	>A> 9079912*PED	Jun 12, 2027				
	>A> 9974790	Dec 12, 2026	U-3229			
	>A> 9974790	Dec 12, 2026	U-3404			
	>A> 9974790*PED	Jun 12, 2027				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
	9216178*PED	May 01, 2033				
	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	9216178	Nov 01, 2032	DP			
	9216178*PED	May 01, 2033				
	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10335390	Sep 04, 2035	DP U-3270			
	10682338	Sep 04, 2035	DP U-2583			
	10682338	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
	11324721	Sep 04, 2035	DP U-2583			
	11324721	Sep 04, 2035	DP U-3169			
	11324721	Sep 04, 2035	DP U-3270			
	11324721	Sep 04, 2035	DP U-3302			
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 001	10137124	Oct 10, 2037	U-2826			
	10137124	Oct 10, 2037	U-2827			
	10137124	Oct 10, 2037	U-2828			
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 001	10584124	Oct 10, 2038	DS	U-2826		
	10584124	Oct 10, 2038	DS	U-2827		
	10584124	Oct 10, 2038	DS	U-2828		
	10584124	Oct 10, 2038	DS	U-3450		
	10584124	Oct 10, 2038	DS	U-3451		
	10584124	Oct 10, 2038	DS	U-3452		
	10584124	Oct 10, 2038	DS	U-3453		
	10786489	Oct 10, 2038	DP	U-2971		
	10786489	Oct 10, 2038	DP	U-2972		
	10786489	Oct 10, 2038	DP	U-2973		
	10786489	Oct 10, 2038	DP	U-2974		
	10786489	Oct 10, 2038	DP	U-2975		
	10786489	Oct 10, 2038	DP	U-2976		
	10786489	Oct 10, 2038	DP	U-2977		
	10786489	Oct 10, 2038	DP	U-3450		
	10786489	Oct 10, 2038	DP	U-3451		
	10786489	Oct 10, 2038	DP	U-3452		
	10786489	Oct 10, 2038	DP	U-3453		
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 002	10137124	Oct 10, 2037		U-2826		
	10137124	Oct 10, 2037		U-2827		
	10137124	Oct 10, 2037		U-2828		
	10137124	Oct 10, 2037		U-3450		
	10137124	Oct 10, 2037		U-3451		
	10137124	Oct 10, 2037		U-3452		
	10137124	Oct 10, 2037		U-3453		
	10172851	Oct 10, 2037		U-2826		
	10172851	Oct 10, 2037		U-2827		
	10172851	Oct 10, 2037		U-2828		
	10584124	Oct 10, 2038	DS	U-2826		
	10584124	Oct 10, 2038	DS	U-2827		
	10584124	Oct 10, 2038	DS	U-2828		
	10584124	Oct 10, 2038	DS	U-3450		
	10584124	Oct 10, 2038	DS	U-3451		
	10584124	Oct 10, 2038	DS	U-3452		
	10584124	Oct 10, 2038	DS	U-3453		
	10786489	Oct 10, 2038	DP	U-2971		
	10786489	Oct 10, 2038	DP	U-2972		
	10786489	Oct 10, 2038	DP	U-2973		
	10786489	Oct 10, 2038	DP	U-2974		
	10786489	Oct 10, 2038	DP	U-2975		
	10786489	Oct 10, 2038	DP	U-2976		
	10786489	Oct 10, 2038	DP	U-2977		
	10786489	Oct 10, 2038	DP	U-3450		
	10786489	Oct 10, 2038	DP	U-3451		
	10786489	Oct 10, 2038	DP	U-3452		
	10786489	Oct 10, 2038	DP	U-3453		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	10220155	Jul 17, 2026	DP		D-185	Mar 28, 2025
	10357616	Jan 20, 2026	DP		NCE	Dec 05, 2022
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP	U-3355		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	8536122	Mar 20, 2026	DS DP U-3355			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	DP U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-3469			
	8536122	Mar 20, 2026	DS DP U-3469			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	11382957	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	11382957	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	11382957	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	11318191	Feb 17, 2041	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	11318191	Feb 17, 2041	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	11318191	Feb 17, 2041	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	11318191	Feb 17, 2041	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	11318191	Feb 17, 2041	DP U-3162			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					I-892	Jun 16, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SINCALIDE - SINCALIDE</u>						
N 210850 001	11110063	Apr 20, 2038	DP U-3481			
	11110063	Apr 20, 2038	DP U-3482			
	11110063	Apr 20, 2038	DP U-3483			
	11318100	Apr 20, 2038	DP U-3477			
	11318100	Apr 20, 2038	DP U-3478			
	11318100	Apr 20, 2038	DP U-3479			
	11318100	Apr 20, 2038	DP U-3480			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 003	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
<u>SIROLIMUS - FYARRO</u>						
N 213312 001	11497737	Oct 28, 2040	DP			
<u>SIROLIMUS - HYFTOR</u>						
N 213478 001					NP	Mar 22, 2025
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	9687506	Feb 10, 2030	DP U-3394			
	9687506	Feb 10, 2030	DP U-3395			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	10479686	Jul 07, 2030	DP U-3390			
	9345724	Jul 07, 2030	DS DP U-2015			
	9585912	Jul 07, 2030	DS DP			
	9687506	Feb 10, 2030	DP U-3394			
	9687506	Feb 10, 2030	DP U-3395			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033	U-2499			
	10213400*PED	Sep 15, 2033				
	10864181	Mar 15, 2033	U-1532			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
<u>SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	10251896	Dec 24, 2033	U-3460		NCE	Sep 29, 2027
	10857162	Dec 24, 2033	U-3460			
	11071742	Dec 24, 2033	DP			
	9872865	Dec 24, 2033	U-3460			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	10479686	Jul 07, 2030	DP U-3390			
	9345724	Jul 07, 2030	DS DP U-2015			
	9585912	Jul 07, 2030	DS DP			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	10596190	Jan 05, 2038	U-3443		NP	Sep 20, 2025
	11291728	Jul 01, 2039	DP			
>A>	11510984	Jul 01, 2039	DP			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	11406662	Feb 10, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	11406662	Feb 10, 2032	DS			
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001					ODE* PED	Apr 07, 2024 Oct 07, 2024
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002					ODE* PED	Apr 07, 2024 Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001					M-277	Apr 27, 2025
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002					M-277	Apr 27, 2025
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001					M-277	Apr 27, 2025
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002					M-277	Apr 27, 2025
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	11338007	Jun 01, 2037	DP U-2039			
	11338007	Jun 01, 2037	DP U-2040			
	11338007*PED	Dec 01, 2037				
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11439597	Nov 05, 2034	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11439597	Nov 05, 2034	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	10266523	Mar 30, 2036	DS DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	10519146	May 21, 2038	DS DP			
	11236091	May 20, 2040	DS DP U-3306			
	11426404	Aug 11, 2040	U-3306			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	9895388	Nov 25, 2033	U-3365			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	11389461	Oct 28, 2036	DP			
	11395828	Oct 28, 2036	U-2109			
	11395828	Oct 28, 2036	U-3401			
	11395828	Oct 28, 2036	U-3402			
	11491166	Oct 28, 2036	DP			
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001					M-281	Jul 14, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002					M-281	Jul 14, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001					NPP	Jul 14, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 002					NPP	Jul 14, 2025
<u>SUCRALFATE - SUCRALFATE</u>						
A 211884 001					CGT	Sep 11, 2022
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	11337962	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	11364224	Jan 29, 2036	U-72			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	11382917	Dec 24, 2038	DP U-3397			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10195160	May 19, 2036	DP		NCE	May 23, 2027
	10426743	May 19, 2036	U-2625			
	10647649	Nov 13, 2038	DS			
	11458108	May 19, 2036	DP			
<u>TASIMELTEON - TASIMELTEON</u>						
A 211607 001					>A> PC	Jun 27, 2023
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11285129	Jan 25, 2033	U-3343			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
<u>TAZAROTENE - TAZAROTENE</u>						
A 214136 001					CGT	Mar 13, 2023
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	11311482	May 11, 2038	U-2368			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	>A> 11491163	Apr 11, 2033	U-3491			
	>A> 11491163	Apr 11, 2033	U-3492			
	>A> 8410088	Aug 25, 2034	DS DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	9439985	Jan 30, 2029	DP			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	7737168	Sep 04, 2031	U-2346			
<u>TECOVIRIMAT - TPOXX</u>						
N 214518 001	10576165	Aug 02, 2031	DP		NCE	Jul 13, 2023
	7737168	Sep 04, 2031	U-3377			
	8039504	Jul 23, 2027	DP			
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024	U-3377			
	9233097	Aug 02, 2031	DP			
	9907859	Aug 02, 2031	U-3377			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	7847061	Nov 01, 2025	U-1320	Y		
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320	Y		
	9060992*PED	May 01, 2026				
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7709493	Feb 28, 2031	DS U-1979			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	8541448	Aug 01, 2033	DS DP			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275		NPP	Oct 17, 2025
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u>						
N 022231 001					NCE	Sep 14, 2027
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u>						
N 216318 001	11311554	Mar 25, 2039	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	>A> 11497753	Mar 19, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
>A>	11497753	Mar 19, 2030	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
>A>	11497753	Mar 19, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	10226473	Nov 30, 2030	U-1500		NP	Mar 28, 2025
	10716794	Nov 30, 2030	U-1500			
	11304960	Jan 08, 2029	DP U-1500			
	11311555	Nov 30, 2030	U-1500			
	11364249	Nov 30, 2030	U-1500			
	11433083	Nov 30, 2030	U-1500			
	11464735	Apr 28, 2041	DP U-1500			
	8778922	Jan 08, 2029	DP U-1500			
	8865695	Jan 08, 2029	U-1500			
	9943527	Nov 30, 2030	U-1500			
	9949985	Nov 30, 2030	U-1500			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 001	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 002	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 003	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			M-283	May 09, 2025
	8425934	Apr 17, 2030	DP		PED	Nov 28, 2023
	8425934*PED	Oct 17, 2030			PED	May 05, 2024
	RE46276	Oct 30, 2024	DS DP U-1935		PED	Nov 09, 2025
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			M-283	May 09, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	8425934	Apr 17, 2030	DP		PED	Nov 28, 2023
	8425934*PED	Oct 17, 2030			PED	May 05, 2024
	RE46276	Oct 30, 2024	DS DP U-1935		PED	Nov 09, 2025
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592 001					CGT	Aug 25, 2022
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592 002					CGT	Aug 25, 2022
<u>TIOPRONIN - THIOLA EC</u>						
N 211843 001	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026
<u>TIOPRONIN - THIOLA EC</u>						
N 211843 002	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	>A> 11497750	Mar 12, 2038	U-3015			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	11504365	Nov 05, 2039	U-3476			
	6821987	Apr 26, 2023	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	11504365	Nov 05, 2039	U-3476			
	6821987	Apr 26, 2023	DS DP U-3100			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	11484671	Nov 07, 2024	DP U-909			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					I-879	Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002					I-879	Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 206119 001					PC	Sep 06, 2022
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11433046	Aug 21, 2040	U-3413			
	11433046	Aug 21, 2040	U-3414			
	11433046	Aug 21, 2040	U-3415			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-895	Jun 22, 2025
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-895	Jun 22, 2025
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-895	Jun 22, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027		U-1849		
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027		U-1849		
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	11324710	Aug 22, 2038		U-2368		
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001	10988436	May 03, 2039	DS		NP	Apr 28, 2025
	11072577	May 03, 2039		U-3370		
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11504370	Mar 25, 2033		U-2788		
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11504370	Mar 25, 2033		U-2788		
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001					M-271	Jun 24, 2024
<u>UMBRALISIB TOSYLATE - UKONIO</u>						
N 213176 001	10981919	Jul 02, 2033		U-3063		
	10981919	Jul 02, 2033		U-3064		
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10995095	Oct 17, 2036		U-3298	I-880	Dec 14, 2024
	11365198	Oct 17, 2036		U-3275	I-883	Jan 14, 2025
	>A> 11512092	Oct 17, 2036		U-3275	I-886	Mar 16, 2025
	>A> 11512092	Oct 17, 2036		U-3371	I-888	Apr 29, 2025
	>A> 11512092	Oct 17, 2036		U-3487		
	8962629	Jan 15, 2031	DS	U-3255		
	8962629	Jan 15, 2031	DS	U-3275		
	8962629	Jan 15, 2031	DS	U-3341		
	8962629	Jan 15, 2031	DS	U-3371		
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	10344036	Oct 17, 2036	DP		I-883	Jan 14, 2025
	10550126	Oct 17, 2036		U-3298	I-886	Mar 16, 2025
	10730883	Oct 17, 2036	DP		NCE	Aug 16, 2024
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS	U-3341		
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	10202393	Oct 17, 2036	DP		I-886	Mar 16, 2025
	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS	U-3341		
	9951080	Oct 17, 2036	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	RE47221	Dec 01, 2030	DS			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001 >A>	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002 >A>	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003 >A>	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004 >A>	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005 >A>	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006 >A>	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007 >A>	11517609	Nov 06, 2035	U-282			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11224598	Oct 19, 2035	U-1900			
<u>VASOPRESSIN - VASOPRESSIN</u>						
A 211538 001					PC	Jul 17, 2022
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
<u>VENLAFAXINE BESYLATE - VENLAFAXINE BESYLATE</u>						
N 215429 001	6717015	Mar 27, 2023	DS DP U-451			
	7776358	May 16, 2028	DP			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	11439642	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	11439642	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	11439642	May 19, 2031	U-3062			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	>A> 11458143	Sep 04, 2029	U-727			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	>A> 11458143	Sep 04, 2029	U-727			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	>A> 11458143	Sep 04, 2029	U-727			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2023	DS DP U-3056			
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7304078	Dec 23, 2027	DS DP U-1512			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	11458134	Jun 15, 2027	DP U-3463			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	11458134	Jun 15, 2027	DP U-3463			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	11458134	Jun 15, 2027	DP U-3463			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	11458134	Jun 15, 2027	DP U-3463			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11452720	Feb 06, 2035	U-3459			
	9018210	Nov 25, 2033	DS DP			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036			U-3133	
	11020382	Dec 02, 2036			U-3134	
	11452720	Feb 06, 2035			U-3459	
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034			U-2676	
	9248199	Jan 29, 2034			U-2715	
	9447071	Feb 06, 2035	DS DP			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036			U-3133	
	11020382	Dec 02, 2036			U-3134	
	11452720	Feb 06, 2035			U-3459	
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034			U-2676	
	9248199	Jan 29, 2034			U-2715	
	9447071	Feb 06, 2035	DS DP			
<u>VUTRISIRAN - AMVUTTRA</u>						
N 215515 001	10131907	Aug 24, 2028	DS DP U-3396		NCE	Jun 13, 2027
	10208307	Jul 28, 2036	DS DP U-3396			
	10570391	Nov 16, 2032	DS DP U-3396			
	10612024	Aug 14, 2035	DS DP U-3396			
	10683501	Jul 28, 2036	DS DP U-3396			
	10806791	Dec 04, 2028	DS			
	11286486	Jul 28, 2036	DS DP U-3396			
	11401517	Aug 14, 2035	DS DP U-3396			
	8106022	Dec 12, 2029	DS DP U-3396			
	8828956	Dec 04, 2028	DS DP U-3396			
	9370581	Dec 04, 2028	DS DP U-3396			
	9399775	Nov 16, 2032	DS DP U-3396			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745			
	10570139	Apr 22, 2034	U-2145			
	10570139	Apr 22, 2034	U-3063			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-3063			
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216249 001					CGT	Dec 24, 2022
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216249 002					CGT	Dec 24, 2022
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003					M-232	Jan 28, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004					M-232	Jan 28, 2025
<u>ZONISAMIDE - ZONISADE</u>						
N 214273 001	11478456	Aug 18, 2038		U-3458		
	>A> 11529333	Aug 18, 2038	DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 42ND Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm